Combination_ID	PMID	Disease_id	NP_id	NP_name	AT_id	AT_name	Cell_line_ID1	Cell_type_IC501	NP_IC50_1	AT_IC50_1	NP_AT1	Cell_line_ID2	Cell_type_IC502	NP_IC50_2	AT_IC50_2	NP_AT2	Cell_line_ID3	Cell_type_IC503	NP_IC50_3	AT_IC50_3	NP_AT3	Cell_line_ID4	Cell_type_IC504	NP_IC50_4	AT_IC50_4	NP_AT4	Cell_line_ID5	Cell_type_IC505	NP_IC50_5	AT_IC50_5	NP_AT5	Cell_line_ID6	Cell_type_IC506	NP_IC50_6	AT_IC50_6	NP_AT6	Target_id	Target_name	MOA	Cell_type_activity1	NP_activity_1	AT_activity_1	NP_AT_activity1	Cell_type_activity2	NP_activity_2	AT_activity_2	NP_AT_activity2	Cell_type_activity3	NP_activity_3	AT_activity_3	NP_AT_activity3	Cell_type_activity4	NP_activity_4	AT_activity_4	NP_AT_activity4	Cell_type_activity5	NP_activity_5	AT_activity_5	NP_AT_activity5	Cell_type_activity6	NP_activity_6	AT_activity_6	NP_AT_activity6	Effects_order	Effects_group	Combination_effect	conclusions
C49909	7579563	DIS0023	NP3882	L-cavanine	DR9021	5-fluorouracil	NEWCL00236	MIA PaCa-2	72h:0.06mM	72h:0.363mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy offers a viable means of improving L-canavanine's intrinsic efficacy while decreasing the concentration of 5-FU required to produce the same cytotoxic effect.
C83293	8010874	DIS0037	NP1339	Vitamin C	DR1669	Cisplatin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Ascorbic acid renders cisplatin more effective as an antitumor agent.
C58098	9269999	DIS0022	NP5424	Flavopiridol	DR1669	Cisplatin	NEWCL00170	A-549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A-549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Administration of flavopiridol for 24 h followed 3 days later by exposure to 5-fluorouracil resulted in a highly synergistic interaction.
C93281	9815832	DIS0024	NP5424	Flavopiridol	DR8841	Mitomycin C	NEWCL00116	MKN74	.	.	300 nM :1 ug.ml	NEWCL00050	MDA-MB-468	.	.	300 nM :1 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol potentiates the cytotoxic effect of the chemotherapeutic agent MMC by promoting drug-induced apoptosis in tumor cells.
C10758	11096359	DIS0029	NP9279	Genistein	DR1669	Cisplatin	NEWCL20405	HTB-186	.	.	6 uM:1 uM	NEWCL00010	CRL-8805	.	.	6 uM:1 uM	NEWCL00303	MHH-MED-1	.	.	6 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HTB-186	.	.	.	CRL-8805	.	.	.	MED-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Genistein can significantly enhance the antiproliferative and cytotoxic action of cisplatin.
C44725	11489836	DIS0117	NP5424	Flavopiridol	DR2391	Gemcitabine	NEWCL00116	MKN74	.	.	300 nm :1uM	NEWCL00082	HCT 116	.	.	150 nm:10 nm	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit (RR-M2).
C95252	11967955	DIS0129	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00253	PC-3	.	.	1.10uM	NEWCL00251	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances cytotoxicity of doxorubicin in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation.
C95252	11967955	DIS0129	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00253	PC-3	.	.	1.10uM	NEWCL00251	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances cytotoxicity of doxorubicin in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation.
C45375	12125982	DIS0029	NP9279	Genistein	DR9249	"1,3-bis(2-chloroethyl)-1-nitrosourea"	NEWCL00279	U-87MG ATCC	.	.	20 uM:50uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	U-87MG ATCC	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Genistein at typical adult dietary plasma levels can significantly enhance the antiproliferative and cytotoxic action of BCNU.
C91158	12135670	DIS0025	NP6993	Arsenic trioxide	DR8244	Imatinib	NEWCL00048	K-562	0.35 ±  0.075uM	1.11 ±  0.12uM	1 uM:1 uM	NEWCL20402	MO7p210	0.060 ±  0.0067uM	1.99 ±  0.18uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	As2O3 in combination with imatinib showed favorable cytotoxicity and proapoptotic activity in chronic myelogenous leckemia.
C77987	12231544	DIS0025	NP5424	Flavopiridol	DR8244	Imatinib	NEWCL00048	K-562	.	.	150 nM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	K-562	643.64%	145.00%	8714.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
C77987	12231544	DIS0025	NP5424	Flavopiridol	DR8244	Imatinib	NEWCL00048	K-562	.	.	150 nM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	K-562	98.31%	100.00%	7909.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
C77987	12231544	DIS0025	NP5424	Flavopiridol	DR8244	Imatinib	NEWCL00048	K-562	.	.	150 nM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	K-562	2.09%	10.99%	0.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
C77987	12231544	DIS0025	NP5424	Flavopiridol	DR8244	Imatinib	NEWCL00048	K-562	.	.	150 nM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0223	Bcr-Abl	Up-regulation	K-562	5.02%	1.46%	5.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
C77987	12231544	DIS0025	NP5424	Flavopiridol	DR8244	Imatinib	NEWCL00048	K-562	.	.	150 nM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-CDC2	Down-regulation	K-562	23.77%	57.02%	18.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
C77987	12231544	DIS0025	NP5424	Flavopiridol	DR8244	Imatinib	NEWCL00048	K-562	.	.	150 nM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9634	P-STAT5	Down-regulation	K-562	10.53%	29.48%	65.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
C77987	12231544	DIS0025	NP5424	Flavopiridol	DR8244	Imatinib	NEWCL00048	K-562	.	.	150 nM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Prb	Down-regulation	K-562	4.17%	3.80%	92.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
C77987	12231544	DIS0025	NP5424	Flavopiridol	DR8244	Imatinib	NEWCL00048	K-562	.	.	150 nM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	K-562	21.61%	33.81%	174.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
C29048	12429642	DIS0129	NP0016	Silibinin	DR4469	Doxorubicin	NEWCL00251	DU145	.	.	100 uM:25 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4688	Chk1	Up-regulation	DU145	44.67%	85.70%	100.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis."
C29048	12429642	DIS0129	NP0016	Silibinin	DR4469	Doxorubicin	NEWCL00251	DU145	.	.	100 uM:25 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Chk2	Down-regulation	DU145	58.14%	32.35%	2.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis."
C56247	12479366	DIS0021	NP5424	Flavopiridol	DR6300	Trastuzumab	NEWCL00052	SK-BR-3	.	.	100 nM:4 nM	NEWCL00049	MDA-MB-231	.	.	100 nM:4 nM	NEWCL00051	MDA-MB-453	.	.	100 nM:4 nM	NEWCL20452	HBL-100	.	.	100 nM:4 nM	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	SK-BR-3	42.08%	31.39%	73.44%	MDA-MB-231	.	.	.	MDA-MB-453	.	.	.	HBL-100	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells associated with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
C56247	12479366	DIS0021	NP5424	Flavopiridol	DR6300	Trastuzumab	NEWCL00052	SK-BR-3	.	.	100 nM:4 nM	NEWCL00049	MDA-MB-231	.	.	100 nM:4 nM	NEWCL00051	MDA-MB-453	.	.	100 nM:4 nM	NEWCL20452	HBL-100	.	.	100 nM:4 nM	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	SK-BR-3	33.02%	6.89%	62.46%	MDA-MB-231	.	.	.	MDA-MB-453	.	.	.	HBL-100	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells associated with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
C56247	12479366	DIS0021	NP5424	Flavopiridol	DR6300	Trastuzumab	NEWCL00052	SK-BR-3	.	.	100 nM:4 nM	NEWCL00049	MDA-MB-231	.	.	100 nM:4 nM	NEWCL00051	MDA-MB-453	.	.	100 nM:4 nM	NEWCL20452	HBL-100	.	.	100 nM:4 nM	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	SK-BR-3	54.33%	56.31%	60.12%	MDA-MB-231	.	.	.	MDA-MB-453	.	.	.	HBL-100	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells associated with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
C56247	12479366	DIS0021	NP5424	Flavopiridol	DR6300	Trastuzumab	NEWCL00052	SK-BR-3	.	.	100 nM:4 nM	NEWCL00049	MDA-MB-231	.	.	100 nM:4 nM	NEWCL00051	MDA-MB-453	.	.	100 nM:4 nM	NEWCL20452	HBL-100	.	.	100 nM:4 nM	.	.	.	.	.	.	.	.	.	.	MO7847	P-RB	Down-regulation	SK-BR-3	14.36%	1.99%	32.93%	MDA-MB-231	.	.	.	MDA-MB-453	.	.	.	HBL-100	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells associated with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
C56247	12479366	DIS0021	NP5424	Flavopiridol	DR6300	Trastuzumab	NEWCL00052	SK-BR-3	.	.	100 nM:4 nM	NEWCL00049	MDA-MB-231	.	.	100 nM:4 nM	NEWCL00051	MDA-MB-453	.	.	100 nM:4 nM	NEWCL20452	HBL-100	.	.	100 nM:4 nM	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Down-regulation	SK-BR-3	51.04%	77.17%	38.12%	MDA-MB-231	.	.	.	MDA-MB-453	.	.	.	HBL-100	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells associated with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
C35524	12609832	DIS0028	NP6993	Arsenic trioxide	DR5834	Docosahexaenoic acid	NEWCL00022	HL-60	.	.	1 uM:25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HL-60	3.21%	18.08%	594.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells.
C80977	12649194	DIS0025	NP1928	Carnosic acid	DR3078	"1,25-dihydroxyvitamin D3"	NEWCL20420	HL60-G	.	.	10 um:1 nm	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-porsk	Up-regulation	HL60-G	45.26%	89.04%	105.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium."
C80977	12649194	DIS0025	NP1928	Carnosic acid	DR3078	"1,25-dihydroxyvitamin D3"	NEWCL20420	HL60-G	.	.	10 um:1 nm	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Up-regulation	HL60-G	369.30%	473.36%	496.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium."
C80977	12649194	DIS0025	NP1928	Carnosic acid	DR3078	"1,25-dihydroxyvitamin D3"	NEWCL20420	HL60-G	.	.	10 um:1 nm	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7389	P-MEK1	Up-regulation	HL60-G	70.74%	121.19%	432.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium."
C23550	12771887	DIS0022	NP5424	Flavopiridol	DR3681	Depsipeptide	NEWCL00201	NCI-H322	.	.	150 nmol.L:10.50ng.ml	NEWCL00180	NCI-H460	.	.	150 nmol.L:10.50ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The depsipeptide plus flavopiridol combination exhibits powerful and selective cytocidal activity against cancer but not normal cells. Apoptosis induced by this combination is mediated by the mitochondria-dependent death pathway.
C23550	12771887	DIS0022	NP5424	Flavopiridol	DR3681	Depsipeptide	NEWCL00100	TE-12	.	.	150 nmol.L:10.50ng.ml	NEWCL00101	TE-13	.	.	150 nmol.L:10.50ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The depsipeptide plus flavopiridol combination exhibits powerful and selective cytocidal activity against cancer but not normal cells. Apoptosis induced by this combination is mediated by the mitochondria-dependent death pathway.
C56247	12839951	DIS0021	NP5424	Flavopiridol	DR6300	Trastuzumab	NEWCL00051	MDA-MB-453	.	.	300 nM :200 ng.ml	NEWCL00160	BT-474	.	.	300 nM :200 ng.ml	NEWCL00052	SK-BR-3	.	.	300 nM :200 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MDA453	.	.	.	BT474	.	.	.	SK-BR-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Synergy between flavopiridol and trastuzumab can result from enhanced apoptosis, and that combination effects on EGFR expression are involved in the interaction."
C27185	12866029	DIS0129	NP0016	Silibinin	DR1669	Cisplatin	NEWCL00251	DU145	.	.	100 uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cdc25C	Down-regulation	DU145	12.60%	8.35%	54.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin-induced growth inhibition and apoptotic death.
C27185	12866029	DIS0129	NP0016	Silibinin	DR1669	Cisplatin	NEWCL00251	DU145	.	.	100 uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cdc2	Down-regulation	DU145	61.52%	6.66%	75.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin-induced growth inhibition and apoptotic death.
C27185	12866029	DIS0129	NP0016	Silibinin	DR1669	Cisplatin	NEWCL00251	DU145	.	.	100 uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	DU145	67.94%	85.21%	94.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin-induced growth inhibition and apoptotic death.
C27185	12866029	DIS0129	NP0016	Silibinin	DR1669	Cisplatin	NEWCL00251	DU145	.	.	100 uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4688	Chk1	Down-regulation	DU145	14.73%	75.79%	37.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin-induced growth inhibition and apoptotic death.
C27185	12866029	DIS0129	NP0016	Silibinin	DR1669	Cisplatin	NEWCL00251	DU145	.	.	100 uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1804	Wee1	Up-regulation	DU145	234.92%	24.28%	62.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin-induced growth inhibition and apoptotic death.
C10758	12950722	DIS0122	NP9279	Genistein	DR1669	Cisplatin	NEWCL00025	p39	.	.	20 uM:1.10 ug.ml	NEWCL00013	P22 cell line	.	.	20 uM:1.10 ug.ml	NEWCL00090	MeWo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	p39	14.49%	41.73%	279.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C10758	12950722	DIS0122	NP9279	Genistein	DR1669	Cisplatin	NEWCL00025	p39	.	.	20 uM:1.10 ug.ml	NEWCL00013	P22 cell line	.	.	20 uM:1.10 ug.ml	NEWCL00090	MeWo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Up-regulation	p39	8.60%	40.05%	84.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C10758	12950722	DIS0122	NP9279	Genistein	DR1669	Cisplatin	NEWCL00025	p39	.	.	20 uM:1.10 ug.ml	NEWCL00013	P22 cell line	.	.	20 uM:1.10 ug.ml	NEWCL00090	MeWo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1139	Apaf-1	Up-regulation	p39	8.40%	5.17%	81.82%	p22	8.11%	5.09%	125.22%	 A101D	26.25%	9.63%	86.08%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C10758	12950722	DIS0122	NP9279	Genistein	DR1669	Cisplatin	NEWCL00025	p39	.	.	20 uM:1.10 ug.ml	NEWCL00013	P22 cell line	.	.	20 uM:1.10 ug.ml	NEWCL00090	MeWo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	p39	2.52%	1.72%	79.09%	p22	21.48%	38.84%	78.09%	 A101D	22.63%	10.20%	61.37%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C10758	12950722	DIS0122	NP9279	Genistein	DR1669	Cisplatin	NEWCL00025	p39	.	.	20 uM:1.10 ug.ml	NEWCL00013	P22 cell line	.	.	20 uM:1.10 ug.ml	NEWCL00090	MeWo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	p39	38.62%	217.54%	283.91%	p22	6.17%	13.47%	75.57%	 A101D	10.71%	12.66%	65.05%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C10758	12950722	DIS0122	NP9279	Genistein	DR1669	Cisplatin	NEWCL00025	p39	.	.	20 uM:1.10 ug.ml	NEWCL00013	P22 cell line	.	.	20 uM:1.10 ug.ml	NEWCL00090	MeWo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	p39	8.52%	12.07%	84.25%	p22	7.89%	2.56%	69.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	K-562	7.62%	7.55%	14.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	K-562	19.72%	2.97%	351.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	K-562	1.34%	2.05%	6.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Up-regulation	K-562	37.91%	2.19%	32.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Smac	Up-regulation	K-562	2518.51%	530.74%	2277.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	K-562	8.62%	0.03%	0.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	K-562	0.13%	1.06%	5.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	K-562	7.78%	12.10%	13.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	K-562	12.31%	16.06%	16.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	K-562	20.23%	17.40%	46.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C12652	14687026	DIS0025	NP8435	Apicidin	DR8244	Imatinib	NEWCL00048	K-562	.	.	800nm.L:500nm.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0223	Bcr-Abl	Down-regulation	K-562	0.21%	5.91%	24.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
C23550	15014036	DIS0119	NP5424	Flavopiridol	DR3681	Depsipeptide	NEWCL00306	NCI-H2373	.	.	150 nm :50 ng.ml	NEWCL00248	NCI-H2052	.	.	150 nm :50 ng.ml	NEWCL00247	REN	.	.	150 nm :50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5524	Cyclin A	Down-regulation	H513	11.51%	9.20%	37.22%	H28	1.01%	15.38%	52.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Flavopiridol abrogates depsipeptide-mediated induction of p21 expression, in part, via inhibition of protein kinase C signaling and markedly potentiates the cytotoxic effects of depsipeptide in MPM cells."
C23550	15014036	DIS0119	NP5424	Flavopiridol	DR3681	Depsipeptide	NEWCL00306	NCI-H2373	.	.	150 nm :50 ng.ml	NEWCL00248	NCI-H2052	.	.	150 nm :50 ng.ml	NEWCL00247	REN	.	.	150 nm :50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7847	RB	Down-regulation	H513	58.87%	51.90%	58.91%	H28	3.14%	5.98%	67.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Flavopiridol abrogates depsipeptide-mediated induction of p21 expression, in part, via inhibition of protein kinase C signaling and markedly potentiates the cytotoxic effects of depsipeptide in MPM cells."
C23550	15014036	DIS0119	NP5424	Flavopiridol	DR3681	Depsipeptide	NEWCL00306	NCI-H2373	.	.	150 nm :50 ng.ml	NEWCL00248	NCI-H2052	.	.	150 nm :50 ng.ml	NEWCL00247	REN	.	.	150 nm :50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p44.42	Down-regulation	H513	21.35%	11.32%	43.91%	H28	7.22%	14.26%	56.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Flavopiridol abrogates depsipeptide-mediated induction of p21 expression, in part, via inhibition of protein kinase C signaling and markedly potentiates the cytotoxic effects of depsipeptide in MPM cells."
C59500	15039284	DIS0015	NP5424	Flavopiridol	DR8611	Bortezomib	NEWCL00048	K-562	.	.	200 nM:8 nM	NEWCL00068	LAMA-84	.	.	200 nM:8 nM	NEWCL20364	K-562-R	.	.	200 nM:8 nM	NEWCL20453	LAMA82-R	.	.	200 nM:8 nM 	NEWCL00019	U-937	.	.	200 nM:8 nM 	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	K-562	73.60%	155.42%	47453.25%	LAMA-84	833.38%	20.83%	71214.55%	K-562-R	.	.	.	LAMA82-R	.	.	.	U-937	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Bortezomib interacts synergistically with flavopiridol to induce mitochondrial dysfunction and apoptosis, blockade of the IkappaB/NF-kappaB pathway and activation of the SAPK/JNK cascade."
C59500	15039284	DIS0015	NP5424	Flavopiridol	DR8611	Bortezomib	NEWCL00048	K-562	.	.	200 nM:8 nM	NEWCL00068	LAMA-84	.	.	200 nM:8 nM	NEWCL20364	K-562-R	.	.	200 nM:8 nM	NEWCL20453	LAMA82-R	.	.	200 nM:8 nM 	NEWCL00019	U-937	.	.	200 nM:8 nM 	.	.	.	.	.	.	Smac	Up-regulation	K-562	57.21%	2244.32%	140391.62%	LAMA-84	73.14%	0.02%	3632.14%	K-562-R	.	.	.	LAMA82-R	.	.	.	U-937	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Bortezomib interacts synergistically with flavopiridol to induce mitochondrial dysfunction and apoptosis, blockade of the IkappaB/NF-kappaB pathway and activation of the SAPK/JNK cascade."
C59500	15039284	DIS0015	NP5424	Flavopiridol	DR8611	Bortezomib	NEWCL00048	K-562	.	.	200 nM:8 nM	NEWCL00068	LAMA-84	.	.	200 nM:8 nM	NEWCL20364	K-562-R	.	.	200 nM:8 nM	NEWCL20453	LAMA82-R	.	.	200 nM:8 nM 	NEWCL00019	U-937	.	.	200 nM:8 nM 	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	K-562	12.22%	17.29%	91.76%	LAMA-84	70.08%	56.85%	95.45%	K-562-R	.	.	.	LAMA82-R	.	.	.	U-937	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Bortezomib interacts synergistically with flavopiridol to induce mitochondrial dysfunction and apoptosis, blockade of the IkappaB/NF-kappaB pathway and activation of the SAPK/JNK cascade."
C59500	15039284	DIS0015	NP5424	Flavopiridol	DR8611	Bortezomib	NEWCL00048	K-562	.	.	200 nM:8 nM	NEWCL00068	LAMA-84	.	.	200 nM:8 nM	NEWCL20364	K-562-R	.	.	200 nM:8 nM	NEWCL20453	LAMA82-R	.	.	200 nM:8 nM 	NEWCL00019	U-937	.	.	200 nM:8 nM 	.	.	.	.	.	MO9634	P-STAT5	Down-regulation	K-562	23.14%	23.83%	77.09%	LAMA-84	86.74%	49.02%	95.78%	K-562-R	.	.	.	LAMA82-R	.	.	.	U-937	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Bortezomib interacts synergistically with flavopiridol to induce mitochondrial dysfunction and apoptosis, blockade of the IkappaB/NF-kappaB pathway and activation of the SAPK/JNK cascade."
C59500	15039284	DIS0015	NP5424	Flavopiridol	DR8611	Bortezomib	NEWCL00048	K-562	.	.	200 nM:8 nM	NEWCL00068	LAMA-84	.	.	200 nM:8 nM	NEWCL20364	K-562-R	.	.	200 nM:8 nM	NEWCL20453	LAMA82-R	.	.	200 nM:8 nM 	NEWCL00019	U-937	.	.	200 nM:8 nM 	.	.	.	.	.	MO0223	P-Bcr-abl	Down-regulation	K-562	0.05%	0.82%	32.61%	LAMA-84	2.66%	3.88%	83.35%	K-562-R	16.59%	4.83%	18.19%	LAMA82-R	38.76%	15.57%	50.11%	U-937	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Bortezomib interacts synergistically with flavopiridol to induce mitochondrial dysfunction and apoptosis, blockade of the IkappaB/NF-kappaB pathway and activation of the SAPK/JNK cascade."
C59500	15039284	DIS0015	NP5424	Flavopiridol	DR8611	Bortezomib	NEWCL00048	K-562	.	.	200 nM:8 nM	NEWCL00068	LAMA-84	.	.	200 nM:8 nM	NEWCL20364	K-562-R	.	.	200 nM:8 nM	NEWCL20453	LAMA82-R	.	.	200 nM:8 nM 	NEWCL00019	U-937	.	.	200 nM:8 nM 	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	K-562	7.79%	1.11%	6.49%	LAMA-84	3.87%	1.09%	32.17%	K-562-R	15.28%	5.82%	16.48%	LAMA82-R	90.42%	60.49%	85.42%	U-937	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Bortezomib interacts synergistically with flavopiridol to induce mitochondrial dysfunction and apoptosis, blockade of the IkappaB/NF-kappaB pathway and activation of the SAPK/JNK cascade."
C59500	15039284	DIS0015	NP5424	Flavopiridol	DR8611	Bortezomib	NEWCL00048	K-562	.	.	200 nM:8 nM	NEWCL00068	LAMA-84	.	.	200 nM:8 nM	NEWCL20364	K-562-R	.	.	200 nM:8 nM	NEWCL20453	LAMA82-R	.	.	200 nM:8 nM 	NEWCL00019	U-937	.	.	200 nM:8 nM 	.	.	.	.	.	MO6742	P-AKT	Down-regulation	K-562	32.31%	11.42%	51.24%	LAMA-84	47.29%	45.89%	62.55%	K-562-R	16.30%	7.26%	18.18%	LAMA82-R	27.21%	18.57%	24.04%	U-937	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Bortezomib interacts synergistically with flavopiridol to induce mitochondrial dysfunction and apoptosis, blockade of the IkappaB/NF-kappaB pathway and activation of the SAPK/JNK cascade."
C59500	15039284	DIS0015	NP5424	Flavopiridol	DR8611	Bortezomib	NEWCL00048	K-562	.	.	200 nM:8 nM	NEWCL00068	LAMA-84	.	.	200 nM:8 nM	NEWCL20364	K-562-R	.	.	200 nM:8 nM	NEWCL20453	LAMA82-R	.	.	200 nM:8 nM 	NEWCL00019	U-937	.	.	200 nM:8 nM 	.	.	.	.	.	MO6898	PARP	Up-regulation	K-562	33.62%	8.71%	27.63%	LAMA-84	3.13%	2.85%	4.45%	K-562-R	17.84%	6.01%	21.43%	LAMA82-R	8.82%	17.33%	14.31%	U-937	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Bortezomib interacts synergistically with flavopiridol to induce mitochondrial dysfunction and apoptosis, blockade of the IkappaB/NF-kappaB pathway and activation of the SAPK/JNK cascade."
C00179	15298755	DIS0024	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00352	AGS	.	.	5 umol.L:0.1 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AGS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining curcumin with 5-FU significantly increased growth inhibition of AGS cells compared with either curcumin or 5-FU alone.
C71805	15374632	DIS0115	NP2294	Geraniol	DR9021	5-fluorouracil	NEWCL00073	Caco-2	8Days: 250uM	8Days: 0.4uM	150uM:0.25uM	NEWCL00076	SW620	8Days: 330uM	8Days: 2.0uM	150uM:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Thymidylate synthase	Down-regulation	Caco-2	46.88%	43.45%	61.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Geraniol modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts.
C71805	15374632	DIS0115	NP2294	Geraniol	DR9021	5-fluorouracil	NEWCL00073	Caco-2	8Days: 250uM	8Days: 0.4uM	150uM:0.25uM	NEWCL00076	SW620	8Days: 330uM	8Days: 2.0uM	150uM:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Thymidine kinase	Down-regulation	Caco-2	22.52%	37.43%	28.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Geraniol modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts.
C99457	15457130	DIS0021	NP2960	Epigallocatechin gallate	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	25 uM:0.01 uM	NEWCL00049	MDA-MB-231	.	.	25 uM:0.01 uM	NEWCL00156	T-47D	.	.	25 uM:0.01 uM	NEWCL00161	Hs 578T	.	.	25 uM:0.01 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	MCF-7	.	.	.	MDA-MB-231	.	.	.	T47-D	.	.	.	HS578T	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells.
C97303	15486061	DIS0037	NP9846	Phytosphingosine	DR5586	Gamma-ray irradiation	NEWCL20365	Jurkat T cells	.	.	5 ug.mL:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9 	Up-regulation	Jurkat T cells	1.48%	0.52%	2.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."
C97303	15486061	DIS0037	NP9846	Phytosphingosine	DR5586	Gamma-ray irradiation	NEWCL20365	Jurkat T cells	.	.	5 ug.mL:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	Jurkat T cells	8.15%	17.68%	44.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."
C97303	15486061	DIS0037	NP9846	Phytosphingosine	DR5586	Gamma-ray irradiation	NEWCL20365	Jurkat T cells	.	.	5 ug.mL:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	Jurkat T cells	20.44%	18.75%	9.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."
C97303	15486061	DIS0037	NP9846	Phytosphingosine	DR5586	Gamma-ray irradiation	NEWCL20365	Jurkat T cells	.	.	5 ug.mL:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	Jurkat T cells	2.57%	12.63%	6.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."
C97303	15486061	DIS0037	NP9846	Phytosphingosine	DR5586	Gamma-ray irradiation	NEWCL20365	Jurkat T cells	.	.	5 ug.mL:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	Jurkat T cells	17.31%	18.90%	34.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."
C97303	15486061	DIS0037	NP9846	Phytosphingosine	DR5586	Gamma-ray irradiation	NEWCL20365	Jurkat T cells	.	.	5 ug.mL:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	Jurkat T cells	35.04%	34.79%	6.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."
C97303	15486061	DIS0037	NP9846	Phytosphingosine	DR5586	Gamma-ray irradiation	NEWCL20365	Jurkat T cells	.	.	5 ug.mL:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	Jurkat T cells	9.08%	5.95%	5.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."
C97303	15486061	DIS0037	NP9846	Phytosphingosine	DR5586	Gamma-ray irradiation	NEWCL20365	Jurkat T cells	.	.	5 ug.mL:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	Jurkat T cells	7.38%	0.93%	1.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."
C97303	15486061	DIS0037	NP9846	Phytosphingosine	DR5586	Gamma-ray irradiation	NEWCL20365	Jurkat T cells	.	.	5 ug.mL:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Up-regulation	Jurkat T cells	0.09%	0.56%	1.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."
C36127	15767548	DIS0129	NP1427	Estramustine	DR7626	Docetaxel	NEWCL00253	PC-3	.	.	1nM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CathepsinK	Up-regulation	PC-3	7.00%	10.59%	25.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	These results provide novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
C36127	15767548	DIS0129	NP1427	Estramustine	DR7626	Docetaxel	NEWCL00253	PC-3	.	.	1nM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Annexin A2	Up-regulation	PC-3	4.20%	0.25%	77.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	These results provide novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
C36127	15767548	DIS0129	NP1427	Estramustine	DR7626	Docetaxel	NEWCL00253	PC-3	.	.	1nM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CathepsinC	Down-regulation	PC-3	14.11%	38.40%	68.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	These results provide novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
C44725	15770523	DIS0021	NP5424	Flavopiridol	DR2391	Gemcitabine	NEWCL00155	MCF-7	.	.	10nM:100nM	NEWCL00049	MDA-MB-231	.	.	10nM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	A sequence dependent potentiation of the effect of gemcitabine by flavopiridol was demonstrated in breast cancer cell lines and it was independent of ER status. This was accompanied by enhanced apoptosis and the up regulation of p21(WAF-1) protein.
C62137	15987718	DIS0020	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10134	Caki	.	.	30 uM:100 ng.ml	NEWCL00082	HCT 116	.	.	30 uM:100 ng.ml	NEWCL00344	HT29	.	.	30 uM:100 ng.ml	NEWCL00129	Hep-G2	.	.	30 uM:100 ng.ml	NEWCL00283	Hep3B	.	.	30 uM:100 ng.ml	.	.	.	.	.	.	.	.	Caki	.	.	.	HCT116	.	.	.	HT29	.	.	.	HepG2	.	.	.	Hep3B	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5).
C78281	16108016	DIS0129	NP5775	Cyclopamine	DR9742	Gefitinib	NEWCL00253	PC-3	.	.	10 uM:40 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined cyclopamine and gefitinib were more effective at suppressing the invasiveness of PC3 cells through matrigel in vitro as the drugs alone.
C10359	16166455	DIS0115	NP6905	Curcumin	DR2742	Celecoxib	NEWCL00077	HT-29	.	.	15 umol.L:5 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	HT-29	39.55%	14.60%	90.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin potentiates the growth inhibitory effect of celecoxib. The synergistic growth inhibitory effect was mediated through a mechanism that probably involves inhibition of the COX-2 pathway and may involve other non-COX-2 pathways.
C10359	16166455	DIS0115	NP6905	Curcumin	DR2742	Celecoxib	NEWCL00077	HT-29	.	.	15 umol.L:5 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9759	COX-1	Up-regulation	HT-29	25.56%	26.22%	18.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin potentiates the growth inhibitory effect of celecoxib. The synergistic growth inhibitory effect was mediated through a mechanism that probably involves inhibition of the COX-2 pathway and may involve other non-COX-2 pathways.
C50414	16230417	DIS0126	NP3067	Paclitaxel	DR6126	Amifostine	NEWCL10187	Hec50co	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	JunC	Down-regulation	Hec50co	30.52%	27.37%	36.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Amifostine and paclitaxel shown a potential anticancer synergistic effect in vitro and in vivo, whereas amifostine maintained a protective role in peripheral blood profiles."
C50414	16230417	DIS0126	NP3067	Paclitaxel	DR6126	Amifostine	NEWCL10187	Hec50co	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	JunB	Down-regulation	Hec50co	14.10%	11.19%	24.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Amifostine and paclitaxel shown a potential anticancer synergistic effect in vitro and in vivo, whereas amifostine maintained a protective role in peripheral blood profiles."
C50414	16230417	DIS0126	NP3067	Paclitaxel	DR6126	Amifostine	NEWCL10187	Hec50co	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	JunD	Up-regulation	Hec50co	6.82%	7.21%	5.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Amifostine and paclitaxel shown a potential anticancer synergistic effect in vitro and in vivo, whereas amifostine maintained a protective role in peripheral blood profiles."
C75169	16309236	DIS0025	NP3247	Artemisinin	DR9093	Sodium butyrate	NEWCL00032	Molt-4	.	.	20 uM:1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Molt-4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	DHA in combination with butyric acid acts synergistically at low doses.
C00179	16340194	DIS0114	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00077	HT-29	15.9uM	17.3uM	20uM:50uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HT-29	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of curcumin and 5-FU showed synergism at higher doses against the human colon cancer cell line HT-29. This synergism was associated with the decreased expression of COX-2 protein.
C06862	16405922	DIS0031	NP3545	Schisandrol B	DR4469	Doxorubicin	NEWCL00140	SMMC-7721	.	.	50uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	SMMC-7721	9.63%	28.43%	252.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Sch B may bring benefit to clinical chemotherapy by reducing significantly the cumulative doses of DOX and its associated cardiotoxicities.
C06862	16405922	DIS0031	NP3545	Schisandrol B	DR4469	Doxorubicin	NEWCL00140	SMMC-7721	.	.	50uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	SMMC-7721	10.71%	158.29%	246.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Sch B may bring benefit to clinical chemotherapy by reducing significantly the cumulative doses of DOX and its associated cardiotoxicities.
C06862	16405922	DIS0031	NP3545	Schisandrol B	DR4469	Doxorubicin	NEWCL00140	SMMC-7721	.	.	50uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	SMMC-7721	6.47%	3.39%	51.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Sch B may bring benefit to clinical chemotherapy by reducing significantly the cumulative doses of DOX and its associated cardiotoxicities.
C06862	16405922	DIS0031	NP3545	Schisandrol B	DR4469	Doxorubicin	NEWCL00140	SMMC-7721	.	.	50uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	SMMC-7721	3.09%	15.63%	5.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Sch B may bring benefit to clinical chemotherapy by reducing significantly the cumulative doses of DOX and its associated cardiotoxicities.
C62137	16471035	DIS0129	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00251	DU145	.	.	30 uM: 20 ng.ml	NEWCL00252	LNCaP	.	.	30 uM: 20 ng.ml	NEWCL00253	PC-3	.	.	30 uM: 20 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DU146	.	.	.	LNCaP	.	.	.	PC3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined curcumin and TRAIL treatment produced the most loss of viable cells by inducing apoptosis.
C10359	16507392	DIS0023	NP6905	Curcumin	DR2742	Celecoxib	NEWCL00234	p34	.	.	15uM:10uM	NEWCL00236	MIA PaCa-2	.	15uM:10uM	.	NEWCL00242	Panc-1	.	.	15uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-34	.	.	.	MIAPaCa	.	.	.	Panc-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin synergistically augments the growth inhibition inserted by celecoxib in pancreatic cancer cells expressing COX-2. The synergistic effect was mediated through inhibition of COX-2.
C69906	16571651	DIS0098	NP8310	Sulforaphane	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00225	SaOS-2	.	.	50 ng.L:30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	SaOS-2	2.03%	0.41%	94.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.
C69906	16571651	DIS0098	NP8310	Sulforaphane	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00225	SaOS-2	.	.	50 ng.L:30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	SaOS-2	51.45%	2.07%	79.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.
C69906	16571651	DIS0098	NP8310	Sulforaphane	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00225	SaOS-2	.	.	50 ng.L:30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	SaOS-2	0.83%	0.85%	65.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.
C69906	16571651	DIS0098	NP8310	Sulforaphane	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00225	SaOS-2	.	.	50 ng.L:30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	SaOS-2	0.00%	2.87%	79.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.
C29997	16931628	DIS0037	NP5233	Wogonin	DR9921	Tumor necrosis factor alpha	NEWCL00064	CCRF-CEM	.	.	30 uM: 20 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CCRF-CEM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Wogonin attenuates NF-kappaB activity by shifting TNFalpha-induced free radical .O(2)(-) to a more reduced nonradical product, H(2)O(2), and thereby sensitizes TNFalpha-resistant leukemia cells to TNFalpha-induced apoptosis."
C76673	16951203	DIS0021	NP5424	Flavopiridol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00155	MCF-7	.	.	200 nmol.L:250 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	Bcl-2 MCF-7	2.07%	6.32%	16.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway.
C76673	16951203	DIS0021	NP5424	Flavopiridol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00155	MCF-7	.	.	200 nmol.L:250 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	Bcl-2 MCF-7	31.10%	52.19%	-9.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway.
C69500	16987264	DIS0101	NP6459	Vinblastine	DR7548	Bleomycin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of vinblastine and bleomycin achieved a high rate of objective responses in a subgroup of elderly and symptomatic patients, without considerable toxicity."
C69830	17143496	DIS0037	NP9846	Phytosphingosine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL20365	Jurkat T cells	.	.	2 ug.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	Jurkat T cells	507.04%	623.84%	1258.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction.
C69830	17143496	DIS0037	NP9846	Phytosphingosine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL20365	Jurkat T cells	.	.	2 ug.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Up-regulation	Jurkat T cells	7.82%	7.69%	92.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction.
C69830	17143496	DIS0037	NP9846	Phytosphingosine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL20365	Jurkat T cells	.	.	2 ug.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	Jurkat T cells	510.99%	761.87%	601.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction.
C69830	17143496	DIS0037	NP9846	Phytosphingosine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL20365	Jurkat T cells	.	.	2 ug.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Jurkat T cells	6.81%	307.86%	906.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction.
C69830	17143496	DIS0037	NP9846	Phytosphingosine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL20365	Jurkat T cells	.	.	2 ug.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	Jurkat T cells	3.64%	5.47%	40.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction.
C69830	17143496	DIS0037	NP9846	Phytosphingosine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL20365	Jurkat T cells	.	.	2 ug.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	Jurkat T cells	4.25%	13.20%	74.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction.
C69830	17143496	DIS0037	NP9846	Phytosphingosine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL20365	Jurkat T cells	.	.	2 ug.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	Jurkat T cells	2.97%	15.58%	84.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction.
C14624	17174384	DIS0124	NP6905	Curcumin	DR4267	TRAILApo2L 	NEWCL00231	SK-OV-3	.	.	15 uM:2.5 ug.ml	NEWCL00229	ES-2	.	.	15 uM:2.5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HONE1	3.03%	16.53%	44.80%	CNE2	6.82%	27.28%	53.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis.
C14624	17174384	DIS0124	NP6905	Curcumin	DR4267	TRAILApo2L 	NEWCL00231	SK-OV-3	.	.	15 uM:2.5 ug.ml	NEWCL00229	ES-2	.	.	15 uM:2.5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HONE1	10.18%	55.37%	85.97%	CNE2	3.59%	17.62%	30.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis.
C14624	17174384	DIS0124	NP6905	Curcumin	DR4267	TRAILApo2L 	NEWCL00231	SK-OV-3	.	.	15 uM:2.5 ug.ml	NEWCL00229	ES-2	.	.	15 uM:2.5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HONE1	10.66%	31.59%	48.96%	CNE2	18.04%	65.73%	104.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis.
C14624	17174384	DIS0124	NP6905	Curcumin	DR4267	TRAILApo2L 	NEWCL00231	SK-OV-3	.	.	15 uM:2.5 ug.ml	NEWCL00229	ES-2	.	.	15 uM:2.5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	HONE1	21.61%	36.39%	45.62%	CNE2	10.32%	32.15%	38.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis.
C14624	17174384	DIS0124	NP6905	Curcumin	DR4267	TRAILApo2L 	NEWCL00231	SK-OV-3	.	.	15 uM:2.5 ug.ml	NEWCL00229	ES-2	.	.	15 uM:2.5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	HONE1	27.84%	43.83%	54.76%	CNE2	15.78%	46.58%	54.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis.
C14624	17174384	DIS0124	NP6905	Curcumin	DR4267	TRAILApo2L 	NEWCL00231	SK-OV-3	.	.	15 uM:2.5 ug.ml	NEWCL00229	ES-2	.	.	15 uM:2.5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	HONE1	20.39%	38.40%	63.29%	CNE2	12.34%	34.47%	45.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis.
C14624	17174384	DIS0124	NP6905	Curcumin	DR4267	TRAILApo2L 	NEWCL00231	SK-OV-3	.	.	15 uM:2.5 ug.ml	NEWCL00229	ES-2	.	.	15 uM:2.5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HONE1	7.10%	32.37%	50.56%	CNE2	11.13%	28.23%	57.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis.
C68221	17230508	DIS0129	NP0016	Silibinin	DR8320	Mitoxantrone	NEWCL00251	DU145	.	.	20 uM:50 nM	NEWCL00252	LNCaP	.	.	20 uM:50 nM	NEWCL00253	PC-3	.	.	20 uM:50 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DU145	.	.	.	LNCaP	.	.	.	PC3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of silibinin and mitoxantrone exhibits a pattern of synergy in reducing cell viability with increased apoptosis.
C62137	17289836	DIS0129	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	30 uM:20 ng.ml	NEWCL00251	DU145	.	.	30 uM:20 ng.ml	NEWCL00253	PC-3	.	.	30 uM:20 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	LNCaP	.	.	.	DU145	.	.	.	PC3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin sensitizes prostate cancer cells to TRAIL by inhibiting Akt-regulated NF-kappaB and NF-kappaB-dependent antiapoptotic Bcl-2, Bcl-xL, and XIAP."
C71184	17318783	DIS0031	NP9453	Schisandrol A	DR4469	Doxorubicin	NEWCL00129	Hep-G2	72h:>150uM	.	.	NEWCL20429	Hep-G2.DR	72h:>150uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	SCH acts by affecting the normal formation and functioning of the Pgp-substrate complexes.
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	MIA PaCa-2 tumor	47.02%	5.88%	49.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7003	ICAM-1	Down-regulation	MIA PaCa-2 tumor	0.51%	28.55%	47.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	MIA PaCa-2 tumor	52.22%	88.62%	89.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	MIA PaCa-2 tumor	7.99%	4.25%	47.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	MIA PaCa-2 tumor	61.29%	8.39%	62.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	MIA PaCa-2 tumor	4.93%	3.33%	8.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MIA PaCa-2 tumor	61.26%	0.84%	56.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	MIA PaCa-2 tumor	11.37%	34.24%	73.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	IAP-1	Down-regulation	MIA PaCa-2 tumor	35.68%	29.39%	51.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	MIA PaCa-2 tumor	39.17%	28.96%	54.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	MIA PaCa-2 tumor	68.86%	54.30%	77.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	17440100	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	MIA PaCa-2 tumor	34.49%	1.05%	18.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C88883	17487361	DIS0021	NP2960	Epigallocatechin gallate	DR5291	4-hydroxy-tamoxifen	NEWCL00049	MDA-MB-231	.	.	25 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic cytotoxicity elicited by the combination of EGCG and 4-OHT results from an earlier induction of apoptosis but this was not caused by an increase in G1-arrest or 4-OHT-mediated changes in the metabolism of EGCG.
C00057	17593102	DIS0129	NP2960	Epigallocatechin gallate	DR0904	Bicalutamide	NEWCL00333	NRP-152	.	.	20 umol.L:10 umol.L	NEWCL00334	NRP-154	.	.	20 umol.L:10 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells.
C44115	17804742	DIS0029	NP0016	Silibinin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00039	U-251MG	.	.	150 umol.L:100 ng.mL	NEWCL00279	U-87MG ATCC	.	.	150 umol.L:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	U-251MG	0.00%	2.88%	26.48%	U-87MG ATCCMG	20.11%	8.45%	52.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
C80755	17823925	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	25 ng.mL:25 ng.mL	NEWCL00251	DU145	.	.	25 ng.mL:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	PC-3	4.27%	5.13%	31.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol pretreatment altered the expression of IAPs and Bax, and decreased Akt phosphorylation in PC-3 cells, leading to increased caspase activation and apoptosis."
C80755	17823925	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	25 ng.mL:25 ng.mL	NEWCL00251	DU145	.	.	25 ng.mL:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	PC-3	21.96%	9.52%	37.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol pretreatment altered the expression of IAPs and Bax, and decreased Akt phosphorylation in PC-3 cells, leading to increased caspase activation and apoptosis."
C80755	17823925	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	25 ng.mL:25 ng.mL	NEWCL00251	DU145	.	.	25 ng.mL:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	PC-3	15.63%	42.04%	56.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol pretreatment altered the expression of IAPs and Bax, and decreased Akt phosphorylation in PC-3 cells, leading to increased caspase activation and apoptosis."
C80755	17823925	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	25 ng.mL:25 ng.mL	NEWCL00251	DU145	.	.	25 ng.mL:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	PC-3	20.78%	0.03%	36.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol pretreatment altered the expression of IAPs and Bax, and decreased Akt phosphorylation in PC-3 cells, leading to increased caspase activation and apoptosis."
C62137	17916240	DIS0129	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	10.20uM:50 nM	NEWCL00252	LNCaP	.	.	10.20uM:50 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	PC-3	30.90%	10.13%	46.02%	LNCaP	28.78%	72.78%	95.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhanced the apoptosis-inducing potential of TRAIL in androgen-unresponsive PC-3 cells and sensitized androgen-responsive TRAIL-resistant LNCaP cells.
C43718	17926190	DIS0025	NP6128	Gossypol	DR8244	Imatinib	NEWCL00048	K-562	.	.	5 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c 	Up-regulation	K-562	120.51%	97.44%	377.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
C43718	17926190	DIS0025	NP6128	Gossypol	DR8244	Imatinib	NEWCL00048	K-562	.	.	5 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Up-regulation	K-562	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
C43718	17926190	DIS0025	NP6128	Gossypol	DR8244	Imatinib	NEWCL00048	K-562	.	.	5 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Down-regulation	K-562	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
C43718	17926190	DIS0025	NP6128	Gossypol	DR8244	Imatinib	NEWCL00048	K-562	.	.	5 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	K-562	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
C23002	17933449	DIS0021	NP6084	Resveratrol	DR4854	Roscovitine	NEWCL00155	MCF-7	.	.	50 uM:6.9 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MCF-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
C85964	17942301	DIS0021	NP5783	Toremifene	DR9491	Atamestane	NEWCL00155	MCF-7	1± 0.3uM	60.4± 17.2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of toremifene plus atamestane was as effective as toremifene or tamoxifen alone but may not provide any additional benefit over toremifene alone or tamoxifen alone.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP(85KD)	Up-regulation	LNCaP	1098.76%	63.09%	2949.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	LNCaP	1624.11%	407.56%	1584.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	LNCaP	2373.52%	207.79%	2352.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	P-BAD(Ser112)	Down-regulation	LNCaP	55.59%	10.06%	68.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	LNCaP	53.68%	3.67%	17.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ClAP-1	Down-regulation	LNCaP	5.08%	1.10%	69.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	LNCaP	9.28%	0.30%	73.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR4	Up-regulation	LNCaP	660.67%	596.34%	647.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2163	FADD	Up-regulation	LNCaP	10.96%	2.56%	3.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FLIP	Up-regulation	LNCaP	91.93%	90.76%	91.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	LNCaP	8.97%	5.20%	61.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	UPA	Down-regulation	LNCaP	7.18%	1.98%	49.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8345	Angiopoietin 1	Down-regulation	LNCaP	45.16%	3.79%	78.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C28720	17998943	DIS0129	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	40 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Angiopoietin 2	Down-regulation	LNCaP	2.38%	7.18%	16.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
C54915	18187663	DIS0028	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00019	U-937	.	48h:51.89 ±  11.97 ng.mL	.	NEWCL00019	U-937	.	48h:6.63 ±  0.57 ng.mL	5 nM:7.5 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
C48767	18225555	DIS0129	NP2960	Epigallocatechin gallate	DR5670	Ibuprofen	NEWCL00251	DU145	.	.	40 ug.ml:1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"EGCG+ibuprofen treatment has a synergistic effect on apoptosis, and xidative stress, directly or indirectly via ceramide synthesis mediated pro-apoptotic signaling."
C02843	18371987	DIS0021	NP2960	Epigallocatechin gallate	DR4213	Raloxifene	NEWCL00049	MDA-MB-231	.	.	25 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	MDA-MB-231	61.84%	65.84%	87.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic cytotoxicity elicited by the combination of EGCG and raloxifene results from an earlier and greater induction of apoptosis.
C02843	18371987	DIS0021	NP2960	Epigallocatechin gallate	DR4213	Raloxifene	NEWCL00049	MDA-MB-231	.	.	25 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MDA-MB-232	0.09%	35.72%	39.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic cytotoxicity elicited by the combination of EGCG and raloxifene results from an earlier and greater induction of apoptosis.
C02843	18371987	DIS0021	NP2960	Epigallocatechin gallate	DR4213	Raloxifene	NEWCL00049	MDA-MB-231	.	.	25 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	MDA-MB-233	7.71%	22.42%	10.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic cytotoxicity elicited by the combination of EGCG and raloxifene results from an earlier and greater induction of apoptosis.
C02843	18371987	DIS0021	NP2960	Epigallocatechin gallate	DR4213	Raloxifene	NEWCL00049	MDA-MB-231	.	.	25 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VEGFR1	Up-regulation	MDA-MB-234	2.03%	5.71%	23.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic cytotoxicity elicited by the combination of EGCG and raloxifene results from an earlier and greater induction of apoptosis.
C28784	18374481	DIS0025	NP8210	Galangin	DR8244	Imatinib	NEWCL00048	K-562	12 ±  0.8uM	.	40uM:0.25 uM	NEWCL00069	KCL-22	.	.	40uM:0.25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Galangin caused a decrease in Bcl-2 levels and markedly increased the apoptotic activity of imatinib both in sensitive or imatinib-resistant Bcr-Abl+ cell lines.
C76871	18381438	DIS0115	NP5424	Flavopiridol	DR3489	Irinotecan	NEWCL00082	HCT 116	.	.	300 nmol.L:5 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HCT 116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
C49644	18398671	DIS0024	NP1559	Luteolin	DR1669	Cisplatin	NEWCL00352	AGS	48h:29.6 ±  3.8 ;72h:23.5 ±  2.4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AGS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"A combinational treatment of cisplatin and luteolin induced more effectively cell growth inhibition, compared to cisplatin treatment alone."
C13325	18414057	DIS0022	NP6905	Curcumin	DR7799	Sulfinosine	NEWCL00180	NCI-H460	.	.	15 uM:10 uM	NEWCL20388	NCI-H460R	.	.	15 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	NCI-H460	.	.	.	NCI-H460R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sulfinosine and curcumin overcome MDR in non-small cell lung carcinoma cell line (NSCLC) by regulating the expression of MDR-related genes mdr1, gst-pi and topo Iialpha."
C02521	18497562	DIS0115	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	200 uM:947 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HCT 116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"RSV synergistically promotes 5-FU-mediated apoptosis at its higher concentration irrespective of p53. Conversely, it inhibits 5-FU-triggered apoptosis at lower concentrations in p53+/+ cells."
C83616	18546267	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00128	Tu 212	.	.	30 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	Tu 212	24.55%	99.48%	99.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combined treatment resulted in significantly greater inhibition of tumor growth and delayed tumor progression as a result of increased apoptosis, decreased cell proliferation and reduced pEGFR and pAKT compared to the single agent treatment groups."
C83616	18546267	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00128	Tu 212	.	.	30 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	Tu 212	82.70%	99.30%	99.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combined treatment resulted in significantly greater inhibition of tumor growth and delayed tumor progression as a result of increased apoptosis, decreased cell proliferation and reduced pEGFR and pAKT compared to the single agent treatment groups."
C83616	18546267	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00128	Tu 212	.	.	30 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	Tu 212	42.28%	108.20%	62.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combined treatment resulted in significantly greater inhibition of tumor growth and delayed tumor progression as a result of increased apoptosis, decreased cell proliferation and reduced pEGFR and pAKT compared to the single agent treatment groups."
C83616	18546267	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00128	Tu 212	.	.	30 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Down-regulation	Tu 212	10.30%	26.60%	5.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combined treatment resulted in significantly greater inhibition of tumor growth and delayed tumor progression as a result of increased apoptosis, decreased cell proliferation and reduced pEGFR and pAKT compared to the single agent treatment groups."
C32745	18680719	DIS0114	NP4440	Kaempferol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00074	SW480	.	.	40 uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	SW480	1.16%	243.22%	297.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis.
C32745	18680719	DIS0114	NP4440	Kaempferol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00074	SW480	.	.	40 uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0832	Cleaved-caspase-10	Up-regulation	SW480	4.94%	58.78%	152.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis.
C32745	18680719	DIS0114	NP4440	Kaempferol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00074	SW480	.	.	40 uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	SW480	4.12%	9.50%	123.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis.
C32745	18680719	DIS0114	NP4440	Kaempferol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00074	SW480	.	.	40 uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SW480	0.93%	12.80%	467.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis.
C15778	18708285	DIS0114	NP4931	Lycopene	DR8164	Eicosapentaenoic acid	NEWCL00077	HT-29	.	.	2 uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	HT-29	8.06%	5.08%	63.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Low concentration of lycopene and EPA could synergistically inhibit the proliferation of colon cancer cells. The inhibitory mechanism was associated with suppression of phosphatidylinositol 3-kinase/Akt signaling pathway.
C15778	18708285	DIS0114	NP4931	Lycopene	DR8164	Eicosapentaenoic acid	NEWCL00077	HT-29	.	.	2 uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6760	PPAR-gamma	Up-regulation	HT-29	14.08%	7.04%	39.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Low concentration of lycopene and EPA could synergistically inhibit the proliferation of colon cancer cells. The inhibitory mechanism was associated with suppression of phosphatidylinositol 3-kinase/Akt signaling pathway.
C15778	18708285	DIS0114	NP4931	Lycopene	DR8164	Eicosapentaenoic acid	NEWCL00077	HT-29	.	.	2 uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	HT-29	29.91%	23.24%	57.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Low concentration of lycopene and EPA could synergistically inhibit the proliferation of colon cancer cells. The inhibitory mechanism was associated with suppression of phosphatidylinositol 3-kinase/Akt signaling pathway.
C28720	18948169	DIS0029	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00125	A-172	.	.	20 uM: 100 ng.ml	NEWCL00279	U-87MG ATCC	.	.	20 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	A-172	7.74%	17.08%	54.98%	U-87MG ATCC	2.08%	9.64%	44.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	18948169	DIS0029	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00125	A-172	.	.	20 uM: 100 ng.ml	NEWCL00279	U-87MG ATCC	.	.	20 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PEA-15	Down-regulation	A-172	3.10%	3.37%	34.54%	U-87MG ATCC	1.42%	19.76%	54.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	18948169	DIS0029	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00125	A-172	.	.	20 uM: 100 ng.ml	NEWCL00279	U-87MG ATCC	.	.	20 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Up-regulation	A-172	5.44%	33.31%	125.25%	U-87MG ATCC	4.82%	59.13%	66.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	18948169	DIS0029	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00125	A-172	.	.	20 uM: 100 ng.ml	NEWCL00279	U-87MG ATCC	.	.	20 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-172	4.75%	10.71%	76.29%	U-87MG ATCC	3.33%	22.90%	75.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	18948169	DIS0029	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00125	A-172	.	.	20 uM: 100 ng.ml	NEWCL00279	U-87MG ATCC	.	.	20 uM: 100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	A-172	272.28%	365.79%	1654.13%	U-87MG ATCC	24.00%	42.63%	177.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C69906	18980980	DIS0129	NP8310	Sulforaphane	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	LNCaP	13.45%	2.79%	13.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis."
C69906	18980980	DIS0129	NP8310	Sulforaphane	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	LNCaP	97.94%	88.71%	106.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis."
C32745	19001439	DIS0029	NP4440	Kaempferol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	200 uM:100 ng.mL	NEWCL00039	U-251MG	.	.	200 uM:100 ng.mL	NEWCL10059	U-373MG ATCC	.	.	200 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	U-87MG ATCC	15.60%	372.58%	451.23%	U251	24.01%	171.82%	193.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin.
C32745	19001439	DIS0029	NP4440	Kaempferol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	200 uM:100 ng.mL	NEWCL00039	U-251MG	.	.	200 uM:100 ng.mL	NEWCL10059	U-373MG ATCC	.	.	200 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	U-87MG ATCC	141.41%	313.62%	397.11%	U251	2.53%	288.75%	358.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin.
C32745	19001439	DIS0029	NP4440	Kaempferol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	200 uM:100 ng.mL	NEWCL00039	U-251MG	.	.	200 uM:100 ng.mL	NEWCL10059	U-373MG ATCC	.	.	200 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	U-87MG ATCC	1.90%	52.18%	137.75%	U251	6.66%	84.12%	275.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin.
C32745	19001439	DIS0029	NP4440	Kaempferol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	200 uM:100 ng.mL	NEWCL00039	U-251MG	.	.	200 uM:100 ng.mL	NEWCL10059	U-373MG ATCC	.	.	200 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	U-87MG ATCC	4.11%	48.04%	99.03%	U251	7.53%	70.50%	465.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin.
C32745	19001439	DIS0029	NP4440	Kaempferol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	200 uM:100 ng.mL	NEWCL00039	U-251MG	.	.	200 uM:100 ng.mL	NEWCL10059	U-373MG ATCC	.	.	200 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	U-87MG ATCC	24.96%	39.50%	66.94%	U251	8.43%	14.13%	26.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin.
C85986	19022961	DIS0129	NP9279	Genistein	DR2728	17-beta estradiol	NEWCL00252	LNCaP	.	.	18h; 15 umol.L:15 umol.L	NEWCL00253	PC-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Genistein decreases the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.
C10758	19025644	DIS0124	NP9279	Genistein	DR1669	Cisplatin	NEWCL00230	A2780	.	.	10 uM:250nM	NEWCL00309	A2780/C200	.	.	25 uM:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A2780	7.42%	19.53%	27.93%	A2780/C200	17.47%	41.81%	136.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C10758	19025644	DIS0124	NP9279	Genistein	DR1669	Cisplatin	NEWCL00230	A2780	.	.	10 uM:250nM	NEWCL00309	A2780/C200	.	.	25 uM:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	A2780	8.04%	30.61%	37.05%	A2780/C200	8.63%	18.87%	22.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C10758	19025644	DIS0124	NP9279	Genistein	DR1669	Cisplatin	NEWCL00230	A2780	.	.	10 uM:250nM	NEWCL00309	A2780/C200	.	.	25 uM:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	A2780	9.85%	13.58%	18.04%	A2780/C200	16.43%	27.61%	28.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C10758	19025644	DIS0124	NP9279	Genistein	DR1669	Cisplatin	NEWCL00230	A2780	.	.	10 uM:250nM	NEWCL00309	A2780/C200	.	.	25 uM:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A2780	26.17%	19.53%	23.82%	A2780/C200	7.95%	21.74%	25.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C10758	19025644	DIS0124	NP9279	Genistein	DR1669	Cisplatin	NEWCL00230	A2780	.	.	10 uM:250nM	NEWCL00309	A2780/C200	.	.	25 uM:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ClAP-1	Down-regulation	A2780	16.64%	1.59%	63.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.
C28720	19082499	DIS0023	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00236	MIA PaCa-2	.	.	50 ug.ml: 5 ng.ml	NEWCL20440	Hs 766T	.	.	50 ug.ml: 5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MIA PaCa-2	.	.	.	Hs 766T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of epigallocatechin-3-gallate and TRAIL synergistically increase the apoptosis and cleavage of procaspase-3 in pancreatic cancer cells.
C79238	19084572	DIS0024	NP5023	Gambogic acid	DR9021	5-fluorouracil	NEWCL00145	BGC-823	48h:0.96± 0.03uM	48h:153.75± 11.37uM	1uM:300uM	NEWCL20441	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	BGC-823	47.42%	0.92%	80.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	GA attenuated 5-FU-induced apoptosis by modulating metabolic enzymes of 5-FU and the antigastric cancer effect of two drugs combination was much stronger than that of GA or 5-FU alone.
C79238	19084572	DIS0024	NP5023	Gambogic acid	DR9021	5-fluorouracil	NEWCL00145	BGC-823	48h:0.96± 0.03uM	48h:153.75± 11.37uM	1uM:300uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	BGC-823	146094.70%	4.79%	113715.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	GA attenuated 5-FU-induced apoptosis by modulating metabolic enzymes of 5-FU and the antigastric cancer effect of two drugs combination was much stronger than that of GA or 5-FU alone.
C49723	19084597	DIS0129	NP3478	Eugenol	DR8472	2-methoxyestradiol	NEWCL00252	LNCaP	.	.	41 ug.ml:0.5 uM	NEWCL00253	PC-3	.	.	41 ug.ml:0.5 uM	NEWCL00251	DU145	.	.	41 ug.ml:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	LNCaP	.	.	.	PC3	.	.	.	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining 2-ME(2) with eugenol (i) inhibited growth of prostate cancer cells and induced apoptosis at lower concentrations than either single agent alone.
C13933	19142175	DIS0023	NP4620	Apigenin	DR2391	Gemcitabine	NEWCL00238	CD18	.	.	25 uM:10 uM	NEWCL00241	AsPC-1	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	CD18	40.94%	8.93%	75.84%	AsPC-1	67.20%	5.09%	65.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combination treatment with apigenin and gemcitabine inhibited pancreatic cancer cell growth via cell cycle arrest, down-regulation of the prosurvival factor pAkt, and induction of apoptosis."
C13933	19142175	DIS0023	NP4620	Apigenin	DR2391	Gemcitabine	NEWCL00238	CD18	.	.	25 uM:10 uM	NEWCL00241	AsPC-1	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B	Down-regulation	CD18	60.03%	17.10%	83.98%	AsPC-1	29.79%	7.42%	89.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combination treatment with apigenin and gemcitabine inhibited pancreatic cancer cell growth via cell cycle arrest, down-regulation of the prosurvival factor pAkt, and induction of apoptosis."
C62137	19192720	DIS0129	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	30 uM: 20 ng.ml	.	.	.	.	30 uM: 20 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	PC-3	8.27%	7.05%	96.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin and TRAIL combination regimen is also the most effective treatment for inhibiting the growth of PC3 xenografts compared to curcumin or TRAIL monotherpy. The inhibition of PC3 tumors by combined treatment correlated with significant reduction in expression of p-Akt and NF-kappaB in tumor tissue.
C62137	19192720	DIS0129	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	30 uM: 20 ng.ml	.	.	.	.	30 uM: 20 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	PC-3	39.72%	1.17%	96.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin and TRAIL combination regimen is also the most effective treatment for inhibiting the growth of PC3 xenografts compared to curcumin or TRAIL monotherpy. The inhibition of PC3 tumors by combined treatment correlated with significant reduction in expression of p-Akt and NF-kappaB in tumor tissue.
C76631	19268463	DIS0025	NP8435	Apicidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00048	K-562	.	.	0.5 uM:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	K-562	68.06%	1.47%	1775.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of apicidin and TRAIL may be an effective strategy for treating TRAIL-resistant Bcr-Abl expressing CML cells.
C76631	19268463	DIS0025	NP8435	Apicidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00048	K-562	.	.	0.5 uM:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	K-562	0.92%	0.85%	2523.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of apicidin and TRAIL may be an effective strategy for treating TRAIL-resistant Bcr-Abl expressing CML cells.
C76631	19268463	DIS0025	NP8435	Apicidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00048	K-562	.	.	0.5 uM:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	PI3K	Down-regulation	K-562	90.96%	17.38%	94.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of apicidin and TRAIL may be an effective strategy for treating TRAIL-resistant Bcr-Abl expressing CML cells.
C76631	19268463	DIS0025	NP8435	Apicidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00048	K-562	.	.	0.5 uM:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	K-562	32.53%	3.40%	90.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of apicidin and TRAIL may be an effective strategy for treating TRAIL-resistant Bcr-Abl expressing CML cells.
C76631	19268463	DIS0025	NP8435	Apicidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00048	K-562	.	.	0.5 uM:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0223	Bcr-Abl	Down-regulation	K-562	84.22%	2.26%	91.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of apicidin and TRAIL may be an effective strategy for treating TRAIL-resistant Bcr-Abl expressing CML cells.
C76631	19268463	DIS0025	NP8435	Apicidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00048	K-562	.	.	0.5 uM:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	K-562	65.50%	4.13%	85.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of apicidin and TRAIL may be an effective strategy for treating TRAIL-resistant Bcr-Abl expressing CML cells.
C79594	19329312	DIS0031	NP8924	Alpha linolenic acid	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	8.3u± u0.2uM	.	NEWCL00049	MDA-MB-231	10.2 ±  0.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The DOX- LNA conjugate showed substantially higher tumor-specific cytotoxicity compared with DOX.
C06799	19383353	DIS0094	NP6905	Curcumin	DR8611	Bortezomib	NEWCL00286	U266B1	.	.	5 uM:1 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	U266	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin potentiates the therapeutic efficacy of bortezomib in multiple myeloma. Combined of curcumin with bortezomib inhibited IL-6/sIL-6R-induced STAT3 and Erk phosphorylation.
C20416	19429088	DIS0029	NP4127	Daidzein	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00122	LN-229	.	.	100uM:100ng.ml	NEWCL00124	NCH89	.	.	100uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	LN-229	33.33%	46.67%	566.67%	NCH89	0.00%	0.00%	9900.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2."
C20416	19429088	DIS0029	NP4127	Daidzein	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00122	LN-229	.	.	100uM:100ng.ml	NEWCL00124	NCH89	.	.	100uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	LN-229	0.00%	600.00%	9900.00%	NCH89	100.00%	2400.00%	9900.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2."
C20416	19429088	DIS0029	NP4127	Daidzein	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00122	LN-229	.	.	100uM:100ng.ml	NEWCL00124	NCH89	.	.	100uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	LN-229	0.00%	700.00%	9900.00%	NCH89	0.00%	0.00%	9900.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2."
C20416	19429088	DIS0029	NP4127	Daidzein	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00122	LN-229	.	.	100uM:100ng.ml	NEWCL00124	NCH89	.	.	100uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C-FLIP	Up-regulation	LN-229	7.00%	9.00%	2.00%	NCH89	0.00%	5.00%	10.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2."
C20416	19429088	DIS0029	NP4127	Daidzein	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00122	LN-229	.	.	100uM:100ng.ml	NEWCL00124	NCH89	.	.	100uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Up-regulation	LN-229	5.00%	0.00%	4.00%	NCH89	4.00%	4.00%	6.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2."
C20416	19429088	DIS0029	NP4127	Daidzein	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00122	LN-229	.	.	100uM:100ng.ml	NEWCL00124	NCH89	.	.	100uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Up-regulation	LN-229	7.00%	10.00%	4.00%	NCH89	11.00%	0.00%	-60.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2."
C20416	19429088	DIS0029	NP4127	Daidzein	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00122	LN-229	.	.	100uM:100ng.ml	NEWCL00124	NCH89	.	.	100uM:20ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	LN-229	70.00%	0.00%	75.00%	NCH89	99.00%	4.00%	99.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2."
C42547	19438509	DIS0129	NP5233	Wogonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	5.10.25uM:50 ng.mL	NEWCL00253	PC-3	.	.	.	NEWCL00251	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	LNCaP	1.55%	21.10%	29.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Wogonin enhances TRAIL-induced cytotoxicity through up-regulation of p53 and Puma, mediated by ROS."
C42547	19438509	DIS0129	NP5233	Wogonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	5.10.25uM:50 ng.mL	NEWCL00253	PC-3	.	.	.	NEWCL00251	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	LNCaP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Wogonin enhances TRAIL-induced cytotoxicity through up-regulation of p53 and Puma, mediated by ROS."
C42547	19438509	DIS0129	NP5233	Wogonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	5.10.25uM:50 ng.mL	NEWCL00253	PC-3	.	.	.	NEWCL00251	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	LNCaP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Wogonin enhances TRAIL-induced cytotoxicity through up-regulation of p53 and Puma, mediated by ROS."
C42547	19438509	DIS0129	NP5233	Wogonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	5.10.25uM:50 ng.mL	NEWCL00253	PC-3	.	.	.	NEWCL00251	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	LNCaP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Wogonin enhances TRAIL-induced cytotoxicity through up-regulation of p53 and Puma, mediated by ROS."
C42547	19438509	DIS0129	NP5233	Wogonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	5.10.25uM:50 ng.mL	NEWCL00253	PC-3	.	.	.	NEWCL00251	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	LNCaP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Wogonin enhances TRAIL-induced cytotoxicity through up-regulation of p53 and Puma, mediated by ROS."
C83616	19470788	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00168	Tu 686	.	.	30 uM:0.5 uM	NEWCL00128	Tu 212	.	.	30 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	Tu 686	227.97%	251.35%	239.55%	Tu 212	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Erlotinib treatment activates p53, which plays a critical role in synergistic growth inhibition by erlotinib and EGCG via inhibiting nuclear factor-kappaB signaling pathway."
C83616	19470788	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00168	Tu 686	.	.	30 uM:0.5 uM	NEWCL00128	Tu 212	.	.	30 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Up-regulation	Tu 686	956.42%	1167.77%	1007.39%	Tu 212	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Erlotinib treatment activates p53, which plays a critical role in synergistic growth inhibition by erlotinib and EGCG via inhibiting nuclear factor-kappaB signaling pathway."
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	250uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SK-N-BE(2)	8.83%	7.45%	11.54%	SH-SY5Y	18.97%	1.56%	50.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	250uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	SK-N-BE(2)	47.06%	3.48%	67.30%	SH-SY5Y	7.04%	3.52%	43.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	SK-N-BE(2)	26.07%	14.20%	34.19%	SH-SY5Y	72.17%	43.83%	96.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Smac	Up-regulation	SK-N-BE(2)	101.28%	113.02%	350.28%	SH-SY5Y	214.66%	18.44%	339.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AIF	Up-regulation	SK-N-BE(2)	87.00%	53.35%	110.71%	SH-SY5Y	13.64%	32.68%	154.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	N-Myc	Down-regulation	SK-N-BE(2)	16.48%	12.53%	32.36%	SH-SY5Y	58.37%	35.29%	77.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	survivin	Down-regulation	SK-N-BE(2)	58.64%	6.96%	68.25%	SH-SY5Y	80.90%	70.36%	88.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	SK-N-BE(2)	130.97%	184.39%	213.70%	SH-SY5Y	87.39%	13.25%	309.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	TBid	Up-regulation	SK-N-BE(2)	140.56%	73.49%	628.48%	SH-SY5Y	5.72%	1.97%	3.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	calpain	Up-regulation	SK-N-BE(2)	238.74%	29.06%	408.42%	SH-SY5Y	57.38%	21.68%	270.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	caspase-3	Up-regulation	SK-N-BE(2)	91.55%	41.29%	106.08%	SH-SY5Y	241.11%	31.19%	348.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C31558	19505441	DIS0018	NP9279	Genistein	DR9868	HA14-1	NEWCL00213	SK-N-BE(2)	.	.	250uM:10uM	NEWCL00215	SH-SY5Y	.	.	100uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SBDP	Up-regulation	SK-N-BE(2)	77.27%	72.10%	120.10%	SH-SY5Y	18.87%	10.76%	65.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
C46103	19513519	DIS0022	NP7102	Elemene	DR1669	Cisplatin	NEWCL00180	NCI-H460	24h:40uM;  48h:16uM; 72h:9 uM	.	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL00170	A-549	 24h:76uM;  48h:34uM ;  72h:16 uM ;  	.	24h.48h; 30 ug.ml:2 or 4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	NCI-H460	26.27%	71.45%	345.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	19513519	DIS0022	NP7102	Elemene	DR1669	Cisplatin	NEWCL00180	NCI-H460	24h:40uM;  48h:16uM; 72h:9 uM	.	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL00170	A-549	 24h:76uM;  48h:34uM ;  72h:16 uM ;  	.	24h.48h; 30 ug.ml:2 or 4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Up-regulation	NCI-H460	70.24%	61.04%	622.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	19513519	DIS0022	NP7102	Elemene	DR1669	Cisplatin	NEWCL00180	NCI-H460	24h:40uM;  48h:16uM; 72h:9 uM	.	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL00170	A-549	 24h:76uM;  48h:34uM ;  72h:16 uM ;  	.	24h.48h; 30 ug.ml:2 or 4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	NCI-H460	92.98%	103.41%	566.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	19513519	DIS0022	NP7102	Elemene	DR1669	Cisplatin	NEWCL00180	NCI-H460	24h:40uM;  48h:16uM; 72h:9 uM	.	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL00170	A-549	 24h:76uM;  48h:34uM ;  72h:16 uM ;  	.	24h.48h; 30 ug.ml:2 or 4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-H460	5.61%	62.41%	279.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C24892	19583730	DIS0131	NP4705	Dicoumarol	DR4469	Doxorubicin	NEWCL10073	RT-112	.	.	100 um:1um	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	RT-112	11.07%	350.01%	23.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.
C24892	19583730	DIS0131	NP4705	Dicoumarol	DR4469	Doxorubicin	NEWCL10073	RT-112	.	.	100 um:1um	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	RT-112	1.90%	0.81%	576.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.
C24892	19583730	DIS0131	NP4705	Dicoumarol	DR4469	Doxorubicin	NEWCL10073	RT-112	.	.	100 um:1um	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Up-regulation	RT-112	2.52%	1.46%	396.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.
C24892	19583730	DIS0131	NP4705	Dicoumarol	DR4469	Doxorubicin	NEWCL10073	RT-112	.	.	100 um:1um	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	RT-112	11.07%	492.39%	512.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.
C45042	19585117	DIS0031	NP8829	Oroxylin A	DR9021	5-fluorouracil	NEWCL00129	Hep-G2	48h:39.79± 2.84uM	48h:792.15± 14.65uM	50uM:750uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	Hep-G2	60.39%	0.88%	156.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU and oroxylin A combinations were synergistic and oroxylin A increased the sensitivity of HepG2 cells to 5-FU by modulating the metabolic enzymes of 5-FU and apoptotic-related proteins.
C45042	19585117	DIS0031	NP8829	Oroxylin A	DR9021	5-fluorouracil	NEWCL00129	Hep-G2	48h:39.79± 2.84uM	48h:792.15± 14.65uM	50uM:750uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Hep-G2	22.80%	1.66%	61.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU and oroxylin A combinations were synergistic and oroxylin A increased the sensitivity of HepG2 cells to 5-FU by modulating the metabolic enzymes of 5-FU and apoptotic-related proteins.
C45042	19585117	DIS0031	NP8829	Oroxylin A	DR9021	5-fluorouracil	NEWCL00129	Hep-G2	48h:39.79± 2.84uM	48h:792.15± 14.65uM	50uM:750uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Hep-G2	653.07%	527.51%	744.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU and oroxylin A combinations were synergistic and oroxylin A increased the sensitivity of HepG2 cells to 5-FU by modulating the metabolic enzymes of 5-FU and apoptotic-related proteins.
C45042	19585117	DIS0031	NP8829	Oroxylin A	DR9021	5-fluorouracil	NEWCL00129	Hep-G2	48h:39.79± 2.84uM	48h:792.15± 14.65uM	50uM:750uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	Hep-G2	0.94%	40.71%	44.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU and oroxylin A combinations were synergistic and oroxylin A increased the sensitivity of HepG2 cells to 5-FU by modulating the metabolic enzymes of 5-FU and apoptotic-related proteins.
C45042	19585117	DIS0031	NP8829	Oroxylin A	DR9021	5-fluorouracil	NEWCL00129	Hep-G2	48h:39.79 ±  2.84	48h:792.61 ±  14.65 uM	50 uM:750 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	Hep-G2	33.36%	67.23%	72.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU and oroxylin A combinations were synergistic and oroxylin A increased the sensitivity of HepG2 cells to 5-FU by modulating the metabolic enzymes of 5-FU and apoptotic-related proteins.
C45042	19585117	DIS0031	NP8829	Oroxylin A	DR9021	5-fluorouracil	NEWCL00129	Hep-G2	48h:39.79 ±  2.84	48h:792.61 ±  14.65 uM	50 uM:750 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Hep-G2	0.23%	2.51%	51.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU and oroxylin A combinations were synergistic and oroxylin A increased the sensitivity of HepG2 cells to 5-FU by modulating the metabolic enzymes of 5-FU and apoptotic-related proteins.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	HCT 116 tumor	88.90%	8.30%	93.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	HCT 116 tumor	65.27%	32.19%	70.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HCT 116 tumor	2.99%	1.52%	29.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	HCT 116 tumor	2.56%	0.14%	41.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7003	ICAM-1	Down-regulation	HCT 116 tumor	42.61%	45.60%	67.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	HCT 116 tumor	55.57%	0.94%	50.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2971	CXCR4	Down-regulation	HCT 116 tumor	52.08%	0.24%	70.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	HCT 116 tumor	22.93%	7.14%	25.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	IAP-1	Down-regulation	HCT 116 tumor	1.17%	2.89%	70.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	HCT 116 tumor	1.14%	2.43%	84.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	HCT 116 tumor	7.71%	0.80%	46.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C28149	19623659	DIS0115	NP6905	Curcumin	DR8297	Capecitabine	NEWCL20352	HCT 116 tumor	.	.	1mg.kg:60mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116 tumor	0.73%	0.99%	7.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.
C79198	19626588	DIS0114	NP8625	Gamma tocotrienol	DR3599_DR2742	Atorvastatin	NEWCL00344	HT29	30uM	30uM	.	NEWCL00082	HCT 116	17.5uM	17.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	HT29	31.22%	124.94%	180.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Atorvastatin with gamma-tocotrienol and celecoxib exhibited a strong synergy against human colon cancer cells in causing cell cycle arrest and apoptosis.
C79198	19626588	DIS0114	NP8625	Gamma tocotrienol	DR3599_DR2742	 Celecoxib	NEWCL00344	HT29	30uM	30uM	.	NEWCL00082	HCT 116	17.5uM	17.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	HT29	31.22%	103.36%	271.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Atorvastatin with gamma-tocotrienol and celecoxib exhibited a strong synergy against human colon cancer cells in causing cell cycle arrest and apoptosis.
C90715	19661313	DIS0114	NP1886	Scutellarin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	100 uM:500 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3834	Cleaved-caspase-6	Up-regulation	HCT 116P53	73.60%	101402.98%	567933.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Scutellarin sensitizes 5FU-evoked colon cancer cell apoptosis through enhanced caspase-6 activation.
C90715	19661313	DIS0114	NP1886	Scutellarin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	100 uM:500 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cleaved-lamin-A	Up-regulation	HCT 116P53	15.74%	104154.19%	319399.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Scutellarin sensitizes 5FU-evoked colon cancer cell apoptosis through enhanced caspase-6 activation.
C58370	19664237	DIS0022	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL00170	A-549	.	.	2.5 uM:3 ug.ml	NEWCL00180	NCI-H460	.	.	2.5 uM:3 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	12.01%	66.60%	73.59%	NCI-H460	10.05%	55.94%	42.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
C58370	19664237	DIS0022	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL00170	A-549	.	.	2.5 uM:3 ug.ml	NEWCL00180	NCI-H460	.	.	2.5 uM:3 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Clusterin	Down-regulation	A-549	5.75%	36.39%	45.66%	NCI-H460	27.81%	63.13%	86.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
C58370	19664237	DIS0022	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL00170	A-549	.	.	2.5 uM:3 ug.ml	NEWCL00180	NCI-H460	.	.	2.5 uM:3 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	A-549	7.24%	19.85%	12.63%	NCI-H460	5.42%	13.53%	22.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
C58370	19664237	DIS0022	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL00170	A-549	.	.	2.5 uM:3 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	15.78%	62.47%	72.81%	NCI-H460	5.56%	39.03%	57.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
C58370	19664237	DIS0022	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL00170	A-549	.	.	2.5 uM:3 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	1.29%	1.16%	7.34%	NCI-H460	136.19%	304.07%	348.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
C58370	19664237	DIS0022	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL00170	A-549	.	.	2.5 uM:3 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Clusterin	Down-regulation	A-549	0.75%	30.41%	7107.99%	NCI-H460	50.40%	63.34%	84.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
C58370	19664237	DIS0022	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL00170	A-549	.	.	2.5 uM:3 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	A-549	9.42%	3.46%	10.30%	NCI-H460	382.95%	325.01%	402.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	SK-N-DZ	2.55%	0.02%	13.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	EGFR	Down-regulation	SK-N-DZ	38.67%	8.37%	50.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	SK-N-DZ	6.18%	3.95%	46.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SK-N-DZ	73.85%	36.30%	39.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SK-N-DZ	51.62%	62.55%	72.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	SK-N-DZ	5.62%	10.23%	3.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	SK-N-DZ	53.61%	40.82%	54.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Calpain	Up-regulation	SK-N-DZ	7.88%	16.79%	20.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SBDP(145kD)	Up-regulation	SK-N-DZ	93.23%	62.90%	62.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C29751	19695221	DIS0018	NP4620	Apigenin	DR9868	HA14-1	NEWCL00220	SK-N-DZ	.	.	2.5 uM: 100 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SBDP(120kD)	Up-regulation	SK-N-DZ	83.75%	6.34%	83.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
C37903	19716895	DIS0129	NP6128	Gossypol	DR0261	Zoledronic	NEWCL00251	DU145	.	.	5 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	GP significantly enhances the anti-tumor activity of ZA in hormone- and drug-resistant prostate cancer cells by targeting many pivotal apoptosis-related proteins.
C85406	19720557	DIS0036	NP4240	Esculetin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00360	SAS	.	.	5 ug.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Esculetin enhances TRAIL-induced apoptosis primarily through upregulation of DR5.
C58370	19769630	DIS0124	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL20375	COC1	48h:1.89uM; 72h:1.48uM; 96h:0.92uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells.
C16256	19885610	DIS0021	NP4620	Apigenin	DR9021	5-fluorouracil	NEWCL00051	MDA-MB-453	24h:59.45uM; 48h:59.71; 72h:35.15;	24h:91.04mM;  48h:93.34uM; 72h: 91.39;	5.10.50.100uM:90uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Erbp2	Down-regulation	MDA-MB-453	28.79%	43.67%	78.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	5-fluorouracil acts synergistically with apigenin inhibiting cell growth and inducing apoptosis via the down-regulation of ErbB2 expression and Akt signaling.
C16256	19885610	DIS0021	NP4620	Apigenin	DR9021	5-fluorouracil	NEWCL00051	MDA-MB-453	24h:59.45uM; 48h:59.71uM; 72h:35.15uM;	24h:91.04mM;  48h:93.34uM; 72h: 91.39;	5.10.50.100uM:90uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MDA-MB-453	3.92%	30.60%	48.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	5-fluorouracil acts synergistically with apigenin inhibiting cell growth and inducing apoptosis via the down-regulation of ErbB2 expression and Akt signaling.
C59960	19892808	DIS0129	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	48h 50 ug mL:100 ng mLu1	NEWCL00251	DU145	.	.	48h 50 ug mL:100 ng mLu1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C17041	19903580	DIS0115	NP4621	PG490	DR9021	5-fluorouracil	NEWCL10080	NCI-H630	 72h:1.39nM	.	25nM:25uM	NEWCL00082	HCT 116	72h:5.51nM	.	25nM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP1	Up-regulation	HCT 116	14.57%	637.80%	1082.98%	NCI-H630	36.00%	0.86%	117.73%	PKO	208.09%	3502.60%	3161.82%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	PG490 strongly enhanced the cytotoxicity of 5-FU. PG490 also simultaneously induced ROS and inhibited NF-KappaB activity and significantly enhanced the cytotoxic effect of 5-FU in three CRC cell lines in vitro.
C17041	19903580	DIS0115	NP4621	PG490	DR9021	5-fluorouracil	NEWCL10080	NCI-H630	 72h:1.39nM	.	25nM:25uM	NEWCL00082	HCT 116	72h:5.51nM	.	25nM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HCT 116	2233.33%	231.75%	4591.49%	NCI-H630	48.60%	0.47%	2272.38%	PKO	532.69%	1606.04%	19.48%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	PG490 strongly enhanced the cytotoxicity of 5-FU. PG490 also simultaneously induced ROS and inhibited NF-KappaB activity and significantly enhanced the cytotoxic effect of 5-FU in three CRC cell lines in vitro.
C17041	19903580	DIS0115	NP4621	PG490	DR9021	5-fluorouracil	NEWCL10080	NCI-H630	 72h:1.39nM	.	25nM:25uM	NEWCL00082	HCT 116	72h:5.51nM	.	25nM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT 116	348.20%	47.40%	329.46%	NCI-H630	88.12%	2.97%	98.15%	PKO	300.91%	37.01%	601.93%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	PG490 strongly enhanced the cytotoxicity of 5-FU. PG490 also simultaneously induced ROS and inhibited NF-KappaB activity and significantly enhanced the cytotoxic effect of 5-FU in three CRC cell lines in vitro.
C17041	19903580	DIS0115	NP4621	PG490	DR9021	5-fluorouracil	NEWCL10080	NCI-H630	 72h:1.39nM	.	25nM:25uM	NEWCL00082	HCT 116	72h:5.51nM	.	25nM:25uM	NEWCL00353	RKO	.	.	25nM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Up-regulation	HCT 116	67.15%	0.71%	51.94%	NCI-H630	27.76%	7.01%	80.95%	RKO	56.29%	85.69%	90.48%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	PG490 strongly enhanced the cytotoxicity of 5-FU. PG490 also simultaneously induced ROS and inhibited NF-KappaB activity and significantly enhanced the cytotoxic effect of 5-FU in three CRC cell lines in vitro.
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MIA PaCa-2 tumor	2.62%	1.52%	18.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	MIA PaCa-2 tumor	0.15%	0.98%	51.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	MIA PaCa-2 tumor	33.66%	11.82%	24.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	MIA PaCa-2 tumor	14.18%	11.01%	14.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	MIA PaCa-2 tumor	9.97%	7.60%	41.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	MIA PaCa-2 tumor	4.93%	29.20%	35.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	MIA PaCa-2 tumor	44.77%	41.21%	46.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	MIA PaCa-2 tumor	31.86%	31.05%	29.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7003	ICAM-1	Down-regulation	MIA PaCa-2 tumor	36.34%	32.04%	25.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	MIA PaCa-2 tumor	15.85%	19.46%	11.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2971	CXCR4	Down-regulation	MIA PaCa-2 tumor	3.70%	6.88%	17.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C52131	19908231	DIS0023	NP6084	Resveratrol	DR2391	Gemcitabine	NEWCL20351	MIA PaCa-2 tumor	.	.	40mg.kg:25mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	MIA PaCa-2 tumor	12.62%	30.58%	28.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3	Up-regulation	HT-29	6.06%	17.51%	18.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HT-29	4.93%	6.05%	168.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HT-29	0.16%	2.86%	115.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	HT-29	1.28%	0.64%	83.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	HT-29	29.89%	20.78%	69.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	HT-29	19.77%	9.55%	63.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	HT-29	0.73%	0.24%	66.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	HT-29	19.57%	0.43%	43.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Down-regulation	HT-29	5.40%	3.78%	34.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C33955	19909554	DIS0114	NP9279	Genistein	DR6637	Indole-3-carbinol	NEWCL00077	HT-29	.	.	300uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3	Up-regulation	HT-29	11.23%	25.88%	47.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.
C91220	19916747	DIS0124	NP8797	Celastrol	DR4267	TRAILApo2L 	NEWCL00135	OVCAR-8	17.7ng.ml	46.4ng.ml	10 uM:160 ng.ml	NEWCL00076	SW620	121.1ng.ml	423.5ng.ml	10 uM:160 ng.ml	NEWCL00302	PLA-801D	31.1ng.ml	250.5ng.ml	10 uM:160 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	OVCAR-8	9.74%	359.21%	292.61%	SW620	126.84%	67.96%	699.49%	95-D	4.41%	13.65%	27.84%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic anticancer capabilities achieved by combining TRAIL/APO-2L and celastrol.
C91220	19916747	DIS0124	NP8797	Celastrol	DR4267	TRAILApo2L 	NEWCL00135	OVCAR-8	17.7ng.ml	46.4ng.ml	10 uM:160 ng.ml	NEWCL00076	SW620	121.1ng.ml	423.5ng.ml	10 uM:160 ng.ml	NEWCL00302	PLA-801D	31.1ng.ml	250.5ng.ml	10 uM:160 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	OVCAR-8	13.93%	241.67%	220.51%	SW620	85.49%	106.37%	344.69%	95-D	6.69%	22.86%	151.83%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic anticancer capabilities achieved by combining TRAIL/APO-2L and celastrol.
C91220	19916747	DIS0124	NP8797	Celastrol	DR4267	TRAILApo2L 	NEWCL00135	OVCAR-8	17.7ng.ml	46.4ng.ml	10 uM:160 ng.ml	NEWCL00076	SW620	121.1ng.ml	423.5ng.ml	10 uM:160 ng.ml	NEWCL00302	PLA-801D	31.1ng.ml	250.5ng.ml	10 uM:160 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	OVCAR-8	4.36%	16.47%	121.71%	SW620	.	.	.	95-D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic anticancer capabilities achieved by combining TRAIL/APO-2L and celastrol.
C30154	19934274	DIS0122	NP8797	Celastrol	DR6516	Temozolomide	NEWCL00190	SK-MEL-173	.	.	0.25 umol.L:20 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SK-MEL-173	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Celastrol treatment increased the levels of ubiquitinated proteins, reduced the levels of tumor necrosis factor-alpha-induced IkappaB phosphorylation, and blocked NF-kappaB translocation to the nucleus."
C03328	19939880	DIS0029	NP6740	Capsaicin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	200 uM:100 ng.ml	NEWCL00312	U-343MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
C25024	19954924	DIS0021	NP8625	Gamma tocotrienol	DR2742	Celecoxib	NEWCL20376	neoplastic +SA mammary epithelial	.	8.6 uM	0.25 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P-P65	Down-regulation	U2OS	7.71%	13.65%	29.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined low dose treatment of Gamma-tocotrienol and celecoxibthe showed synergistic antiproliferative effects of against +SA mammary tumor cells in culture.
C25024	19954924	DIS0021	NP8625	Gamma tocotrienol	DR2742	Celecoxib	NEWCL20376	neoplastic +SA mammary epithelial	.	8.6 uM	0.25 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9759	COX-1	Down-regulation	neoplastic +SA mammary epithelial	10.85%	3.04%	43.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined low dose treatment of Gamma-tocotrienol and celecoxibthe showed synergistic antiproliferative effects of against +SA mammary tumor cells in culture.
C25024	19954924	DIS0021	NP8625	Gamma tocotrienol	DR2742	Celecoxib	NEWCL20376	neoplastic +SA mammary epithelial	.	8.6 uM	0.25 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	neoplastic +SA mammary epithelial	10.87%	14.91%	60.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined low dose treatment of Gamma-tocotrienol and celecoxibthe showed synergistic antiproliferative effects of against +SA mammary tumor cells in culture.
C25024	19954924	DIS0021	NP8625	Gamma tocotrienol	DR2742	Celecoxib	NEWCL20376	neoplastic +SA mammary epithelial	.	8.6 uM	0.25 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	neoplastic +SA mammary epithelial	3.12%	4.07%	37.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined low dose treatment of Gamma-tocotrienol and celecoxibthe showed synergistic antiproliferative effects of against +SA mammary tumor cells in culture.
C36985	20011976	DIS0094	NP2960	Epigallocatechin gallate	DR8611	Bortezomib	NEWCL00061	KM-3	.	.	25.50 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	KM-3	4.64%	17.45%	50.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined EGCG and bortezomib showed synergistic anticancer effect partly via regulating NF-kappaB pathway.
C36985	20011976	DIS0094	NP2960	Epigallocatechin gallate	DR8611	Bortezomib	NEWCL00061	KM-3	.	.	25.50 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P-p65	Up-regulation	KM-3	19.37%	71.59%	256.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined EGCG and bortezomib showed synergistic anticancer effect partly via regulating NF-kappaB pathway.
C36985	20011976	DIS0094	NP2960	Epigallocatechin gallate	DR8611	Bortezomib	NEWCL00061	KM-3	.	.	25.50 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IkBa	Up-regulation	KM-3	10.61%	58.38%	2.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined EGCG and bortezomib showed synergistic anticancer effect partly via regulating NF-kappaB pathway.
C36985	20011976	DIS0094	NP2960	Epigallocatechin gallate	DR8611	Bortezomib	NEWCL00061	KM-3	.	.	25.50 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	KM-3	0.85%	3.93%	10.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined EGCG and bortezomib showed synergistic anticancer effect partly via regulating NF-kappaB pathway.
C36985	20011976	DIS0094	NP2960	Epigallocatechin gallate	DR8611	Bortezomib	NEWCL00061	KM-3	.	.	25.50 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	KM-3	3.62%	95.35%	43.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined EGCG and bortezomib showed synergistic anticancer effect partly via regulating NF-kappaB pathway.
C36985	20011976	DIS0094	NP2960	Epigallocatechin gallate	DR8611	Bortezomib	NEWCL00061	KM-3	.	.	25.50 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	KM-3	5.20%	3.31%	198.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined EGCG and bortezomib showed synergistic anticancer effect partly via regulating NF-kappaB pathway.
C54915	20013316	DIS0023	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00236	MIA PaCa-2	.	.	20nM:1.25ng.ml	NEWCL20441	S2-013	.	.	20nM:1.25ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MIA PaCa-2	9.45%	9.79%	196.07%	S2-VP10	39.78%	1.90%	166.67%	S2-013	106.49%	4.57%	92.75%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Combined therapy with triptolide and TRAIL significantly decreased the cell viability in all the cell lines and increased apoptotic cell death as a result of caspase-3 and caspase-9 activation.
C28720	20037825	DIS0122	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00036	A-375	.	150 ng.mL	10.20 ug.mL:25ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line.
C79000	20106644	DIS0031	NP4245	Beta aescin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:65.7± 2.5ug.ml	48h:21.1± 1.2ug.ml	21.6ug.ml:5.4ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SMMC - 7721	46.43%	64.98%	68.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Mixtures of beta-aescin and 5-FU showed a synergistic effect on the 50% inhibitory effect when their ratio was 4:1 when compared with either agent alone.
C09745	20196146	DIS0105	NP1309	Cinchonine	DR2875_DR8051	Hydrocinchonine + Quinidine	NEWCL00276	MES-SA	17.8731± 1.1963nM	18.5943± 1.2825nM; 	19.0776± 0.9987nM	NEWCL20442	MES-SA.DX5 	201.8033±  5.8571	632.6404± 8.5260nM; 	80.5603± 5.0556nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Hydrocinchonine exerted MDR reversal activity and synergistic apoptotic effect with TAX in MES-SA/DX5 cells almost comparable with quinidine and cinchonine as a potent MDR-reversal and combined therapy agent with TAX.
C28144	20206141	DIS0015	NP5424	Flavopiridol	DR9185	"Pyrrolo-1,5-benzoxazepine"	NEWCL00048	K-562	.	.	500 nM:5 uM	NEWCL00068	LAMA-84	.	.	500 nM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	K-562	.	.	.	LAMA-84	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells."
C67056	20232120	DIS0122	NP2960	Epigallocatechin gallate	DR2632	Vorinostat	NEWCL00036	A-375	.	.	10 ug.mL:1 uM	NEWCL00194	G-361	.	.	10 ug.mL:1 uM	NEWCL00193	Hs 294T	.	.	10 ug.mL:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-375	3.44%	64.61%	63.77%	G-361	0.11%	11.79%	37.85%	Hs-294T	15.24%	150.15%	332.14%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."
C67056	20232120	DIS0122	NP2960	Epigallocatechin gallate	DR2632	Vorinostat	NEWCL00036	A-375	.	.	10 ug.mL:1 uM	NEWCL00194	G-361	.	.	10 ug.mL:1 uM	NEWCL00193	Hs 294T	.	.	10 ug.mL:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	A-375	13.20%	18.05%	20.82%	G-361	30.75%	49.57%	76.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."
C67056	20232120	DIS0122	NP2960	Epigallocatechin gallate	DR2632	Vorinostat	NEWCL00036	A-375	.	.	10 ug.mL:1 uM	NEWCL00194	G-361	.	.	10 ug.mL:1 uM	NEWCL00193	Hs 294T	.	.	10 ug.mL:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Down-regulation	A-375	16.82%	19.05%	39.22%	G-361	28.55%	41.28%	47.50%	Hs-294T	10.55%	60.33%	66.89%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."
C67056	20232120	DIS0122	NP2960	Epigallocatechin gallate	DR2632	Vorinostat	NEWCL00036	A-375	.	.	10 ug.mL:1 uM	NEWCL00194	G-361	.	.	10 ug.mL:1 uM	NEWCL00193	Hs 294T	.	.	10 ug.mL:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	A-375	28.13%	57.95%	97.22%	G-361	101.74%	142.91%	327.63%	Hs-294T	3.23%	48.03%	99.39%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."
C67056	20232120	DIS0122	NP2960	Epigallocatechin gallate	DR2632	Vorinostat	NEWCL00036	A-375	.	.	10 ug.mL:1 uM	NEWCL00194	G-361	.	.	10 ug.mL:1 uM	NEWCL00193	Hs 294T	.	.	10 ug.mL:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	A-375	1.33%	9.92%	25.78%	G-361	21.04%	62.60%	100.54%	Hs-294T	34.64%	92.22%	143.27%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."
C67056	20232120	DIS0122	NP2960	Epigallocatechin gallate	DR2632	Vorinostat	NEWCL00036	A-375	.	.	10 ug.mL:1 uM	NEWCL00194	G-361	.	.	10 ug.mL:1 uM	NEWCL00193	Hs 294T	.	.	10 ug.mL:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-375	9.38%	23.21%	27.32%	G-361	1.65%	3.93%	0.17%	Hs-294T	1.58%	2.08%	2.60%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."
C67056	20232120	DIS0122	NP2960	Epigallocatechin gallate	DR2632	Vorinostat	NEWCL00036	A-375	.	.	10 ug.mL:1 uM	NEWCL00194	G-361	.	.	10 ug.mL:1 uM	NEWCL00193	Hs 294T	.	.	10 ug.mL:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	A-375	11.59%	18.72%	36.52%	G-361	5.62%	7.67%	23.31%	Hs-294T	8.01%	6.81%	37.69%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."
C56350	20459793	DIS0124	NP4440	Kaempferol	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	20 uM:40 .80uM; 2h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc.
C32605	20473900	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00082	HCT 116	.	.	1 uM:1 0uM	NEWCL00344	HT29	.	.	1 uM:1 0uM	NEWCL00082	HCT 116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5260	SRC	Down-regulation	SW620	0.23%	5.41%	7.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
C32605	20473900	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00076	SW620	.	.	1 uM:1 0uM	.	.	.	.	1 uM:1 0uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9202	P-IGF1R	Down-regulation	SW620	10.18%	17.90%	30.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
C32605	20473900	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00076	SW620	.	.	1 uM:1 0uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HER3	Down-regulation	SW620	18.68%	25.92%	37.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
C32605	20473900	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00076	SW620	.	.	1 uM:1 0uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HER2	Down-regulation	SW620	9.83%	62.38%	68.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
C32605	20473900	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00076	SW620	.	.	1 uM:1 0uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	EGFR	Down-regulation	SW620	12.31%	39.07%	53.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
C32605	20473900	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00076	SW620	.	.	1 uM:1 0uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	SW620	30.25%	72.68%	86.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
C32605	20473900	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00076	SW620	.	.	1 uM:1 0uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	SW620	14.26%	43.49%	75.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
C32605	20473900	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00076	SW620	.	.	1 uM:1 0uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	SW620	61.01%	71.43%	81.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
C32605	20473900	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00076	SW620	.	.	1 uM:1 0uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	SW620	15.15%	28.08%	9.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
C89196	20480521	DIS0031	NP4705	Dicoumarol	DR2391	Gemcitabine	NEWCL10046	KKU-100	0.15 ±  0.07uM	.	10 uM:1 nM	NEWCL10007	KKU-213B	0.24 ±  0.14uM	.	10 uM:1 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	KKU-100	10.61%	6.11%	3.39%	KKU-M214	7.07%	2.01%	5.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	NQO1 may be important in sensitizing cells to anticancer drugs and inhibition of NQO1 may be a strategy for the treatment of CCA.
C89196	20480521	DIS0031	NP4705	Dicoumarol	DR2391	Gemcitabine	NEWCL10046	KKU-100	0.15 ±  0.07uM	.	10 uM:1 nM	NEWCL10007	KKU-213B	0.24 ±  0.14uM	.	10 uM:1 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Down-regulation	KKU-100	26.53%	0.05%	15.07%	KKU-M214	18.37%	12.05%	16.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	NQO1 may be important in sensitizing cells to anticancer drugs and inhibition of NQO1 may be a strategy for the treatment of CCA.
C23300	20540768	DIS0122	NP1168	Quercetin	DR6516	Temozolomide	NEWCL00006	DB-1	.	.	75 uM:400 uM	NEWCL00086	SK-Mel-28	.	.	75 uM:400 uM	NEWCL00089	SK-Mel-5	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4172	P-ATM	Up-regulation	DB-1	10.65%	304.06%	202.66%	SK-Mel-28	288.96%	289.74%	275.98%	SK-Mel-5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR6516	Temozolomide	NEWCL00006	DB-1	.	.	75 uM:400 uM	NEWCL00086	SK-Mel-28	.	.	75 uM:400 uM	NEWCL00089	SK-Mel-5	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DNApk	Up-regulation	DB-1	195.18%	494.43%	401.70%	SK-Mel-28	243.02%	201.16%	121.93%	SK-Mel-5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR6516	Temozolomide	NEWCL00006	DB-1	.	.	75 uM:400 uM	NEWCL00086	SK-Mel-28	.	.	75 uM:400 uM	NEWCL00089	SK-Mel-5	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53(S-37)	Up-regulation	DB-1	8.45%	12.02%	118.08%	SK-Mel-28	.	.	.	SK-Mel-5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR6516	Temozolomide	NEWCL00006	DB-1	.	.	75 uM:400 uM	NEWCL00086	SK-Mel-28	.	.	75 uM:400 uM	NEWCL00089	SK-Mel-5	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53(S-392)	Up-regulation	DB-1	27.65%	258.17%	261.92%	SK-Mel-28	.	.	.	SK-Mel-5	413.52%	787.31%	1034.94%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR6516	Temozolomide	NEWCL00006	DB-1	.	.	75 uM:400 uM	NEWCL00086	SK-Mel-28	.	.	75 uM:400 uM	NEWCL00089	SK-Mel-5	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	DB-1	208.78%	112.40%	564.91%	SK-Mel-28	.	.	.	SK-Mel-5	167.62%	21.61%	259.68%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR6516	Temozolomide	NEWCL00006	DB-1	.	.	75 uM:400 uM	NEWCL00086	SK-Mel-28	.	.	75 uM:400 uM	NEWCL00089	SK-Mel-5	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	DB-1	.	.	.	SK-Mel-28	.	.	.	SK-Mel-5	43.58%	87.22%	515.45%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR0371	temozolomide	NEWCL00086	SK-MEL-28	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4172	P-ATM	Up-regulation	DB-1	1.43%	288.96%	416.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR0371	temozolomide	NEWCL00086	SK-MEL-28	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DNApk	Up-regulation	DB-1	770.61%	855.76%	704.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR0371	temozolomide	NEWCL00086	SK-MEL-28	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53(S-392)	Up-regulation	DB-1	31.20%	261.46%	382.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR0371	temozolomide	NEWCL00086	SK-MEL-28	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53(S-15)	Up-regulation	DB-1	767.68%	1590.52%	1592.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR0371	temozolomide	NEWCL00086	SK-MEL-28	.	.	75 uM:400 uM	NEWCL00006	DB-1	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	DB-1	767.68%	1590.52%	1592.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C23300	20540768	DIS0122	NP1168	Quercetin	DR0371	temozolomide	NEWCL00086	SK-MEL-28	.	.	75 uM:400 uM	NEWCL00006	DB-1	.	.	75 uM:400 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	DB-1	767.68%	1590.52%	1592.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
C02666	20558290	DIS0129	NP1559	Luteolin	DR9742	Gefitinib	NEWCL00253	PC-3	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	EGFR	Up-regulation	PC-3	108.33%	108.33%	142.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase.
C02666	20558290	DIS0129	NP1559	Luteolin	DR9742	Gefitinib	NEWCL00253	PC-3	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C-FOS	Up-regulation	PC-3	7.81%	46.09%	6.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase.
C02666	20558290	DIS0129	NP1559	Luteolin	DR9742	Gefitinib	NEWCL00253	PC-3	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MKK4	Up-regulation	PC-3	27.81%	81.20%	38.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase.
C02666	20558290	DIS0129	NP1559	Luteolin	DR9742	Gefitinib	NEWCL00253	PC-3	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	CDKN1B	Up-regulation	PC-3	66.15%	43.59%	33.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase.
C02666	20558290	DIS0129	NP1559	Luteolin	DR9742	Gefitinib	NEWCL00253	PC-3	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CDC25A	Up-regulation	PC-3	69.75%	83.33%	77.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase.
C02666	20558290	DIS0129	NP1559	Luteolin	DR9742	Gefitinib	NEWCL00253	PC-3	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	17.5 uM:22 uM; 35 uM :44uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5524	CCNA2	Down-regulation	PC-3	75.94%	84.28%	79.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase.
C28471	20582416	DIS0025	NP6308	Thymoquinone	DR4469	Doxorubicin	NEWCL00022	HL-60	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone improved the anti-cancer properties of doxorubicin in a cell line-specific manner.
C02843	20664987	DIS0021	NP2960	Epigallocatechin gallate	DR4213	Raloxifene	NEWCL00049	MDA-MB-231	.	.	25 uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Up-regulation	MDA-MB-231	6.04%	12.42%	33.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of EGCG and raloxifene effectively reduced the mitogenic and survival signaling in MDA-MB-231 cells.
C02843	20664987	DIS0021	NP2960	Epigallocatechin gallate	DR4213	Raloxifene	NEWCL00049	MDA-MB-231	.	.	25 uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	MDA-MB-231	27.28%	37.63%	23.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of EGCG and raloxifene effectively reduced the mitogenic and survival signaling in MDA-MB-231 cells.
C02843	20664987	DIS0021	NP2960	Epigallocatechin gallate	DR4213	Raloxifene	NEWCL00049	MDA-MB-231	.	.	25 uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-p70S6K	Down-regulation	MDA-MB-231	23.70%	9.53%	29.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of EGCG and raloxifene effectively reduced the mitogenic and survival signaling in MDA-MB-231 cells.
C02843	20664987	DIS0021	NP2960	Epigallocatechin gallate	DR4213	Raloxifene	NEWCL00049	MDA-MB-231	.	.	25 uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MDA-MB-231	0.92%	0.15%	2.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of EGCG and raloxifene effectively reduced the mitogenic and survival signaling in MDA-MB-231 cells.
C02843	20664987	DIS0021	NP2960	Epigallocatechin gallate	DR4213	Raloxifene	NEWCL00049	MDA-MB-231	.	.	25 uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Up-regulation	MDA-MB-231	22.04%	86.90%	-36.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of EGCG and raloxifene effectively reduced the mitogenic and survival signaling in MDA-MB-231 cells.
C54915	20691980	DIS0031	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL20374	KMCH	.	.	50 nM:1.25 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	KMCH	144.15%	267.67%	347.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TRAIL and triptolide in combination decreased cell viability and enhanced apoptosis.
C54915	20691980	DIS0031	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL20374	KMCH	.	.	50 nM:1.25 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	KMCH	8.95%	60.11%	76.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TRAIL and triptolide in combination decreased cell viability and enhanced apoptosis.
C42410	21069336	DIS0022	NP8606	Fisetin	DR2176	Cyclophosphamide	NEWCL00298	LL/2 (LLC1)	24h:59± 9uM; 48h:27± 0.3uM	.	.	NEWCL20411	EAhy926	24h:77± 9uM; 48h:28± 0.3uM	.	.	NEWCL10334	3T3-L1	24h:210± 14uM; 48h:136± 13uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	LL/2 (LLC1)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Fisetin not only displays in vitro and in vivo antiangiogenic properties, but also can markedly improve the in vivo antitumour effect of CPA."
C53856	21088503	DIS0021	NP8797	Celastrol	DR6300	Trastuzumab	NEWCL00052	SK-BR-3	24h:0.13± 0.02uM	.	.	NEWCL00160	BT-474	24h:0.16± 0.02uM	.	.	NEWCL20443	21MT-1	24h:0.53± 0.13uM	.	.	NEWCL20455	JIMT-1	24h:0.48± 0.02uM	.	.	NEWCL10081	MCF-7	24h:1.56± 0.24uM	.	.	NEWCL00329	MCF-10A	24h:1.23± 0.47uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	JIMT-1	.	.	.	MCF-7	.	.	.	MCF-10A	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Celastrol strongly synergized with ErbB2-targeted therapeutics Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol."
C53856	21088503	DIS0021	NP8797	Celastrol	DR6077	Lapatinib	NEWCL00052	SK-BR-3	24h:0.13± 0.02uM	.	.	NEWCL00160	BT-474	24h:0.16± 0.02uM	.	.	NEWCL20443	21MT-1	24h:0.53± 0.13uM	.	.	NEWCL20455	JIMT-1	24h:0.48± 0.02uM	.	.	NEWCL10081	MCF-7	24h:1.56± 0.24uM	.	.	NEWCL00329	MCF-10A	24h:1.23± 0.47uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	JIMT-1	.	.	.	MCF-7	.	.	.	MCF-10A	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Celastrol strongly synergized with ErbB2-targeted therapeutics Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol."
C33678	21092078	DIS0029	NP5424	Flavopiridol	DR5291	4-hydroxy-tamoxifen	NEWCL00354	MON	60uM	50uM	5 uM:100nM	NEWCL00258	G-401	50uM	40uM	5 uM:100nM	NEWCL00097	A-204	100uM	80uM	5 uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combining flavopiridol with 4OH-Tam potently inhibited the growth of RT cells by increasing the ability of either drug alone to induce caspases 2 and 3 thereby causing apoptosis.
C97546	21159609	DIS0022	NP0016	Silibinin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	50uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	NCI-H1975	21.34%	71.56%	79.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
C97546	21159609	DIS0022	NP0016	Silibinin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	50uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Down-regulation	NCI-H1975	0.83%	5.32%	65.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
C74471	21159612	DIS0018	NP5424	Flavopiridol	DR2632	Vorinostat	NEWCL00214	CHLA-136	.	.	0.2 uM :2 uM	NEWCL00219	CHLA-90	.	.	0.2 uM :2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	CHLA-136	11.56%	6.60%	34.70%	CHLA-90	12.91%	1.84%	52.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. The combination caused reduction in the expression of G(2)/M proteins (cyclin B1, Mad2, MPM2) in 2 cell lines with mt TP53 but not in those with wt TP53."
C74471	21159612	DIS0018	NP5424	Flavopiridol	DR2632	Vorinostat	NEWCL00214	CHLA-136	.	.	0.2 uM :2 uM	NEWCL00219	CHLA-90	.	.	0.2 uM :2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	CHLA-136	10.62%	4.03%	17.02%	CHLA-90	13.71%	5.76%	132.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. The combination caused reduction in the expression of G(2)/M proteins (cyclin B1, Mad2, MPM2) in 2 cell lines with mt TP53 but not in those with wt TP53."
C98052	21168265	DIS0021	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00155	MCF-7	.	.	25 uM:0.1 uM	NEWCL00049	MDA-MB-231	.	.	25 uM:0.1 uM	NEWCL00162	BT-549	.	.	25 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-p70S6K	Down-regulation	MCF-7	4.08%	97.07%	97.79%	MDA-MB-231	25.01%	43.30%	54.16%	BT-549	3.18%	93.16%	92.84%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.
C98052	21168265	DIS0021	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00155	MCF-7	.	.	25 uM:0.1 uM	NEWCL00049	MDA-MB-231	.	.	25 uM:0.1 uM	NEWCL00162	BT-549	.	.	25 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MCF-7	78.47%	12.04%	88.51%	MDA-MB-231	71.73%	-10.97%	90.10%	BT-549	17.80%	6.86%	42.23%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.
C31005	21186985	DIS0124	NP6084	Resveratrol	DR6385	Nutlin-3	NEWCL20391	A2780.CP70	.	.	25 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A2780.CP70	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation.
C69094	21195158	DIS0115	NP9120	Chrysin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00082	HCT 116	.	.	40 uM:0.1 ng.mL	NEWCL00149	HeLa	.	.	40 uM:1.0 ng.mL	NEWCL00129	Hep-G2	.	.	40 uM:1.0 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	.	5.21%	2.55%	48.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Chrysin can enhance the apoptosis induced by TRAIL, and the apoptosis is caspase-dependent and related to the activation of caspase 8."
C80755	21209944	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	30 mg.kg:15 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TRAIL-R1.DR5	Up-regulation	PC-3	49.09%	11.08%	41.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.
C80755	21209944	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	30 mg.kg:15 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TRAIL-R2.DR4	Up-regulation	PC-3	1.90%	6.46%	1.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.
C80755	21209944	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	30 mg.kg:15 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	PC-3	3.78%	4.85%	12.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.
C80755	21209944	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	30 mg.kg:15 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Up-regulation	PC-3	0.54%	7.19%	8.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.
C80755	21209944	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	30 mg.kg:15 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	PC-3	11.51%	16.43%	42.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.
C80755	21209944	DIS0129	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00253	PC-3	.	.	30 mg.kg:15 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	PC-3	20.25%	3.56%	62.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR5808	MG262	NEWCL00048	K-562	.	.	0.4uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	K-562	0.37%	0.78%	6.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR5808	MG262	NEWCL00048	K-562	.	.	0.4uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	K-562	34.72%	35.29%	43.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR5808	MG262	NEWCL00048	K-562	.	.	0.4uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	K-562	8.88%	4.67%	33.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR3952	MG132	NEWCL00048	K-562	.	.	0.4uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	K-562	2.62%	1.60%	3.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR3952	MG132	NEWCL00048	K-562	.	.	0.4uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	K-562	2.61%	0.68%	9.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR3952	MG132	NEWCL00048	K-562	.	.	0.4uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	K-562	3.49%	7.36%	37.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR3952	MG132	NEWCL00048	K-562	.	.	0.4uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	K-562	3.73%	6.54%	34.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR5808	MG262	NEWCL00048	K-562	.	.	0.4 uM:0.025 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	K-562u	103.22%	124.01%	134.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR5808	MG262	NEWCL00048	K-562	.	.	0.4 uM:0.025 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	K-562u	3.10%	50.16%	56.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR5808	MG262	NEWCL00048	K-562	.	.	0.4 uM:0.025 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	K-562u	3.37%	46.69%	23.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR3952	MG132	NEWCL00048	K-562	.	.	0.4 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	K-562u	103.22%	112.76%	122.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR3952	MG132	NEWCL00048	K-562	.	.	0.4 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	K-562u	3.10%	1.43%	52.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR3952	MG132	NEWCL00048	K-562	.	.	0.4 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	K-562u	3.37%	8.34%	32.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR5808	MG262	NEWCL00048	K-562	.	.	0.4 uM:0.025 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	K-562	1.07%	0.49%	46.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C74792	21216092	DIS0025	NP5023	Gambogic acid	DR3952	MG132	NEWCL00048	K-562	.	.	0.4 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	K-562	1.07%	29.64%	1.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4294	Fas L	Up-regulation	NT2-D1	120.59%	101.86%	129.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	NT2-D1	18.13%	79.62%	89.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	NT2-D1	57.73%	7.87%	25.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	TBid	Up-regulation	NT2-D1	96.74%	45.16%	242.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	NT2-D1	1255.43%	715.70%	1150.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	NT2-D1	39.40%	4.20%	88.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	NT2-D1	40.24%	33.29%	73.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53	Up-regulation	NT2-D1	558.76%	348.37%	640.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	NT2-D1	558.57%	526.65%	785.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C06446	21216935	DIS0128	NP8606	Fisetin	DR1669	Cisplatin	NEWCL10054	NT2-D1	.	.	20uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	NT2-D1	25.19%	71.28%	263.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.
C79794	21220494	DIS0029	NP0718	Delta-9-tetrahydrocanbinol	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	0.9uM:75uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B	Up-regulation	U-87MG ATCCMG	3.77%	43.73%	159.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combined administration of Delta(9)-Tetrahydrocannabinol and temozolomide exerts a strong antitumoral action in glioma xenografts, an effect that is also observed in tumors that are resistant to TMZ treatment."
C89761	21333438	DIS0124	NP0439	Tetrandrine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	10 uM:10.15uM	NEWCL00230	A2780	6 uM	.	6 uM:10.15uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	OVCAR-3	11.10%	135.39%	168.14%	A2780	35.93%	35.93%	134.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.
C89761	21333438	DIS0124	NP0439	Tetrandrine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	10 uM:10.15uM	NEWCL00230	A2780	6 uM	.	6 uM:10.15uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	OVCAR-3	13.43%	127.10%	194.74%	A2780	79.97%	79.97%	127.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.
C89761	21333438	DIS0124	NP0439	Tetrandrine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	10 uM:10.15uM	NEWCL00230	A2780	6 uM	.	6 uM:10.15uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	OVCAR-3	38.68%	33.33%	53.04%	A2780	78.98%	78.98%	122.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.
C89761	21333438	DIS0124	NP0439	Tetrandrine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	10 uM:10.15uM	NEWCL00230	A2780	6 uM	.	6 uM:10.15uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Wnt5a.b	Down-regulation	OVCAR-3	6.79%	0.30%	20.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.
C89761	21333438	DIS0124	NP0439	Tetrandrine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	10 uM:10.15uM	NEWCL00230	A2780	6 uM	.	6 uM:10.15uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	OVCAR-3	5.86%	1.45%	84.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.
C89761	21333438	DIS0124	NP0439	Tetrandrine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	10 uM:10.15uM	NEWCL00230	A2780	6 uM	.	6 uM:10.15uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	OVCAR-3	23.69%	8.76%	74.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.
C04478	21340652	DIS0018	NP6084	Resveratrol	DR0813	hu1418-IL2 immunicytokine	NEWCL00008	NXS2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7139	CD20	Up-regulation	NXS2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	RV in combination with IC provided an enhanced anti-tumor treatment in preclinical model as it lowered the tumor burden and increased survival.
C92301	21418039	DIS0031	NP6993	Arsenic trioxide	DR5605	Polyinosinic acid-polycytidylic acid	NEWCL00140	SMMC-7721	.	.	4 uM: 100 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SMMC-7721	24.01%	20.78%	23.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells.
C92301	21418039	DIS0031	NP6993	Arsenic trioxide	DR5605	Polyinosinic acid-polycytidylic acid	NEWCL00140	SMMC-7721	.	.	4 uM: 100 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	SMMC-7721	9.24%	2.80%	39.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells.
C92301	21418039	DIS0031	NP6993	Arsenic trioxide	DR5605	Polyinosinic acid-polycytidylic acid	NEWCL00140	SMMC-7721	.	.	4 uM: 100 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SMMC-7721	53.57%	4.80%	60.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells.
C92301	21418039	DIS0031	NP6993	Arsenic trioxide	DR5605	Polyinosinic acid-polycytidylic acid	NEWCL00140	SMMC-7721	.	.	4 uM: 100 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	SMMC-7721	44.07%	0.02%	62.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells.
C54208	21472456	DIS0018	NP2960	Epigallocatechin gallate	DR4256	SU5416	NEWCL00215	SH-SY5Y	.	.	50 uM:20 uM	NEWCL00213	SK-N-BE(2)	.	.	50 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	SH-SY5Y	0.16%	38.76%	71.85%	SK-N-BE2	63.56%	0.91%	84.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
C54208	21472456	DIS0018	NP2960	Epigallocatechin gallate	DR4256	SU5416	NEWCL00215	SH-SY5Y	.	.	50 uM:20 uM	NEWCL00213	SK-N-BE(2)	.	.	50 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	EGFR	Down-regulation	SH-SY5Y	13.99%	27.12%	61.30%	SK-N-BE2	7.10%	0.02%	58.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
C54208	21472456	DIS0018	NP2960	Epigallocatechin gallate	DR4256	SU5416	NEWCL00215	SH-SY5Y	.	.	50 uM:20 uM	NEWCL00213	SK-N-BE(2)	.	.	50 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	SH-SY5Y	6.51%	15.92%	18.15%	SK-N-BE2	168.64%	137.14%	221.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
C54208	21472456	DIS0018	NP2960	Epigallocatechin gallate	DR4256	SU5416	NEWCL00215	SH-SY5Y	.	.	50 uM:20 uM	NEWCL00213	SK-N-BE(2)	.	.	50 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	SH-SY5Y	73.75%	14.71%	79.13%	SK-N-BE2	1.62%	0.82%	47.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
C54208	21472456	DIS0018	NP2960	Epigallocatechin gallate	DR4256	SU5416	NEWCL00215	SH-SY5Y	.	.	50 uM:20 uM	NEWCL00213	SK-N-BE(2)	.	.	50 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7847	RB	Up-regulation	SH-SY5Y	33.43%	148.48%	155.99%	SK-N-BE2	177.21%	216.19%	187.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
C54208	21472456	DIS0018	NP2960	Epigallocatechin gallate	DR4256	SU5416	NEWCL00215	SH-SY5Y	.	.	50 uM:20 uM	NEWCL00213	SK-N-BE(2)	.	.	50 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6671	E2F1	Down-regulation	SH-SY5Y	58.64%	33.82%	55.17%	SK-N-BE2	1.31%	1.24%	83.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
C54208	21472456	DIS0018	NP2960	Epigallocatechin gallate	DR4256	SU5416	NEWCL00215	SH-SY5Y	.	.	50 uM:20 uM	NEWCL00213	SK-N-BE(2)	.	.	50 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SH-SY5Y	15.21%	4.88%	58.64%	SK-N-BE2	26.13%	5.56%	62.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
C54208	21472456	DIS0018	NP2960	Epigallocatechin gallate	DR4256	SU5416	NEWCL00215	SH-SY5Y	.	.	50 uM:20 uM	NEWCL00213	SK-N-BE(2)	.	.	50 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	SH-SY5Y	17.92%	10.07%	96.87%	SK-N-BE2	161.67%	96.47%	77.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
C36880	21553345	DIS0029	NP0109	Medione	DR6224	Sodium orthovadate	NEWCL10089	DBTRG-05MG	72h:22 uM	72h:25 uM	13 uM:13 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	M:SO combination is an attractive alternative for glioma treatment.
C23178	21591838	.	NP7303	Silymarin	DR1669	Cisplatin	NEWCL10339	HK2	.	.	.	NEWCL00180	NCI-H460	.	.	.	NEWCL00194	G-361	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Silymarin selectively protects human renal cells from cisplatin-induced cell death.
C23313	21608020	DIS0031	NP6882	Arctigenin	DR1669	Cisplatin	NEWCL00129	Hep-G2	.	.	80 uM:1.0 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hep-G2	7.42%	21.78%	33.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
C23313	21608020	DIS0031	NP6882	Arctigenin	DR1669	Cisplatin	NEWCL00129	Hep-G2	.	.	80 uM:1.0 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Hep-G2	138.40%	294.01%	323.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
C01919	21617941	DIS0031	NP9654	Bufalin	DR2073	Sorafenib	NEWCL00129	Hep-G2	48h:33.65nM	48h:5719.21nM	50nM:6.25 uM	NEWCL00027	PLC.PRF.5	48:157.87nM	48h:3567.7unM	50nM:6.25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	Hep-G2	25.56%	24.39%	.	PLC.PRF.5u	45.65%	70.42%	43.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
C21207	21630164	DIS0024	NP5775	Cyclopamine	DR2391	Gemcitabine	NEWCL00091	CFPAC-1	.	68.3 ±  4.5 uM 	.	NEWCL00233	SW1990	.	306.8 ±  12.3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Gemcitabine-resistant pancreatic cancer cells highly express CSCs markers and some of the HH members, and inhibition of HH by cyclopamine is an effective method of reversing gemcitabine resistance in pancreatic cancer."
C78359	21679466	DIS0094	NP5000	Cladribine	DR9688	S3I-201	NEWCL00286	U266B1	72h:2.43uM	.	2uM:5uM	NEWCL00278	RPMI-8226	72h:0.75uM	.	1umol.L:5umol.L	NEWCL10028	MM1.S	72h:0.18umol.L	.	0.2uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	U266	1.67%	2.92%	40.36%	RPMI-8226	5.71%	1.10%	321.08%	MM1.S	35.09%	6.90%	76.99%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cladribine exhibited inhibitory effects on MM cells in vitro. MM1.S is the only cell line showing significant response to the clinically achievable concentrations of cladribine-induced apoptosis and inactivation of STAT3.
C78359	21679466	DIS0094	NP5000	Cladribine	DR9688	S3I-201	NEWCL00286	U266B1	72h:2.43uM	.	2uM:5uM	NEWCL00278	RPMI-8226	72h:0.75uM	.	1umol.L:5umol.L	NEWCL10028	MM1.S	72h:0.18umol.L	.	0.2uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	U266	32.57%	0.41%	87.11%	RPMI-8226	2.42%	5.58%	152.41%	MM1.S	33.43%	43.45%	211.63%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cladribine exhibited inhibitory effects on MM cells in vitro. MM1.S is the only cell line showing significant response to the clinically achievable concentrations of cladribine-induced apoptosis and inactivation of STAT3.
C78359	21679466	DIS0094	NP5000	Cladribine	DR9688	S3I-201	NEWCL00286	U266B1	72h:2.43uM	.	2uM:5uM	NEWCL00278	RPMI-8226	72h:0.75uM	.	1umol.L:5umol.L	NEWCL10028	MM1.S	72h:0.18umol.L	.	0.2uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	U266	256.15%	4.74%	354.07%	RPMI-8226	5.40%	3.48%	371.46%	MM1.S	260.48%	6.88%	335.21%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cladribine exhibited inhibitory effects on MM cells in vitro. MM1.S is the only cell line showing significant response to the clinically achievable concentrations of cladribine-induced apoptosis and inactivation of STAT3.
C74677	21720559	DIS0023	NP3718	Honokiol	DR2391	Gemcitabine	NEWCL00236	MIA PaCa-2	24h:43.25 uM	.	20uM:10uM	NEWCL00342	Panc1	24h:47.44uM	.	20uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	HK-7	28.01%	2.38%	3.93%	Panc-1	44.73%	5.30%	3.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells."
C83141	21743963	DIS0023	NP7424	Emodin	DR2391	Gemcitabine	NEWCL00233	SW1990	.	.	40 umol.l:20 umol.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Emodin enhances the antitumor effect of gemcitabine in SW1990 pancreatic cancer in vitro and in vivo, which may be via the downregulation of NF-kappaB expression, thus inhibiting the expression of XIAP."
C32605	21774804	DIS0114	NP6905	Curcumin	DR5851	Dasatinib	NEWCL00082	HCT 116	.	.	72h; 10 uM :1uM	NEWCL00077	HT-29	.	.	72h; 10 uM :1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	"The combinatorial therapy inhibited cellular growth, invasion and colonosphere formation and also reduced CSC population as evidenced by the decreased expression of CSC specific markers: CD133, CD44, CD166 and ALDH."
C18844	21810436	DIS0022	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00170	A-549	.	.	20 uM:2.5 uM	NEWCL00171	NCI-H1975	.	.	20 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Down-regulation	A-549	5.05%	89.72%	13.78%	NCI-H1975	45.72%	-10.33%	40.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells.
C02521	21865729	DIS0115	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00344	HT29	.	.	100 uM:10 uM	NEWCL00076	SW620	.	.	100 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Up-regulation	uHT-29	4.58%	13.17%	50.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with resveratrol sensitized colon cancer cells to 5-fluorouracil, inducing a further increase in oxidative stress, which was linked to the inhibition of AKT and STAT3 proteins, which are known to have oncogenic potential in colorectal carcinomas."
C02521	21865729	DIS0115	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00344	HT29	.	.	100 uM:10 uM	NEWCL00076	SW620	.	.	100 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Up-regulation	SW-620	13.82%	15.37%	40.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with resveratrol sensitized colon cancer cells to 5-fluorouracil, inducing a further increase in oxidative stress, which was linked to the inhibition of AKT and STAT3 proteins, which are known to have oncogenic potential in colorectal carcinomas."
C88284	21889928	DIS0028	NP6993	Arsenic trioxide	DR2116	Lonidamine	NEWCL00022	HL-60	.	.	2 uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	HL60	65.33%	65.40%	68.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes."
C88284	21889928	DIS0028	NP6993	Arsenic trioxide	DR2116	Lonidamine	NEWCL00022	HL-60	.	.	2 uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	HL60	62.79%	40.28%	83.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes."
C88284	21889928	DIS0028	NP6993	Arsenic trioxide	DR2116	Lonidamine	NEWCL00022	HL-60	.	.	2 uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	HL60	52.64%	64.26%	75.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes."
C88284	21889928	DIS0028	NP6993	Arsenic trioxide	DR2116	Lonidamine	NEWCL00022	HL-60	.	.	2 uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	HL60	43.74%	61.40%	75.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes."
C88284	21889928	DIS0028	NP6993	Arsenic trioxide	DR2116	Lonidamine	NEWCL00022	HL-60	.	.	2 uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HL60	34.17%	7.15%	173.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes."
C88284	21889928	DIS0028	NP6993	Arsenic trioxide	DR2116	Lonidamine	NEWCL00022	HL-60	.	.	2 uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	HL60	0.89%	13.88%	217.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes."
C88284	21889928	DIS0028	NP6993	Arsenic trioxide	DR2116	Lonidamine	NEWCL00022	HL-60	.	.	2 uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	HL60	13.67%	10.00%	44.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes."
C62662	21889949	DIS0022	NP6993	Arsenic trioxide	DR2632	Vorinostat	NEWCL00181	NCI-H1299	.	.	2uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	NCI-H1299	12.78%	19.02%	40.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined treatment with ATO and SAHA resulted in enhanced suppression of non-small-cell lung carcinoma in vitro in H1299 cells and in vivo in a xenograft mouse model.
C23303	21898527	DIS0025	NP6636	Daunorubicin	DR4137	Rapamycin	NEWCL00063	SUP-B15	72h:0.039 ±  0.003 umol.L	72h:50.040 ±  10.556 nmol.L	0.1 umol.L:50 nmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-P70S6K	Down-regulation	SUP-B15	33.39%	64.63%	62.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	"RAPA effectively eliminated this deleterious side effect of DNR, which might enhance DNR's ability to kill drug-resistant cancer."
C23303	21898527	DIS0025	NP6636	Daunorubicin	DR4137	Rapamycin	NEWCL00063	SUP-B15	72h:0.039 ±  0.003 umol.L	72h:50.040 ±  10.556 nmol.L	0.1 umol.L:50 nmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7832	P-4EBP1	Down-regulation	SUP-B15	21.73%	5.52%	18.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	"RAPA effectively eliminated this deleterious side effect of DNR, which might enhance DNR's ability to kill drug-resistant cancer."
C04341	21904777	DIS0022	NP7102	Elemene	DR0490	Etoposide	NEWCL00170	A-549	24h:50 ug.ml; 48h:29 ug.ml; 72h:20 ug.ml	.	20ug.mL:15ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	1.34%	241.41%	294.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic antitumor effect of Beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells.
C04341	21904777	DIS0022	NP7102	Elemene	DR0490	Etoposide	NEWCL00170	A-549	24h:50 ug.ml; 48h:29 ug.ml; 72h:20 ug.ml	.	20ug.mL:15ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	17.24%	49.63%	69.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic antitumor effect of Beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells.
C04341	21904777	DIS0022	NP7102	Elemene	DR0490	Etoposide	NEWCL00170	A-549	24h:50 ug.ml; 48h:29 ug.ml; 72h:20 ug.ml	.	20ug.mL:15ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	A-549	10.98%	126.85%	125.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic antitumor effect of Beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells.
C04341	21904777	DIS0022	NP7102	Elemene	DR0490	Etoposide	NEWCL00170	A-549	24h:50 ug.ml; 48h:29 ug.ml; 72h:20 ug.ml	.	20ug.mL:15ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	A-549	8.48%	199.63%	207.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic antitumor effect of Beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells.
C04341	21904777	DIS0022	NP7102	Elemene	DR0490	Etoposide	NEWCL00170	A-549	24h:50 ug.ml; 48h:29 ug.ml; 72h:20 ug.ml	.	20ug.mL:15ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	A-549	12.62%	41.47%	44.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic antitumor effect of Beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells.
C81026	21932983	DIS0024	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00115	SNU-668	.	48h:>=500uM	0.3mM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	SNU-668	8.42%	6.32%	27.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	21932983	DIS0024	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00115	SNU-668	.	48h:>=500uM	0.3mM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SNU-668	0.64%	16.41%	27.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C29833	21939359	DIS0127	NP3478	Eugenol	DR2391	Gemcitabine	NEWCL00149	HeLa	500 uM	 35 mM	150 uM : 25 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol enhances the chemotherapeutic potential of gemcitabine and induces anticarcinogenic and anti-inflammatory activity in human cervical cancer cells.
C07748	21965742	DIS0129	NP6084	Resveratrol	DR0258	Flutamide	NEWCL00252	LNCaP	.	.	50 uM:10-4M	NEWCL00253	PC-3	.	.	50 uM:10-4M	NEWCL00251	DU145	.	.	50 uM:10-4M	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	LNCaP	.	.	.	PC3	.	.	.	DU145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of resveratrol with flutamide had a synergistic effect on down-regulation of androgen receptor (AR).
C53884	21971583	DIS0025	NP1644	Vincristine	DR7260	VE-465	NEWCL00059	THP-1	.	96h:35.4 ±  13.0nM	1nM:30nM	NEWCL10083	KY821	.	96h:40.5 ±  28.5nM	1nM:30nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells."
C18844	21986579	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00155	MCF-7	48h:40uM	48h:5uM	40uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	MCF-7	21.74%	2.39%	36.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells. The combination of MMC and curcumin inhibits MCF-7 cell proliferation and cell cycle progression in vitro and in vivo via the p38 MAPK pathway.
C18844	21986579	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00155	MCF-7	48h:40uM	48h:5uM	40uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5524	Cyclin A	Down-regulation	MCF-7	7.52%	2.53%	10.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells. The combination of MMC and curcumin inhibits MCF-7 cell proliferation and cell cycle progression in vitro and in vivo via the p38 MAPK pathway.
C18844	21986579	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00155	MCF-7	48h:40uM	48h:5uM	40uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	MCF-7	25.12%	7.77%	12.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells. The combination of MMC and curcumin inhibits MCF-7 cell proliferation and cell cycle progression in vitro and in vivo via the p38 MAPK pathway.
C18844	21986579	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00155	MCF-7	48h:40uM	48h:5uM	40uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	MCF-7	18.06%	6.36%	50.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells. The combination of MMC and curcumin inhibits MCF-7 cell proliferation and cell cycle progression in vitro and in vivo via the p38 MAPK pathway.
C18844	21986579	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00155	MCF-7	48h:40uM	48h:5uM	40uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	MCF-7	8.84%	17.65%	13.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells. The combination of MMC and curcumin inhibits MCF-7 cell proliferation and cell cycle progression in vitro and in vivo via the p38 MAPK pathway.
C18844	21986579	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00155	MCF-7	48h:40uM	48h:5uM	40uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Up-regulation	MCF-7	5.08%	30.42%	8.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells. The combination of MMC and curcumin inhibits MCF-7 cell proliferation and cell cycle progression in vitro and in vivo via the p38 MAPK pathway.
C18844	21986579	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00155	MCF-7	48h:40uM	48h:5uM	40uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Down-regulation	MCF-7	2.98%	20.34%	11.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells. The combination of MMC and curcumin inhibits MCF-7 cell proliferation and cell cycle progression in vitro and in vivo via the p38 MAPK pathway.
C21358	22001324	DIS0111	NP6993	Arsenic trioxide	DR9249	"1,3-bis(2-chloroethyl)-1-nitrosourea"	NEWCL00212	HONE-1	.	24h:84.2±  6.4uM	5uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-I	Up-regulation	HONE-1	103.63%	35.57%	204.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors.
C21358	22001324	DIS0111	NP6993	Arsenic trioxide	DR9249	"1,3-bis(2-chloroethyl)-1-nitrosourea"	NEWCL00212	HONE-1	.	24h:84.2±  6.4uM	5uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-II	Up-regulation	HONE-1	166.89%	46.89%	346.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors.
C04523	22011009	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	72h:0.42uMu± u0.05ug.ml 	0.01uM:0.2ug.ml	NEWCL00155	MCF-7	.	72h:0.42uMu± u0.11ug.ml	"0.02uM:0.07ug.ml 
"	NEWCL00149	HeLa	.	72h:0.28uMu± u0.07ug.ml	0.01uM:0.19ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7879	MDR1	Down-regulation	Hep-G2	15.49%	62.68%	54.70%	MCF-7	64.14%	72.60%	73.01%	HeLa	38.34%	51.54%	14.08%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol potentiates cytotoxic properties of doxorubicin used in the study through increasing their intracellular level due to p-glycoprotein inhibition and downregulation of mdr1 gene.
C69094	22086925	DIS0025	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ATL	.	.	.	TRAIL-R2	.	.	.	TRAIL-R1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin overcomed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
C69094	22086925	DIS0025	NP9120	Chrysin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00316	SP+	.	.	50 um:50 ng.ml	NEWCL00350	MT-2	.	.	50 um:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MT-2	0.59%	3.53%	12.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin overcomed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
C69094	22086925	DIS0025	NP9120	Chrysin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00316	SP+	.	.	50 um:50 ng.ml	NEWCL00350	MT-2	.	.	50 um:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1113	Caspase-2	Down-regulation	MT-2	3.32%	34.76%	65.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin overcomed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
C69094	22086925	DIS0025	NP9120	Chrysin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00316	SP+	.	.	50 um:50 ng.ml	NEWCL00350	MT-2	.	.	50 um:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	MT-2	0.38%	8.17%	31.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin overcomed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
C69094	22086925	DIS0025	NP9120	Chrysin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00316	SP+	.	.	50 um:50 ng.ml	NEWCL00350	MT-2	.	.	50 um:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	MT-2	1.02%	9.12%	63.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin overcomed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
C69094	22086925	DIS0025	NP9120	Chrysin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00316	SP+	.	.	50 um:50 ng.ml	NEWCL00350	MT-2	.	.	50 um:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	MT-2	9.87%	10.52%	34.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin overcomed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
C87321	22137263	DIS0129	NP4931	Lycopene	DR6961	T0901317	NEWCL00251	DU145	.	.	5 uM:2uM	NEWCL00253	PC-3	.	.	5 uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DU145	.	.	.	PC3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Lycopene and the LXRalpha agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARgamma-LXRalpha-ABCA1 pathway.
C15497	22139409	DIS0122	NP6628	Aloin	DR1669	Cisplatin	NEWCL00205	B16-F10	.	.	500 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation.
C42257	22160570	DIS0022	NP9279	Genistein	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	81uM:7.82uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-H1975	63.35%	373.41%	1563.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of EGFR.
C42257	22160570	DIS0022	NP9279	Genistein	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	81uM:7.82uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	NCI-H1975	106.90%	185.98%	437.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of EGFR.
C42257	22160570	DIS0022	NP9279	Genistein	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	81uM:7.82uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	NCI-H1975	2.69%	5.14%	42.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of EGFR.
C42257	22160570	DIS0022	NP9279	Genistein	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	81uM:7.82uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Down-regulation	NCI-H1975	8.33%	10.23%	11.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of EGFR.
C42257	22160570	DIS0022	NP9279	Genistein	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	81uM:7.82uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Down-regulation	NCI-H1975	9.30%	2.91%	56.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of EGFR.
C42257	22160570	DIS0022	NP9279	Genistein	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	81uM:7.82uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	NCI-H1975	2.68%	13.21%	40.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of EGFR.
C97187	22206675	DIS0022	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	5uM: 5ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	A-549	69.00%	184.70%	358.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model.
C64007	22238500	DIS0114	NP2974	Mangiferin	DR0141	Oxaliplatin	NEWCL00149	HeLa	.	48h:11.92uM	.	NEWCL00344	HT29	.	48h:12.3uM	.	NEWCL00155	MCF-7	.	48h:6.21uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Mangiferin in combination with oxaliplatin favours apoptotic cell death and thereby improves the efficacy of oxaliplatin in vitro.
C90316	22290509	DIS0021	NP6905	Curcumin	DR7217	Trichostatin A	NEWCL00314	MDA-MB-435	48h:20 uM; 	0.4 uM	20 uM : 0.2 uM	NEWCL00052	SK-BR-3	10 uM	0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MDA-MB435eB	30.66%	140.47%	200.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells via JNK activation.
C90316	22290509	DIS0021	NP6905	Curcumin	DR7217	Trichostatin A	NEWCL00314	MDA-MB-435	48h:20 uM; 	0.4 uM	20 uM : 0.2 uM	NEWCL00052	SK-BR-3	10 uM	0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	MDA-MB435eB	19.86%	38.92%	138.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells via JNK activation.
C90316	22290509	DIS0021	NP6905	Curcumin	DR7217	Trichostatin A	NEWCL00314	MDA-MB-435	48h:20 uM; 	0.4 uM	20 uM : 0.2 uM	NEWCL00052	SK-BR-3	10 uM	0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Down-regulation	MDA-MB435eB	20.52%	39.58%	80.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells via JNK activation.
C90316	22290509	DIS0021	NP6905	Curcumin	DR7217	Trichostatin A	NEWCL00314	MDA-MB-435	48h:20 uM; 	0.4 uM	20 uM : 0.2 uM	NEWCL00052	SK-BR-3	10 uM	0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MDA-MB435eB	20.16%	260.97%	495.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells via JNK activation.
C90316	22290509	DIS0021	NP6905	Curcumin	DR7217	Trichostatin A	NEWCL00314	MDA-MB-435	48h:20 uM; 	0.4 uM	20 uM : 0.2 uM	NEWCL00052	SK-BR-3	10 uM	0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MDA-MB435eB	36.48%	45.65%	89.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells via JNK activation.
C90316	22290509	DIS0021	NP6905	Curcumin	DR7217	Trichostatin A	NEWCL00314	MDA-MB-435	48h:20 uM; 	0.4 uM	20 uM : 0.2 uM	NEWCL00052	SK-BR-3	10 uM	0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	p53	Down-regulation	.	39.29%	21.08%	90.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells via JNK activation.
C90316	22290509	DIS0021	NP6905	Curcumin	DR7217	Trichostatin A	NEWCL00314	MDA-MB-435	48h:20 uM; 	0.4 uM	20 uM : 0.2 uM	NEWCL00052	SK-BR-3	10 uM	0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	.	.	0.14%	2.51%	3.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells via JNK activation.
C90316	22290509	DIS0021	NP6905	Curcumin	DR7217	Trichostatin A	NEWCL00314	MDA-MB-435	48h:20 uM; 	0.4 uM	20 uM : 0.2 uM	NEWCL00052	SK-BR-3	10 uM	0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	.	76.91%	45.60%	84.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells via JNK activation.
C49659	22306340	DIS0024	NP4621	Triptolide	DR1669	Cisplatin	NEWCL10016	SC-M1	.	.	5ng.ml:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SC-M1	128.70%	302.05%	406.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo.
C49659	22306340	DIS0024	NP4621	Triptolide	DR1669	Cisplatin	NEWCL10016	SC-M1	.	.	5ng.ml:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SC-M1	11.66%	445.04%	491.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo.
C49659	22306340	DIS0024	NP4621	Triptolide	DR1669	Cisplatin	NEWCL10016	SC-M1	.	.	5ng.ml:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	SC-M1	41.69%	52.79%	49.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo.
C49659	22306340	DIS0024	NP4621	Triptolide	DR1669	Cisplatin	NEWCL10016	SC-M1	.	.	5ng.ml:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome-c	Up-regulation	SC-M1	262.44%	289.82%	326.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	5 uM:4 Gy	NEWCL00253	PC-3	.	.	5 uM:4 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	LNCap	152.32%	93.26%	125.90%	PC-3	0.32%	7.90%	7.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	5 uM:4 Gy	NEWCL00253	PC-3	.	.	5 uM:4 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Up-regulation	LNCap	734.34%	12.10%	17.85%	PC-3	5.51%	24.66%	47.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	5 uM:4 Gy	NEWCL00253	PC-3	.	.	5 uM:4 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2597	ATG5	Up-regulation	LNCap	100.93%	120.61%	152.90%	PC-3	50.35%	177.26%	208.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2597	ATG5	Up-regulation	LNCap	5.25%	9.23%	18.60%	PC-3	1066.67%	9743.75%	11365.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	5 uM:4 Gy	NEWCL00253	PC-3	.	.	5 uM:4 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	LNCap	10.20%	38.64%	30.17%	PC-3	49.32%	33.83%	72.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	5 uM:4 Gy	NEWCL00253	PC-3	.	.	5 uM:4 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-II	Up-regulation	LNCap	1388.98%	28.14%	1166.50%	PC-3	53.32%	93.77%	109.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	5 uM:4 Gy	NEWCL00253	PC-3	.	.	5 uM:4 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	LNCap	69.31%	90.48%	52.82%	PC-3	10.78%	10.78%	12.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	5 uM:4 Gy	NEWCL00253	PC-3	.	.	5 uM:4 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	LNCap	21.02%	30.02%	82.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	5 uM:4 Gy	NEWCL00253	PC-3	.	.	5 uM:4 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	LNCap	31.60%	12.62%	29.65%	PC-3	9.25%	16.06%	83.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C37715	22363680	DIS0129	NP6993	Arsenic trioxide	DR5752	Androgen	NEWCL00252	LNCaP	.	.	5 uM:4 Gy	NEWCL00253	PC-3	.	.	5 uM:4 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-P70S6K	Down-regulation	LNCap	31.95%	8.37%	35.05%	PC-3	8.08%	13.99%	47.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
C23576	22415970	DIS0021	NP6084	Resveratrol	DR8776	Melphalan	NEWCL00155	MCF-7	120 uM	110 uM	100 uM:50 uM	NEWCL00049	MDA-MB-231	370 uM	305 uM	100 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	MCF-7	328.39%	54.19%	499.39%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.
C23576	22415970	DIS0021	NP6084	Resveratrol	DR8776	Melphalan	NEWCL00155	MCF-7	120 uM	110 uM	100 uM:50 uM	NEWCL00049	MDA-MB-231	370 uM	305 uM	100 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MCF-7	42.83%	54.19%	138.97%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.
C23576	22415970	DIS0021	NP6084	Resveratrol	DR8776	Melphalan	NEWCL00155	MCF-7	120 uM	110 uM	100 uM:50 uM	NEWCL00049	MDA-MB-231	370 uM	305 uM	100 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	MCF-7	30.82%	35.35%	127.88%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.
C23576	22415970	DIS0021	NP6084	Resveratrol	DR8776	Melphalan	NEWCL00155	MCF-7	120 uM	110 uM	100 uM:50 uM	NEWCL00049	MDA-MB-231	370 uM	305 uM	100 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9803	P-Chk2	Up-regulation	MCF-7	8.68%	15.00%	42.41%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.
C23576	22415970	DIS0021	NP6084	Resveratrol	DR8776	Melphalan	NEWCL00155	MCF-7	120 uM	110 uM	100 uM:50 uM	NEWCL00049	MDA-MB-231	370 uM	305 uM	100 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CDC25A	Up-regulation	MCF-7	0.03%	5.06%	4.95%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.
C23576	22415970	DIS0021	NP6084	Resveratrol	DR8776	Melphalan	NEWCL00155	MCF-7	120 uM	110 uM	100 uM:50 uM	NEWCL00049	MDA-MB-231	370 uM	305 uM	100 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3122	Cyclin E	Up-regulation	MCF-7	10.23%	12.56%	10.51%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.
C23576	22415970	DIS0021	NP6084	Resveratrol	DR8776	Melphalan	NEWCL00155	MCF-7	120 uM	110 uM	100 uM:50 uM	NEWCL00049	MDA-MB-231	370 uM	305 uM	100 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5524	Cyclin A	Down-regulation	MCF-7	5.77%	5.75%	24.84%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.
C23576	22415970	DIS0021	NP6084	Resveratrol	DR8776	Melphalan	NEWCL00155	MCF-7	120 uM	110 uM	100 uM:50 uM	NEWCL00049	MDA-MB-231	370 uM	305 uM	100 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	MCF-7	3.06%	4.87%	6.33%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.
C49649	22483553	DIS0022	NP6905	Curcumin	DR1669	Cisplatin	NEWCL20360	A549.DDP	.	48h:18.06± 1.9uM	15uM:1.5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A549.DDP	133.24%	65.47%	173.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Combined curcumin and DDP treatment markedly inhibited A549/DDP cells proliferation, reversed cisplatin resistance and triggered apoptotic death by promoting HIF-1alpha degradation and activating caspase-3, respectively."
C49649	22483553	DIS0022	NP6905	Curcumin	DR1669	Cisplatin	NEWCL20360	A549.DDP	.	48h:18.06± 1.9uM	15uM:1.5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A549.DDP	3544.40%	402.83%	3110.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Combined curcumin and DDP treatment markedly inhibited A549/DDP cells proliferation, reversed cisplatin resistance and triggered apoptotic death by promoting HIF-1alpha degradation and activating caspase-3, respectively."
C49133	22497997	DIS0023	NP2960	Epigallocatechin gallate	DR2742	Celecoxib	NEWCL00235	COLO 357	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Colo357	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG synergistically boosts celecoxib-mediated effects and reduces the levels of celecoxib required to elicit beneficial effects on tumorigenic mediators by a factor of ten.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ICAD	Up-regulation	SK-N-BE(2)	99.28%	0.24%	103.72%	IMR-32	23.60%	20.89%	24.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SBDP	Up-regulation	SK-N-BE(2)	82.66%	6.61%	97.13%	IMR-32	2.03%	2.92%	7.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	SK-N-BE(2)	34.46%	5.21%	19.40%	IMR-32	0.43%	17.28%	76.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Calpain	Down-regulation	SK-N-BE(2)	35.62%	4.37%	46.19%	IMR-32	48.98%	26.48%	48.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	SK-N-BE(2)	24.50%	3.22%	2.53%	IMR-32	50.69%	32.46%	24.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SK-N-BE(2)	132.57%	74.33%	104.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	N-myc	Down-regulation	SK-N-BE(2)	10.81%	25.38%	69.60%	IMR-32	24.36%	10.18%	55.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8368	Notch-1	Down-regulation	SK-N-BE(2)	45.42%	32.80%	61.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Htert	Down-regulation	SK-N-BE(2)	9.75%	6.72%	18.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ID2	Down-regulation	SK-N-BE(2)	42.34%	46.51%	56.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C13798	22498172	DIS0018	NP2960	Epigallocatechin gallate	DR3141	N-(4-hydroxyphenyl) retimide	NEWCL00213	SK-N-BE(2)	.	.	50 uM:0.5uM	NEWCL00222	IMR-32	.	.	50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Up-regulation	SK-N-BE(2)	44.74%	95.93%	91.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
C23114	22513291	DIS0023	NP6920	Guggulsterone	DR2391	Gemcitabine	NEWCL00236	MIA PaCa-2	 	.	10mg.kg:125mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	MiaPaCa-2	21.40%	9.22%	37.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of guggulsterone to gemcitabine enhanced antitumor efficacy through apoptosis induction by suppressing Akt and nuclear factor KappaB activity and by modulating apoptosis-related protein expression in pancreatic cancer.
C23114	22513291	DIS0023	NP6920	Guggulsterone	DR2391	Gemcitabine	NEWCL00236	MIA PaCa-2	 	.	10mg.kg:125mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MiaPaCa-2	33.06%	2.44%	12.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of guggulsterone to gemcitabine enhanced antitumor efficacy through apoptosis induction by suppressing Akt and nuclear factor KappaB activity and by modulating apoptosis-related protein expression in pancreatic cancer.
C23114	22513291	DIS0023	NP6920	Guggulsterone	DR2391	Gemcitabine	NEWCL00236	MIA PaCa-2	 	.	10mg.kg:125mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MiaPaCa-2	22.93%	0.09%	37.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of guggulsterone to gemcitabine enhanced antitumor efficacy through apoptosis induction by suppressing Akt and nuclear factor KappaB activity and by modulating apoptosis-related protein expression in pancreatic cancer.
C83756	22530672	DIS0029	NP6084	Resveratrol	DR6516	Temozolomide	NEWCL00040	SHG-44	.	.	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CFAP	Up-regulation	SHG-44	77.49%	151.50%	266.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
C83756	22530672	DIS0029	NP6084	Resveratrol	DR6516	Temozolomide	NEWCL00040	SHG-44	.	.	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	SHG-44	4.50%	33.78%	64.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
C83756	22530672	DIS0029	NP6084	Resveratrol	DR6516	Temozolomide	NEWCL00040	SHG-44	.	.	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-AMPK	Up-regulation	SHG-44	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
C83756	22530672	DIS0029	NP6084	Resveratrol	DR6516	Temozolomide	NEWCL00040	SHG-44	.	.	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	p-mTOR	Down-regulation	SHG-44	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
C83756	22530672	DIS0029	NP6084	Resveratrol	DR6516	Temozolomide	NEWCL00040	SHG-44	.	.	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SHG-44	19.66%	32.85%	66.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
C46103	22545969	DIS0129	NP7102	Elemene	DR1669	Cisplatin	NEWCL00251	DU145	.	24h: 192; 48h:96;  72h:40 uM	40 ug.ml:4.8.16 uM	NEWCL00253	PC-3	.	24h: 136;  48h:80;  72h:26 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	DU145	14.49%	1.79%	186.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer.
C46103	22545969	DIS0129	NP7102	Elemene	DR1669	Cisplatin	NEWCL00251	DU145	.	24h: 192; 48h:96;  72h:40 uM	40 ug.ml:4.8.16 uM	NEWCL00253	PC-3	.	24h: 136;  48h:80;  72h:26 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	DU145	5.97%	72.62%	292.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer.
C46103	22545969	DIS0129	NP7102	Elemene	DR1669	Cisplatin	NEWCL00251	DU145	.	24h: 192; 48h:96;  72h:40 uM	40 ug.ml:4.8.16 uM	NEWCL00253	PC-3	.	24h: 136;  48h:80;  72h:26 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	DU145	1.24%	20.10%	34.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer.
C46103	22545969	DIS0129	NP7102	Elemene	DR1669	Cisplatin	NEWCL00251	DU145	.	24h: 192; 48h:96;  72h:40 uM	40 ug.ml:4.8.16 uM	NEWCL00253	PC-3	.	24h: 136;  48h:80;  72h:26 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	DU145	8.32%	21.38%	49.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer.
C46103	22545969	DIS0129	NP7102	Elemene	DR1669	Cisplatin	NEWCL00251	DU145	.	24h:192uM	40ug.ml:8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c (C)	Up-regulation	DU145	12.12%	13.76%	68.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer.
C49659	22617708	DIS0023	NP4621	Triptolide	DR1669	Cisplatin	NEWCL00342	PANC1	.	.	25nM:16uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HSP27	Down-regulation	PANC1	1.68%	2.31%	73.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined therapy of TPL and DDP triggers a synergic apoptosis via inhibiting HSP27 in human gemcitabine-resistant pancreatic carcinoma and has a strong potential to be developed into a new effective regimen for pancreatic cancer treatment.
C72340	22665077	DIS0022	NP5233	Wogonin	DR1669	Cisplatin	NEWCL00170	A-549	.	.	10 uM:10 uM	NEWCL00149	HeLa	.	.	7.5 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	28.53%	44.76%	93.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species.
C72340	22665077	DIS0022	NP5233	Wogonin	DR1669	Cisplatin	NEWCL00170	A-549	.	.	10 uM:10 uM	NEWCL00149	HeLa	.	.	7.5 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	77.67%	23.39%	237.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species.
C72340	22665077	DIS0022	NP5233	Wogonin	DR1669	Cisplatin	NEWCL00170	A-549	.	.	10 uM:10 uM	NEWCL00149	HeLa	.	.	7.5 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	273.76%	189.71%	254.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species.
C55738	22698937	DIS0124	NP6636	Daunorubicin	DR0141	Oxaliplatin	NEWCL00231	SK-OV-3	48h:18.5 uM	48h:33.7 uM	2.44uM:24.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Composite micelles showed reduced systematic toxicity and greater synergistic effect than combination of small molecules of hydrophilic platinum drug Oxa(II) and hydrophobic drug DRB both in vitro and in vivo.
C76452	22708678	DIS0025	NP8310	Sulforaphane	DR8244	Imatinib	NEWCL10110	KU812	.	.	30uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	KU812	11.29%	29.03%	29.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/Beta-catenin function.
C76452	22708678	DIS0025	NP8310	Sulforaphane	DR8244	Imatinib	NEWCL10110	KU812	.	.	30uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	KU812	8.42%	4.56%	12.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/Beta-catenin function.
C76452	22708678	DIS0025	NP8310	Sulforaphane	DR8244	Imatinib	NEWCL10110	KU812	.	.	30uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	KU812	1.84%	8.51%	20.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/Beta-catenin function.
C76452	22708678	DIS0025	NP8310	Sulforaphane	DR8244	Imatinib	NEWCL10110	KU812	.	.	30uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	KU812	27.90%	19.80%	45.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/Beta-catenin function.
C76452	22708678	DIS0025	NP8310	Sulforaphane	DR8244	Imatinib	NEWCL10110	KU812	.	.	30uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	KU812	12.78%	32.78%	34.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/Beta-catenin function.
C63080	22832932	DIS0115	NP8902	Ursolic acid	DR8297	Capecitabine	NEWCL00082	HCT 116	48h:9.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C-FLIP	Down-regulation	HCT 116	22.12%	14.31%	25.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Ursolic acid can inhibit the growth and metastasis of CRC and further enhance the therapeutic effects of capecitabine through the suppression of multiple biomarkers linked to inflammation, proliferation, invasion, angiogenesis, and metastasis."
C63080	22832932	DIS0115	NP8902	Ursolic acid	DR8297	Capecitabine	NEWCL00082	HCT 116	48h:9.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116	18.55%	13.34%	33.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Ursolic acid can inhibit the growth and metastasis of CRC and further enhance the therapeutic effects of capecitabine through the suppression of multiple biomarkers linked to inflammation, proliferation, invasion, angiogenesis, and metastasis."
C63080	22832932	DIS0115	NP8902	Ursolic acid	DR8297	Capecitabine	NEWCL00082	HCT 116	48h:9.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	HCT 116	18.91%	15.66%	29.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Ursolic acid can inhibit the growth and metastasis of CRC and further enhance the therapeutic effects of capecitabine through the suppression of multiple biomarkers linked to inflammation, proliferation, invasion, angiogenesis, and metastasis."
C63080	22832932	DIS0115	NP8902	Ursolic acid	DR8297	Capecitabine	NEWCL00082	HCT 116	48h:9.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	HCT 116	34.20%	19.67%	49.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Ursolic acid can inhibit the growth and metastasis of CRC and further enhance the therapeutic effects of capecitabine through the suppression of multiple biomarkers linked to inflammation, proliferation, invasion, angiogenesis, and metastasis."
C63080	22832932	DIS0115	NP8902	Ursolic acid	DR8297	Capecitabine	NEWCL00082	HCT 116	48h:9.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	HCT 116	8.97%	5.10%	7.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Ursolic acid can inhibit the growth and metastasis of CRC and further enhance the therapeutic effects of capecitabine through the suppression of multiple biomarkers linked to inflammation, proliferation, invasion, angiogenesis, and metastasis."
C63080	22832932	DIS0115	NP8902	Ursolic acid	DR8297	Capecitabine	NEWCL00082	HCT 116	48h:9.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	HCT 116	2.34%	2.62%	13.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Ursolic acid can inhibit the growth and metastasis of CRC and further enhance the therapeutic effects of capecitabine through the suppression of multiple biomarkers linked to inflammation, proliferation, invasion, angiogenesis, and metastasis."
C62668	22895079	DIS0025	NP0551	Oridonin	DR8244	Imatinib	NEWCL00063	SUP-B15	72h:7.8 ±  1.1886 uM	72h:1.3 ±  0.14 uM	3 uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4654	P-Abl	Down-regulation	SUP-B15	40.34%	86.20%	88.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
C62668	22895079	DIS0025	NP0551	Oridonin	DR8244	Imatinib	NEWCL00063	SUP-B15	72h:7.8 ±  1.1886 uM	72h:1.3 ±  0.14 uM	3 uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	SUP-B15	39.60%	19.42%	70.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
C62668	22895079	DIS0025	NP0551	Oridonin	DR8244	Imatinib	NEWCL00063	SUP-B15	72h:7.8 ±  1.1886 uM	72h:1.3 ±  0.14 uM	3 uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR (ser2448)	Down-regulation	SUP-B15	53.65%	39.28%	56.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
C62668	22895079	DIS0025	NP0551	Oridonin	DR8244	Imatinib	NEWCL00063	SUP-B15	72h:7.8 ±  1.1886 uM	72h:1.3 ±  0.14 uM	3 uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	p-p70S6K (Thr389)	Down-regulation	SUP-B15	64.92%	31.42%	60.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
C62668	22895079	DIS0025	NP0551	Oridonin	DR8244	Imatinib	NEWCL00063	SUP-B15	72h:7.8 ±  1.1886 uM	72h:1.3 ±  0.14 uM	3 uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7832	P-4EBP1	Down-regulation	SUP-B15	46.32%	22.38%	52.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
C62668	22895079	DIS0025	NP0551	Oridonin	DR8244	Imatinib	NEWCL00063	SUP-B15	72h:7.8 ±  1.1886 uM	72h:1.3 ±  0.14 uM	3 uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-Lyn (Tyr396)	Down-regulation	SUP-B15	35.23%	38.62%	66.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
C62668	22895079	DIS0025	NP0551	Oridonin	DR8244	Imatinib	NEWCL00063	SUP-B15	72h:7.8 ±  1.1886 uM	72h:1.3 ±  0.14 uM	3 uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9634	p-Stat5a (Thr694 )	Down-regulation	SUP-B15	67.87%	88.88%	63.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
C61221	22919067	DIS0124	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00231	SK-OV-3	.	.	0.37 uM:11.19 uM	NEWCL20404	OV2008	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SKOV3	74.43%	21.63%	125.83%	OV2008	37.34%	55.79%	352.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
C61221	22919067	DIS0124	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00231	SK-OV-3	.	.	0.37 uM:11.19 uM	NEWCL20404	OV2008	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SKOV3	6.85%	7.09%	250.92%	OV2008	115.96%	0.65%	332.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
C61221	22919067	DIS0124	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00231	SK-OV-3	.	.	0.37 uM:11.19 uM	NEWCL20404	OV2008	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B	Up-regulation	SKOV3	7.18%	30.27%	66.49%	OV2008	168.01%	0.19%	321.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
C61221	22919067	DIS0124	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00231	SK-OV-3	.	.	0.37 uM:11.19 uM	NEWCL20404	OV2008	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2597	ATG5	Up-regulation	SKOV3	49.32%	60.43%	168.78%	OV2008	19.11%	22.41%	22.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
C61221	22919067	DIS0124	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00231	SK-OV-3	.	.	0.37 uM:11.19 uM	NEWCL20404	OV2008	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7832	P-4EBP1	Down-regulation	SKOV3	1.10%	4.48%	2417.38%	OV2008	1.58%	50.55%	789.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
C61221	22919067	DIS0124	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00231	SK-OV-3	.	.	0.37 uM:11.19 uM	NEWCL20404	OV2008	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	SKOV3	12.64%	0.71%	66.87%	OV2008	45.81%	2.65%	88.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
C61221	22919067	DIS0124	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00231	SK-OV-3	.	.	0.37 uM:11.19 uM	NEWCL20404	OV2008	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	SKOV3	24.03%	13.03%	36.53%	OV2008	36.17%	45.41%	57.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
C07326	22923287	DIS0036	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL00269	CAL-27	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	CAL-27	16.74%	8.06%	31.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
C07326	22923287	DIS0036	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL00269	CAL-27	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TIMP2	Up-regulation	CAL-28	9.35%	58.67%	52.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
C07326	22923287	DIS0036	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL00269	CAL-27	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	CAL-29	1.00%	2.89%	7.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
C07326	22923287	DIS0036	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL00269	CAL-27	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	CAL-30	9.46%	9.34%	1.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
C07326	22923287	DIS0036	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL00269	CAL-27	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Down-regulation	CAL-31	4.66%	12.63%	27.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
C07326	22923287	DIS0036	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL00269	CAL-27	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-P38	Down-regulation	CAL-32	1.31%	5.18%	32.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
C07326	22923287	DIS0036	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL00269	CAL-27	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	CAL-33	0.37%	15.35%	26.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
C78929	22942757	DIS0029	NP3067	Paclitaxel	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	1 umol.L:1000 ng.mL	NEWCL00279	U-87MG ATCC	.	.	1 umol.L:1000 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR5	Up-regulation	U-87MG ATCC	4.73%	5.75%	3.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	PX can sensitize U87 cells and U87-SLCs to TRAIL treatment through an extrinsic pathway of cell apoptosis.
C78929	22942757	DIS0029	NP3067	Paclitaxel	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	1 umol.L:1000 ng.mL	NEWCL00279	U-87MG ATCC	.	.	1 umol.L:1000 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	U-87MG ATCC	26.32%	26.77%	28.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	PX can sensitize U87 cells and U87-SLCs to TRAIL treatment through an extrinsic pathway of cell apoptosis.
C78929	22942757	DIS0029	NP3067	Paclitaxel	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	1 umol.L:1000 ng.mL	NEWCL00279	U-87MG ATCC	.	.	1 umol.L:1000 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	U-87MG ATCC	6.84%	7.30%	7.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	PX can sensitize U87 cells and U87-SLCs to TRAIL treatment through an extrinsic pathway of cell apoptosis.
C36880	22957270	DIS0022	NP0109	Medione	DR6224	Sodium orthovadate	NEWCL00170	A-549	72h:24 uM	72h:20 uM	17.5 uM : 17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Menadione : sodium orthovanadate combination eliminates and inhibits migration of detached cancer cells.
C98672	22965008	DIS0022	NP0016	Silibinin	DR2632	Vorinostat	NEWCL00181	NCI-H1299	.	.	75uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	NCI-H1299	30.00%	190.00%	350.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR7217	Trichostatin A	NEWCL00181	NCI-H1299	.	.	75uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-H1299	20.00%	10.00%	1400.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR7217	Trichostatin A	NEWCL00181	NCI-H1299	.	.	75uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	NCI-H1299	140.00%	50.00%	900.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR7217	Trichostatin A	NEWCL00181	NCI-H1299	.	.	75uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	NCI-H1299	30.00%	20.00%	500.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR2632	Vorinostat	NEWCL00181	NCI-H1299	.	.	75uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	Mcl-1(L)	Down-regulation	NCI-H1299	40.00%	20.00%	70.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR2632	Vorinostat	NEWCL00181	NCI-H1299	.	.	75uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	NCI-H1299	90.00%	60.00%	70.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR2632	Vorinostat	NEWCL00181	NCI-H1299	.	.	75uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	NCI-H1299	10.00%	50.00%	90.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR2632	Vorinostat	NEWCL00181	NCI-H1299	.	.	75uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-CDC2	Down-regulation	NCI-H1299	40.00%	90.00%	99.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR2632	Vorinostat	NEWCL00181	NCI-H1299	.	.	75uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	NCI-H1299	70.00%	95.00%	99.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR7217	Trichostatin A	NEWCL00181	NCI-H1299	.	.	75uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	Mcl-1(L)	Down-regulation	NCI-H1299	40.00%	10.00%	80.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR7217	Trichostatin A	NEWCL00181	NCI-H1299	.	.	75uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	NCI-H1299	90.00%	10.00%	100.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR7217	Trichostatin A	NEWCL00181	NCI-H1299	.	.	75uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	NCI-H1299	10.00%	20.00%	100.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR7217	Trichostatin A	NEWCL00181	NCI-H1299	.	.	75uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-CDC2	Down-regulation	NCI-H1299	40.00%	20.00%	100.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C98672	22965008	DIS0022	NP0016	Silibinin	DR7217	Trichostatin A	NEWCL00181	NCI-H1299	.	.	75uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	NCI-H1299	70.00%	60.00%	99.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."
C00179	23017833	DIS0001	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00099	EC9706	.	.	50 mM:327 mg.ml	NEWCL00098	Eca-109	.	.	50 mM:327 mg.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"NF-kappaB signaling pathway was constitutively activated in the ESCC cell lines. Curcumin suppressed the activation of NF-kappaB via the inhibition of IkappaBalpha phosphorylation, and downregulated the expressions of Bcl-2 and CyclinD1 in ESCC cell lines."
C54372	23018309	DIS0031	NP6854	Vitamin K2	DR2073	Sorafenib	NEWCL00129	Hep-G2	.	.	1uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hep-G2	7.98%	16.33%	64.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined treatment with sorafenib and vitamin K2 can work synergistically to inhibit the growth of hepatocellular carcinoma cells.
C54372	23018309	DIS0031	NP6854	Vitamin K2	DR2073	Sorafenib	NEWCL00129	Hep-G2	.	.	1uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p-ERK	Down-regulation	Hep-G2	7.06%	2.77%	32.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined treatment with sorafenib and vitamin K2 can work synergistically to inhibit the growth of hepatocellular carcinoma cells.
C54372	23018309	DIS0031	NP6854	Vitamin K2	DR2073	Sorafenib	NEWCL00129	Hep-G2	.	.	1uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	Hep-G2	18.18%	2.68%	46.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined treatment with sorafenib and vitamin K2 can work synergistically to inhibit the growth of hepatocellular carcinoma cells.
C10758	23056046	DIS0127	NP9279	Genistein	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	25 uM : 250 nM ; 24h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-P70S6K	Up-regulation	HeLa	2.20%	10.75%	28.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Genistein enhanced the antitumor activity of cisplatin and reduced the expression of NF-kappaB, p-mTOR, p-p70S6K1, p-4E-BP1, and p-Akt."
C42934	23060566	DIS0115	NP0649	Ellagic acid	DR9021	5-fluorouracil	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hep-G2	14.49%	21.74%	155.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ellagic acid synergistically potentiated chemosensitivity to 5-fluorouracil in colorectal cancer cells.
C72463	23146690	DIS0035	NP6084	Resveratrol	DR3243	Clofarabine	NEWCL00246	MSTO-211H	.	.	15 uM:40 nM	NEWCL00337	MeT-5A	.	.	15 uM:40 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Sp1	Down-regulation	MSTO-211H	7.48%	5.53%	32.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities.
C72463	23146690	DIS0035	NP6084	Resveratrol	DR3243	Clofarabine	NEWCL00246	MSTO-211H	.	.	15 uM:40 nM	NEWCL00337	MeT-5A	.	.	15 uM:40 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C-Met	Down-regulation	MSTO-211H	35.67%	15.73%	35.33%	MeT-5A	9.78%	15.69%	11.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities.
C72463	23187004	DIS0035	NP6084	Resveratrol	DR3243	Clofarabine	NEWCL00246	MSTO-211H	.	.	20 uM:40 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MSTO-211H	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Clofarabine and resveratrol cooperatively exerted cytotoxic effects in MSTO-211H cells. The observed synergism was mediated, at least in part, through suppression of the Nrf2 and PI3K/Akt signalings."
C02533	23205102	DIS0023	NP9654	Bufalin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	0.01uM:0.5ug.mL	NEWCL00236	MIA PaCa-2	.	.	0.01uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	BxPC-3	6.12%	21.80%	34.01%	MiaPaCa-2	10.57%	70.42%	120.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer.
C02533	23205102	DIS0023	NP9654	Bufalin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	0.01uM:0.5ug.mL	NEWCL00236	MIA PaCa-2	.	.	0.01uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ASK1	Up-regulation	BxPC-3	.	.	.	MiaPaCa-2	24.13%	19.50%	47.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer.
C02533	23205102	DIS0023	NP9654	Bufalin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	0.01uM:0.5ug.mL	NEWCL00236	MIA PaCa-2	.	.	0.01uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	BxPC-3	3.54%	9.58%	20.09%	MiaPaCa-2	9.34%	6.78%	35.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer.
C02533	23205102	DIS0023	NP9654	Bufalin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	0.01uM:0.5ug.mL	NEWCL00236	MIA PaCa-2	.	.	0.01uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Down-regulation	BxPC-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer.
C71701	23207250	DIS0127	NP3478	Eugenol	DR9021	5-fluorouracil	NEWCL00149	HeLa	24h:315.79 ±  9.1uM	24h:20.8 ±  3.9uM	158 uM:10.5 uM	NEWCL00129	Hep-G2	24h:34.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Eugenol interacts synergistically with 5-fluorouracil against human cervical cancer, HeLa cell lines, by blocking the cell cycle and inducing apoptosis."
C59960	23224239	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00129	Hep-G2	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	Hep-G2	93.72%	114.67%	1309.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.
C59960	23224239	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00129	Hep-G2	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3834	Cleaved-caspase-6	Up-regulation	Hep-G2	95.50%	34.91%	541.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.
C59960	23224239	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00129	Hep-G2	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hep-G2	52.53%	29.06%	247.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.
C59960	23224239	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00129	Hep-G2	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Hep-G2	31.31%	12.30%	799.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.
C76367	23226540	DIS0111	NP6128	Gossypol	DR2391	Gemcitabine	NEWCL00340	CNE-2	72h:16.7uM	72h: >100uM	.	NEWCL00155	MCF-7	72h:20.63uM	72h:>100uM	.	NEWCL10025	YCC-16	72h:8.85uM	72h:>100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	CNE-2	1.34%	1.70%	0.10%	MCF-7	8.88%	6.75%	11.63%	YCC16	21.30%	9.54%	21.13%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
C76367	23226540	DIS0111	NP6128	Gossypol	DR2391	Gemcitabine	NEWCL00340	CNE-2	72h:16.7uM	72h: >100uM	.	NEWCL00155	MCF-7	72h:20.63uM	72h:>100uM	.	NEWCL10025	YCC-16	72h:8.85uM	72h:>100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7894	NOXA	Up-regulation	CNE-2	4.35%	0.93%	5.17%	MCF-7	166.46%	13.72%	166.25%	YCC16	95.38%	49.59%	95.28%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
C76367	23226540	DIS0111	NP6128	Gossypol	DR2391	Gemcitabine	NEWCL00340	CNE-2	72h:16.7uM	72h: >100uM	.	NEWCL00155	MCF-7	72h:20.63uM	72h:>100uM	.	NEWCL10025	YCC-16	72h:8.85uM	72h:>100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	CNE-2	20.78%	2.38%	28.27%	MCF-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
C76367	23226540	DIS0111	NP6128	Gossypol	DR2391	Gemcitabine	NEWCL00340	CNE-2	72h:16.7uM	72h: >100uM	.	NEWCL00155	MCF-7	72h:20.63uM	72h:>100uM	.	NEWCL10025	YCC-16	72h:8.85uM	72h:>100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	CNE-2	4.87%	4.71%	1.93%	MCF-7	26.49%	-6.69%	30.49%	YCC16	5.16%	5.24%	7.65%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
C03836	23226792	DIS0112	NP1168	Quercetin	DR9021	5-fluorouracil	NEWCL00099	EC9706	.	.	50 uM:0.2 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IKBalpha	Down-regulation	EC9706	62.77%	3.40%	31.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-KappaB.
C85683	23229294	DIS0021	NP1559	Luteolin	DR2742	Celecoxib	NEWCL00155	MCF-7	.	.	50 uM:75 uM	NEWCL00049	MDA-MB-231	.	.	50 uM:75 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MCF-7	26.74%	12.32%	24.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of celecoxib and luteolin provided superior inhibition of breast cancer cell growth than either celecoxib or luteolin treatment alone. Decreased levels of Akt phosphorylation (pAkt) were noted after celecoxib and luteolin combination treatment.
C22952	23231932	DIS0019	NP9219	Withaferin A	DR2073	Sorafenib	NEWCL10335	B-CPAP	72h:1.55 uM	72h:6.3 uM	0.775uM :3.15uM	NEWCL10372	SW1736	72h:2.5 uM	72h:7.6 uM	1.25uM :3.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	B-CPAP	18.55%	25.28%	53.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with sorafenib + withaferin showed synergistic efficacy in papillary and anaplastic cancers in vitro with significant induction of apoptosis.
C22952	23231932	DIS0019	NP9219	Withaferin A	DR2073	Sorafenib	NEWCL10335	B-CPAP	72h:1.55 uM	72h:6.3 uM	0.775uM :3.15uM	NEWCL10372	SW1736	72h:2.5 uM	72h:7.6 uM	1.25uM :3.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7635	BRAF	Down-regulation	B-CPAP	25.74%	22.07%	73.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with sorafenib + withaferin showed synergistic efficacy in papillary and anaplastic cancers in vitro with significant induction of apoptosis.
C72385	23284992	DIS0031	NP8797	Celastrol	DR6631	ABT-737	NEWCL00129	Hep-G2	.	.	1.25 uM :10 uM	NEWCL00141	Bel-7402	.	.	1.25 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hep-G2	4.17%	15.76%	134.96%	Bel-7402	23.62%	18.08%	138.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells by upregulating Noxa.
C72385	23284992	DIS0031	NP8797	Celastrol	DR6631	ABT-737	NEWCL00129	Hep-G2	.	.	1.25 uM :10 uM	NEWCL00141	Bel-7402	.	.	1.25 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	Hep-G2	13.79%	1.13%	48.90%	Bel-7402	4.34%	17.25%	22.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells by upregulating Noxa.
C72385	23284992	DIS0031	NP8797	Celastrol	DR6631	ABT-737	NEWCL00129	Hep-G2	.	.	1.25 uM :10 uM	NEWCL00141	Bel-7402	.	.	1.25 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Hep-G2	36.62%	54.97%	107.72%	Bel-7402	190.26%	33.41%	116.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells by upregulating Noxa.
C72385	23284992	DIS0031	NP8797	Celastrol	DR6631	ABT-737	NEWCL00129	Hep-G2	.	.	1.25 uM :10 uM	NEWCL00141	Bel-7402	.	.	1.25 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Hep-G2	6.86%	1.74%	4.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells by upregulating Noxa.
C72385	23284992	DIS0031	NP8797	Celastrol	DR6631	ABT-737	NEWCL00129	Hep-G2	.	.	1.25 uM :10 uM	NEWCL00141	Bel-7402	.	.	1.25 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	Hep-G2	40.65%	38.51%	9.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells by upregulating Noxa.
C82390	23299550	DIS0021	NP6905	Curcumin	DR1563	Tamoxifen	NEWCL00155	MCF-7	96h:9.718uM; 48h:9.815uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of curcumin and tamoxifen resulted in a synergistic survival inhibition in MCF-7/LCC2 and MCF-7/LCC9 cells.
C42547	23371323	DIS0022	NP5233	Wogonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	10 uM: 10 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	A-549	9.86%	0.24%	62.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins.
C42547	23371323	DIS0022	NP5233	Wogonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	10 uM: 10 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CIAP-2	Down-regulation	A-549	3.55%	4.29%	7.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins.
C46103	23397083	DIS0022	NP7102	Elemene	DR1669	Cisplatin	NEWCL00180	NCI-H460	24h:89.5ug.ml; 48h:70.6ug.ml; 72h:68.2ug.ml; 	24h:40uM;  48h:16uM;  72h:9 uM; 	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL00170	A-549	24h:62.0ug.ml; 48h:55.6ug.ml; 72h:56.4ug.ml;  	24h:76uM;  48h:34uM; 72h:16 uM; 	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL20444	NL20	 126 to 145 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	NCI-H460	3.29%	16.28%	36.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression.
C46103	23397083	DIS0022	NP7102	Elemene	DR1669	Cisplatin	NEWCL00180	NCI-H460	24h:89.5ug.ml; 48h:70.6ug.ml; 72h:68.2ug.ml; 	24h:40uM;  48h:16uM;  72h:9 uM; 	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL00170	A-549	24h:62.0ug.ml; 48h:55.6ug.ml; 72h:56.4ug.ml;  	24h:76uM;  48h:34uM; 72h:16 uM; 	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL20444	NL20	 126 to 145 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-CDC2	Up-regulation	NCI-H460	2.94%	2.27%	43.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression.
C46103	23397083	DIS0022	NP7102	Elemene	DR1669	Cisplatin	NEWCL00180	NCI-H460	24h:89.5ug.ml; 48h:70.6ug.ml; 72h:68.2ug.ml; 	24h:40uM;  48h:16uM;  72h:9 uM; 	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL00170	A-549	24h:62.0ug.ml; 48h:55.6ug.ml; 72h:56.4ug.ml;  	24h:76uM;  48h:34uM; 72h:16 uM; 	24h.48h; 30 ug.ml:2 or 4 uM	NEWCL20444	NL20	 126 to 145 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	.	5.14%	11.79%	55.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression.
C46690	23431365	DIS0129	NP4620	Apigenin	DR4267	TRAILApo2L 	NEWCL00251	DU145	.	.	20 umol.L:50 ng.m	NEWCL00252	LNCaP	.	.	20 umol.L:50 ng.m	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DU145	.	.	.	LNCaP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2.
C17620	23436279	DIS0124	NP5023	Gambogic acid	DR4469	Doxorubicin	NEWCL00231	SK-OV-3	.	.	0.4uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SK-OV-3	3.88%	70.70%	198.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis.
C17620	23436279	DIS0124	NP5023	Gambogic acid	DR4469	Doxorubicin	NEWCL00231	SK-OV-3	.	.	0.4uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	SK-OV-3	145.26%	256.81%	4068.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis.
C17620	23436279	DIS0124	NP5023	Gambogic acid	DR4469	Doxorubicin	NEWCL00231	SK-OV-3	.	.	0.4uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Up-regulation	SK-OV-3	6.42%	55.37%	158.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis.
C17620	23436279	DIS0124	NP5023	Gambogic acid	DR4469	Doxorubicin	NEWCL00231	SK-OV-3	.	.	0.4uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	SK-OV-3	37.53%	46.87%	63.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis.
C49186	23464475	DIS0020	NP5023	Gambogic acid	DR0749	Sunitinib	NEWCL00256	786-O	.	.	0.5uM : 2uM	NEWCL00282	Caki-1	.	.	0.5uM : 2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	786-O	10.40%	6.24%	47.74%	Caki-1	57.39%	21.23%	73.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The joint use of GA and SU can provide greater antitumor efficacy compared to either drug alone.
C49186	23464475	DIS0020	NP5023	Gambogic acid	DR0749	Sunitinib	NEWCL00256	786-O	.	.	0.5uM : 2uM	NEWCL00282	Caki-1	.	.	0.5uM : 2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	786-O	127.39%	90.16%	184.89%	Caki-1	213.83%	126.97%	263.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The joint use of GA and SU can provide greater antitumor efficacy compared to either drug alone.
C49186	23464475	DIS0020	NP5023	Gambogic acid	DR0749	Sunitinib	NEWCL00256	786-O	.	.	0.5uM : 2uM	NEWCL00282	Caki-1	.	.	0.5uM : 2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	786-O	11.18%	76.43%	71.06%	Caki-1	19.16%	19.43%	49.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The joint use of GA and SU can provide greater antitumor efficacy compared to either drug alone.
C46103	23564782	DIS0130	NP7102	Elemene	DR1669	Cisplatin	NEWCL00349	5637	 24h:85ug.ml;  48h:78ug.ml;  72h:72 ug.ml	24h:52.0uM;  48h:36.0uM;   72h:20.0 uM ;  	40 ug.ml:4.8.16 uM	NEWCL00047	T24	24h:76ug.ml;  48h:72 ug.ml; 72h:67 ug.ml	24h: 112.0uM;   48h:68.0uM ;  72h:36.0 uM	24; 48 ; 72h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	 beta-elemene augments the antitumor activity of cisplatin in human bladder cancer by enhancing the induction of cellular apoptosis via a caspase-dependent mechanism.
C10758	23621233	DIS0031	NP9279	Genistein	DR1669	Cisplatin	NEWCL00030	HCCLM3	48h:152.33uM	48h:52.75uM	59.3uM:83uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Down-regulation	HCCLM3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Genistein reinforced the inhibitory effect of cisplatin on HCC cell proliferation and tumour recurrence and metastasis after curative hepatectomy in nude mice, possibly through mitigation of cisplatin-induced MMP-2 upregulation."
C82644	23649759	DIS0031	NP8797	Celastrol	DR7572	PHA665752	NEWCL00141	Bel-7402	.	72h:0.0833uM	.	NEWCL00031	Huh-7	.	72h:1.2276uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo.
C34772	23660868	DIS0028	NP6993	Arsenic trioxide	DR3078	"1,25-dihydroxyvitamin D3"	NEWCL00022	HL-60	.	.	1.0 uM: 100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HL-60	2.17%	-1.08%	1.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis."
C34772	23660868	DIS0028	NP6993	Arsenic trioxide	DR3078	"1,25-dihydroxyvitamin D3"	NEWCL00022	HL-60	.	.	1.0 uM: 100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Up-regulation	HL-60	2.17%	1.04%	1.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis."
C34772	23660868	DIS0028	NP6993	Arsenic trioxide	DR3078	"1,25-dihydroxyvitamin D3"	NEWCL00022	HL-60	.	.	1.0 uM: 100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	.	HL-60	0.55%	0.52%	1.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis."
C34772	23660868	DIS0028	NP6993	Arsenic trioxide	DR3078	"1,25-dihydroxyvitamin D3"	NEWCL00022	HL-60	.	.	1.0 uM: 100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HL-60	0.44%	0.21%	0.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis."
C24621	23664889	DIS00021	NP6459	Vinblastine	DR5673	noliposomal C6-ceramide	NEWCL00129	Hep-G2	.	.	47uM:0.2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B	Up-regulation	Hep-G2	43.51%	18.25%	165.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In vitro and in vivo data support a synergistic antitumor activity of the nanoliposomal C6-ceramide and vinblastine combination, potentially mediated by an autophagy mechanism."
C24621	23664889	DIS00021	NP6459	Vinblastine	DR5673	noliposomal C6-ceramide	NEWCL00129	Hep-G2	.	.	47uM:0.2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Up-regulation	Hep-G2	12.40%	5.27%	12.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In vitro and in vivo data support a synergistic antitumor activity of the nanoliposomal C6-ceramide and vinblastine combination, potentially mediated by an autophagy mechanism."
C06709	23708557	DIS0029	NP7094	Noscapine	DR6516	Temozolomide 	NEWCL00279	U-87MG ATCC	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U-87MG ATCCMG	374.46%	218.43%	605.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects."
C06709	23708557	DIS0029	NP7094	Noscapine	DR6516	Temozolomide 	NEWCL00279	U-87MG ATCC	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	U-87MG ATCCMG	11.82%	28.33%	80.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects."
C06709	23708557	DIS0029	NP7094	Noscapine	DR3226	Bis-chloroethylnitrosourea	NEWCL00279	U-87MG ATCC	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U-87MG ATCCMG	374.46%	357.91%	391.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects."
C06709	23708557	DIS0029	NP7094	Noscapine	DR3226	Bis-chloroethylnitrosourea	NEWCL00279	U-87MG ATCC	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	U-87MG ATCCMG	11.82%	11.88%	18.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects."
C06709	23708557	DIS0029	NP7094	Noscapine	DR1669	Cisplatin	NEWCL00279	U-87MG ATCC	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U-87MG ATCCMG	374.46%	264.78%	419.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects."
C06709	23708557	DIS0029	NP7094	Noscapine	DR1669	Cisplatin	NEWCL00279	U-87MG ATCC	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	U-87MG ATCCMG	11.82%	97.65%	23.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects."
C15089	23744430	DIS0021	NP5833	Dihydroartemisinin	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	20 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7	7.05%	98.29%	312.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combinative treatment remarkably decreased the mitochondrial membrane potential and activated caspase cascades more than the mono-treatment.
C15089	23744430	DIS0021	NP5833	Dihydroartemisinin	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	20 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Caspase-7	Down-regulation	MCF-7	5.34%	9.02%	17.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combinative treatment remarkably decreased the mitochondrial membrane potential and activated caspase cascades more than the mono-treatment.
C15089	23744430	DIS0021	NP5833	Dihydroartemisinin	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	20 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	MCF-7	8.79%	24.00%	75.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combinative treatment remarkably decreased the mitochondrial membrane potential and activated caspase cascades more than the mono-treatment.
C76781	23786838	DIS0114	NP3718	Honokiol	DR0141	Oxaliplatin	NEWCL00077	HT-29	.	.	1uM:0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P-P65	Down-regulation	HT-29	0.62%	1.24%	14.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.
C76781	23786838	DIS0114	NP3718	Honokiol	DR0141	Oxaliplatin	NEWCL00077	HT-29	.	.	1uM:0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	HT-29	5.19%	13.90%	-1.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.
C76781	23786838	DIS0114	NP3718	Honokiol	DR0141	Oxaliplatin	NEWCL00077	HT-29	.	.	1uM:0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	HT-29	2.24%	4.71%	16.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.
C78169	23801065	DIS0023	NP2294	Geraniol	DR2391	Gemcitabine	NEWCL00243	BXPC-3	.	.	20uumol.l :20uumol.l ; 24h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Geraniol significantly increased the antiproliferative and apoptosis-inducing effects of gemcitabine on BXPC-3 cells.
C39064	23803076	DIS0127	NP4621	Triptolide	DR9529	Aspirin	NEWCL00137	Siha	.	.	100 nM: 10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Siha	334.59%	348.65%	474.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Aspirin and triptolide combination treatment has synergistic anti-tumor effects on cervical cancer cells.
C39064	23803076	DIS0127	NP4621	Triptolide	DR9529	Aspirin	NEWCL00137	Siha	.	.	100 nM: 10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	Siha	250.23%	16.60%	312.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Aspirin and triptolide combination treatment has synergistic anti-tumor effects on cervical cancer cells.
C89866	23807219	DIS0023	NP6128	Gossypol	DR9750	HMT G9a	NEWCL00242	PANC-1	.	.	2.5 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-II	Up-regulation	PANC-1	3.92%	1.96%	266.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells."
C89866	23807219	DIS0023	NP6128	Gossypol	DR9750	HMT G9a	NEWCL00242	PANC-1	.	.	2.5 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8442	BNIP3(dimer)	Up-regulation	PANC-1	22.47%	39.33%	38.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells."
C89866	23807219	DIS0023	NP6128	Gossypol	DR9750	HMT G9a	NEWCL00242	PANC-1	.	.	2.5 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8442	BNIP3(monomer)	Up-regulation	PANC-1	36.21%	44.83%	42.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells."
C62137	23846485	DIS0021	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00156	T-47D	.	.	20 uM:50 ng.ml	NEWCL00052	SK-BR-3	.	.	20 uM:50 ng.ml	NEWCL00155	MCF-7	.	.	20 uM:100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	MCF-7	0.02%	2.03%	53.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
C62137	23846485	DIS0021	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00156	T-47D	.	.	20 uM:50 ng.ml	NEWCL00052	SK-BR-3	.	.	20 uM:50 ng.ml	NEWCL00155	MCF-7	.	.	20 uM:100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7	4.55%	1.75%	153.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
C62137	23846485	DIS0021	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00156	T-47D	.	.	20 uM:50 ng.ml	NEWCL00052	SK-BR-3	.	.	20 uM:50 ng.ml	NEWCL00155	MCF-7	.	.	20 uM:100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	MCF-7	2.61%	6.03%	85.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
C62137	23846485	DIS0021	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00156	T-47D	.	.	20 uM:50 ng.ml	NEWCL00052	SK-BR-3	.	.	20 uM:50 ng.ml	NEWCL00155	MCF-7	.	.	20 uM:100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	MCF-7	0.07%	3.31%	183.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
C62137	23846485	DIS0021	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00156	T-47D	.	.	20 uM:50 ng.ml	NEWCL00052	SK-BR-3	.	.	20 uM:50 ng.ml	NEWCL00155	MCF-7	.	.	20 uM:100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	.	MCF-7	0.10%	2.73%	-1.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
C62137	23846485	DIS0021	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00156	T-47D	.	.	20 uM:50 ng.ml	NEWCL00052	SK-BR-3	.	.	20 uM:50 ng.ml	NEWCL00155	MCF-7	.	.	20 uM:100 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Up-regulation	MCF-7	1.50%	2.64%	1.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
C19645	23848205	DIS0020	NP6905	Curcumin	DR0749	Sunitinib	NEWCL00256	786-O	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128uM	.	128uM:2250uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	SMMC-7721	18.26%	6.76%	68.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128uM	.	128uM:2250uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	SMMC-7721	60.86%	283.35%	456.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128uM	.	128uM:2250uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	PI3K	Down-regulation	SMMC-7721	61.24%	67.83%	85.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128uM	.	128uM:2250uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	SMMC-7721	48.93%	66.44%	84.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128uM	.	128uM:2250uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IkappaB	Down-regulation	SMMC-7721	25.77%	3.80%	62.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128uM	.	128uM:2250uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IKK	Down-regulation	SMMC-7721	21.53%	4.31%	65.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128uM	.	128uM:2250uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-kappaB(nuclearl)	Down-regulation	SMMC-7721	37.22%	21.90%	75.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128.10 ±  1.41 uM	.	128 uM:2250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SMMC-7721	37.05%	192.86%	355.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128.10 ±  1.41 uM	.	128 uM:2250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SMMC-7721	260.98%	822.15%	804.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128.10 ±  1.41 uM	.	128 uM:2250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SMMC-7721	116.12%	159.04%	138.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128.10 ±  1.41 uM	.	128 uM:2250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	SMMC-7721	126.36%	695.56%	746.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128.10 ±  1.41 uM	.	128 uM:2250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	SMMC-7721	11.64%	56.33%	86.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128.10 ±  1.41 uM	.	128 uM:2250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	SMMC-7721	12.97%	80.76%	91.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128.10 ±  1.41 uM	.	128 uM:2250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	PI3K	Down-regulation	SMMC-7721	30.49%	55.70%	77.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128.10 ±  1.41 uM	.	128 uM:2250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	SMMC-7721	67.12%	76.38%	87.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C01053	23859016	DIS0031	NP5233	Wogonin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:128.10 ±  1.41 uM	.	128 uM:2250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IKK	Down-regulation	SMMC-7721	29.66%	22.11%	66.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
C48781	23883479	DIS0025	NP6993	Arsenic trioxide	DR6872	Nilotinib	NEWCL20364	K562-r	.	.	1.5 mM:8 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9850	P-c-Jun	Up-regulation	K562-r	3.22%	4.17%	11.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	ATO synergistically potentiated the apoptotic efficacy of the TKI AMN107 in imatinib-resistant CML cell.
C48781	23883479	DIS0025	NP6993	Arsenic trioxide	DR6872	Nilotinib	NEWCL20364	K562-r	.	.	1.5 mM:8 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	K562-r	22.30%	15.55%	39.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	ATO synergistically potentiated the apoptotic efficacy of the TKI AMN107 in imatinib-resistant CML cell.
C48781	23883479	DIS0025	NP6993	Arsenic trioxide	DR6872	Nilotinib	NEWCL20364	K562-r	.	.	1.5 mM:8 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-c-abl	Down-regulation	K562-r	5.11%	81.72%	75.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	ATO synergistically potentiated the apoptotic efficacy of the TKI AMN107 in imatinib-resistant CML cell.
C48781	23883479	DIS0025	NP6993	Arsenic trioxide	DR6872	Nilotinib	NEWCL20364	K562-r	.	.	1.5 mM:8 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7803	P-CrkL	Down-regulation	K562-r	0.93%	41.21%	42.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	ATO synergistically potentiated the apoptotic efficacy of the TKI AMN107 in imatinib-resistant CML cell.
C04317	23958791	DIS0022	NP4621	Triptolide	DR0767	Vasostatin	NEWCL00082	HCT 116	.	.	27.5nM:5nM	NEWCL10158	HUVEC	.	.	27.5nM:5nM	NEWCL10120	HEK293	.	.	27.5nM:5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HCT 116	49.46%	46.96%	132.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
C04317	23958791	DIS0022	NP4621	Triptolide	DR0767	Vasostatin	NEWCL00082	HCT 116	.	.	27.5nM:5nM	NEWCL10158	HUVEC	.	.	27.5nM:5nM	NEWCL10120	HEK293	.	.	27.5nM:5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HCT 116	6.71%	4.85%	189.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
C04317	23958791	DIS0022	NP4621	Triptolide	DR0767	Vasostatin	NEWCL00082	HCT 116	.	.	27.5nM:5nM	NEWCL10158	HUVEC	.	.	27.5nM:5nM	NEWCL10120	HEK293	.	.	27.5nM:5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ClAP-1	Down-regulation	HCT 116	36.40%	23.48%	74.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
C04317	23958791	DIS0022	NP4621	Triptolide	DR0767	Vasostatin	NEWCL00082	HCT 116	.	.	27.5nM:5nM	NEWCL10158	HUVEC	.	.	27.5nM:5nM	NEWCL10120	HEK293	.	.	27.5nM:5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116	8.74%	3.71%	5.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
C04317	23958791	DIS0022	NP4621	Triptolide	DR0767	Vasostatin	NEWCL00082	HCT 116	.	.	27.5nM:5nM	NEWCL10158	HUVEC	.	.	27.5nM:5nM	NEWCL10120	HEK293	.	.	27.5nM:5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	HCT 116	11.13%	8.32%	6.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
C04317	23958791	DIS0022	NP4621	Triptolide	DR0767	Vasostatin	NEWCL00082	HCT 116	.	.	27.5nM:5nM	NEWCL10158	HUVEC	.	.	27.5nM:5nM	NEWCL10120	HEK293	.	.	27.5nM:5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT 116	18.57%	9.51%	55.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
C04317	23958791	DIS0022	NP4621	Triptolide	DR0767	Vasostatin	NEWCL00082	HCT 116	.	.	27.5nM:5nM	NEWCL10158	HUVEC	.	.	27.5nM:5nM	NEWCL10120	HEK293	.	.	27.5nM:5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	HCT 116	10.40%	28.39%	84.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
C04317	23958791	DIS0022	NP4621	Triptolide	DR0767	Vasostatin	NEWCL00082	HCT 116	.	.	27.5nM:5nM	NEWCL10158	HUVEC	.	.	27.5nM:5nM	NEWCL10120	HEK293	.	.	27.5nM:5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-kappaB p65	Down-regulation	HCT 116	14.54%	10.20%	3.26%	HUVEC	3.25%	-6.67%	40.14%	HEK293	14.43%	3.75%	33.73%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
C72944	23999913	DIS0129	NP9279	Genistein	DR1078	Cabazitaxel	NEWCL00003	ARCaPM	72h:105.5 uM	.	.	NEWCL00253	PC-3	72h:98.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Genistein increases the expression of pro-apoptotic protein Bax, activates apoptotic signals, and enhances the response to cabazitaxel treatment in mCRPC cells."
C12224	24055188	DIS0031	NP6084	Resveratrol	DR0490	Etoposide	NEWCL00129	Hep-G2	72h: 43.92 uM 	72h:28.48± 1.53	50 uM:10 uM	NEWCL00082	HCT 116	72h:82.83 uM	72h: 35.11± 2.6	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	Hep-G2	18.07%	19.33%	21.19%	HCT-116	12.37%	20.61%	12.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of resveratrol and etoposide showed synergistic anti-proliferative effect on hepatocellular carcinoma cells.
C02157	24064951	DIS0092	NP2960	Epigallocatechin gallate	DR7217	Trichostatin A	NEWCL00056	CA46	.	.	24ug.mL:30ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CA46	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Epigallocatechin-3-gallate and trichostatin A synergistically inhibit human lymphoma cell proliferation through epigenetic modification of p16INK4a.
C59960	24116276	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	Huh-7	66.98%	32.88%	78.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation."
C59960	24116276	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	Huh-7	8.46%	8.98%	170.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation."
C59960	24116276	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	Huh-7	2.75%	8.67%	268.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation."
C59960	24116276	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3834	Cleaved-caspase-6	Up-regulation	Huh-7	42.47%	15.44%	899.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation."
C59960	24116276	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Huh-7	6.71%	2.84%	167.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation."
C59960	24116276	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	Huh-7	7.56%	7.29%	62.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation."
C59960	24116276	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Huh-7	5.36%	0.40%	170.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation."
C59960	24116276	DIS0031	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	6 ug.ml:5 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Huh-7	23.86%	19.20%	23.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation."
C23676	24126433	DIS0115	NP4620	Apigenin	DR7304	ABT-263	NEWCL00079	DLD-1	.	.	20 umol.L: 0.5 umol.L	NEWCL00082	HCT 116	.	.	20 umol.L: 1 umol.L	NEWCL10146	HCT8	.	.	20 umol.L: 1 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263 via inhibition of the Mcl-1, AKT, and ERK prosurvival regulators."
C23676	24126433	DIS0115	NP4620	Apigenin	DR7304	ABT-263	NEWCL00344	HT29	.	.	20 umol.L: 0.5 umol.L	NEWCL00081	SW48	.	.	20 umol.L: 1 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Down-regulation	HCT116	2.34%	3.74%	7.41%	HCT-8	27.91%	27.14%	30.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263 via inhibition of the Mcl-1, AKT, and ERK prosurvival regulators."
C23676	24126433	DIS0115	NP4620	Apigenin	DR7304	ABT-263	NEWCL00344	HT29	.	.	20 umol.L: 0.5 umol.L	NEWCL00081	SW48	.	.	20 umol.L: 1 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	HCT116	2.64%	6.59%	33.54%	HCT-8	13.52%	22.84%	27.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263 via inhibition of the Mcl-1, AKT, and ERK prosurvival regulators."
C23676	24126433	DIS0115	NP4620	Apigenin	DR7304	ABT-263	NEWCL00344	HT29	.	.	20 umol.L: 0.5 umol.L	NEWCL00081	SW48	.	.	20 umol.L: 1 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HCT116	11.13%	1.10%	37.59%	HCT-8	-13.79%	-9.76%	37.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263 via inhibition of the Mcl-1, AKT, and ERK prosurvival regulators."
C04523	24161697	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR	.	.	50uM:1uM	NEWCL00049	MDA-MB-231	.	.	50uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7879	MDR1	Down-regulation	MCF-7.adr	82.12%	1.09%	57.30%	MDA-MB-231	71.01%	1.66%	27.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	24161697	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR	.	.	50uM:1uM	NEWCL00049	MDA-MB-231	.	.	50uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7872	MRP1	Down-regulation	MCF-7.adr	42.80%	2.40%	35.43%	MDA-MB-231	9.06%	0.91%	16.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C49649	24223665	DIS0034	NP6905	Curcumin	DR1669	Cisplatin	NEWCL00148	HEp-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin enhances the effectiveness of cisplatin by suppressing CD133 + cancer stem cells in laryngeal carcinoma treatment.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	112.16%	777.89%	913.93%	NCI-H460	205.26%	193.22%	126.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	26.50%	1310.09%	1414.14%	NCI-H460	296.28%	761.90%	1199.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	A-549	504.84%	1309.67%	1447.47%	NCI-H460	183.84%	122.01%	383.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	A-549	8.57%	153.78%	562.43%	NCI-H460	8.57%	452.59%	832.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4294	Fas L	Up-regulation	A-549	1.35%	67.70%	196.14%	NCI-H460	5.89%	5.81%	112.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	303.51%	285.15%	370.35%	NCI-H460	0.62%	20.69%	88.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Up-regulation	A-549	3.45%	17.66%	34.53%	NCI-H460	0.05%	0.61%	6.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	1.66%	52.63%	82.63%	NCI-H460	6.39%	41.18%	55.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	A-549	72.93%	64.46%	77.20%	NCI-H460	7.19%	-21.66%	48.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	24300974	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	48h:3.56± 0.36uM	48h:21.88± 3.21uM	3.5uM:22uM	NEWCL00180	NCI-H460	48h:4.05± 0.51uM	48h:25.76± 4.03uM	4uM:26uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	A-549	3.05%	24.49%	89.02%	NCI-H460	2.46%	37.35%	54.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C77184	24334603	DIS0025	NP5023	Gambogic acid	DR8244	Imatinib	NEWCL10111	KBM-5	48h:0.32uM	.	.	NEWCL10162	KBM5-T315I	48h:0.35uM	.	.	NEWCL00048	K-562	48h:0.40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
C89336	24392034	DIS0021	NP6993	Arsenic trioxide	DR4137	temsirolimus	NEWCL00049	MDA-MB-231	.	.	2 uM:5ng.ml	NEWCL00155	MCF-7	.	.	2 uM:5ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT(S473)	Up-regulation	MDA-MB-468	4.18%	112.24%	28.68%	MCF-7	35.11%	84.28%	7.47%	SkBr3	19.88%	102.75%	12.50%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.
C89336	24392034	DIS0021	NP6993	Arsenic trioxide	DR4137	temsirolimus	NEWCL00049	MDA-MB-231	.	.	2 uM:5ng.ml	NEWCL00155	MCF-7	.	.	2 uM:5ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-p70S6K	Down-regulation	MDA-MB-468	2.96%	61.78%	57.24%	MCF-7	10.90%	32.06%	34.29%	SkBr3	13.59%	68.80%	56.37%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.
C23313	24395429	DIS0022	NP6882	Arctigenin	DR1669	Cisplatin	NEWCL00180	NCI-H460	.	.	10 uM:2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	NCI-H460	18.27%	4.98%	46.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arctigenin has a therapeutic potential in combination with chemotherapeutic agents for NSLC.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	.	.	15uM:1uM	NEWCL00243	BxPC-3	.	.	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	PANC-1	85.31%	66.27%	641.67%	BxPC-3	252.35%	150.51%	717.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	.	.	15uM:1uM	NEWCL00243	BxPC-3	.	.	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	PANC-1	6.12%	0.29%	7.14%	BxPC-3	108.10%	18.15%	195.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	.	.	15uM:1uM	NEWCL00243	BxPC-3	.	.	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	PANC-1	1.52%	7.10%	10.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	.	.	15uM:1uM	NEWCL00243	BxPC-3	.	.	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	PANC-1	61.27%	0.22%	54.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	.	.	15uM:1uM	NEWCL00243	BxPC-3	.	.	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	PANC-1	12.06%	63.19%	80.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	.	.	15uM:1uM	NEWCL00243	BxPC-3	.	.	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ClAP-1	Down-regulation	PANC-1	18.88%	89.00%	99.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	.	.	15uM:1uM	NEWCL00243	BxPC-3	.	.	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	PANC-1	42.72%	6.24%	90.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	96h:18.0 uM	72h:36.87 uM	15uM:1uM	NEWCL00243	BxPC-3	96h: 16.9 uM	72h: 6.60 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	PANC-1	32.68%	12.16%	162.11%	BxPC-3	69.47%	118.64%	200.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	96h:18.0 uM	72h:36.87 uM	15uM:1uM	NEWCL00243	BxPC-3	96h: 16.9 uM	72h: 6.60 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	PANC-1	2.72%	1.32%	4.68%	BxPC-3	0.26%	42.76%	66.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	96h:18.0 uM	72h:36.87 uM	15uM:1uM	NEWCL00243	BxPC-3	96h: 16.9 uM	72h: 6.60 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	PANC-1	2.84%	0.08%	8.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	96h:18.0 uM	72h:36.87 uM	15uM:1uM	NEWCL00243	BxPC-3	96h: 16.9 uM	72h: 6.60 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	PANC-1	25.85%	2.93%	32.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	96h:18.0 uM	72h:36.87 uM	15uM:1uM	NEWCL00243	BxPC-3	96h: 16.9 uM	72h: 6.60 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	PANC-1	4.51%	19.74%	38.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	96h:18.0 uM	72h:36.87 uM	15uM:1uM	NEWCL00243	BxPC-3	96h: 16.9 uM	72h: 6.60 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CIAP-1	Down-regulation	PANC-1	14.14%	7.24%	99.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C09488	24424498	DIS0023	NP1541	6-shogaol	DR2391	Gemcitabine	NEWCL00242	PANC-1	96h:18.0 uM	72h:36.87 uM	15uM:1uM	NEWCL00243	BxPC-3	96h: 16.9 uM	72h: 6.60 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	PANC-1	5.58%	16.61%	46.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.
C44965	24428916	DIS0028	NP6993	Arsenic trioxide	DR1651	Buthionine sulfoximine	NEWCL00022	HL-60	.	.	3 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	HL60	81.72%	9.50%	177.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
C44965	24428916	DIS0028	NP6993	Arsenic trioxide	DR1651	Buthionine sulfoximine	NEWCL00022	HL-60	.	.	3 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	TBid	Up-regulation	HL60	15.99%	22.43%	10.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
C44965	24428916	DIS0028	NP6993	Arsenic trioxide	DR1651	Buthionine sulfoximine	NEWCL00022	HL-60	.	.	3 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	P-MCL1	Up-regulation	HL60	113.43%	4.46%	149.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
C44965	24428916	DIS0028	NP6993	Arsenic trioxide	DR1651	Buthionine sulfoximine	NEWCL00022	HL-60	.	.	3 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	P-Bcl-xL	Up-regulation	HL60	75.63%	1.51%	84.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
C01361	24462458	DIS0020	NP4705	Dicoumarol	DR1669	Cisplatin	NEWCL00348	ACHN	.	.	50uM:50ng.mL	NEWCL00257	A-498	.	.	50uM:50ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	ACHN	73.21%	2.22%	83.93%	A498	74.38%	61.74%	242.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Dicoumarol showed sensitizing effect of on TRAIL-mediated apoptosis.
C00179	24476216	DIS0021	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	70 uM	16 uM 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	The addition of curcumin as an adjuvant therapy during 5-FU treatment enhance the chemotherapeutic effectiveness of 5-FU by protecting normal cells from reduced viability and thus permitting higher dosing or longer treatment times.
C10758	24504162	DIS0114	NP9279	Genistein	DR1669	Cisplatin	NEWCL00155	MCF-7	.	.	10u5 M:10u10 M	NEWCL00077	HT-29	.	.	10u5 M:10u10 M	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Genistein modulates the anti-tumor activity of cisplatin in MCF-7 breast and HT-29 colon cancer cells.
C58165	24518414	DIS0114	NP2960	Epigallocatechin gallate	DR9093	Sodium butyrate	NEWCL00353	RKO	50 uM	.	10 uM : 5 mM	NEWCL00082	HCT 116	.	.	10 uM : 5 mM	NEWCL00344	HT29	.	.	10 uM : 5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	HT-29	41.33%	159.38%	193.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"At low and physiologically achievable concentrations, combinatorial EGCG and NaB are effective in promoting apoptosis, inducing cell cycle arrest and DNA-damage in CRC cells."
C58165	24518414	DIS0114	NP2960	Epigallocatechin gallate	DR9093	Sodium butyrate	NEWCL00353	RKO	50 uM	.	10 uM : 5 mM	NEWCL00082	HCT 116	.	.	10 uM : 5 mM	NEWCL00344	HT29	.	.	10 uM : 5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	HT-29	56.29%	77.76%	75.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"At low and physiologically achievable concentrations, combinatorial EGCG and NaB are effective in promoting apoptosis, inducing cell cycle arrest and DNA-damage in CRC cells."
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	BxPC-3	109.26%	122.57%	132.95%	PANC1	50.12%	103.76%	113.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	BxPC-3	0.15%	0.72%	48.29%	PANC1	0.94%	9.46%	24.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	BxPC-3	1.00%	0.63%	1.80%	PANC1	0.16%	5.22%	2.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	BxPC-3	2.35%	10.25%	35.85%	PANC1	5.74%	3.73%	32.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	BxPC-3	2.71%	2.71%	32.99%	PANC1	11.55%	8.50%	11.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	BxPC-3	3.32%	4.83%	12.81%	PANC1	0.33%	0.50%	12.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	BxPC-3	30.03%	32.87%	70.23%	PANC1	0.97%	0.16%	0.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	BxPC-3	5.47%	9.98%	54.98%	PANC1	0.38%	6.24%	0.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	BxPC-3	13.16%	5.17%	17.50%	PANC1	0.59%	2.52%	15.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	BxPC-3	0.19%	3.69%	48.05%	PANC1	4.85%	3.85%	48.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C60643	24522113	DIS0023	NP8751	Shikonin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	.	NEWCL00342	PANC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	BxPC-3	3.09%	6.00%	12.18%	PANC1	1.11%	4.58%	4.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.
C97187	24530290	DIS0020	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	10 uM:250 ng.ml	NEWCL00348	ACHN	.	.	10 uM:250 ng.ml	NEWCL00257	A-498	.	.	10 uM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	786-O	13.10%	25.56%	5.62%	ACHN	.	.	.	A498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.
C97187	24530290	DIS0020	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	10 uM:250 ng.ml	NEWCL00348	ACHN	.	.	10 uM:250 ng.ml	NEWCL00257	A-498	.	.	10 uM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Up-regulation	786-O	12.44%	7.89%	5.61%	ACHN	.	.	.	A498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.
C97187	24530290	DIS0020	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	10 uM:250 ng.ml	NEWCL00348	ACHN	.	.	10 uM:250 ng.ml	NEWCL00257	A-498	.	.	10 uM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	786-O	6.87%	0.86%	16.09%	ACHN	.	.	.	A498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.
C97187	24530290	DIS0020	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	10 uM:250 ng.ml	NEWCL00348	ACHN	.	.	10 uM:250 ng.ml	NEWCL00257	A-498	.	.	10 uM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	786-O	0.68%	4.23%	24.62%	ACHN	.	.	.	A498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.
C97187	24530290	DIS0020	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	10 uM:250 ng.ml	NEWCL00348	ACHN	.	.	10 uM:250 ng.ml	NEWCL00257	A-498	.	.	10 uM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FLIP	Up-regulation	786-O	28.01%	10.94%	49.20%	ACHN	.	.	.	A498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.
C97187	24530290	DIS0020	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	10 uM:250 ng.ml	NEWCL00348	ACHN	.	.	10 uM:250 ng.ml	NEWCL00257	A-498	.	.	10 uM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR4	Up-regulation	786-O	2.52%	0.83%	0.09%	ACHN	.	.	.	A498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.
C97187	24530290	DIS0020	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	10 uM:250 ng.ml	NEWCL00348	ACHN	.	.	10 uM:250 ng.ml	NEWCL00257	A-498	.	.	10 uM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR5	Up-regulation	786-O	5.65%	2.57%	12.37%	ACHN	.	.	.	A498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.
C97187	24530290	DIS0020	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	10 uM:250 ng.ml	NEWCL00348	ACHN	.	.	10 uM:250 ng.ml	NEWCL00257	A-498	.	.	10 uM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	786-O	36.11%	1.94%	70.45%	ACHN	7.95%	2.08%	16.11%	A498	4.31%	6.94%	12.98%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.
C97187	24530290	DIS0020	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	10 uM:250 ng.ml	NEWCL00348	ACHN	.	.	10 uM:250 ng.ml	NEWCL00257	A-498	.	.	10 uM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	786-O	5.35%	2.00%	22.27%	ACHN	35.35%	6.25%	18.96%	A498	23.88%	2.57%	35.11%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.
C85754	24615207	DIS0022	NP8797	Celastrol	DR2632	Vorinostat	NEWCL00231	SK-OV-3	.	.	1uM:2.5uM	NEWCL00302	PLA-801D	.	.	1uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	SK-OV-3	42.25%	50.98%	107.39%	95-D	73.73%	195.92%	276.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergistic anticancer effects of celastrol and SAHA was demonstrated due to their reciprocal sensitisation, which was simultaneously regulated by NF-kappaB and E-cadherin."
C85754	24615207	DIS0022	NP8797	Celastrol	DR2632	Vorinostat	NEWCL00231	SK-OV-3	.	.	1uM:2.5uM	NEWCL00302	PLA-801D	.	.	1uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	SK-OV-3	5.18%	2.61%	62.65%	95-D	7.65%	9.72%	47.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergistic anticancer effects of celastrol and SAHA was demonstrated due to their reciprocal sensitisation, which was simultaneously regulated by NF-kappaB and E-cadherin."
C85754	24615207	DIS0022	NP8797	Celastrol	DR2632	Vorinostat	NEWCL00231	SK-OV-3	.	.	1uM:2.5uM	NEWCL00302	PLA-801D	.	.	1uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SK-OV-3	22.08%	45.01%	181.09%	95-D	18.88%	15.43%	115.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergistic anticancer effects of celastrol and SAHA was demonstrated due to their reciprocal sensitisation, which was simultaneously regulated by NF-kappaB and E-cadherin."
C85754	24615207	DIS0022	NP8797	Celastrol	DR2632	Vorinostat	NEWCL00231	SK-OV-3	.	.	1uM:2.5uM	NEWCL00302	PLA-801D	.	.	1uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	SK-OV-3	33.10%	19.19%	49.76%	95-D	3.75%	13.90%	15.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergistic anticancer effects of celastrol and SAHA was demonstrated due to their reciprocal sensitisation, which was simultaneously regulated by NF-kappaB and E-cadherin."
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Up-regulation	H9c2	29.84%	70.59%	3.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	H9c2	48.84%	54.67%	110.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Up-regulation	H9c2	41.57%	85.39%	86.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	H9c2	80.83%	109.36%	132.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Up-regulation	H9c2	0.03%	6.43%	8.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	H9c2	2.45%	5.95%	51.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4294	Fas L	Up-regulation	H9c2	2.50%	0.36%	10.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	H9c2	0.32%	27.67%	55.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Up-regulation	H9c2	1.98%	4.73%	4.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	H9c2	49.33%	46.53%	64.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ICAD	Down-regulation	H9c2	24.67%	16.13%	60.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	H9c2	30.61%	27.04%	47.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C45714	24632453	DIS0022	NP3369	Neferine	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ICAD	Down-regulation	H9c2	33.62%	30.66%	55.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.
C54915	24662747	DIS0023	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00236	MIA PaCa-2	.	.	50nM:1.25ng.ml	NEWCL10017	S2-VP10	.	.	50nM:1.25ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	MIA PaCa-2	72.74%	13.95%	403.43%	S2-VP10	17.36%	6.55%	-9.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
C54915	24662747	DIS0023	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00236	MIA PaCa-2	.	.	50nM:1.25ng.ml	NEWCL10017	S2-VP10	.	.	50nM:1.25ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	MIA PaCa-2	109.47%	58.91%	354.77%	S2-VP10	18.73%	12.77%	236.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
C54915	24662747	DIS0023	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00236	MIA PaCa-2	.	.	50nM:1.25ng.ml	NEWCL10017	S2-VP10	.	.	50nM:1.25ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MIA PaCa-2	38.51%	28.86%	72.54%	S2-VP10	10.29%	3.67%	349.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
C54915	24662747	DIS0023	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00236	MIA PaCa-2	.	.	50nM:1.25ng.ml	NEWCL10017	S2-VP10	.	.	50nM:1.25ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C-FLIP(S)	Down-regulation	MIA PaCa-2	83.61%	15.88%	89.80%	S2-VP10	61.80%	12.23%	72.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
C54915	24662747	DIS0023	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00236	MIA PaCa-2	.	.	50nM:1.25ng.ml	NEWCL10017	S2-VP10	.	.	50nM:1.25ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MIA PaCa-2	6.73%	6.51%	1.71%	S2-VP10	-21.18%	9.69%	23.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
C69480	24677352	DIS0031	NP7303	Silymarin	DR4469	Doxorubicin	NEWCL00129	Hep-G2	24h; 396.5 ±  83.5 ng.mL ; 48 h ;  208 ±  12 ng.mL	 24h; 6.94 ±  0.04 uM; 48h; 2± 0.1 uM	300 ng.mL:4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined applications of doxorubicin and silymarin caused higher apoptosis and necrosis of cells in 24 h than that of single agent applications.
C89846	24707876	DIS0029	NP4621	Triptolide	DR6516	Temozolomide	NEWCL10145	GIC-1	72h: 99.1nM	72h: 705.7 uM	25 nM: 300 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	GIC-1	135.70%	39.83%	220.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling."
C89846	24707876	DIS0029	NP4621	Triptolide	DR6516	Temozolomide	NEWCL10145	GIC-1	72h: 99.1nM	72h: 705.7 uM	25 nM: 300 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	GIC-1	24.88%	9.09%	87.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling."
C89846	24707876	DIS0029	NP4621	Triptolide	DR6516	Temozolomide	NEWCL10145	GIC-1	72h: 99.1nM	72h: 705.7 uM	25 nM: 300 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IkBa	Down-regulation	GIC-1	66.32%	56.66%	81.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling."
C89846	24707876	DIS0029	NP4621	Triptolide	DR6516	Temozolomide	NEWCL10145	GIC-1	72h: 99.1nM	72h: 705.7 uM	25 nM: 300 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P-p65	Down-regulation	GIC-1	38.20%	5.05%	36.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling."
C89846	24707876	DIS0029	NP4621	Triptolide	DR6516	Temozolomide	NEWCL10145	GIC-1	72h: 99.1nM	72h: 705.7 uM	25 nM: 300 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	GIC-1	3.46%	10.32%	62.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling."
C89846	24707876	DIS0029	NP4621	Triptolide	DR6516	Temozolomide	NEWCL10145	GIC-1	72h: 99.1nM	72h: 705.7 uM	25 nM: 300 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	GIC-1	57.85%	40.47%	74.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling."
C89846	24707876	DIS0029	NP4621	Triptolide	DR6516	Temozolomide	NEWCL10145	GIC-1	72h: 99.1nM	72h: 705.7 uM	25 nM: 300 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	GIC-1	6.00%	7.13%	57.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling."
C87745	24720675	DIS0114	NP4621	Triptolide	DR0141	Oxaliplatin	NEWCL00074	SW480	48h:16.7 ng.mL	48h:20.8 ug.mL	10ug.mL:20ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo.
C03351	24729783	DIS0021	NP8625	Gamma tocotrienol	DR7504	GW9662	.	.	.	.	2 uM:3.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Up-regulation	SA	6.70%	8.20%	210.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined Gamma -tocotrienol and PPAR Gamma antagonists treatment in PPAR Gamma negative/silenced breast cancer cells are mediated through PPAR Gamma -independent mechanisms that are associated with a downregulation in COX-2, PGDS, and PGD2 synthesis."
C03351	24729783	DIS0021	NP8625	Gamma tocotrienol	DR7504	GW9662	.	.	.	.	2 uM:3.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PGDS	Up-regulation	SA	128.26%	262.17%	263.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined Gamma -tocotrienol and PPAR Gamma antagonists treatment in PPAR Gamma negative/silenced breast cancer cells are mediated through PPAR Gamma -independent mechanisms that are associated with a downregulation in COX-2, PGDS, and PGD2 synthesis."
C98114	24743574	DIS0020	NP6905	Curcumin	DR7812	Dactolisib	NEWCL10134	Caki	.	.	30 uM:2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR4	Up-regulation	Caki	12.71%	10.68%	31.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level.
C98114	24743574	DIS0020	NP6905	Curcumin	DR7812	Dactolisib	NEWCL10134	Caki	.	.	30 uM:2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C-FLIP	Up-regulation	Caki	12.55%	1.77%	35.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level.
C98114	24743574	DIS0020	NP6905	Curcumin	DR7812	Dactolisib	NEWCL10134	Caki	.	.	30 uM:2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CLAP2	Up-regulation	Caki	13.29%	0.90%	29.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level.
C98114	24743574	DIS0020	NP6905	Curcumin	DR7812	Dactolisib	NEWCL10134	Caki	.	.	30 uM:2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Up-regulation	Caki	18.41%	1.06%	64.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level.
C98114	24743574	DIS0020	NP6905	Curcumin	DR7812	Dactolisib	NEWCL10134	Caki	.	.	30 uM:2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Up-regulation	Caki	8.51%	29.31%	64.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level.
C98114	24743574	DIS0020	NP6905	Curcumin	DR7812	Dactolisib	NEWCL10134	Caki	.	.	30 uM:2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	Caki	8.13%	20.06%	73.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level.
C80755	24892721	DIS0031	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00129	Hep-G2	24h:50umol.L 48h:35umol.L	.	50 umol.l :10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol could augment TRAIL sensitivity by downregulating survivin.
C82677	24944076	DIS0021	NP7687	Pterostilbene	DR0067	3-methyladenine	NEWCL00049	MDA-MB-231	.	.	80 uM:10 ug.mL	NEWCL00162	BT-549	.	.	80 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	MDA-MB-231	4.74%	13.64%	1.86%	BT-549	0.18%	1.94%	13.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The anti-tumor efficiency of pterostilbene is promoted with a combined treatment of Fas signaling or autophagy inhibitors in triple negative breast cancer cells.
C82598	24953273	DIS0031	NP4621	Triptolide	DR2073	Sorafenib	NEWCL00031	HuH-7	.	.	50 nM :1.25uM	NEWCL00027	PLC.PRF.5	.	.	50 nM :2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of triptolide and sorafenib was superior to either drug alone in inducing apoptosis and decreasing viability, whereas triptolide alone was sufficient to decrease nuclear factor kappaB activity."
C53856	24965400	DIS0031	NP8797	Celastrol	DR6077	Lapatinib	NEWCL00051	MDA-MB-453	.	.	5uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celastrol enhanced the anticancer effect of lapatinib in human hepatocellular carcinoma cells in vitro.
C34810	25050915	DIS0029	NP6905	Curcumin	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	390 ug.ml	.	1.25 ug.ml:15.625 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	PI3K	Down-regulation	U-87MG ATCCMG	2.52%	5.95%	11.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling.
C34810	25050915	DIS0029	NP6905	Curcumin	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	390 ug.ml	.	1.25 ug.ml:15.625 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	P-Bad	Down-regulation	U-87MG ATCCMG	3.64%	9.65%	28.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling.
C34810	25050915	DIS0029	NP6905	Curcumin	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	390 ug.ml	.	1.25 ug.ml:15.625 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	U-87MG ATCCMG	2.53%	12.35%	22.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling.
C34810	25050915	DIS0029	NP6905	Curcumin	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	390 ug.ml	.	1.25 ug.ml:15.625 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	U-87MG ATCCMG	2.21%	27.05%	45.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling.
C07892	25182442	DIS0021	NP5470	Hesperidin	DR4469	Doxorubicin	NEWCL00155	MCF-7	11 umol.L	700 nmol.L	3.5 umol.L:230 nmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MCF-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Co-chemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism effect through inhibition of Pgp expression.
C57596	25202045	DIS0023	NP9279	Genistein	DR9021	5-fluorouracil	NEWCL00236	MIA PaCa-2	.	.	100uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MIA PaCa-2	3.53%	26.59%	1.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells.
C57596	25202045	DIS0023	NP9279	Genistein	DR9021	5-fluorouracil	NEWCL00236	MIA PaCa-2	.	.	100uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MIA PaCa-2	1.55%	6.36%	12.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells.
C57596	25202045	DIS0023	NP9279	Genistein	DR9021	5-fluorouracil	NEWCL00236	MIA PaCa-2	.	.	100uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MIA PaCa-2	37.95%	32.31%	45.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells.
C44388	25202376	DIS0024	NP7968	Deguelin	DR1669	Cisplatin	NEWCL00113	MGC-803	48h:10.74ug.m 72h: 6.52 ug.ml	48h:7.66ug.ml 72h: 3.89 ug.ml	6.25 ug.mL:3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6676	BRCA1	Down-regulation	MGC-803	61.59%	11.13%	55.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined treatment of deguelin and cisplatin exhibited a marked inhibition of MGC-803 cell proliferation when compared with that of the single therapies in vitro.
C44388	25202376	DIS0024	NP7968	Deguelin	DR1669	Cisplatin	NEWCL00113	MGC-803	48h:10.74ug.m 72h: 6.52 ug.ml	48h:7.66ug.ml 72h: 3.89 ug.ml	6.25 ug.mL:3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	XRCC1	Down-regulation	MGC-803	15.42%	9.43%	1.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined treatment of deguelin and cisplatin exhibited a marked inhibition of MGC-803 cell proliferation when compared with that of the single therapies in vitro.
C95159	25289088	DIS0031	NP9745	Picropodophyllin	DR2073	Sorafenib	NEWCL00357	HLF	.	.	0.2 uM:3 uM	NEWCL00027	PLC.PRF.5	.	.	0.2 uM:3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HLF	.	.	.	PLC	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.
C04404	25313766	DIS0022	NP6459	Vinblastine	DR7626_DR1563	Docetaxel + Tamoxifen	NEWCL00049	MDA-MB-231	24h:25uM; 48h:1uM	:24h:50uM; 48h:25uM 	48h:10uM	NEWCL00181	NCI-H1299	24h:50uM; 48h:10uM	24h:30uM; 48h:30uM 	48h:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy of breast and lung cancer cell lines using docetaxel or vinblastine with tamoxifen synergistically increases the anti-proliferative affect of single agents.
C64633	25333675	DIS0029	NP3555	Evodiamine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	24h:12 uM	.	10 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U-87MG ATCC	98.45%	4.73%	121.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway.
C98052	25336146	DIS0021	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00155	MCF-7	.	.	100 uM:20 nM	NEWCL00049	MDA-MB-231	.	.	100 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-S6K1(T389)	Down-regulation	MCF-7	84.77%	96.80%	95.84%	MDA-MB-231	68.60%	88.92%	89.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of rapamycin and resveratrol is able to block upregulation of autophagy and induce apoptosis in breast cancer cells.
C98052	25336146	DIS0021	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00155	MCF-7	.	.	100 uM:20 nM	NEWCL00049	MDA-MB-231	.	.	100 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-S6(S240.244)	Down-regulation	MCF-7	6.40%	99.06%	98.99%	MDA-MB-231	21.71%	95.03%	93.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of rapamycin and resveratrol is able to block upregulation of autophagy and induce apoptosis in breast cancer cells.
C98052	25336146	DIS0021	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00155	MCF-7	.	.	100 uM:20 nM	NEWCL00049	MDA-MB-231	.	.	100 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0920	P-eIF4B(S422)	Down-regulation	MCF-7	77.45%	83.54%	85.81%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of rapamycin and resveratrol is able to block upregulation of autophagy and induce apoptosis in breast cancer cells.
C98052	25336146	DIS0021	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00155	MCF-7	.	.	100 uM:20 nM	NEWCL00049	MDA-MB-231	.	.	100 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PDCD4	Up-regulation	MCF-7	535.62%	1261.91%	762.19%	MDA-MB-231	186.30%	186.27%	40.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of rapamycin and resveratrol is able to block upregulation of autophagy and induce apoptosis in breast cancer cells.
C98052	25336146	DIS0021	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00155	MCF-7	.	.	100 uM:20 nM	NEWCL00049	MDA-MB-231	.	.	100 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Up-regulation	MCF-7	139.84%	17.85%	90.28%	MDA-MB-231	193.58%	5.47%	172.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of rapamycin and resveratrol is able to block upregulation of autophagy and induce apoptosis in breast cancer cells.
C98052	25336146	DIS0021	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00155	MCF-7	.	.	100 uM:20 nM	NEWCL00049	MDA-MB-231	.	.	100 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	MCF-7	63.28%	22.19%	87.35%	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of rapamycin and resveratrol is able to block upregulation of autophagy and induce apoptosis in breast cancer cells.
C90522	25339540	DIS0028	NP1168	Quercetin	DR4469	adriamycin	NEWCL20372	K562.ADR	48h:100.14± 4.13 ug.mL	48h:42.86± 3.31ug.mL	100ug.mL:12ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	K562.ADR	56.75%	19.13%	60.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells.
C90522	25339540	DIS0028	NP1168	Quercetin	DR4469	adriamycin	NEWCL20372	K562.ADR	48h:100.14± 4.13 ug.mL	48h:42.86± 3.31ug.mL	100ug.mL:12ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	K562.ADR	40.73%	9.72%	74.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells.
C90522	25339540	DIS0028	NP1168	Quercetin	DR4469	adriamycin	NEWCL20372	K562.ADR	48h:100.14± 4.13 ug.mL	48h:42.86± 3.31ug.mL	100ug.mL:12ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim	Up-regulation	K562.ADR	2034.83%	2003.90%	1873.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells.
C90522	25339540	DIS0028	NP1168	Quercetin	DR4469	adriamycin	NEWCL20372	K562.ADR	48h:100.14± 4.13 ug.mL	48h:42.86± 3.31ug.mL	100ug.mL:12ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Up-regulation	K562.ADR	1537.80%	1387.76%	1364.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells.
C90522	25339540	DIS0028	NP1168	Quercetin	DR4469	adriamycin	NEWCL20372	K562.ADR	48h:100.14± 4.13 ug.mL	48h:42.86± 3.31ug.mL	100ug.mL:12ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	K562.ADR	229.00%	5.27%	222.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells.
C90522	25339540	DIS0028	NP1168	Quercetin	DR4469	Doxorubicin	NEWCL20372	K562.ADR	48h:100.14± 4.13 ug.mL	48h:42.86± 3.31ug.mL	100ug.mL:12ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	K562.ADR	61.03%	59.47%	63.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells.
C90522	25339540	DIS0028	NP1168	Quercetin	DR4469	Doxorubicin	NEWCL20372	K562.ADR	48h:100.14± 4.13 ug.mL	48h:42.86± 3.31ug.mL	100ug.mL:12ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	K562.ADR	34.57%	11.33%	55.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells.
C90522	25339540	DIS0028	NP1168	Quercetin	DR4469	adriamycin	NEWCL20372	K562.ADR	48h:100.14± 4.13 ug.mL	48h:42.86± 3.31ug.mL	100ug.mL:12ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p-ERK1.2	Down-regulation	K562.ADR	61.03%	59.47%	63.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells.
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	PANC1	37.52%	41.63%	41.65%	AsPC1	123.13%	913.00%	160.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	PANC1	78.84%	35.89%	70.76%	AsPC1	25.09%	2.61%	31.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	PANC1	16.46%	7.63%	42.59%	AsPC1	8.53%	10.43%	39.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Porin-2	Up-regulation	PANC1	15.02%	9.27%	15.47%	AsPC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	PANC1	3.43%	0.63%	18.93%	AsPC1	64.30%	47.32%	62.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	PANC1	26.68%	3.55%	30.74%	AsPC1	24.05%	8.12%	28.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	PANC1	12.74%	12.11%	26.31%	AsPC1	38.50%	11.21%	39.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	NICD	Down-regulation	PANC1	.	.	.	AsPC1	48.13%	15.81%	44.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8368	Notch-1	Down-regulation	PANC1	46.36%	0.28%	42.23%	AsPC1	23.26%	19.71%	21.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	PANC1	.	.	.	AsPC1	42.66%	6.95%	16.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	PANC1	.	.	.	AsPC1	10.50%	48.33%	18.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C38290	25344906	DIS0023	NP6308	Thymoquinone	DR2391	Gemcitabine	NEWCL00342	PANC1	48h: 25.12 ±  0.67 uM	48h: 49.96 ±  2.34 uM	25 uM: 100nM	NEWCL00241	AsPC-1	48h: 21.9 ±  0.37 uM	48h: 28.1 ±  1.32 uM	21 uM: 100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-S6	Down-regulation	PANC1	.	.	.	AsPC1	7.78%	1.75%	45.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."
C17908	25361002	DIS0119	NP0050	Phenethyl isothiocyate	DR1669	Cisplatin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of cisplatin with the natural compound PEITC induces a strong MPM cell death, while remaining safe for PMC, with limited emergence of cell resistance compared to drugs used alone."
C16256	25363523	DIS0031	NP4620	Apigenin	DR9021	5-fluorouracil	NEWCL00169	SK-Hep-1	48h:18uM	48h:431uM	4uM:100ug.mL	NEWCL00141	BEL-7402	48h:37ug.mL	48h:660ug.mL	4uM:100ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SK-Hep-1	3.17%	118.73%	192.03%	BEL-7402	129.10%	133.47%	144.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apigenin may potentiate the cytotoxicity of 5-FU in HCC via inhibition of ROS-mediated drug resistance and concurrent activation of the mitochondrial pathways of apoptosis.
C16256	25363523	DIS0031	NP4620	Apigenin	DR9021	5-fluorouracil	NEWCL00169	SK-Hep-1	48h:18uM	48h:431uM	4uM:100ug.mL	NEWCL00141	BEL-7402	48h:37ug.mL	48h:660ug.mL	4uM:100ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SK-Hep-1	128.93%	129.42%	136.48%	BEL-7402	14.35%	12.71%	114.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apigenin may potentiate the cytotoxicity of 5-FU in HCC via inhibition of ROS-mediated drug resistance and concurrent activation of the mitochondrial pathways of apoptosis.
C16256	25363523	DIS0031	NP4620	Apigenin	DR9021	5-fluorouracil	NEWCL00169	SK-Hep-1	48h:18uM	48h:431uM	4uM:100ug.mL	NEWCL00141	BEL-7402	48h:37ug.mL	48h:660ug.mL	4uM:100ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SK-Hep-1	1.58%	2.59%	38.60%	BEL-7402	2.94%	0.42%	9.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apigenin may potentiate the cytotoxicity of 5-FU in HCC via inhibition of ROS-mediated drug resistance and concurrent activation of the mitochondrial pathways of apoptosis.
C10758	25364470	DIS0022	NP9279	Genistein	DR1669	Cisplatin	NEWCL00170	A-549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-549	29.76%	11.48%	51.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo.
C10758	25364470	DIS0022	NP9279	Genistein	DR1669	Cisplatin	NEWCL00170	A-549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	P-PI3K	Down-regulation	A-549	30.22%	11.07%	66.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo.
C92153	25405645	DIS0021	NP6993	Arsenic trioxide	DR8137	Cotylenin A	NEWCL00155	MCF-7	.	.	4uM:3.5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	MCF-7	61.35%	237.77%	618.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
C92153	25405645	DIS0021	NP6993	Arsenic trioxide	DR8137	Cotylenin A	NEWCL00155	MCF-7	.	.	4uM:3.5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	MCF-7	88.00%	97.04%	111.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
C92153	25405645	DIS0021	NP6993	Arsenic trioxide	DR8137	Cotylenin A	NEWCL00155	MCF-7	.	.	4uM:3.5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Up-regulation	MCF-7	100.15%	117.26%	66.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
C92153	25405645	DIS0021	NP6993	Arsenic trioxide	DR8137	Cotylenin A	NEWCL00155	MCF-7	.	.	4uM:3.5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	MCF-7	1.11%	6.06%	60.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
C12588	25446377	DIS0026	NP6993	Arsenic trioxide	DR3952	MG132	NEWCL00019	U-937	.	.	1 uM:0.25 uM	NEWCL00095	Raji	.	.	1 uM:0.25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3 II	Up-regulation	U-937	16.43%	11.55%	12.33%	Raji	18.64%	48.77%	35.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Synergism between ATO and MG132 was attained in Raji cells by disruption of the perinuclear mitochondrial cluster, blockage of selective autophagy of mitochondria (mitophagy) by VCR, increased mitochondrial mass, and upregulation of BNIP3 by VPA."
C12588	25446377	DIS0026	NP6993	Arsenic trioxide	DR3952	MG132	NEWCL00019	U-937	.	.	1 uM:0.25 uM	NEWCL00095	Raji	.	.	1 uM:0.25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3 I	Down-regulation	U-937	2.20%	16.34%	18.17%	Raji	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Synergism between ATO and MG132 was attained in Raji cells by disruption of the perinuclear mitochondrial cluster, blockage of selective autophagy of mitochondria (mitophagy) by VCR, increased mitochondrial mass, and upregulation of BNIP3 by VPA."
C41311	25486955	DIS0088	NP6308	Thymoquinone	DR2080	Topotecan	NEWCL00019	U-937	24h:31.27 uM; 48h:21.39 uM	24h:207.25 nM; 48h:35.49 nM	10 uML 50 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	U-937	31.54%	54.20%	9.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone, when combined with topotecan in noncytotoxic doses, produced synergistic antiproliferative and proapoptotic effects in AML cells."
C41311	25486955	DIS0088	NP6308	Thymoquinone	DR2080	Topotecan	NEWCL00019	U-937	24h:31.27 uM; 48h:21.39 uM	24h:207.25 nM; 48h:35.49 nM	10 uML 50 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	U-937	36.32%	57.67%	95.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone, when combined with topotecan in noncytotoxic doses, produced synergistic antiproliferative and proapoptotic effects in AML cells."
C41311	25486955	DIS0088	NP6308	Thymoquinone	DR2080	Topotecan	NEWCL00019	U-937	24h:31.27 uM; 48h:21.39 uM	24h:207.25 nM; 48h:35.49 nM	10 uML 50 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Down-regulation	U-937	20.15%	20.32%	35.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone, when combined with topotecan in noncytotoxic doses, produced synergistic antiproliferative and proapoptotic effects in AML cells."
C41311	25486955	DIS0088	NP6308	Thymoquinone	DR2080	Topotecan	NEWCL00019	U-937	24h:31.27 uM; 48h:21.39 uM	24h:207.25 nM; 48h:35.49 nM	10 uML 50 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	U-937	10.10%	1.78%	12.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Thymoquinone, when combined with topotecan in noncytotoxic doses, produced synergistic antiproliferative and proapoptotic effects in AML cells."
C21577	25504439	DIS0122	NP6047	Metformin	DR8750	Trametinib	NEWCL10393	D04	.	.	10mM:4nM; 5mM:4nM	NEWCL10361	MM485	.	.	10mM:4nM; 5mM:4nM	NEWCL10360	MM415	.	.	10mM:4nM; 5mM:4nM	NEWCL10199	MaMel27II	.	.	10mM:4nM;  5mM:4nM	.	SW1271	.	.	10mM:30nM	.	NCI-NCI-H2347	.	.	10mM:30nM	MO6742	P-AKT	Down-regulation	DO4	91.34%	1.49%	92.73%	MM485	0.67%	5.29%	0.54%	MM415	63.08%	5.81%	62.41%	MaMel27II	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin and trametinib combinations are effective in preclinical models and may be a possible option for treatment of NRAS mutant cancers.
C21577	25504439	DIS0122	NP6047	Metformin	DR8750	Trametinib	NEWCL10393	D04	.	.	10mM:4nM; 5mM:4nM	NEWCL10361	MM485	.	.	10mM:4nM; 5mM:4nM	NEWCL10360	MM415	.	.	10mM:4nM; 5mM:4nM	NEWCL10199	MaMel27II	.	.	10mM:4nM;  5mM:4nM	.	SW1271	.	.	10mM:30nM	.	NCI-NCI-H2347	.	.	10mM:30nM	.	P-S6	Down-regulation	DO4	66.27%	4.87%	72.55%	MM485	93.61%	83.09%	93.63%	MM415	22.15%	7.05%	93.52%	MaMel27II	0.32%	6.59%	59.40%	SW1271	92.41%	87.53%	92.23%	NCI-H2347	25.66%	1.46%	94.20%	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin and trametinib combinations are effective in preclinical models and may be a possible option for treatment of NRAS mutant cancers.
C21577	25504439	DIS0122	NP6047	Metformin	DR8750	Trametinib	NEWCL10393	D04	.	.	10mM:4nM; 5mM:4nM	NEWCL10361	MM485	.	.	10mM:4nM; 5mM:4nM	NEWCL10360	MM415	.	.	10mM:4nM; 5mM:4nM	NEWCL10199	MaMel27II	.	.	10mM:4nM;  5mM:4nM	.	SW1271	.	.	10mM:30nM	.	NCI-NCI-H2347	.	.	10mM:30nM	.	P-ERK	Up-regulation	DO4	1.66%	55.40%	62.10%	MM485	3.77%	55.23%	41.13%	MM415	2.08%	53.28%	62.47%	MaMel27II	4.99%	27.08%	31.31%	SW1271	.	.	.	NCI-H2347	4.61%	88.44%	87.70%	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin and trametinib combinations are effective in preclinical models and may be a possible option for treatment of NRAS mutant cancers.
C21577	25504439	DIS0122	NP6047	Metformin	DR8750	Trametinib	NEWCL10393	D04	24h:5.2mM	24h:0.7nM	10mM:4nM	NEWCL10360	MM415	24h:7.15mM	24h:1.3nM	10mM:4nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	DO4	91.32%	1.58%	92.71%	MM415	54.90%	23.53%	55.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin and trametinib combinations are effective in preclinical models and may be a possible option for treatment of NRAS mutant cancers.
C21577	25504439	DIS0122	NP6047	Metformin	DR8750	Trametinib	NEWCL10393	D04	24h:5.2mM	24h:0.7nM	10mM:4nM	NEWCL10360	MM415	24h:7.15mM	24h:1.3nM	10mM:4nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-S6	Down-regulation	DO4	63.75%	9.92%	70.03%	MM415	16.01%	6.96%	93.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin and trametinib combinations are effective in preclinical models and may be a possible option for treatment of NRAS mutant cancers.
C21577	25504439	DIS0122	NP6047	Metformin	DR8750	Trametinib	NEWCL10393	D04	24h:5.2mM	24h:0.7nM	10mM:4nM	NEWCL10360	MM415	24h:7.15mM	24h:1.3nM	10mM:4nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	DO4	2.47%	59.10%	59.24%	MM415	0.87%	52.53%	63.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin and trametinib combinations are effective in preclinical models and may be a possible option for treatment of NRAS mutant cancers.
C78830	25535978	DIS0025	NP6636	Daunorubicin	DR1229	PP242	NEWCL10125	NB4	.	.	0.5 umol.L:0.1 umol.L	NEWCL00059	THP-1	.	.	0.2 umol.L:0.1 umol.L	NEWCL00063	SUP-B15	.	.	0.1 umol.L:0.1 umol.L	.	.	.	.	.	.	.	.	.	.	NEWCL10069	JEKO-1	.	.	.	MO0518	P-mTOR	Down-regulation	NB4	27.52%	77.31%	71.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	"PP242 effectively eliminated this deleterious side effect of DNR and synergistically enhanced the anticancer ability of DNR treatment. PP242, especially in combination with DNR, exerts significant antileukemia effects."
C78830	25535978	DIS0025	NP6636	Daunorubicin	DR1229	PP242	NEWCL10125	NB4	.	.	0.5 umol.L:0.1 umol.L	NEWCL00059	THP-1	.	.	0.2 umol.L:0.1 umol.L	NEWCL00063	SUP-B15	.	.	0.1 umol.L:0.1 umol.L	.	.	.	.	.	.	.	.	.	.	NEWCL10069	JEKO-1	.	.	.	MO5288	MCL-1	Down-regulation	NB4	3.71%	42.14%	65.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	"PP242 effectively eliminated this deleterious side effect of DNR and synergistically enhanced the anticancer ability of DNR treatment. PP242, especially in combination with DNR, exerts significant antileukemia effects."
C71528	25536607	DIS0015	NP2960	Epigallocatechin gallate	DR8026	Potinib	NEWCL00048	K-562	50 uM	87.12 nM	50 uM:87.12 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	K-562	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes.
C45716	25536616	DIS0129	NP6308	Thymoquinone	DR0261	Zoledronic	NEWCL00251	DU145	72h:51 uM	72h:72.4uM	60 uM:40 uM	NEWCL00253	PC-3	72h:55.3 uM 	72h:95.0uM	60 uM:40 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of TQ and ZA resulted in a significant synergistic cytotoxic activity and DNA fragmentation when compared to any single agent alone, in a dose- and time-dependent manner."
C23445	25596561	DIS0025	NP3067	Paclitaxel	DR6631	ABT-737	NEWCL00048	K-562	.	.	0.2 uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	K-562	196.73%	61.82%	309.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	BH3 mimetics synergize with paclitaxel in the killing of CML cells.
C23445	25596561	DIS0025	NP3067	Paclitaxel	DR6631	ABT-737	NEWCL00048	K-562	.	.	0.2 uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim-EL	Up-regulation	K-562	205.23%	15.79%	484.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	BH3 mimetics synergize with paclitaxel in the killing of CML cells.
C32534	25596735	DIS0020	NP1928	Carnosic acid	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00282	Caki-1	.	.	20 uM: 50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Caki	31.40%	10.22%	157.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells."
C32534	25596735	DIS0020	NP1928	Carnosic acid	DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells."
C10155	25619640	DIS0020	NP1541	6-shogaol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10134	Caki	.	.	20 uM:50 ng.ml; 24h	NEWCL00049	MDA-MB-231	.	.	20 uM:50 ng.ml; 24h	NEWCL00279	U-87MG ATCC	.	.	20 uM:50 ng.ml; 24h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	Caki	16.54%	30.95%	137.61%	MDA-MB-231	10.56%	20.08%	68.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	6-Shogaol enhances renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated cytochrome c release and down-regulation of c-FLIP(L) expression.
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	HCT 116.FUR	73.03%	60.64%	291.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1867	ZEB1	Up-regulation	HCT 116.FUR	.	.	.	SW480-FUR	10.99%	228.71%	136.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116.FUR	23.53%	4.95%	46.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	HCT 116.FUR	10.44%	8.43%	16.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP1	Down-regulation	HCT 116.FUR	43.34%	75.66%	90.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	HCT 116.FUR	41.30%	48.27%	26.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HCT 116.FUR	49.01%	78.80%	52.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2909	EZH2	Down-regulation	HCT 116.FUR	.	.	.	SW480-FUR	35.02%	25.10%	33.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0309	BMI1	Down-regulation	HCT 116.FUR	.	.	.	SW480-FUR	8.89%	7.77%	27.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SUZ12	Down-regulation	HCT 116.FUR	.	.	.	SW480-FUR	75.33%	68.59%	86.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C00179	25653233	DIS0115	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	.	.	.	NEWCL20423	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Ring1B	Down-regulation	HCT 116.FUR	.	.	.	SW480-FUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."
C20036	25683253	DIS0019	NP6047	Metformin	DR2073	Sorafenib	NEWCL10375	HTh74	.	.	5uM:5uM	.	.	.	.	5uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	HTh74	12.27%	19.42%	8.64%	HTh74Rdox	60.72%	71.57%	33.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sorafenib and metformin synergistically decreased the proliferation of ATC cell lines and the outgrowth of their derived cancer stem cells.
C20036	25683253	DIS0019	NP6048	Metformin	DR2074	Sorafenib	NEWCL10375	HTh74	.	.	5uM:6uM	.	.	.	.	5uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2700	ERK	Down-regulation	HTh74	0.43%	5.45%	7.65%	HTh74Rdox	14.88%	28.21%	2.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sorafenib and metformin synergistically decreased the proliferation of ATC cell lines and the outgrowth of their derived cancer stem cells.
C20036	25683253	DIS0019	NP6049	Metformin	DR2075	Sorafenib	NEWCL10375	HTh74	.	.	5uM:7uM	.	.	.	.	5uM:7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HTh74	6.95%	36.76%	32.11%	HTh74Rdox	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sorafenib and metformin synergistically decreased the proliferation of ATC cell lines and the outgrowth of their derived cancer stem cells.
C49889	25688715	DIS0029	NP8751	Shikonin	DR8028	Erlotinib	NEWCL00279	U-87MG ATCC	.	.	0.3 uM :0.01 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	U-87MG ATCCMG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Shikonin not only dose-dependently inhibited EGFR phosphorylation and decreased phosphorylation of EGFR downstream molecules, including AKT, P44/42MAPK and PLCgamma1, but also together with erlotinib synergistically inhibited deltaEGFR phosphorylation in U87MG."
C56963	25716014	DIS0022	NP6905	Curcumin	DR3943	Carboplatin	NEWCL00170	A-549	.	.	10 uM :100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	8.93%	2.53%	-1.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."
C56963	25716014	DIS0022	NP6905	Curcumin	DR3943	Carboplatin	NEWCL00170	A-549	.	.	10 uM :100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	A-549	195.44%	398.98%	466.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."
C56963	25716014	DIS0022	NP6905	Curcumin	DR3943	Carboplatin	NEWCL00170	A-549	.	.	10 uM :100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53	Up-regulation	A-549	5.81%	97.10%	449.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."
C56963	25716014	DIS0022	NP6905	Curcumin	DR3943	Carboplatin	NEWCL00170	A-549	.	.	10 uM :100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	A-549	15.53%	38.89%	97.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."
C56963	25716014	DIS0022	NP6905	Curcumin	DR3943	Carboplatin	NEWCL00170	A-549	.	.	10 uM :100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	25.17%	116.12%	104.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."
C56963	25716014	DIS0022	NP6905	Curcumin	DR3943	Carboplatin	NEWCL00170	A-549	.	.	10 uM :100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-549	5.04%	32.50%	61.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."
C56963	25716014	DIS0022	NP6905	Curcumin	DR3943	Carboplatin	NEWCL00170	A-549	.	.	10 uM :100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Up-regulation	A-549	12.72%	5.64%	30.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."
C56963	25716014	DIS0022	NP6905	Curcumin	DR3943	Carboplatin	NEWCL00170	A-549	.	.	10 uM :100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IkBa	Down-regulation	.	43.32%	75.60%	77.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."
C56963	25716014	DIS0022	NP6905	Curcumin	DR3943	Carboplatin	NEWCL00170	A-549	.	.	10 uM :100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	.	7.33%	38.82%	60.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."
C02521	25736303	DIS0123	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00103	TE-1	48h:248.6 uMu	48h:480.8uMu	50uM:70uM	NEWCL00259	A-431	48h:174.6 uMu	48h:322.9 uMu	50uM:70uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	TE1	11.27%	11.81%	77.41%	A431	56.56%	26.45%	364.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis.
C02521	25736303	DIS0123	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00103	TE-1	48h:248.6 uMu	48h:480.8uMu	50uM:70uM	NEWCL00259	A-431	48h:174.6 uMu	48h:322.9 uMu	50uM:70uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	TE1	3.51%	23.58%	52.99%	A431	149.24%	144.35%	313.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis.
C02521	25736303	DIS0123	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00103	TE-1	48h:248.6 uMu	48h:480.8uMu	50uM:70uM	NEWCL00259	A-431	48h:174.6 uMu	48h:322.9 uMu	50uM:70uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	TE1	35.33%	28.44%	49.02%	A431	36.24%	24.48%	54.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis.
C70316	25755712	DIS0124	NP9796	Betulinic Acid	DR9021	5-fluorouracil	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	OVCAR 432	.	.	.	RMS-13	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. Ovarian carcinoma cells on concurrent or 5-FU followed by BA treatment show increased Sub-G1 cell population, increased rate of cell apoptosis and morphological changes in mitochondrial membrane."
C89336	25758096	DIS0028	NP6993	Arsenic trioxide	DR4137	Rapamycin	NEWCL00022	HL-60	.	.	IuM:20nM	NEWCL00019	U-937	.	.	IuM:20nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-Akt	Down-regulation	.	.	.	.	U-937	44.93%	55.76%	89.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of drugs increased apoptosis in HL-60 cells and increased the percentage of cells in G(0)/G(1) phase in both cell lines.
C60738	25770930	DIS0031	NP9120	Chrysin	DR1669	Cisplatin	NEWCL00082	HCT 116	.	.	20 uM:10 ug.mL	NEWCL00129	Hep-G2	.	.	40 uM:5 ug.mL	NEWCL00343	CNE-1	.	.	40 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	HCT 116	69.37%	24.56%	89.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of chrysin and cisplatin promoted both extrinsic apoptosis by activating caspase-8 and intrinsic apoptosis by increasing the release of cytochrome c and activating caspase-9 in Hep G2 cells.
C60738	25770930	DIS0031	NP9120	Chrysin	DR1669	Cisplatin	NEWCL00082	HCT 116	.	.	20 uM:10 ug.mL	NEWCL00129	Hep-G2	.	.	40 uM:5 ug.mL	NEWCL00343	CNE-1	.	.	40 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT 116	16.04%	32.06%	45.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of chrysin and cisplatin promoted both extrinsic apoptosis by activating caspase-8 and intrinsic apoptosis by increasing the release of cytochrome c and activating caspase-9 in Hep G2 cells.
C60738	25770930	DIS0031	NP9120	Chrysin	DR1669	Cisplatin	NEWCL00082	HCT 116	.	.	20 uM:10 ug.mL	NEWCL00129	Hep-G2	.	.	40 uM:5 ug.mL	NEWCL00343	CNE-1	.	.	40 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR5	Up-regulation	HCT 116	3.85%	42.18%	186.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of chrysin and cisplatin promoted both extrinsic apoptosis by activating caspase-8 and intrinsic apoptosis by increasing the release of cytochrome c and activating caspase-9 in Hep G2 cells.
C30610	25773666	DIS0005	NP0074	Acteoside	DR6642	Thymic stromal lymphopoietin	NEWCL10327	HMC-1	.	.	10ug.ml:20 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	HMC-1	0.58%	12.46%	84.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	"Acteoside is a specific regulator of MDM2 activation in TSLP-stimulated mast cells, which indicates its potential use for the treatment of mast cell-mediated inflammatory diseases."
C30610	25773666	DIS0005	NP0074	Acteoside	DR6642	Thymic stromal lymphopoietin	NEWCL10327	HMC-1	.	.	10ug.ml:20 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HMC-1	15.24%	1.54%	54.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	"Acteoside is a specific regulator of MDM2 activation in TSLP-stimulated mast cells, which indicates its potential use for the treatment of mast cell-mediated inflammatory diseases."
C62720	25815518	DIS0094	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00278	RPMI-8226	.	.	4uM: 1mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	RPMI-8226	6.75%	8.63%	10.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9."
C62720	25815518	DIS0094	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00278	RPMI-8226	.	.	4uM: 1mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	RPMI-8226	3.48%	0.80%	2.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9."
C62720	25815518	DIS0094	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00278	RPMI-8226	.	.	4uM: 1mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Up-regulation	RPMI-8226	1.05%	2.55%	3.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9."
C62720	25815518	DIS0094	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00278	RPMI-8226	.	.	4uM: 1mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Acetylated-H3	Up-regulation	RPMI-8226	2.06%	2.78%	4.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9."
C62720	25815518	DIS0094	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00278	RPMI-8226	.	.	4uM: 1mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	RPMI-8226	6.79%	5.57%	8.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9."
C62720	25815518	DIS0094	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00278	RPMI-8226	.	.	4uM: 1mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	H3K9me2	Down-regulation	RPMI-8226	5.48%	2.15%	8.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9."
C17620	25824409	DIS0021	NP5023	Gambogic acid	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR	48h:1 uM	48h:1.5 uM	1 uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7.ADR	248.38%	6.07%	1613.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
C83616	25860284	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00168	Tu 686	.	.	30 uM:1 uM	NEWCL00128	Tu 212	.	.	30 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim	Up-regulation	Tu 686	14.21%	652.95%	644.23%	Tu 212	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.
C83616	25860284	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00168	Tu 686	.	.	30 uM:1 uM	NEWCL00128	Tu 212	.	.	30 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Tu 686	24.31%	13.06%	59.05%	Tu 212	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.
C83616	25860284	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00168	Tu 686	.	.	30 uM:1 uM	NEWCL00128	Tu 212	.	.	30 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Up-regulation	Tu 686	57.85%	43.32%	47.66%	Tu 212	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.
C83616	25860284	DIS0133	NP2960	Epigallocatechin gallate	DR8028	Erlotinib	NEWCL00168	Tu 686	.	.	30 uM:1 uM	NEWCL00128	Tu 212	.	.	30 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Up-regulation	Tu 686	1.18%	747.77%	494.80%	Tu 212	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.
C57395	25875356	DIS0022	NP2960	Epigallocatechin gallate	DR1669	Cisplatin	.	.	.	.	100mg.kg:20mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P65	Up-regulation	.	5.32%	19.73%	13.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	"Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice."
C93800	25876645	DIS0115	NP6740	Capsaicin	DR3720	"3,3'-diindolylmethane"	NEWCL00082	HCT 116	.	.	100 uM :25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	HCT 116	191.61%	416.34%	413.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis."
C93800	25876645	DIS0115	NP6740	Capsaicin	DR3720	"3,3'-diindolylmethane"	NEWCL00082	HCT 116	.	.	100 uM :25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Up-regulation	HCT 116	74.44%	49.81%	52.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis."
C93800	25876645	DIS0115	NP6740	Capsaicin	DR3720	"3,3'-diindolylmethane"	NEWCL00082	HCT 116	.	.	100 uM :25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	HCT 116	19.48%	17.89%	91.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis."
C93800	25876645	DIS0115	NP6740	Capsaicin	DR3720	"3,3'-diindolylmethane"	NEWCL00082	HCT 116	.	.	100 uM :25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Up-regulation	HCT 116	439.57%	410.60%	666.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis."
C93800	25876645	DIS0115	NP6740	Capsaicin	DR3720	"3,3'-diindolylmethane"	NEWCL00082	HCT 116	.	.	100 uM :25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PUMA	Up-regulation	HCT 116	585.02%	600.80%	993.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis."
C93800	25876645	DIS0115	NP6740	Capsaicin	DR3720	"3,3'-diindolylmethane"	NEWCL00082	HCT 116	.	.	100 uM :25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116	81.90%	22.30%	56.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis."
C93800	25876645	DIS0115	NP6740	Capsaicin	DR3720	"3,3'-diindolylmethane"	NEWCL00082	HCT 116	.	.	100 uM :25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8765	Traf2	Down-regulation	HCT 116	86.39%	7.50%	76.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis."
C93800	25876645	DIS0115	NP6740	Capsaicin	DR3720	"3,3'-diindolylmethane"	NEWCL00082	HCT 116	.	.	100 uM :25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Traf3	Down-regulation	HCT 116	69.98%	7.97%	61.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis."
C01771	25896445	DIS0022	NP0016	Silibinin	DR6637	Indole-3-carbinol	NEWCL20426	H1799	.	.	10uM:10uM	NEWCL20439	H1198	.	.	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	H1799	0.70%	2.60%	6.90%	H1198	0.80%	0.59%	3.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators.
C01771	25896445	DIS0022	NP0016	Silibinin	DR6637	Indole-3-carbinol	NEWCL20426	H1799	.	.	10uM:10uM	NEWCL20439	H1198	.	.	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	H1799	1.04%	2.27%	43.29%	H1198	2.19%	1.73%	55.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators.
C01771	25896445	DIS0022	NP0016	Silibinin	DR6637	Indole-3-carbinol	NEWCL20426	H1799	.	.	10uM:10uM	NEWCL20439	H1198	.	.	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	H1799	.	.	.	H1198	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators.
C01771	25896445	DIS0022	NP0016	Silibinin	DR6637	Indole-3-carbinol	NEWCL20426	H1799	.	.	10uM:10uM	NEWCL20439	H1198	.	.	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	H1799	0.52%	4.77%	32.47%	H1198	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators.
C84654	25917288	DIS0025	NP8058	Thioguanine	DR7335	Pralatrexate	NEWCL00032	MOLT-4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"The combination of 6-TG and PDX, with the inclusion of leucovorin rescue, allows for a safe and effective regimen in MTAP-deficient T-cell ALL."
C63502	25922640	DIS0022	NP2960	Epigallocatechin gallate	DR1590	Leptomycin B	NEWCL00170	A-549	.	.	20 uM:0.5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination treatment of LMB and EGCG augments LMB-induced cytotoxicity through enhanced ROS production and the modulation of drug metabolism and p21/survivin pathways.
C57395	25927922	DIS0124	NP2960	Epigallocatechin gallate	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	9.49 ±  0.13 uM	10uM:10uM	NEWCL00231	SK-OV-3	.	9.65 ±  0.56 uM	10uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CTR1	Down-regulation	OVCAR3	0.11%	19.61%	68.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin Influx transporter CTR1 in ovary cancer.
C06615	25933112	DIS0031	NP6740	Capsaicin	DR9021	5-fluorouracil	NEWCL00067	QBC939	173.3 ± 1.34uM	.	60 uM:40 uM	NEWCL00066	SK-CHA-1	189.04 ±  1.39uM	.	60 uM:40 uM	NEWCL00106	MZ-CHA-1	219.04 ±  1.19uM	.	60 uM:40 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3 II	Up-regulation	QBC939	6.87%	6.67%	16.44%	SK-CHA-1	.	.	.	MZ-CHA-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin enhances 5FU sensitivity of cholangiocarcinoma through the inhibition of 5FU-induced autophagy by activating the PI3K/AKT/mTOR pathway.
C02521	25936796	DIS0122	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00205	B16-F10	.	.	25 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-AMPK	Up-regulation	B16F10	16.52%	0.99%	15.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Co-treatment using resveratrol and 5-FU inhibited cell proliferation are more efficiently compared with use of either drug alone.
C02521	25936796	DIS0122	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00205	B16-F10	.	.	25 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	B16F10	21.76%	20.99%	45.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Co-treatment using resveratrol and 5-FU inhibited cell proliferation are more efficiently compared with use of either drug alone.
C02521	25936796	DIS0122	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00205	B16-F10	.	.	25 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0607	VASP	Down-regulation	B16F10	8.02%	10.90%	30.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Co-treatment using resveratrol and 5-FU inhibited cell proliferation are more efficiently compared with use of either drug alone.
C02521	25936796	DIS0122	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00205	B16-F10	.	.	25 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	B16F10	14.63%	41.78%	58.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Co-treatment using resveratrol and 5-FU inhibited cell proliferation are more efficiently compared with use of either drug alone.
C44873	25971429	DIS0129	NP6905	Curcumin	DR0904	Bicalutamide	NEWCL00253	PC-3	.	72h; 30 uM	40 uM:30 uM	NEWCL00251	DU145	.	 24h; 10uM	40 uM:30 uM	NEWCL00252	LNCaP	.	.	40 uM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"There are synergistic effects of curcumin and bicalutamide. Curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein."
C57395	25988128	DIS0127	NP2960	Epigallocatechin gallate	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	25 uM:250 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Up-regulation	HeLa	0.49%	18.95%	18.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	EGCG increases the sensitization of cisplatin to cervical cancer cells by inhibiting cell survival and inducing apoptosis.
C14052	25991668	DIS0129	NP2010	Delphinidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	50 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	LNCaP	2.39%	3.82%	380.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage."
C14052	25991668	DIS0129	NP2010	Delphinidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	50 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HDAC3	Up-regulation	LNCaP	2.77%	1.61%	144.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage."
C14052	25991668	DIS0129	NP2010	Delphinidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	50 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	LNCaP	45.01%	54.05%	68.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage."
C14052	25991668	DIS0129	NP2010	Delphinidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	50 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	LNCaP	0.43%	27.92%	58.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage."
C14052	25991668	DIS0129	NP2010	Delphinidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	30uM:50 ng.ml	NEWCL20438	Dul45	.	.	30 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	LNCaP	1.14%	1.06%	96.51%	Dul45	1.07%	0.81%	90.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage."
C14052	25991668	DIS0129	NP2010	Delphinidin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00252	LNCaP	.	.	30uM:50 ng.ml	NEWCL20438	Dul45	.	.	30 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	LNCaP	2.78%	4.91%	54.20%	Dul45	16.21%	13.94%	65.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage."
C39312	26011145	DIS0129	NP1168	Quercetin	DR8472	2-methoxyestradiol	NEWCL00253	PC-3	.	.	75mg.kg: 150mg.kg	NEWCL00252	LNCaP	.	.	75mg.kg: 150mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax 	Up-regulation	PC-3	10.70%	16.11%	32.52%	LNCaP	18.19%	3.52%	14.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of quercetin and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth.
C39312	26011145	DIS0129	NP1168	Quercetin	DR8472	2-methoxyestradiol	NEWCL00253	PC-3	.	.	75mg.kg: 150mg.kg	NEWCL00252	LNCaP	.	.	75mg.kg: 150mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	PC-3	29.24%	27.27%	34.56%	LNCaP	15.05%	43.48%	91.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of quercetin and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth.
C39312	26011145	DIS0129	NP1168	Quercetin	DR8472	2-methoxyestradiol	NEWCL00253	PC-3	.	.	75mg.kg: 150mg.kg	NEWCL00252	LNCaP	.	.	75mg.kg: 150mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	PC-3	5.23%	.	12.85%	LNCaP	3.90%	22.48%	38.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of quercetin and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth.
C39312	26011145	DIS0129	NP1168	Quercetin	DR8472	2-methoxyestradiol	NEWCL00253	PC-3	.	.	75mg.kg: 150mg.kg	NEWCL00252	LNCaP	.	.	75mg.kg: 150mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	PC-3	9.00%	14.14%	16.28%	LNCaP	9.59%	14.16%	22.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of quercetin and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth.
C39312	26011145	DIS0129	NP1168	Quercetin	DR8472	2-methoxyestradiol	NEWCL00253	PC-3	.	.	75mg.kg: 150mg.kg	NEWCL00252	LNCaP	.	.	75mg.kg: 150mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	PC-3	3.75%	10.54%	9.49%	LNCaP	2.38%	3.72%	5.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of quercetin and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth.
C27097	26062577	DIS0029	NP7102	Elemene	DR6516	Temozolomide	NEWCL00123	T98G	48h:59 ug.ml	.	40 ug.ml:500 uM	NEWCL00279	U-87MG ATCC	48h:61.02 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4172	P-ATM	Up-regulation	GBM T98G	57.90%	72.76%	34.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway.
C27097	26062577	DIS0029	NP7102	Elemene	DR6516	Temozolomide	NEWCL00123	T98G	48h:59 ug.ml	.	40 ug.ml:500 uM	NEWCL00279	U-87MG ATCC	48h:61.02 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	GBM T98G	65.13%	16.49%	93.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway.
C15436	26125846	DIS0015	NP6084	Resveratrol	DR8244	Imatinib	NEWCL00048	K-562	.	.	50 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	K-562	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Treatment with resveratrol (concentration-dependent) and imatinib mesylate showed significantly greater inhibition of K562 cell growth and a higher apoptosis rate of K562 cells than imatinib mesylate medication alone and the control group.
C27959	26136140	DIS0022	NP3718	Honokiol	DR1182	Chloroquine	NEWCL00170	A-549	.	.	40uM:20uM	NEWCL00180	NCI-H460	.	.	30uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Up-regulation	A-549	1.15%	1.04%	4.77%	NCI-H460	4.59%	7.66%	0.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Honokiol exhibits enhanced antitumor effects with chloroquine by inducing cell death and inhibiting autophagy in human non-small cell lung cancer cells.
C27959	26136140	DIS0022	NP3718	Honokiol	DR1182	Chloroquine	NEWCL00170	A-549	.	.	40uM:20uM	NEWCL00180	NCI-H460	.	.	30uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3	Up-regulation	A-549	190.49%	188.83%	187.25%	NCI-H460	200.35%	233.99%	237.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Honokiol exhibits enhanced antitumor effects with chloroquine by inducing cell death and inhibiting autophagy in human non-small cell lung cancer cells.
C21946	26156237	DIS0021	NP6084	Resveratrol	DR6300	Trastuzumab	NEWCL00155	MCF-7	33.701 ±  2.69 ug.ml	82.975 ±  5.95 ug.ml	33.701 ± 2.69 ug.ml:82.975 ± 5.95 ug.ml	NEWCL00156	T-47D	11.994 ±  0.3 ug.ml 	 9.506 ±  0.08 ug.ml	11.994 ± 0.3 ug.ml : 9.506 ± 0.08 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MCF-7	231.98%	118.38%	149.09%	T47D	0.81%	0.62%	0.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herceptin / resveratrol combinations improved the cytotoxic profile of herceptin in both T47D and MCF-7 breast cancer cell lines.
C21946	26156237	DIS0021	NP6084	Resveratrol	DR6300	Trastuzumab	NEWCL00155	MCF-7	33.701 ±  2.69 ug.ml	82.975 ±  5.95 ug.ml	33.701 ± 2.69 ug.ml:82.975 ± 5.95 ug.ml	NEWCL00156	T-47D	11.994 ±  0.3 ug.ml 	 9.506 ±  0.08 ug.ml	11.994 ± 0.3 ug.ml : 9.506 ± 0.08 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MCF-7	8.76%	2.44%	9.02%	T47D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herceptin / resveratrol combinations improved the cytotoxic profile of herceptin in both T47D and MCF-7 breast cancer cell lines.
C21946	26156237	DIS0021	NP6084	Resveratrol	DR6300	Trastuzumab	NEWCL00155	MCF-7	33.701 ±  2.69 ug.ml	82.975 ±  5.95 ug.ml	33.701 ± 2.69 ug.ml:82.975 ± 5.95 ug.ml	NEWCL00156	T-47D	11.994 ±  0.3 ug.ml 	 9.506 ±  0.08 ug.ml	11.994 ± 0.3 ug.ml : 9.506 ± 0.08 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	MCF-7	32.70%	20.89%	33.09%	T47D	2.73%	3.49%	9.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Herceptin / resveratrol combinations improved the cytotoxic profile of herceptin in both T47D and MCF-7 breast cancer cell lines.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MOLT-4	20.19%	11.24%	52.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	MOLT-4	48.50%	37.07%	83.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	MOLT-4	42.83%	9.33%	76.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MOLT-4	1239.44%	35.58%	1870.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	MOLT-4	334.82%	103.17%	1656.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MOLT-4	605.41%	82.39%	670.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HDAC2	Down-regulation	MOLT-4	11.32%	19.59%	5.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HDAC3	Down-regulation	MOLT-4	2.84%	1.58%	58.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1613	HDAC6	Down-regulation	MOLT-4	15.42%	1.64%	63.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C94552	26156322	DIS0037	NP1644	Vincristine	DR2632	Vorinostat	NEWCL00032	MOLT-4	48h:840nM	48h:3.3nM	0.3nM-3:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Acetylated-H3	Up-regulation	MOLT-4	148.59%	72.84%	920.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.
C02976	26183715	DIS0115	NP5888	Cucurbitacin B	DR9742	Gefitinib	NEWCL00344	HT29	24h:10uM; 48h:1uM	24h:50uM; 48h:20uM	"24h:0.5uM:10uM 
48h:0.1uM:10uM"	NEWCL00082	HCT 116	24h:60uM; 48h:40uM	24h:50uM; 48h:25uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HT-29	51.92%	51.68%	95.68%	HCT 116	95.81%	2.47%	25.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines.
C02976	26183715	DIS0115	NP5888	Cucurbitacin B	DR9742	Gefitinib	NEWCL00344	HT29	24h:10uM; 48h:1uM	24h:50uM; 48h:20uM	"24h:0.5uM:10uM 
48h:0.1uM:10uM"	NEWCL00082	HCT 116	24h:60uM; 48h:40uM	24h:50uM; 48h:25uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	HT-29	68.20%	54.53%	81.31%	HCT 116	88.84%	7.26%	63.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines.
C02976	26183715	DIS0115	NP5888	Cucurbitacin B	DR9742	Gefitinib	NEWCL00344	HT29	24h:10uM; 48h:1uM	24h:50uM; 48h:20uM	"24h:0.5uM:10uM 
48h:0.1uM:10uM"	NEWCL00082	HCT 116	24h:60uM; 48h:40uM	24h:50uM; 48h:25uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Up-regulation	HT-29	290.48%	175.21%	325.26%	HCT 116	332.06%	143.40%	218.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines.
C02976	26183715	DIS0115	NP5888	Cucurbitacin B	DR9742	Gefitinib	NEWCL00344	HT29	24h:10uM; 48h:1uM	24h:50uM; 48h:20uM	"24h:0.5uM:10uM 
48h:0.1uM:10uM"	NEWCL00082	HCT 116	24h:60uM; 48h:40uM	24h:50uM; 48h:25uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HT-29	64.78%	28.52%	68.73%	HCT 116	5.88%	0.19%	59.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines.
C02976	26183715	DIS0115	NP5888	Cucurbitacin B	DR9742	Gefitinib	NEWCL00344	HT29	24h:10uM; 48h:1uM	24h:50uM; 48h:20uM	"24h:0.5uM:10uM 
48h:0.1uM:10uM"	NEWCL00082	HCT 116	24h:60uM; 48h:40uM	24h:50uM; 48h:25uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	EGFR	Down-regulation	HT-29	6.19%	13.65%	26.52%	HCT 116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines.
C02976	26183715	DIS0115	NP5888	Cucurbitacin B	DR9742	Gefitinib	NEWCL00344	HT29	24h:10uM; 48h:1uM	24h:50uM; 48h:20uM	"24h:0.5uM:10uM 
48h:0.1uM:10uM"	NEWCL00082	HCT 116	24h:60uM; 48h:40uM	24h:50uM; 48h:25uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	HT-29	15.86%	95.64%	88.75%	HCT 116	2.73%	45.05%	14.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines.
C02976	26183715	DIS0115	NP5888	Cucurbitacin B	DR9742	Gefitinib	NEWCL00344	HT29	24h:10uM; 48h:1uM	24h:50uM; 48h:20uM	"24h:0.5uM:10uM 
48h:0.1uM:10uM"	NEWCL00082	HCT 116	24h:60uM; 48h:40uM	24h:50uM; 48h:25uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	STAT3	Down-regulation	HT-29	7.68%	17.45%	7.05%	HCT 116	21.68%	1.91%	17.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines.
C02976	26183715	DIS0115	NP5888	Cucurbitacin B	DR9742	Gefitinib	NEWCL00344	HT29	24h:10uM; 48h:1uM	24h:50uM; 48h:20uM	"24h:0.5uM:10uM 
48h:0.1uM:10uM"	NEWCL00082	HCT 116	24h:60uM; 48h:40uM	24h:50uM; 48h:25uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	HT-29	91.47%	27.91%	45.93%	HCT 116	38.92%	3.10%	39.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines.
C28724	26208739	DIS0115	NP6128	Gossypol	DR9021	5-fluorouracil	NEWCL00077	HT-29	48h:26.11 ±  1.04 umol.L	.	20 umol.L:150 umol.mL	NEWCL00082	HCT 116	48h: 14.11 ±  1.08 umol.L	.	10 umol.L:30 umol.mL	NEWCL00353	RKO	48h:21.83 ±  1.05 umol.L	.	20 umol.L :15 umol.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HT-29	399.39%	329.12%	722.37%	HCT116	217.27%	237.30%	627.80%	RKO	11.93%	26.84%	326.86%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
C28724	26208739	DIS0115	NP6128	Gossypol	DR9021	5-fluorouracil	NEWCL00077	HT-29	48h:26.11 ±  1.04 umol.L	.	20 umol.L:150 umol.mL	NEWCL00082	HCT 116	48h: 14.11 ±  1.08 umol.L	.	10 umol.L:30 umol.mL	NEWCL00353	RKO	48h:21.83 ±  1.05 umol.L	.	20 umol.L :15 umol.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HT-29	25.46%	98.87%	508.10%	HCT116	282.25%	197.55%	318.95%	RKO	14.39%	82.81%	74.85%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
C28724	26208739	DIS0115	NP6128	Gossypol	DR9021	5-fluorouracil	NEWCL00077	HT-29	48h:26.11 ±  1.04 umol.L	.	20 umol.L:150 umol.mL	NEWCL00082	HCT 116	48h: 14.11 ±  1.08 umol.L	.	10 umol.L:30 umol.mL	NEWCL00353	RKO	48h:21.83 ±  1.05 umol.L	.	20 umol.L :15 umol.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	HT-29	.	.	.	HCT116	63.30%	13.20%	41.85%	RKO	12.15%	1.06%	66.70%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
C28724	26208739	DIS0115	NP6128	Gossypol	DR9021	5-fluorouracil	NEWCL00077	HT-29	48h:26.11 ±  1.04 umol.L	.	20 umol.L:150 umol.mL	NEWCL00082	HCT 116	48h: 14.11 ±  1.08 umol.L	.	10 umol.L:30 umol.mL	NEWCL00353	RKO	48h:21.83 ±  1.05 umol.L	.	20 umol.L :15 umol.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-p70S6K	Down-regulation	HT-29	.	.	.	HCT116	77.17%	10.45%	42.25%	RKO	44.92%	3.55%	69.68%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
C28724	26208739	DIS0115	NP6128	Gossypol	DR9021	5-fluorouracil	NEWCL00077	HT-29	48h:26.11 ±  1.04 uM	48h:293.70 ±  2.04 uM	20uuM:150 uM	NEWCL00082	HCT 116	 48h:14.11 ±  1.08 uM	48h:61.48 ±  2.24 uM	10 umol.L :30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	HK-10	5.80%	3.17%	16.58%	HCT116	22.79%	4.77%	63.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
C28724	26208739	DIS0115	NP6128	Gossypol	DR9021	5-fluorouracil	NEWCL00077	HT-29	48h:26.11 ±  1.04 uM	48h:293.70 ±  2.04 uM	20uuM:150 uM	NEWCL00082	HCT 116	 48h:14.11 ±  1.08 uM	48h:61.48 ±  2.24 uM	10 umol.L :30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	HK-11	36.04%	14.95%	48.22%	HCT116	10.85%	2.74%	61.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
C28724	26208739	DIS0115	NP6128	Gossypol	DR9021	5-fluorouracil	NEWCL00077	HT-29	48h:26.11 ±  1.04 uM	48h:293.70 ±  2.04 uM	20uuM:150 uM	NEWCL00082	HCT 116	 48h:14.11 ±  1.08 uM	48h:61.48 ±  2.24 uM	10 umol.L :30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HK-12	52.55%	1.59%	40.84%	HCT116	28.12%	39.09%	67.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
C28724	26208739	DIS0115	NP6128	Gossypol	DR9021	5-fluorouracil	NEWCL00077	HT-29	48h:26.11 ±  1.04 uM	48h:293.70 ±  2.04 uM	20uuM:150 uM	NEWCL00082	HCT 116	 48h:14.11 ±  1.08 uM	48h:61.48 ±  2.24 uM	10 umol.L :30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-p70S6K	Down-regulation	HK-13	9.93%	5.58%	49.51%	HCT116	47.12%	0.46%	63.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
C28724	26208739	DIS0115	NP6128	Gossypol	DR9021	5-fluorouracil	NEWCL00077	HT-29	48h:26.11 ±  1.04 uM	48h:293.70 ±  2.04 uM	20uM:150 uM	NEWCL00082	HCT 116	 48h:14.11 ±  1.08 uM	48h:61.48 ±  2.24 uM	10 umol.L :30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HT-29	39.69%	99.13%	731.92%	HCT116	87.43%	71.46%	270.15%	RKO	13.22%	244.98%	420.27%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
C55665	26215403	DIS0124	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL10160	ID8-NGL	.	.	25uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	ID8-NGL	40.68%	178.96%	185.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
C97853	26235741	DIS0021	NP9331	Plumbagin	DR0261	Zoledronic	NEWCL20363	MDA-MB-231SArfp	.	.	7.5 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MDA-MB-231SArfp	16.74%	4.38%	35.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of Zoledronic acid and Plumbagin synergistically suppresses human breast cancer MDA-MB-231SArfp cells in vitro. Plumbagin can inhibit Zoledronic acid-induced activation of the Notch-1 signaling pathway and subsequently reduce the expression of Bcl-2, thus potentiating cancer cell apoptosis."
C97853	26235741	DIS0021	NP9331	Plumbagin	DR0261	Zoledronic	NEWCL20363	MDA-MB-231SArfp	.	.	7.5 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8368	Notch-1	.	MDA-MB-231SArfp	61.11%	0.44%	28.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of Zoledronic acid and Plumbagin synergistically suppresses human breast cancer MDA-MB-231SArfp cells in vitro. Plumbagin can inhibit Zoledronic acid-induced activation of the Notch-1 signaling pathway and subsequently reduce the expression of Bcl-2, thus potentiating cancer cell apoptosis."
C97853	26235741	DIS0021	NP9331	Plumbagin	DR0261	Zoledronic	NEWCL20363	MDA-MB-231SArfp	.	.	7.5 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6221	Notch-3	.	MDA-MB-231SArfp	17.04%	0.93%	8.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of Zoledronic acid and Plumbagin synergistically suppresses human breast cancer MDA-MB-231SArfp cells in vitro. Plumbagin can inhibit Zoledronic acid-induced activation of the Notch-1 signaling pathway and subsequently reduce the expression of Bcl-2, thus potentiating cancer cell apoptosis."
C97853	26235741	DIS0021	NP9331	Plumbagin	DR0261	Zoledronic	NEWCL20363	MDA-MB-231SArfp	.	.	7.5 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MDA-MB-231SArfp	60.13%	10.63%	73.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of Zoledronic acid and Plumbagin synergistically suppresses human breast cancer MDA-MB-231SArfp cells in vitro. Plumbagin can inhibit Zoledronic acid-induced activation of the Notch-1 signaling pathway and subsequently reduce the expression of Bcl-2, thus potentiating cancer cell apoptosis."
C97853	26235741	DIS0021	NP9331	Plumbagin	DR0261	Zoledronic	NEWCL20363	MDA-MB-231SArfp	.	.	7.5 uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Down-regulation	MDA-MB-231SArfp	10.87%	19.60%	26.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of Zoledronic acid and Plumbagin synergistically suppresses human breast cancer MDA-MB-231SArfp cells in vitro. Plumbagin can inhibit Zoledronic acid-induced activation of the Notch-1 signaling pathway and subsequently reduce the expression of Bcl-2, thus potentiating cancer cell apoptosis."
C45395	26238307	DIS0102	NP6128	Gossypol	DR4469	Doxorubicin	NEWCL00042	SW982	24h:16.2M; 48h:4.7M; 72h:3.9M	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with L gossypol and low-concentration doxorubicin inhibited cell proliferation and induced apoptosis in SW982 HSSCs at a significantly greater level compared with either treatment alone.
C45701	26278546	DIS0028	NP6905	Curcumin	DR7876	Cytarabine	NEWCL20432	Primary AML Cells 	24h:33.5 ±  0.1886 uM	24h:6.1 ±  0.2083 uM	75uM:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Primary AML Cells	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin down regulates MDR genes. Curcumin can be used as MDR modulator as well as chemosensitizer in combination with cytarabine to reduce the cytotoxicity profile as IC50 value decreases when treated in combination.
C33680	26299635	DIS0019	NP6905	Curcumin	DR2073	Sorafenib	NEWCL00262	FTC-133	19.42ug.mL	.	25 uM:2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FTC133	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of curcumin and sorafenib showed synergetic antitumor effect in thyroid cancer cells via PI3K/Akt and ERK pathways.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-375	39.96%	31.29%	89.13%	SK-MEL-28	32.65%	35.50%	9.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	A-375	4.02%	1.76%	5.53%	SK-MEL-28	2.56%	4.84%	6.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-375	22.59%	34.80%	67.96%	SK-MEL-28	33.39%	8.79%	81.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	A-375	13.78%	9.65%	52.91%	SK-MEL-28	27.84%	51.55%	71.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-375	29.30%	22.26%	36.85%	SK-MEL-28	12.64%	16.63%	25.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	A-375	46.11%	59.11%	74.39%	SK-MEL-28	6.45%	36.06%	30.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-MEK1.2	Down-regulation	A-375	40.54%	11.39%	87.47%	SK-MEL-28	1.00%	8.81%	83.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Down-regulation	A-375	71.05%	53.61%	76.57%	SK-MEL-28	32.70%	21.47%	70.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	PI3K	Down-regulation	A-375	76.66%	71.27%	89.12%	SK-MEL-28	17.21%	17.14%	80.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-375	23.97%	11.61%	61.08%	SK-MEL-28	3.42%	10.58%	78.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	A-375	95.76%	5.15%	139.42%	SK-MEL-28	90.76%	0.46%	194.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C07139	26299806	DIS0122	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00036	A-375	.	.	20uM:5uM	NEWCL00086	SK-MEL-28	.	.	20uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	A-375	43.72%	21.11%	90.97%	SK-MEL-28	41.66%	2.82%	89.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
C02521	26310874	DIS0115	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	5 uM:1 nM	NEWCL20380	HCT 116R	.	.	5 uM:1 nM	NEWCL00074	SW480	.	.	5 uM:1 nM	NEWCL00307	SW480R	.	.	5 uM:1 nM	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	HCT 116	71.47%	8.62%	67.48%	HCT 116R	.	.	.	SW480	.	.	.	SW480R	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer."
C02521	26310874	DIS0115	NP6084	Resveratrol	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	5 uM:1 nM	NEWCL20380	HCT 116R	.	.	5 uM:1 nM	NEWCL00074	SW480	.	.	5 uM:1 nM	NEWCL00307	SW480R	.	.	5 uM:1 nM	.	.	.	.	.	.	.	.	.	.	.	Slug	Down-regulation	HCT 116	2.80%	107.14%	17.90%	HCT 116R	.	.	.	SW480	.	.	.	SW480R	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer."
C60407	26314326	DIS0022	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00176	NCI-H838	.	.	40 ug.ml:5 ug.ml	NEWCL00187	NCI-H520	.	.	40 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	H838	.	.	.	H520	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol enhanced anticancer effects of cisplatin on non-small cell lung cancer cell lines by inducing mitochondrial dysfunction and cell apoptosis.
C98672	26349994	DIS0023	NP0016	Silibinin	DR7217	Trichostatin A	NEWCL00342	Panc1	.	.	48h; 50 uM:0.5uM	NEWCL00239	Capan-2	.	.	48h; 50 uM:0.5uM	NEWCL00243	BxPC-3	.	.	48h; 50 uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CDK1	Down-regulation	Panc1	12.50%	8.70%	544.48%	Capan2	8.33%	44.44%	810.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells.
C87955	26351208	DIS0021	NP6047	Metformin	DR7612	Everolimus	NEWCL10345	HCC1428	.	.	100uM:100nm	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-S6	Down-regulation	HCC1428	8.80%	8.65%	25.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
C87955	26351208	DIS0021	NP6047	Metformin	DR7612	Everolimus	NEWCL10345	HCC1428	.	.	100uM:100nm	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7832	P-4EBP1	Down-regulation	HCC1428	3.58%	5.23%	25.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
C57504	26351210	DIS0022	NP3615	Piceatannol	DR2391	Gemcitabine	NEWCL00170	A-549	.	 72h:400 uM ; 	2uM :1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	A-549	109.02%	137.07%	59.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Piceatannol can enhance the cytotoxic effects of gemcitabine by enhancing expression of the proapoptotic protein Bak.
C57504	26351210	DIS0022	NP3615	Piceatannol	DR2391	Gemcitabine	NEWCL00170	A-549	.	 72h:400 uM ; 	2uM :1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	A-549	17.02%	17.96%	42.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Piceatannol can enhance the cytotoxic effects of gemcitabine by enhancing expression of the proapoptotic protein Bak.
C57504	26351210	DIS0022	NP3615	Piceatannol	DR2391	Gemcitabine	NEWCL00170	A-549	.	 72h:400 uM ; 	2uM :1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	A-549	53.79%	93.53%	326.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Piceatannol can enhance the cytotoxic effects of gemcitabine by enhancing expression of the proapoptotic protein Bak.
C57504	26351210	DIS0022	NP3615	Piceatannol	DR2391	Gemcitabine	NEWCL00170	A-549	.	 72h:400 uM ; 	2uM :1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Down-regulation	A-549	21.34%	12.39%	13.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Piceatannol can enhance the cytotoxic effects of gemcitabine by enhancing expression of the proapoptotic protein Bak.
C54915	26426449	DIS0020	NP4621	Triptolide	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00256	786-O	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide sensitizes RCC cells to TRAIL-induced apoptosis through altered TRAIL death receptor and heat shock protein expression.
C08624	26497429	DIS0115	NP6047	Metformin	DR9021	5-fluorouracil	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination treatment of ME/5FU co-loaded hydrogels exhibited significant synergistic therapeutic efficacy in the BALB/c mouse model with transplanted subcutaneously tumor on the base of C26 cell line by inducing apoptosis and cell cycle arrest.
C79203	26505911	DIS0094	NP6993	Arsenic trioxide	DR5410	Recombint mutant human TRAIL	NEWCL00286	U266B1	.	.	5 umol.L :5 ng.mL	NEWCL00278	RPMI-8226	.	.	5 umol.L:200 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ATO and rmhTRAIL had synergistic or additive effects on proliferation inhibition and apoptosis induction in MM cells, and the mechanism underlying the two-drug combination might involve regulation of the expression of several proteins affected by ATO and rmhTRAIL."
C95085	26506421	DIS0021	NP0445	Cardamonin	DR9021	5-fluorouracil	NEWCL10053	SUM190PT	.	.	7.5uM:0.15uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.OCT-4	Up-regulation	uSUM190	97.00%	162.11%	222.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.
C95085	26506421	DIS0021	NP0445	Cardamonin	DR9021	5-fluorouracil	NEWCL10053	SUM190PT	.	.	7.5uM:0.15uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IKBalpha	Up-regulation	SUM190	42.64%	1546.11%	1610.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.
C95085	26506421	DIS0021	NP0445	Cardamonin	DR4469	Doxorubicin	NEWCL10053	SUM190PT	.	.	7.5uM:0.6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Up-regulation	uSUM190	71.62%	484.31%	423.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.
C95085	26506421	DIS0021	NP0445	Cardamonin	DR4469	Doxorubicin	NEWCL10053	SUM190PT	.	.	7.5uM:0.6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IKBalpha	Up-regulation	SUM190	42.64%	982.83%	202.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.
C46676	26511312	DIS0021	NP3806	Ginsenoside compound K	DR1669	Cisplatin	NEWCL00155	MCF-7	.	.	50 umol.L:10 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Up-regulation	MCF-7	0.56%	1.53%	1.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Both CK and DDP can inhibit the proliferation, EMT, and induce the apoptosis in MCF-7 cells, which may be related to the PI3K/Akt pathway. In addition, the combination of CK with DDP can produce a better effect."
C46676	26511312	DIS0021	NP3806	Ginsenoside compound K	DR1669	Cisplatin	NEWCL00155	MCF-7	.	.	50 umol.L:10 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	MCF-7	8.97%	9.65%	11.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Both CK and DDP can inhibit the proliferation, EMT, and induce the apoptosis in MCF-7 cells, which may be related to the PI3K/Akt pathway. In addition, the combination of CK with DDP can produce a better effect."
C49649	26531053	DIS0022	NP6905	Curcumin	DR1669	Cisplatin	NEWCL00170	A-549	40± 9.3uM	30± 5.0uM	10.30.40uM:0.5.1.1.5.3uM	NEWCL00186	NCI-H2170	30± 8.8uM	7± 0.8uM	10.20.30uM:0.5.1.1.5.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin enhanced the inhibitory effects of cisplatin on the highly migratory CD166+/EpCAM+ subpopulation. combined treatments induced cell cycle arrest, therefore triggering CSC growth inhibition via the intrinsic apoptotic pathway."
C60738	26537082	DIS0029	NP9120	Chrysin	DR1669	Cisplatin	NEWCL00279	U-87MG ATCC	 40 uM	20uM	40uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Chrysin additively potentiates the antiproliferative, cell cycle arrest and apoptotic activity of cisplatin in human glioma cancer (U87) cells."
C63570	26622796	DIS0022	NP5023	Gambogic acid	DR9742	Gefitinib	NEWCL20353	NCI-H1975 tumor	.	.	8mg.kg:100mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	NCI-H1975 tumor	339.45%	1799.60%	1832.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Gefitinib in combination with GA resulted in antitumor growth in the EGFR-T790M secondary mutation NCI-H1975 tumor model due to an enhanced apoptotic effect.
C59960	26637867	DIS0019	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00260	8505C	.	.	40 uM:200 ng.ml	NEWCL00261	CAL-62	.	.	40 uM:200 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	8505C	12.76%	18.25%	3.07%	CAL-62	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells."
C59960	26637867	DIS0019	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00260	8505C	.	.	40 uM:200 ng.ml	NEWCL00261	CAL-62	.	.	40 uM:200 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	8505C	6.03%	3.84%	18.18%	CAL-62	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells."
C59960	26637867	DIS0019	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00260	8505C	.	.	40 uM:200 ng.ml	NEWCL00261	CAL-62	.	.	40 uM:200 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	8505C	4.55%	1.18%	1.52%	CAL-62	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells."
C59960	26637867	DIS0019	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00260	8505C	.	.	40 uM:200 ng.ml	NEWCL00261	CAL-62	.	.	40 uM:200 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Up-regulation	8505C	8.61%	0.32%	14.41%	CAL-62	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells."
C59960	26637867	DIS0019	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00260	8505C	.	.	40 uM:200 ng.ml	NEWCL00261	CAL-62	.	.	40 uM:200 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	8505C	68.34%	0.13%	118.08%	CAL-62	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells."
C59960	26637867	DIS0019	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00260	8505C	.	.	40 uM:200 ng.ml	NEWCL00261	CAL-62	.	.	40 uM:200 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	8505C	14.10%	19.15%	19.80%	CAL-62	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells."
C59960	26637867	DIS0019	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00260	8505C	.	.	40 uM:200 ng.ml	NEWCL00261	CAL-62	.	.	40 uM:200 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Down-regulation	8505C	40.59%	12.83%	86.33%	CAL-62	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells."
C41181	26638893	DIS0021	NP5233	Wogonin	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	.	NEWCL00146	Bcap-37	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin increases doxorubicin sensitivity by down-regulation of IGF-1R/AKT signaling pathway in human breast cancer.
C29558	26640224	DIS0059	NP3683	Tricin	DR2461	Ganciclovir	NEWCL10341	MRC-5	621 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Expression of the HCMV UL54 gene was significantly inhibited by combination of GCV with tricin when compared with GCV mono-treatment.
C40830	26645832	DIS0021	NP9796	Betulinic Acid	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	10 uM :10-6uM	NEWCL00049	MDA-MB-231	.	.	10 uM :10-6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MCF-7	.	.	.	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Selective estrogen receptor modulators and betulinic acid act synergistically to target ERalpha and SP1 transcription factor dependent Pygopus expression in breast cancer.
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL10059	U-373MG ATCC	48h:41.7uM	48h:483.5uM	10.20.30uM:250uM	NEWCL00123	T98G	48h:41.5uM	48h:3457.8uM	10.20.30uM:250uM	NEWCL00279	U-87MG ATCC	48h:44.8uM	48h:702.4uM	10.20.30uM:250uM	NEWCL00122	LN-229	.	48h:954.2uM	.	NEWCL00039	U-251MG	.	48h:851.3uM	.	.	.	.	.	.	MO7854	P65	Down-regulation	U373	50.31%	2.42%	47.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL10059	U-373MG ATCC	48h:41.7uM	48h:483.5uM	10.20.30uM:250uM	NEWCL00123	T98G	48h:41.5uM	48h:3457.8uM	10.20.30uM:250uM	NEWCL00279	U-87MG ATCC	48h:44.8uM	48h:702.4uM	10.20.30uM:250uM	NEWCL00122	LN-229	.	48h:954.2uM	.	NEWCL00039	U-251MG	.	48h:851.3uM	.	.	.	.	.	.	MO3577	MGMT	Down-regulation	U373	31.93%	12.11%	25.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL10059	U-373MG ATCC	48h:41.7uM	48h:483.5uM	10.20.30uM:250uM	NEWCL00123	T98G	48h:41.5uM	48h:3457.8uM	10.20.30uM:250uM	NEWCL00279	U-87MG ATCC	48h:44.8uM	48h:702.4uM	10.20.30uM:250uM	NEWCL00122	LN-229	.	48h:954.2uM	.	NEWCL00039	U-251MG	.	48h:851.3uM	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	U373	23.90%	2.76%	5.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL10059	U-373MG ATCC	48h:41.7uM	48h:483.5uM	10.20.30uM:250uM	NEWCL00123	T98G	48h:41.5uM	48h:3457.8uM	10.20.30uM:250uM	NEWCL00279	U-87MG ATCC	48h:44.8uM	48h:702.4uM	10.20.30uM:250uM	NEWCL00122	LN-229	.	48h:954.2uM	.	NEWCL00039	U-251MG	.	48h:851.3uM	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	U373	23.77%	1.32%	10.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL10059	U-373MG ATCC	48h:41.7uM	48h:483.5uM	10.20.30uM:250uM	NEWCL00123	T98G	48h:41.5uM	48h:3457.8uM	10.20.30uM:250uM	NEWCL00279	U-87MG ATCC	48h:44.8uM	48h:702.4uM	10.20.30uM:250uM	NEWCL00122	LN-229	.	48h:954.2uM	.	NEWCL00039	U-251MG	.	48h:851.3uM	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	U373	21.37%	16.94%	101.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL20430	U373-R	.	48h:2529.3 uM	50 mg.kg: 50 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	U373-R	3.83%	1.23%	85.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL20430	U373-R	.	48h:2529.3 uM	50 mg.kg: 50 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P65	Down-regulation	U373-R	50.70%	7.65%	48.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL20430	U373-R	.	48h:2529.3 uM	50 mg.kg: 50 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3577	MGMT	Down-regulation	U373-R	35.31%	19.61%	25.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL20430	U373-R	.	48h:2529.3 uM	50 mg.kg: 50 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8199	Ki67	Down-regulation	U373-R	34.83%	19.47%	21.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL20430	U373-R	.	48h:2529.3 uM	50 mg.kg: 50 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	U373-R	36.89%	22.86%	18.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C53594	26648123	DIS0029	NP8310	Sulforaphane	DR6516	Temozolomide	NEWCL20430	U373-R	.	48h:2529.3 uM	50 mg.kg: 50 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	U373-R	33.43%	11.69%	19.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."
C25294	26656468	DIS0031	NP1559	Luteolin	DR9021	5-fluorouracil	NEWCL00141	BEL-7402	73.0 ±  16.0 uM	5.92 ±  3.4ug.mL	20 uM:1.0 ug.mL	NEWCL00129	Hep-G2	89.7 ±  7.8 uM	10.8 ±  5.2ug.mL	20 uM:1.0 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Bel7402	55.67%	37.30%	87.57%	Hep-G2	10.60%	7.41%	45.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism.
C25294	26656468	DIS0031	NP1559	Luteolin	DR9021	5-fluorouracil	NEWCL00141	BEL-7402	73.0 ±  16.0 uM	5.92 ±  3.4ug.mL	20 uM:1.0 ug.mL	NEWCL00129	Hep-G2	89.7 ±  7.8 uM	10.8 ±  5.2ug.mL	20 uM:1.0 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Bel7402	0.78%	0.47%	70.08%	Hep-G2	0.27%	0.69%	55.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism.
C25294	26656468	DIS0031	NP1559	Luteolin	DR9021	5-fluorouracil	NEWCL00141	BEL-7402	73.0 ±  16.0 uM	5.92 ±  3.4ug.mL	20 uM:1.0 ug.mL	NEWCL00129	Hep-G2	89.7 ±  7.8 uM	10.8 ±  5.2ug.mL	20 uM:1.0 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	Bel7402	15.34%	18.78%	23.96%	Hep-G2	15.17%	18.62%	101.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism.
C25294	26656468	DIS0031	NP1559	Luteolin	DR9021	5-fluorouracil	NEWCL00141	BEL-7402	73.0 ±  16.0 uM	5.92 ±  3.4ug.mL	20 uM:1.0 ug.mL	NEWCL00129	Hep-G2	89.7 ±  7.8 uM	10.8 ±  5.2ug.mL	20 uM:1.0 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Bel7402	180.86%	3.32%	112.53%	Hep-G2	154.11%	34.28%	207.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism.
C07139	26662956	DIS0127	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00149	Hela	.	.	40uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hela	252.35%	1.35%	302.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of fisetin and sorafenib exerted better synergistic effects in vitro and in vivo than either agent used alone against human cervical cancer, and this synergism was based on apoptotic potential through a mitochondrial- and DR5-dependent caspase-8/caspase-3 signaling pathway."
C07139	26662956	DIS0127	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00149	Hela	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	Hela	488.04%	503.77%	1253.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of fisetin and sorafenib exerted better synergistic effects in vitro and in vivo than either agent used alone against human cervical cancer, and this synergism was based on apoptotic potential through a mitochondrial- and DR5-dependent caspase-8/caspase-3 signaling pathway."
C07139	26662956	DIS0127	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00149	Hela	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Hela	455.32%	83.44%	1393.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of fisetin and sorafenib exerted better synergistic effects in vitro and in vivo than either agent used alone against human cervical cancer, and this synergism was based on apoptotic potential through a mitochondrial- and DR5-dependent caspase-8/caspase-3 signaling pathway."
C07139	26662956	DIS0127	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00149	Hela	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR4	Down-regulation	Hela	6.94%	5.26%	1.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of fisetin and sorafenib exerted better synergistic effects in vitro and in vivo than either agent used alone against human cervical cancer, and this synergism was based on apoptotic potential through a mitochondrial- and DR5-dependent caspase-8/caspase-3 signaling pathway."
C07139	26662956	DIS0127	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00149	Hela	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR5	Up-regulation	Hela	81.15%	69.92%	90.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of fisetin and sorafenib exerted better synergistic effects in vitro and in vivo than either agent used alone against human cervical cancer, and this synergism was based on apoptotic potential through a mitochondrial- and DR5-dependent caspase-8/caspase-3 signaling pathway."
C07139	26662956	DIS0127	NP8606	Fisetin	DR2073	Sorafenib	NEWCL00149	Hela	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Hela	66.59%	39.57%	83.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of fisetin and sorafenib exerted better synergistic effects in vitro and in vivo than either agent used alone against human cervical cancer, and this synergism was based on apoptotic potential through a mitochondrial- and DR5-dependent caspase-8/caspase-3 signaling pathway."
C49659	26667576	DIS0111	NP4621	Triptolide	DR1669	Cisplatin	NEWCL10114	HNE-1	.	48h:22.9 uM	10 uM:40 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Up-regulation	HNE1	32.95%	9.33%	98.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TPL could induce cell apoptosis and synergize with DDP by regulating ROS generation and mitochondrial pathways in HNE1/DDP cells.
C49659	26667576	DIS0111	NP4621	Triptolide	DR1669	Cisplatin	NEWCL10114	HNE-1	.	48h:22.9 uM	10 uM:40 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HNE1	79.91%	2.05%	85.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TPL could induce cell apoptosis and synergize with DDP by regulating ROS generation and mitochondrial pathways in HNE1/DDP cells.
C56521	26672603	DIS0114	NP6905	Curcumin	DR2889	Tolfemic acid	NEWCL00082	HCT 116	24h:13.46uM; 48h:3.6 uM;	 24h:70.3 uM; 48h:47.8 uM; 	7.5 uM:50uM; 24h	NEWCL00344	HT29	 24h:12.9 uM; 48h: 4.7 uM;	 24h:55.3 uM; 48h: 46.8uM;	7.5 uM:50uM; 24h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P65	Down-regulation	HCT 116	15.26%	23.02%	34.54%	HT29	2.88%	17.79%	81.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.
C56521	26672603	DIS0114	NP6905	Curcumin	DR2889	Tolfemic acid	NEWCL00082	HCT 116	24h:13.46uM; 48h:3.6 uM;	 24h:70.3 uM; 48h:47.8 uM; 	7.5 uM:50uM; 24h	NEWCL00344	HT29	 24h:12.9 uM; 48h: 4.7 uM;	 24h:55.3 uM; 48h: 46.8uM;	7.5 uM:50uM; 24h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HCT 116	9.33%	14.74%	25.67%	HT29	22.96%	34.76%	46.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.
C56521	26672603	DIS0114	NP6905	Curcumin	DR2889	Tolfemic acid	NEWCL00082	HCT 116	24h:13.46uM; 48h:3.6 uM;	 24h:70.3 uM; 48h:47.8 uM; 	7.5 uM:50uM; 24h	NEWCL00344	HT29	 24h:12.9 uM; 48h: 4.7 uM;	 24h:55.3 uM; 48h: 46.8uM;	7.5 uM:50uM; 24h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Up-regulation	HCT 116	23.93%	14.07%	76.10%	HT29	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.
C57357	26702744	DIS0115	NP5766	Ginsenoside Rh2	DR2724	Sodium selenite	NEWCL00082	HCT 116	.	.	12.5uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HCT 116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sodium selenite and G-Rh2 combination have a synergistic effect on cell growth inhibition (57%) compared with sodium selenite (25%) and G-Rh2 alone (28%) after 24 hours of treatment.
C35251	26707143	DIS0031	NP6905	Curcumin	DR6631	ABT-737	NEWCL00129	Hep-G2	.	.	2 uM :10 uM; 36h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Hep-G2	4.71%	22.70%	60.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin markedly enhanced the antitumor effects of ABT-737 on HepG2 cells, which was partially dependent on the induction of apoptosis. The sustained activation of the ROS-ASK1-c-Jun N-terminal kinase pathway may be an important mediator of the synergistic effect of curcumin and ABT-737."
C35251	26707143	DIS0031	NP6905	Curcumin	DR6631	ABT-737	NEWCL00129	Hep-G2	.	.	2 uM :10 uM; 36h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Hep-G2	32.30%	47.26%	617.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin markedly enhanced the antitumor effects of ABT-737 on HepG2 cells, which was partially dependent on the induction of apoptosis. The sustained activation of the ROS-ASK1-c-Jun N-terminal kinase pathway may be an important mediator of the synergistic effect of curcumin and ABT-737."
C35251	26707143	DIS0031	NP6905	Curcumin	DR6631	ABT-737	NEWCL00129	Hep-G2	.	.	2 uM :10 uM; 36h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hep-G2	34.94%	251.60%	909.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin markedly enhanced the antitumor effects of ABT-737 on HepG2 cells, which was partially dependent on the induction of apoptosis. The sustained activation of the ROS-ASK1-c-Jun N-terminal kinase pathway may be an important mediator of the synergistic effect of curcumin and ABT-737."
C78868	26725939	DIS0020	NP8210	Galangin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10134	Caki	.	.	30 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	Caki	21.14%	31.51%	80.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells.
C18568	26740178	DIS0114	NP8751	Shikonin	DR1669	Cisplatin	NEWCL00082	HCT 116	.	.	1uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6122	MDM2	Down-regulation	HCT 116	10.91%	8.48%	12.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin as a synergistic agent to cisplatin could be a highly efficient way to achieve anticancer synergism by inducing intracellular oxidative stress.
C18568	26740178	DIS0114	NP8751	Shikonin	DR1669	Cisplatin	NEWCL00082	HCT 116	.	.	1uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	HCT 116	9.97%	7.22%	15.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin as a synergistic agent to cisplatin could be a highly efficient way to achieve anticancer synergism by inducing intracellular oxidative stress.
C18568	26740178	DIS0114	NP8751	Shikonin	DR1669	Cisplatin	NEWCL00082	HCT 116	.	.	1uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cdc2	Down-regulation	HCT 116	14.78%	9.16%	79.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin as a synergistic agent to cisplatin could be a highly efficient way to achieve anticancer synergism by inducing intracellular oxidative stress.
C18568	26740178	DIS0114	NP8751	Shikonin	DR1669	Cisplatin	NEWCL00082	HCT 116	.	.	1uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HCT 116	78.86%	153.06%	212.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin as a synergistic agent to cisplatin could be a highly efficient way to achieve anticancer synergism by inducing intracellular oxidative stress.
C18568	26740178	DIS0114	NP8751	Shikonin	DR1669	Cisplatin	NEWCL00082	HCT 116	.	.	1uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116	0.51%	1.80%	53.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin as a synergistic agent to cisplatin could be a highly efficient way to achieve anticancer synergism by inducing intracellular oxidative stress.
C18568	26740178	DIS0114	NP8751	Shikonin	DR1669	Cisplatin	NEWCL00082	HCT 116	.	.	1uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT 116	28.99%	60.93%	70.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin as a synergistic agent to cisplatin could be a highly efficient way to achieve anticancer synergism by inducing intracellular oxidative stress.
C50254	26829656	DIS0029	NP5651	Morusin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	2.5 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	U-87MG ATCCMG	14.25%	6.72%	20.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Morusin induces TRAIL sensitization by regulating EGFR and DR5 in human glioblastoma cells.
C50254	26829656	DIS0029	NP5651	Morusin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	2.5 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	U-87MG ATCCMG	4.96%	55.42%	93.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Morusin induces TRAIL sensitization by regulating EGFR and DR5 in human glioblastoma cells.
C50254	26829656	DIS0029	NP5651	Morusin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	2.5 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U-87MG ATCCMG	2.70%	22.75%	53.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Morusin induces TRAIL sensitization by regulating EGFR and DR5 in human glioblastoma cells.
C50254	26829656	DIS0029	NP5651	Morusin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	.	.	2.5 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	U-87MG ATCCMG	0.26%	13.93%	22.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Morusin induces TRAIL sensitization by regulating EGFR and DR5 in human glioblastoma cells.
C76936	26867799	DIS0031	NP7102	Elemene	DR0141	Oxaliplatin	NEWCL00028	MHCC97-H	.	96h:16.41± 1.11uM	60ug:16uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MHCC97H	1.52%	21.49%	45.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.
C76936	26867799	DIS0031	NP7102	Elemene	DR0141	Oxaliplatin	NEWCL00028	MHCC97-H	.	96h:16.41± 1.11uM	60ug:16uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	MHCC97H	17.34%	26.80%	90.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.
C76936	26867799	DIS0031	NP7102	Elemene	DR0141	Oxaliplatin	NEWCL00028	MHCC97-H	.	96h:16.41± 1.11uM	60ug:16uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MHCC97H	12.85%	28.21%	30.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.
C26848	26893664	DIS0024	NP1549	Naringenin	DR6631	ABT-737	NEWCL00142	SGC-7901	.	.	40 uM: 5 uM ; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SGC-7901	12.52%	27.44%	41.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	ABT-737 in combination with naringenin showed enhanced anticancer effects on gastric cancer cells.
C26848	26893664	DIS0024	NP1549	Naringenin	DR6631	ABT-737	NEWCL00142	SGC-7901	.	.	40 uM: 5 uM ; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SGC-7901	1.54%	1.82%	26.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	ABT-737 in combination with naringenin showed enhanced anticancer effects on gastric cancer cells.
C26848	26893664	DIS0024	NP1549	Naringenin	DR6631	ABT-737	NEWCL00142	SGC-7901	.	.	40 uM: 5 uM ; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Up-regulation	SGC-7901	13.75%	29.27%	42.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	ABT-737 in combination with naringenin showed enhanced anticancer effects on gastric cancer cells.
C24059	26909608	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00297	MDA-Panc-28	.	.	20 uM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	Panc-28	4.45%	5.95%	43.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C24059	26909608	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00297	MDA-Panc-28	.	.	20 uM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Panc-28	63.79%	44.61%	72.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C24059	26909608	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00297	MDA-Panc-28	.	.	20 uM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CIAP-1	Down-regulation	Panc-28	10.32%	6.39%	35.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C24059	26909608	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00297	MDA-Panc-28	.	.	20 uM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C-FLIP	Down-regulation	Panc-28	37.17%	2.76%	66.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C24059	26909608	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00297	MDA-Panc-28	.	.	20 uM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	Panc-28	27.23%	3.73%	47.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C24059	26909608	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00297	MDA-Panc-28	.	.	20 uM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	Panc-28	16.76%	1.99%	59.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C24059	26909608	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00297	MDA-Panc-28	.	.	20 uM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	Panc-28	28.05%	2.76%	61.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C24059	26909608	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00297	MDA-Panc-28	.	.	20 uM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7003	ICAM-1	Down-regulation	Panc-28	19.90%	7.67%	53.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C24059	26909608	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00297	MDA-Panc-28	.	.	20 uM:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	Panc-28	94.51%	25.83%	95.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C77812	26916505	DIS0022	NP3653	Vadium	DR3943	Carboplatin	NEWCL00170	A-549	.	.	25uM:5ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-Smad(cytosol)	Up-regulation	A-549	0.73%	36.95%	9.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of vanadium and carboplatin resulted in synergistic antitumor activity in ex vivo cell cultures, and prompted G0/G1 cell cycle arrest and sensitization of tumor cells to carboplatin-induced apoptosis."
C77812	26916505	DIS0022	NP3653	Vadium	DR3943	Carboplatin	NEWCL00170	A-549	.	.	25uM:5ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-Smad(Nucleus)	Up-regulation	A-549	5.00%	87.61%	38.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of vanadium and carboplatin resulted in synergistic antitumor activity in ex vivo cell cultures, and prompted G0/G1 cell cycle arrest and sensitization of tumor cells to carboplatin-induced apoptosis."
C77812	26916505	DIS0022	NP3653	Vadium	DR3943	Carboplatin	NEWCL00170	A-549	.	.	25uM:5ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAI-1	Up-regulation	A-549	0.28%	95.23%	70.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of vanadium and carboplatin resulted in synergistic antitumor activity in ex vivo cell cultures, and prompted G0/G1 cell cycle arrest and sensitization of tumor cells to carboplatin-induced apoptosis."
C18218	26935527	DIS0021	NP4621	Triptolide	DR9921	Tumor necrosis factor alpha	NEWCL00049	MDA-MB-231	.	.	100 ng.ml:10 ng.ml	NEWCL00155	MCF-7	.	.	100 ng.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MDA-MB-231	157.14%	11.27%	179.93%	MCF-7	8.20%	2.85%	81.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide sensitized human breast cancer cells to TNF Alpha induced apoptosis.
C18218	26935527	DIS0021	NP4621	Triptolide	DR9921	Tumor necrosis factor alpha	NEWCL00049	MDA-MB-231	.	.	100 ng.ml:10 ng.ml	NEWCL00155	MCF-7	.	.	100 ng.ml:10 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	MDA-MB-231	25.34%	1.65%	53.45%	MCF-7	19.88%	10.31%	41.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide sensitized human breast cancer cells to TNF Alpha induced apoptosis.
C04523	26969377	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00155	MCF-7	24h: 230 uM; 48h:141 uM	24h:1146.25 nM; 48h:531.25 nM	84.6 uM:216 nM	NEWCL00049	MDA-MB-231	24h:590 uM; 48h:180 uM	24h:4646 nM; 48h:781.25 nM	108 uM:312 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	P65-NF-KB	Down-regulation	MCF-7	12.79%	9.31%	28.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."
C04523	26969377	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00155	MCF-7	24h: 230 uM; 48h:141 uM	24h:1146.25 nM; 48h:531.25 nM	84.6 uM:216 nM	NEWCL00049	MDA-MB-231	24h:590 uM; 48h:180 uM	24h:4646 nM; 48h:781.25 nM	108 uM:312 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	MCF-7	0.75%	27.81%	80.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."
C04523	26969377	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00155	MCF-7	24h: 230 uM; 48h:141 uM	24h:1146.25 nM; 48h:531.25 nM	84.6 uM:216 nM	NEWCL00049	MDA-MB-231	24h:590 uM; 48h:180 uM	24h:4646 nM; 48h:781.25 nM	108 uM:312 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B	Down-regulation	MCF-7	23.38%	24.78%	67.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."
C04523	26969377	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00155	MCF-7	24h: 230 uM; 48h:141 uM	24h:1146.25 nM; 48h:531.25 nM	84.6 uM:216 nM	NEWCL00049	MDA-MB-231	24h:590 uM; 48h:180 uM	24h:4646 nM; 48h:781.25 nM	108 uM:312 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7891	Beclin-1	Down-regulation	MCF-7	5.94%	53.35%	53.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."
C04523	26969377	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00155	MCF-7	24h: 230 uM; 48h:141 uM	24h:1146.25 nM; 48h:531.25 nM	84.6 uM:216 nM	NEWCL00049	MDA-MB-231	24h:590 uM; 48h:180 uM	24h:4646 nM; 48h:781.25 nM	108 uM:312 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MCF-7	126.46%	411.41%	187.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."
C04523	26969377	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00155	MCF-7	24h: 230 uM; 48h:141 uM	24h:1146.25 nM; 48h:531.25 nM	84.6 uM:216 nM	NEWCL00049	MDA-MB-231	24h:590 uM; 48h:180 uM	24h:4646 nM; 48h:781.25 nM	108 uM:312 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MCF-7	3.76%	12.94%	56.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."
C04523	26969377	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00155	MCF-7	24h: 230 uM; 48h:141 uM	24h:1146.25 nM; 48h:531.25 nM	84.6 uM:216 nM	NEWCL00049	MDA-MB-231	24h:590 uM; 48h:180 uM	24h:4646 nM; 48h:781.25 nM	108 uM:312 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	D43	Up-regulation	MCF-7	31.47%	28.52%	34.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."
C04523	26969377	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00155	MCF-7	24h: 230 uM; 48h:141 uM	24h:1146.25 nM; 48h:531.25 nM	84.6 uM:216 nM	NEWCL00049	MDA-MB-231	24h:590 uM; 48h:180 uM	24h:4646 nM; 48h:781.25 nM	108 uM:312 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	MCF-7	8.80%	6.16%	8.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."
C04523	26969377	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00155	MCF-7	24h: 230 uM; 48h:141 uM	24h:1146.25 nM; 48h:531.25 nM	84.6 uM:216 nM	NEWCL00049	MDA-MB-231	24h:590 uM; 48h:180 uM	24h:4646 nM; 48h:781.25 nM	108 uM:312 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5308	Nrf2	Down-regulation	MCF-7	0.18%	10.25%	27.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."
C62548	27039397	DIS0021	NP3247	Artemisinin	DR7137	25-methoxyl-dammarane-3beta;  12beta;  20-triol	NEWCL00049	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"25-methoxyl-dammarane-3beta, 12beta, 20-triol and artemisinin synergistically inhibit MDA-MB-231 cell proliferation through downregulation of testes-specific protease 50 (TSP50) expression."
C60407	27084520	DIS0022	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00170	A-549	8.3uM	24.04uM	2.5 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	0.36%	21.70%	62.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol combined with cisplatin synergistically induce apoptosis via modulating autophagic cell death in A549 cells.
C60407	27084520	DIS0022	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00170	A-549	8.3uM	24.04uM	2.5 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-549	5.33%	28.13%	87.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol combined with cisplatin synergistically induce apoptosis via modulating autophagic cell death in A549 cells.
C60407	27084520	DIS0022	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00170	A-549	8.3uM	24.04uM	2.5 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3 II	Up-regulation	A-549	2.50%	37.94%	132.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol combined with cisplatin synergistically induce apoptosis via modulating autophagic cell death in A549 cells.
C60407	27084520	DIS0022	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00170	A-549	8.3uM	24.04uM	2.5 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Down-regulation	A-549	10.85%	65.12%	70.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol combined with cisplatin synergistically induce apoptosis via modulating autophagic cell death in A549 cells.
C57932	27094504	DIS0031	NP3718	Honokiol	DR8032	Rosiglitazone	NEWCL20427	Mahlavu 	.	.	20uM:100uM	NEWCL20428	SK-Hep1 	.	.	20uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Mahlavu	.	.	.	SK-Hep1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression."
C42640	27121018	DIS0034	NP9279	Genistein	DR7217	Trichostatin A	NEWCL00148	HEp-2	48h:20uuM	48h:100 nM	20 uM:100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HEp-2	27.83%	29.94%	29.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Trichostatin A potentiates genistein-induced apoptosis and reverses EMT in HEp2 cells.
C42640	27121018	DIS0034	NP9279	Genistein	DR7217	Trichostatin A	NEWCL00148	HEp-2	48h:20uuM	48h:100 nM	20 uM:100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HEp-2	0.63%	1.63%	4.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Trichostatin A potentiates genistein-induced apoptosis and reverses EMT in HEp2 cells.
C42640	27121018	DIS0034	NP9279	Genistein	DR7217	Trichostatin A	NEWCL00148	HEp-2	48h:20uuM	48h:100 nM	20 uM:100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HEp-2	4.74%	4.31%	92.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Trichostatin A potentiates genistein-induced apoptosis and reverses EMT in HEp2 cells.
C42640	27121018	DIS0034	NP9279	Genistein	DR7217	Trichostatin A	NEWCL00148	HEp-2	48h:20uuM	48h:100 nM	20 uM:100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HEp-2	48.22%	45.34%	51.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Trichostatin A potentiates genistein-induced apoptosis and reverses EMT in HEp2 cells.
C42640	27121018	DIS0034	NP9279	Genistein	DR7217	Trichostatin A	NEWCL00148	HEp-2	48h:20uuM	48h:100 nM	20 uM:100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	Down-regulation	HEp-2	11.99%	15.74%	41.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Trichostatin A potentiates genistein-induced apoptosis and reverses EMT in HEp2 cells.
C42640	27121018	DIS0034	NP9279	Genistein	DR7217	Trichostatin A	NEWCL00148	HEp-2	48h:20uuM	48h:100 nM	20 uM:100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p-S6s240.244	Down-regulation	HEp-2	29.49%	12.21%	41.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Trichostatin A potentiates genistein-induced apoptosis and reverses EMT in HEp2 cells.
C42640	27121018	DIS0034	NP9279	Genistein	DR7217	Trichostatin A	NEWCL00148	HEp-2	48h:20uuM	48h:100 nM	20 uM:100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7832	P-4EBP1	Down-regulation	HEp-2	5.34%	5.52%	17.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Trichostatin A potentiates genistein-induced apoptosis and reverses EMT in HEp2 cells.
C05119	27123146	DIS0023	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	25nM:40nM	NEWCL00243	BxPC-3	.	.	25nM:40nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	BxPC-3	41.34%	23.99%	306.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	27123146	DIS0023	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	25nM:40nM	NEWCL00243	BxPC-3	.	.	25nM:40nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	BxPC-3	0.15%	0.60%	53.11%	Panc-1	60.30%	14.57%	55.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	27123146	DIS0023	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	25nM:40nM	NEWCL00243	BxPC-3	.	.	25nM:40nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	Gama-H2AX	Up-regulation	BxPC-3	16.19%	59.49%	81.77%	Panc-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C03662	27177453	DIS0031	NP9032	Allicin	DR9021	5-fluorouracil	NEWCL00169	SK-Hep-1	48h:10.389uM	48h:438.954uM	.	NEWCL00141	BEL-7402	48h:10.004uM	48h:410.336uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SK-Hep-1	8.34%	154.14%	135.48%	BEL-7402	9.78%	176.46%	652.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway.
C03662	27177453	DIS0031	NP9032	Allicin	DR9021	5-fluorouracil	NEWCL00169	SK-Hep-1	48h:10.389uM	48h:438.954uM	.	NEWCL00141	BEL-7402	48h:10.004uM	48h:410.336uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SK-Hep-1	41.58%	3.84%	67.10%	BEL-7402	2.32%	112.99%	112.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway.
C03662	27177453	DIS0031	NP9032	Allicin	DR9021	5-fluorouracil	NEWCL00169	SK-Hep-1	48h:10.389uM	48h:438.954uM	.	NEWCL00141	BEL-7402	48h:10.004uM	48h:410.336uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SK-Hep-1	23.09%	16.06%	80.16%	BEL-7402	0.61%	73.32%	88.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway.
C62137	27190933	DIS0015	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00069	KCl-22	.	.	25.50 uM:10 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin inhibits the cancer cell growth by inducing apoptosis and enhance the therapeutic potential of TRAIL.
C97380	27221674	DIS0124	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00231	SK-OV-3	2.934ug.ml	28.223ug.ml	.	NEWCL00230	A2780	5.359ug.ml	35.414ug.ml	.	NEWCL20445	HEY-sp	2.557ug.ml	30.031 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	P-PI3K	Down-regulation	SK-OV-3-sp	40.85%	58.50%	78.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1alpha in vitro.
C97380	27221674	DIS0124	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00231	SK-OV-3	2.934ug.ml	28.223ug.ml	.	NEWCL00230	A2780	5.359ug.ml	35.414ug.ml	.	NEWCL20445	HEY-sp	2.557ug.ml	30.031 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT-308	Down-regulation	SK-OV-3-sp	60.96%	83.89%	99.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1alpha in vitro.
C97380	27221674	DIS0124	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00231	SK-OV-3	2.934ug.ml	28.223ug.ml	.	NEWCL00230	A2780	5.359ug.ml	35.414ug.ml	.	NEWCL20445	HEY-sp	2.557ug.ml	30.031 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.OCT-4	Down-regulation	SK-OV-3-sp	56.22%	74.33%	84.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1alpha in vitro.
C97380	27221674	DIS0124	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00231	SK-OV-3	2.934ug.ml	28.223ug.ml	.	NEWCL00230	A2780	5.359ug.ml	35.414ug.ml	.	NEWCL20445	HEY-sp	2.557ug.ml	30.031 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	NOG	Down-regulation	SK-OV-3-sp	24.52%	25.27%	34.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1alpha in vitro.
C97380	27221674	DIS0124	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00231	SK-OV-3	2.934ug.ml	28.223ug.ml	.	NEWCL00230	A2780	5.359ug.ml	35.414ug.ml	.	NEWCL20445	HEY-sp	2.557ug.ml	30.031 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7896	CD133	Down-regulation	SK-OV-3-sp	32.47%	33.09%	72.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1alpha in vitro.
C98052	27225870	DIS0130	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL20409	HCV29	.	.	100 uM:20 nM	NEWCL00044	MGH-U1	.	.	100 uM:20 nM	NEWCL00274	639V	.	.	100 uM:20 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HCV29	.	.	.	MGH-U1	.	.	.	639V	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination with rapamycin, resveratrol was able to block rapamycin-induced Akt activation, while maintaining mTOR pathway inhibition."
C98409	27268643	DIS0114	NP3477	Nimbolide	DR9921	Tumor necrosis factor alpha	NEWCL00077	HT-29	.	.	0.1.1.0uM:80 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HT-29	3.16%	52.05%	69.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of nimbolide and TNF-alpha-Increases human colon adenocarcinoma cell death through JNK-mediated DR5 up- regulation.
C98409	27268643	DIS0114	NP3477	Nimbolide	DR9921	Tumor necrosis factor alpha	NEWCL00077	HT-29	.	.	0.1.1.0uM:80 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	HT-29	1.46%	13.17%	13.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of nimbolide and TNF-alpha-Increases human colon adenocarcinoma cell death through JNK-mediated DR5 up- regulation.
C98409	27268643	DIS0114	NP3477	Nimbolide	DR9921	Tumor necrosis factor alpha	NEWCL00077	HT-29	.	.	0.1.1.0uM:80 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	HT-29	72.31%	95.98%	172.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of nimbolide and TNF-alpha-Increases human colon adenocarcinoma cell death through JNK-mediated DR5 up- regulation.
C98409	27268643	DIS0114	NP3477	Nimbolide	DR9921	Tumor necrosis factor alpha	NEWCL00077	HT-29	.	.	0.1.1.0uM:80 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR5	Up-regulation	HT-29	13.58%	50.01%	68.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of nimbolide and TNF-alpha-Increases human colon adenocarcinoma cell death through JNK-mediated DR5 up- regulation.
C34194	27274989	DIS0019	NP7102	Elemene	DR4137	Rapamycin	NEWCL00039	U-251MG	24h:46.72ug.ml	24h:52.24 uM	40 ug.ml:30 uM	NEWCL00279	U-87MG ATCC	24h:61.33 ug.ml	24h:59.38 uM	40 ug.ml:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The novel combination of mTOR inhibitor with Beta-elemene synergistically attenuates tumor cell growth in follicular thyroid cancer, which requires additional preclinical validation."
C16500	27279256	DIS0115	NP1023	Morin	DR6422	MST312	NEWCL00077	HT-29	.	.	50 uM :10uM	NEWCL00076	SW620	.	.	50 uM :10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination treatment with morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase.
C53571	27313664	DIS0029	NP3275	Vitamin D	DR6516	Temozolomide	NEWCL00255	C6	.	24h:1mM	100nM:1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	C6	3.02%	21.53%	37.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined use of TMZ and VD exerts synergistic antitumor effects on rat models of glioblastoma and may represent an effective therapeutic strategy.
C53571	27313664	DIS0029	NP3275	Vitamin D	DR6516	Temozolomide	NEWCL00255	C6	.	24h:1mM	100nM:1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Down-regulation	C6	10.38%	28.18%	55.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combined use of TMZ and VD exerts synergistic antitumor effects on rat models of glioblastoma and may represent an effective therapeutic strategy.
C18543	27330316	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL20360	A549.DDP	2.591± 0.782uM	.	2 uM:10 ug.mL; 24 ; 48 ; 72	NEWCL00170	A-549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A549.DDP	2.74%	0.20%	35.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
C18543	27330316	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	24h:2.261± 0.218 uM	.	2 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	23.50%	17.66%	23.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
C18543	27330316	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL20360	A549.DDP	24h:2.261± 0.218 uM	.	2 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A549.DDP	15.14%	20.67%	23.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
C18543	27330316	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL20360	A549.DDP	24h:2.261± 0.218 uM	.	2 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	A549.DDP	39.75%	0.01%	53.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
C18543	27330316	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL20360	A549.DDP	24h:2.261± 0.218 uM	.	2 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A549.DDP	70.00%	34.58%	84.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
C18543	27330316	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	24h:2.261± 0.218 uM	.	2 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	9.81%	10.81%	26.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
C18543	27330316	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	24h:2.261± 0.218 uM	.	2 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	A-549	43.56%	2.68%	53.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
C18543	27330316	DIS0022	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00170	A-549	24h:2.261± 0.218 uM	.	2 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	A-549	0.73%	0.81%	0.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
C52902	27357249	DIS0024	NP9654	Bufalin	DR1669	Cisplatin	NEWCL00142	SGC-7901	.	.	100 nM:10uM	NEWCL00108	MKN45	.	.	100 nM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells.
C38026	27385212	DIS0114	NP3247	Artemisinin	DR6052	Halofuginone	NEWCL00082	HCT 116	.	.	160uM:10nM	NEWCL00155	MCF-7	.	.	160uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	HCT 116	83.29%	86.01%	94.79%	MCF-7	181.62%	57.17%	307.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1.
C38026	27385212	DIS0114	NP3247	Artemisinin	DR6052	Halofuginone	NEWCL00082	HCT 116	.	.	160uM:10nM	NEWCL00155	MCF-7	.	.	160uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Up-regulation	HCT 116	84.69%	5.10%	117.72%	MCF-7	360.33%	342.19%	361.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1.
C38026	27385212	DIS0114	NP3247	Artemisinin	DR6052	Halofuginone	NEWCL00082	HCT 116	.	.	160uM:10nM	NEWCL00155	MCF-7	.	.	160uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	P-CDK2	Down-regulation	HCT 116	7.33%	35.96%	27.73%	MCF-7	35.78%	10.81%	48.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1.
C05284	27399668	DIS0031	NP9073	Gingerol	DR4469	Doxorubicin	NEWCL00129	Hep-G2	72h:71.9 ±  2.8 uM	72h:680 ±  60 nM	.	.	.	103.1 ±  3.0 uM	4.6 ±  0.9 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Gingerol protected from DOX-induced vascular damage and synergized the cytotoxic effects of DOX against liver cancer cells without influencing the cellular pharmacokinetics.
C57091	27465776	DIS0036	NP3718	Honokiol	DR9021	5-fluorouracil	NEWCL00270	HSC-3	.	.	10ug.ml:10ug.ml	NEWCL00271	HSC-4	.	.	10ug.ml:10ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	p-EGFR	Down-regulation	HSC-3	6.77%	0.19%	10.47%	HSC-4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	HNK and 5-FU exert a synergistic therapeutic effect on OSCC by inducing apoptosis.
C28982	27465776	DIS0072	NP3718	Honokiol	DR9021	5-fluorouracil	NEWCL00270	HSC-3	.	.	10ug.ml:10ug.ml	NEWCL00271	HSC-4	.	.	10ug.ml:10ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VDAC	Up-regulation	HSC-3	2.32%	0.72%	8.27%	HSC-4	9.96%	17.31%	10.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	All-trans retinoic acid in combination with primaquine clears pneumocystis infection.
C08951	27465776	DIS0055	NP3718	Honokiol	DR9021	5-fluorouracil	NEWCL00270	HSC-3	.	.	10ug.ml:10ug.ml	NEWCL00271	HSC-4	.	.	10ug.ml:10ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	HSC-3	0.64%	2.98%	152.63%	HSC-4	14.37%	49.36%	174.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.
C25861	27465776	DIS0023	NP3718	Honokiol	DR9021	5-fluorouracil	NEWCL00270	HSC-3	.	.	10ug.ml:10ug.ml	NEWCL00271	HSC-4	.	.	10ug.ml:10ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HSC-3	56.33%	31.57%	59.65%	HSC-4	20.14%	13.11%	57.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.
C60653	27465776	DIS0288	NP3718	Honokiol	DR9021	5-fluorouracil	NEWCL00270	HSC-3	.	.	10ug.ml:10ug.ml	NEWCL00271	HSC-4	.	.	10ug.ml:10ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HSC-3	107.69%	194.70%	293.44%	HSC-4	9.79%	18.29%	40.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Doxycycline and hAAT in combination also inhibited IL-6 expression from LPS-stimulated NIH/3T3 mouse fibroblast cells, indicating a contributing mechanism of arthritis inhibition."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	Gama-H2AX	Up-regulation	8505C	61.92%	120.15%	109.58%	TPC-1	66.42%	7.27%	91.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53	Up-regulation	8505C	41.55%	17.96%	32.90%	TPC-1	45.50%	20.93%	41.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	8505C	20.02%	76.45%	57.69%	TPC-1	141.11%	40.80%	173.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3 	Up-regulation	8505C	4.33%	8.01%	34.90%	TPC-1	71.81%	0.85%	80.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	Down-regulation	8505C	9.06%	38.93%	43.76%	TPC-1	25.78%	53.35%	76.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	p-mTOR	Down-regulation	8505C	17.24%	38.44%	58.01%	TPC-1	28.51%	13.82%	50.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	p-S6K	Down-regulation	8505C	19.79%	39.77%	49.78%	TPC-1	10.66%	22.50%	57.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	P-NFKB	Down-regulation	8505C	18.69%	36.51%	46.48%	TPC-1	33.37%	52.60%	61.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	xIAP	Down-regulation	8505C	17.89%	0.46%	37.04%	TPC-1	37.34%	26.14%	56.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ClAP-1	Down-regulation	8505C	9.19%	11.30%	23.35%	TPC-1	29.89%	15.10%	63.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4688	p-Chk1	Down-regulation	8505C	2.16%	47.41%	48.17%	TPC-1	3.67%	35.19%	40.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	8505C	27.98%	48.08%	20.35%	TPC-1	38.59%	60.18%	10.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	8505C	9.83%	1.73%	29.41%	TPC-1	30.24%	25.10%	49.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Acetylated-H4	Down-regulation	8505C	59.87%	21.53%	57.81%	TPC-1	1.88%	1.60%	20.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4688	P-Chk1	Down-regulation	8505C	5.05%	41.22%	40.18%	TPC-1	5.39%	35.71%	39.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Down-regulation	8505C	1.41%	28.38%	38.54%	TPC-1	1.18%	45.27%	71.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	8505C	21.52%	36.99%	57.85%	TPC-1	10.66%	3.65%	43.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-S6K	Down-regulation	8505C	16.18%	36.68%	42.73%	TPC-1	6.43%	18.71%	54.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C86383	27470546	DIS0019	NP4621	Triptolide	DR5502	BIIB021	NEWCL00260	8505C	.	24 h:23.81 uM; 48h:4.09 uM; 72h:0.85 uM	40 nM:10 uM	NEWCL00263	TPC-1	.	24 h:29.48 uM; 48h:4.80 uM; 72h:1.15 uM	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	P-NFKB	Down-regulation	8505C	10.72%	29.95%	38.97%	TPC-1	24.89%	40.63%	62.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."
C27955	27472952	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL00076	SW620	48h:30.61uM	48h:0.68uM	10 uM:0.4 uM	NEWCL00353	RKO	48h:48.12uM	48h:0.79uM	10 uM:0.4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SW620	0.73%	3.49%	20.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	27472952	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL00076	SW620	48h:30.61uM	48h:0.68uM	10 uM:0.4 uM	NEWCL00353	RKO	48h:48.12uM	48h:0.79uM	10 uM:0.4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	SW620	4.36%	9.29%	154.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	27472952	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL00076	SW620	48h:30.61uM	48h:0.68uM	10 uM:0.4 uM	NEWCL00353	RKO	48h:48.12uM	48h:0.79uM	10 uM:0.4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	SW620	3.31%	6.04%	41.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	27472952	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL00076	SW620	48h:30.61uM	48h:0.68uM	10 uM:0.4 uM	NEWCL00353	RKO	48h:48.12uM	48h:0.79uM	10 uM:0.4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	SW620	3.52%	6.30%	26.51%	RKO	2.91%	14.49%	26.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	27472952	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL00076	SW620	48h:30.61uM	48h:0.68uM	10 uM:0.4 uM	NEWCL00353	RKO	48h:48.12uM	48h:0.79uM	10 uM:0.4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	SW620	10.21%	9.26%	20.46%	RKO	17.01%	24.53%	45.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	27472952	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL00076	SW620	48h:30.61uM	48h:0.68uM	10 uM:0.4 uM	NEWCL00353	RKO	48h:48.12uM	48h:0.79uM	10 uM:0.4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IKKalpha	Down-regulation	SW620	7.47%	6.51%	44.92%	RKO	0.13%	1.69%	51.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C18543	27473145	DIS0098	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00226	MG-63	48h:0.37mg.L	48h:3.29mg.L	0.1 mg.L:1 mg.L	NEWCL00355	HOS	48h:0.36mg.L	48h:2.79mg.L	0.1 mg.L:1mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4294	Fas L	Down-regulation	MG63	27.80%	10.22%	1.72%	HOS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	27473145	DIS0098	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00226	MG-63	48h:0.37mg.L	48h:3.29mg.L	0.1 mg.L:1 mg.L	NEWCL00355	HOS	48h:0.36mg.L	48h:2.79mg.L	0.1 mg.L:1mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	MG63	4.29%	5.57%	18.85%	HOS	1.78%	5.95%	16.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C18543	27473145	DIS0098	NP5023	Gambogic acid	DR1669	Cisplatin	NEWCL00226	MG-63	48h:0.37mg.L	48h:3.29mg.L	0.1 mg.L:1 mg.L	NEWCL00355	HOS	48h:0.36mg.L	48h:2.79mg.L	0.1 mg.L:1mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	MG63	8.79%	16.88%	26.59%	HOS	4.29%	14.31%	45.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.
C11292	27498706	DIS0029	NP7102	Elemene	DR9742	Gefitinib	NEWCL00039	U-251MG	24h:46.72ug.ml	24h:52.24 uM	40 ug.ml:30 uM	NEWCL00279	U-87MG ATCC	24h:61.33 ug.ml	24h:59.38 uM	40 ug.ml:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Atg16L	Up-regulation	U251	2.18%	5.54%	8.17%	U-87MG ATCC-MG	12.85%	1.18%	17.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	27498706	DIS0029	NP7102	Elemene	DR9742	Gefitinib	NEWCL00039	U-251MG	24h:46.72ug.ml	24h:52.24 uM	40 ug.ml:30 uM	NEWCL00279	U-87MG ATCC	24h:61.33 ug.ml	24h:59.38 uM	40 ug.ml:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-II	Up-regulation	U251	109.39%	48.07%	211.85%	U-87MG ATCC-MG	252.28%	147.16%	294.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	27498706	DIS0029	NP7102	Elemene	DR9742	Gefitinib	NEWCL00039	U-251MG	24h:46.72ug.ml	24h:52.24 uM	40 ug.ml:30 uM	NEWCL00279	U-87MG ATCC	24h:61.33 ug.ml	24h:59.38 uM	40 ug.ml:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U251	225.23%	140.55%	2186.31%	U-87MG ATCC-MG	36.51%	6.22%	151.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	27498706	DIS0029	NP7102	Elemene	DR9742	Gefitinib	NEWCL00039	U-251MG	24h:46.72ug.ml	24h:52.24 uM	40 ug.ml:30 uM	NEWCL00279	U-87MG ATCC	24h:61.33 ug.ml	24h:59.38 uM	40 ug.ml:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	U251	9.03%	0.23%	64.91%	U-87MG ATCC-MG	18.55%	121.05%	323.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	27498706	DIS0029	NP7102	Elemene	DR9742	Gefitinib	NEWCL00039	U-251MG	24h:46.72ug.ml	24h:52.24 uM	40 ug.ml:30 uM	NEWCL00279	U-87MG ATCC	24h:61.33 ug.ml	24h:59.38 uM	40 ug.ml:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	p-EGFR	Down-regulation	U251	39.66%	73.64%	92.93%	U-87MG ATCC-MG	47.46%	64.70%	86.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	27498706	DIS0029	NP7102	Elemene	DR9742	Gefitinib	NEWCL00039	U-251MG	24h:46.72ug.ml	24h:52.24 uM	40 ug.ml:30 uM	NEWCL00279	U-87MG ATCC	24h:61.33 ug.ml	24h:59.38 uM	40 ug.ml:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	Down-regulation	U251	71.03%	58.93%	83.57%	U-87MG ATCC-MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	27498706	DIS0029	NP7102	Elemene	DR9742	Gefitinib	NEWCL00039	U-251MG	24h:46.72ug.ml	24h:52.24 uM	40 ug.ml:30 uM	NEWCL00279	U-87MG ATCC	24h:61.33 ug.ml	24h:59.38 uM	40 ug.ml:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p-ERK	Down-regulation	U251	30.18%	32.52%	76.00%	U-87MG ATCC-MG	44.92%	1.72%	87.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C84861	27508051	DIS0029	NP8902	Ursolic acid	DR6516	Temozolomide	NEWCL00126	LN-18	.	.	12.5uM:25ug.ml	NEWCL00123	T98G	.	.	12.5uM:25ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3577	MGMT	Down-regulation	LN18	8.29%	14.50%	20.90%	T98G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression.
C84861	27508051	DIS0029	NP8902	Ursolic acid	DR6516	Temozolomide	NEWCL00126	LN-18	.	.	12.5uM:25ug.ml	NEWCL00123	T98G	.	.	12.5uM:25ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	P-H2AX	Up-regulation	LN18	107.71%	59.14%	30.28%	T98G	35.38%	11.37%	33.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression.
C72340	27544755	DIS0133	NP5233	Wogonin	DR1669	Cisplatin	NEWCL20378	HN4-cisR	.	.	60uM:10uM	NEWCL20437	HN9-cisR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HN4-cisR	823.66%	247.05%	871.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer.
C72340	27544755	DIS0133	NP5233	Wogonin	DR1669	Cisplatin	NEWCL20378	HN4-cisR	.	.	60uM:10uM	NEWCL20437	HN9-cisR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HN4-cisR	87.73%	9.51%	109.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer.
C72340	27544755	DIS0133	NP5233	Wogonin	DR1669	Cisplatin	NEWCL20378	HN4-cisR	.	.	60uM:10uM	NEWCL20437	HN9-cisR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PUMA	Up-regulation	HN4-cisR	188.96%	132.61%	182.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer.
C72340	27544755	DIS0133	NP5233	Wogonin	DR1669	Cisplatin	NEWCL20378	HN4-cisR	.	.	60uM:10uM	NEWCL20437	HN9-cisR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53	Up-regulation	HN4-cisR	266.62%	65.02%	760.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer.
C72340	27544755	DIS0133	NP5233	Wogonin	DR1669	Cisplatin	NEWCL20378	HN4-cisR	.	.	60uM:10uM	NEWCL20437	HN9-cisR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5308	Nrf2	Down-regulation	HN4-cisR	10.16%	0.11%	24.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer.
C31431	27560113	DIS0028	NP6993	Arsenic trioxide	DR8611	Bortezomib	NEWCL10125	NB4	.	48h:14 nM	200 nM:2 uM	NEWCL10125	NB4	.	48h:17 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A synergistic effect on combining ATO and bortezomib in vitro was noted in both ATO-sensitive and ATO-resistant APL cell lines. The mechanism of this synergy involved downregulation of the nuclear factor-KappaB pathway, increase in unfolded protein response (UPR) and an increase in reactive oxygen species generation in the malignant cell."
C46795	27628049	DIS0022	NP6905	Curcumin	DR2609	Fenretinide	NEWCL00170	A-549	.	.	20uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	NSCLC A-549	95.47%	168.10%	1268.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of curcumin and fenretinide can potentially be effective therapeutic agents for treating NSCLC, at least in part, by regulating endoplasmic reticulum (ER) chaperone protein GRP78."
C85986	27656602	DIS0031	NP9279	Genistein	DR2728	17-beta estradiol	NEWCL00027	PLC.PRF.5	25 uM	25 uM	25 uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Genistein decreases the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.
C29048	27685914	DIS0031	NP0016	Silibinin	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	.	100uM: 25 nm	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4688	Chk1	Up-regulation	Hep-G2	18.69%	28.20%	29.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression.
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Up-regulation	A-549	16.20%	14.16%	36.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Up-regulation	A-549	2.42%	3.69%	26.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR4	Down-regulation	A-549	17.95%	10.34%	-14.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IkBa	Up-regulation	A-549	38.50%	47.47%	45.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-549	0.91%	3.88%	7.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	P-PI3K	Up-regulation	A-549	17.52%	27.28%	23.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Down-regulation	A-549	26.13%	21.60%	-10.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	A-549	31.92%	49.83%	36.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	49.23%	53.36%	6.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	25.02%	20.68%	46.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	A-549	1.32%	67.92%	57.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C59960	27752089	DIS0022	NP4620	Apigenin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00181	NCI-H1299	.	.	20 uM:25 ng.mL	NEWCL10120	HEK293	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	A-549	6.88%	25.74%	212.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .
C33060	27765854	DIS0129	NP8606	Fisetin	DR1078	Cabazitaxel	NEWCL10127	22Rv1	.	.	20 uM: 5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	22Rv1	11.24%	6.81%	0.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
C33060	27765854	DIS0129	NP8606	Fisetin	DR1078	Cabazitaxel	NEWCL10127	22Rv1	.	.	20 uM: 5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	22Rv1	16.10%	12.84%	9.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
C33060	27765854	DIS0129	NP8606	Fisetin	DR1078	Cabazitaxel	NEWCL10127	22Rv1	.	.	20 uM: 5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	22Rv1	31.06%	8.70%	53.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
C33060	27765854	DIS0129	NP8606	Fisetin	DR1078	Cabazitaxel	NEWCL10127	22Rv1	.	.	20 uM: 5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PCXA	Down-regulation	22Rv1	17.67%	45.28%	89.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
C33060	27765854	DIS0129	NP8606	Fisetin	DR1078	Cabazitaxel	NEWCL10127	22Rv1	.	.	20 uM: 5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	22Rv1	81.40%	47.10%	83.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
C33060	27765854	DIS0129	NP8606	Fisetin	DR1078	Cabazitaxel	NEWCL10127	22Rv1	.	.	20 uM: 5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CD31	Down-regulation	22Rv1	10.19%	14.92%	56.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
C33060	27765854	DIS0129	NP8606	Fisetin	DR1078	Cabazitaxel	NEWCL10127	22Rv1	.	.	20 uM: 5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	UPA	Down-regulation	22Rv1	7.70%	50.37%	65.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
C33060	27765854	DIS0129	NP8606	Fisetin	DR1078	Cabazitaxel	NEWCL10127	22Rv1	.	.	20 uM: 5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	p-gp	Down-regulation	22Rv1	45.21%	35.76%	66.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
C61675	27791595	DIS0093	NP1644	Vincristine	DR0366	Belinostat	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	DLBCL	8.58%	57.90%	81.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Vincristine sensitizes DLBCL cells to the cytotoxic effects of belinostat.
C94307	27794399	DIS0022	NP6993	Arsenic trioxide	DR9235	PD173074	NEWCL00184	SK-MES-1	72h:4.5 ±  0.6uM	72h:5.5 ±  1.1uM	2.5uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Up-regulation	SK-MES-1	68.27%	160.75%	295.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined ATO/PD173074 reduced cell viability along with increased sub-G1 population, phosphatidylserine externalization and mitochondrial membrane depolarization more significantly than single treatments."
C94307	27794399	DIS0022	NP6993	Arsenic trioxide	DR9235	PD173074	NEWCL00184	SK-MES-1	72h:4.5 ±  0.6uM	72h:5.5 ±  1.1uM	2.5uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3066	FGFR1	Down-regulation	SK-MES-1	50.95%	29.71%	69.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined ATO/PD173074 reduced cell viability along with increased sub-G1 population, phosphatidylserine externalization and mitochondrial membrane depolarization more significantly than single treatments."
C94307	27794399	DIS0022	NP6993	Arsenic trioxide	DR9235	PD173074	NEWCL00184	SK-MES-1	72h:4.5 ±  0.6uM	72h:5.5 ±  1.1uM	2.5uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5260	P-Src	Down-regulation	SK-MES-1	45.97%	64.26%	66.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined ATO/PD173074 reduced cell viability along with increased sub-G1 population, phosphatidylserine externalization and mitochondrial membrane depolarization more significantly than single treatments."
C94307	27794399	DIS0022	NP6993	Arsenic trioxide	DR9235	PD173074	NEWCL00184	SK-MES-1	72h:4.5 ±  0.6uM	72h:5.5 ±  1.1uM	2.5uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1418	P-cRAF	Down-regulation	SK-MES-1	20.96%	61.64%	56.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combined ATO/PD173074 reduced cell viability along with increased sub-G1 population, phosphatidylserine externalization and mitochondrial membrane depolarization more significantly than single treatments."
C97380	27822011	DIS0031	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL20367	Hep-G2.DDP	.	.	2.25ug.mL:8.92ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5308	Nrf2	Down-regulation	Hep-G2.DDPu	27.28%	17.42%	32.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C97380	27822011	DIS0031	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL20367	Hep-G2.DDP	.	.	2.25ug.mL:8.92ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7859	HO-1	Down-regulation	Hep-G2.DDPu	4.18%	27.32%	39.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C97380	27822011	DIS0031	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL20367	Hep-G2.DDP	.	.	2.25ug.mL:8.92ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0994	NQO1	Down-regulation	Hep-G2.DDPu	4.03%	29.40%	39.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C97380	27822011	DIS0031	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL20367	Hep-G2.DDP	.	.	2.25ug.mL:8.92ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GST	Down-regulation	Hep-G2.DDPu	8.23%	28.72%	40.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C04523	27841296	DIS0115	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00082	HCT 116	17.5 ±  0.2 uM 	17.5 ±  02 uM 	17.5 ± 0.2 uM :17.5 ± 02 uM	NEWCL00344	HT29	187.1 ±  4.7 uM	 0.88 ±  0.03 uM	187.1 ± 4.7 uM: 0.88 ± 0.03 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT 116	4.65%	11.20%	613.51%	HT29	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	27841296	DIS0115	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00082	HCT 116	17.5 ±  0.2 uM 	17.5 ±  02 uM 	17.5 ± 0.2 uM :17.5 ± 02 uM	NEWCL00344	HT29	187.1 ±  4.7 uM	 0.88 ±  0.03 uM	187.1 ± 4.7 uM: 0.88 ± 0.03 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116	10.11%	26.59%	153.30%	HT29	1.12%	46.67%	26.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	27841296	DIS0115	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00082	HCT 116	17.5 ±  0.2 uM 	17.5 ±  02 uM 	17.5 ± 0.2 uM :17.5 ± 02 uM	NEWCL00344	HT29	187.1 ±  4.7 uM	 0.88 ±  0.03 uM	187.1 ± 4.7 uM: 0.88 ± 0.03 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	HCT 116	164.00%	42.86%	503.23%	HT29	136.42%	33.94%	27.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C34528	27863471	DIS0022	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00170	A-549	48h:36 uM	48h:1.5 uM	8.57470uM:0.42873uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	70.01%	78.16%	60.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tanshinone IIA combined with adriamycin could synergistically inhibit migration, induce apoptosis and arrest cell cycle at the S and G2 phases in A549 cells."
C34528	27863471	DIS0022	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00170	A-549	48h:36 uM	48h:1.5 uM	8.57470uM:0.42873uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	193.35%	200.00%	210.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tanshinone IIA combined with adriamycin could synergistically inhibit migration, induce apoptosis and arrest cell cycle at the S and G2 phases in A549 cells."
C34528	27863471	DIS0022	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00170	A-549	48h:36 uM	48h:1.5 uM	8.57470uM:0.42873uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	P-PI3K	Down-regulation	A-549	33.41%	31.36%	45.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tanshinone IIA combined with adriamycin could synergistically inhibit migration, induce apoptosis and arrest cell cycle at the S and G2 phases in A549 cells."
C34528	27863471	DIS0022	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00170	A-549	48h:36 uM	48h:1.5 uM	8.57470uM:0.42873uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-549	11.46%	61.05%	63.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tanshinone IIA combined with adriamycin could synergistically inhibit migration, induce apoptosis and arrest cell cycle at the S and G2 phases in A549 cells."
C34528	27863471	DIS0022	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00170	A-549	48h:36 uM	48h:1.5 uM	8.57470uM:0.42873uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	A-549	22.70%	1.58%	70.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tanshinone IIA combined with adriamycin could synergistically inhibit migration, induce apoptosis and arrest cell cycle at the S and G2 phases in A549 cells."
C34528	27863471	DIS0022	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00170	A-549	48h:36 uM	48h:1.5 uM	8.57470uM:0.42873uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VEGFR2	Down-regulation	A-549	7.34%	11.66%	55.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tanshinone IIA combined with adriamycin could synergistically inhibit migration, induce apoptosis and arrest cell cycle at the S and G2 phases in A549 cells."
C34528	27863471	DIS0022	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00170	A-549	48h:36 uM	48h:1.5 uM	8.57470uM:0.42873uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2 	Down-regulation	A-549	2.44%	2.93%	21.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tanshinone IIA combined with adriamycin could synergistically inhibit migration, induce apoptosis and arrest cell cycle at the S and G2 phases in A549 cells."
C50442	27863838	DIS0021	NP6084	Resveratrol	DR2073	Sorafenib	NEWCL00155	MCF-7	.	14.4 uM	70 uM:6 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	MCF-7	960.18%	361.50%	1767.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage."
C50442	27863838	DIS0021	NP6084	Resveratrol	DR2073	Sorafenib	NEWCL00155	MCF-7	.	14.4 uM	70 uM:6 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MCF-7	1.81%	1.53%	86.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage."
C50442	27863838	DIS0021	NP6084	Resveratrol	DR2073	Sorafenib	NEWCL00155	MCF-7	.	14.4 uM	70 uM:6 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1139	Apaf-1	Up-regulation	MCF-7	343.26%	127.64%	520.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage."
C50442	27863838	DIS0021	NP6084	Resveratrol	DR2073	Sorafenib	NEWCL00155	MCF-7	.	14.4 uM	70 uM:6 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MCF-7	35.60%	8.33%	1.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage."
C50442	27863838	DIS0021	NP6084	Resveratrol	DR2073	Sorafenib	NEWCL00155	MCF-7	.	14.4 uM	70 uM:6 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MCF-7	5.15%	319.11%	977.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage."
C50442	27863838	DIS0021	NP6084	Resveratrol	DR2073	Sorafenib	NEWCL00155	MCF-7	.	14.4 uM	70 uM:6 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	MCF-7	49.28%	0.30%	59.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage."
C50442	27863838	DIS0021	NP6084	Resveratrol	DR2073	Sorafenib	NEWCL00155	MCF-7	.	14.4 uM	70 uM:6 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	MCF-7	8.42%	3.09%	36.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage."
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2163	FADD	Down-regulation	C666-1	9.58%	24.18%	33.33%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	C666-1	6.52%	9.61%	14.46%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FLIP	Down-regulation	C666-1	4.39%	32.57%	66.61%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	C666-1	10.28%	8.31%	16.30%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	C666-1	13.32%	15.65%	17.01%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	C666-1	10.41%	11.37%	3.86%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	C666-1	24.33%	10.80%	50.48%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	C666-1	14.36%	6.72%	75.41%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	C666-1	29.74%	2.63%	57.47%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	C666-1	9.31%	3.51%	69.40%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C28720	27881007	DIS0111	NP2960	Epigallocatechin gallate	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00211	C666-1	.	.	20uM: 100ng.mL	NEWCL00343	CNE-1	.	.	20uM: 100ng.mL	NEWCL00340	CNE-2	.	.	20uM: 100ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	C666-1	0.26%	6.82%	23.71%	CNE-1	.	.	.	CNE-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
C80880	27888802	DIS0025	NP4621	Triptolide	DR7876	Cytarabine	NEWCL20381	NALM-6.R	48h: 0.032± 0.004	48h:  115.00± 23.12	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	Gama-H2AX	Up-regulation	NALM-6.R	13.10%	89.39%	92.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
C80880	27888802	DIS0025	NP4621	Triptolide	DR7876	Cytarabine	NEWCL20381	NALM-6.R	48h: 0.032± 0.004	48h:  115.00± 23.12	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	NALM-6.R	9.52%	41.38%	64.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
C80880	27888802	DIS0025	NP4621	Triptolide	DR7876	Cytarabine	NEWCL20381	NALM-6.R	48h: 0.032± 0.004	48h:  4.82± 0.97	10uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	Gama-H2AX	Up-regulation	NALM-6.R	13.10%	93.01%	89.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
C80880	27888802	DIS0025	NP4621	Triptolide	DR7876	Cytarabine	NEWCL20381	NALM-6.R	48h: 0.032± 0.004	48h:  4.82± 0.97	10uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	NALM-6.R	9.52%	70.57%	129.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
C80880	27888802	DIS0025	NP4621	Triptolide	DR7876	Cytarabine	NEWCL20381	NALM-6.R	48h: 0.032± 0.004	48h:  115.00± 23.12	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4688	P-Chk1	Down-regulation	NALM-6.R	3.89%	1.98%	73.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
C00179	27980427	DIS0024	NP6905	Curcumin	DR9021	5-fluorouracil	.	.	.	.	.	.	.	72h:45.6uM	.	20uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	.	.	.	.	SGCR	107.31%	104.50%	115.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combination of 5 uM curcumin with 5-FU significantly reduced its cytotoxicity in EJ138 cells, while 15 uM curcumin caused an opposite increase."
C16256	28025107	DIS0005	NP4620	Apigenin	DR9021	5-fluorouracil	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of 5-FU and apigenin had a greater effect than each of 5-FU or apigenin alone against solid Ehrlich carcinoma in mice.
C16256	28025107	DIS0005	NP4620	Apigenin	DR9021	5-fluorouracil	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of 5-FU and apigenin had a greater effect than each of 5-FU or apigenin alone against solid Ehrlich carcinoma in mice.
C16256	28025107	DIS0005	NP4620	Apigenin	DR9021	5-fluorouracil	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	MIA PaCa-2 tumor	77.78%	44.44%	77.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of 5-FU and apigenin had a greater effect than each of 5-FU or apigenin alone against solid Ehrlich carcinoma in mice.
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U2OS	46.52%	40.65%	54.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	U2OS	190.86%	103.17%	223.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	U2OS	56.73%	40.50%	52.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	U2OS	82.01%	5.53%	88.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	U2OS	70.36%	70.48%	93.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	U2OS	40.83%	61.68%	64.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	p-p65(Nucleus)	Down-regulation	U2OS	31.15%	24.90%	49.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	U2OS	28.84%	17.91%	41.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	U2OS	20.13%	0.17%	19.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	U2OS	34.34%	18.62%	52.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Down-regulation	U2OS	0.46%	7.73%	22.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Down-regulation	U2OS	18.41%	37.55%	59.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	U2OS	7.04%	23.10%	42.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	m-Calpain	Down-regulation	U2OS	8.64%	21.64%	28.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	U2OS	48.60%	37.94%	54.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C10732	28038429	DIS0098	NP4621	Triptolide	DR7139	AMD3100	NEWCL00227	U2OS	.	.	100 nM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Beta-Catenin	Down-regulation	U2OS	9.92%	28.92%	47.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."
C61221	28061438	DIS0129	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00252	LNCaP	.	.	0.37 uM:11.19 uM	NEWCL00253	PC-3	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	LNCaP	42.87%	26.12%	131.88%	PC3	30.17%	40.53%	374.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells.
C61221	28061438	DIS0129	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00252	LNCaP	.	.	0.37 uM:11.19 uM	NEWCL00253	PC-3	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	LNCaP	11.13%	14.43%	260.26%	PC3	1.55%	155.53%	429.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells.
C61221	28061438	DIS0129	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00252	LNCaP	.	.	0.37 uM:11.19 uM	NEWCL00253	PC-3	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B	Up-regulation	LNCaP	20.71%	39.57%	96.09%	PC3	159.61%	0.34%	382.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells.
C61221	28061438	DIS0129	NP6993	Arsenic trioxide	DR7612	Everolimus	NEWCL00252	LNCaP	.	.	0.37 uM:11.19 uM	NEWCL00253	PC-3	.	.	0.35 uM:12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2597	ATG5	Up-regulation	LNCaP	.	.	.	PC3	39.01%	16.57%	103.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells.
C40238	28066099	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00049	MDA-MB-231	.	.	50 uM:10 uM	NEWCL00050	MDA-MB-468	.	.	50 uM:10 uM	NEWCL00155	MCF-7	.	.	50 uM:10 uM	NEWCL00329	MCF-10A	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	MDA MB-231	.	.	.	MDA MB-468	.	.	.	MCF-7	.	.	.	MCF-10A	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C03873	28106847	DIS0230	NP7818	Morroniside	DR7874	Diosgenin	.	.	.	.	100 ug.mL:100 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Up-regulation	Diosgenin	19.89%	23.88%	21.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of morroniside and diosgenin prevents high glucose-induced cardiomyocytes apoptosis.
C03873	28106847	DIS0230	NP7818	Morroniside	DR7874	Diosgenin	.	.	.	.	100 ug.mL:100 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Down-regulation	Diosgenin	2.25%	2.87%	18.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of morroniside and diosgenin prevents high glucose-induced cardiomyocytes apoptosis.
C03873	28106847	DIS0230	NP7818	Morroniside	DR7874	Diosgenin	.	.	.	.	100 ug.mL:100 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	Diosgenin	7.76%	0.77%	7.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of morroniside and diosgenin prevents high glucose-induced cardiomyocytes apoptosis.
C33862	28107698	DIS0129	NP4620	Apigenin	DR1669	Cisplatin	NEWCL00253	PC-3	.	.	48h; 15 uM: 7.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p50	Up-regulation	PC-3	594.74%	1887.72%	3431.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Apigenin and myricetin exhibited a protective and promising preventive strategy against cisplatin-induced nephrotoxicity due to their antioxidant and anti-inflammatory effects.
C33862	28107698	DIS0129	NP4620	Apigenin	DR1669	Cisplatin	NEWCL00253	PC-3	.	.	48h; 15 uM: 7.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	PC-3	23.75%	33.68%	175.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Apigenin and myricetin exhibited a protective and promising preventive strategy against cisplatin-induced nephrotoxicity due to their antioxidant and anti-inflammatory effects.
C33862	28107698	DIS0129	NP4620	Apigenin	DR1669	Cisplatin	NEWCL00253	PC-3	.	.	48h; 15 uM: 7.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	P-PI3K	Down-regulation	PC-3	316.53%	247.11%	200.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Apigenin and myricetin exhibited a protective and promising preventive strategy against cisplatin-induced nephrotoxicity due to their antioxidant and anti-inflammatory effects.
C33862	28107698	DIS0129	NP4620	Apigenin	DR1669	Cisplatin	NEWCL00253	PC-3	.	.	48h; 15 uM: 7.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-Akt3	Down-regulation	PC-3	34.84%	85.04%	91.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Apigenin and myricetin exhibited a protective and promising preventive strategy against cisplatin-induced nephrotoxicity due to their antioxidant and anti-inflammatory effects.
C33862	28107698	DIS0129	NP4620	Apigenin	DR1669	Cisplatin	NEWCL00253	PC-3	.	.	48h; 15 uM: 7.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-kappaB p50	Down-regulation	PC-3	2.14%	53.24%	71.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Apigenin and myricetin exhibited a protective and promising preventive strategy against cisplatin-induced nephrotoxicity due to their antioxidant and anti-inflammatory effects.
C01496	28108625	DIS0115	NP8057	Parthenolide	DR6727	Balsalazide	NEWCL00082	HCT 116	24h:5uM	24h:20 mmol.L	5mmol.L: 20 mmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	HCT 116	10.28%	17.14%	20.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.
C01496	28108625	DIS0115	NP8057	Parthenolide	DR6727	Balsalazide	NEWCL00082	HCT 116	24h:5uM	24h:20 mmol.L	5mmol.L: 20 mmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP(in nucleus)	Up-regulation	HCT 116	413.74%	293.11%	481.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.
C01496	28108625	DIS0115	NP8057	Parthenolide	DR6727	Balsalazide	NEWCL00082	HCT 116	24h:5uM	24h:20 mmol.L	5mmol.L: 20 mmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	HCT 116	6.20%	5.96%	15.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.
C01496	28108625	DIS0115	NP8057	Parthenolide	DR6727	Balsalazide	NEWCL00082	HCT 116	24h:5uM	24h:20 mmol.L	5mmol.L: 20 mmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116	0.58%	5.39%	6.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.
C01496	28108625	DIS0115	NP8057	Parthenolide	DR6727	Balsalazide	NEWCL00082	HCT 116	24h:5uM	24h:20 mmol.L	5mmol.L: 20 mmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	HCT 116	22.35%	33.10%	46.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.
C01496	28108625	DIS0115	NP8057	Parthenolide	DR6727	Balsalazide	NEWCL00082	HCT 116	24h:5uM	24h:20 mmol.L	5mmol.L: 20 mmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	HCT 116	2.03%	14.23%	31.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.
C01496	28108625	DIS0115	NP8057	Parthenolide	DR6727	Balsalazide	NEWCL00082	HCT 116	24h:5uM	24h:20 mmol.L	5mmol.L: 20 mmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HCT 116	0.90%	7.55%	33.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.
C01496	28108625	DIS0115	NP8057	Parthenolide	DR6727	Balsalazide	NEWCL00082	HCT 116	24h:5uM	24h:20 mmol.L	5mmol.L: 20 mmol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	.	HCT 116	.	3.78%	36.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.
C77214	28119237	DIS0031	NP9796	Betulinic Acid	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	10uM:30ng.ml	NEWCL00027	PLC.PRF.5	.	.	10uM:30ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	Huh-7	12.46%	0.85%	11.38%	PLC.PRF.5	88.96%	49.90%	114.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53/Caspase-3 signaling activation.
C77214	28119237	DIS0031	NP9796	Betulinic Acid	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	10uM:30ng.ml	NEWCL00027	PLC.PRF.5	.	.	10uM:30ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	Huh-7	15.38%	3.02%	19.71%	PLC.PRF.5	21.66%	5.89%	25.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53/Caspase-3 signaling activation.
C77214	28119237	DIS0031	NP9796	Betulinic Acid	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	10uM:30ng.ml	NEWCL00027	PLC.PRF.5	.	.	10uM:30ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Huh-7	11.40%	0.89%	19.26%	PLC.PRF.5	6.81%	7.20%	1.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53/Caspase-3 signaling activation.
C77214	28119237	DIS0031	NP9796	Betulinic Acid	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00031	Huh-7	.	.	10uM:30ng.ml	NEWCL00027	PLC.PRF.5	.	.	10uM:30ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Huh-7	30.47%	2.15%	42.68%	PLC.PRF.5	20.35%	5.67%	28.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53/Caspase-3 signaling activation.
C04523	28126034	DIS0024	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20359	SGC-7901.DOX	.	.	50 mg.l: 1 mg.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	SGC-7901.DOX	32.73%	0.45%	60.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	28126034	DIS0024	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20359	SGC-7901.DOX	.	.	50 mg.l: 1 mg.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	Down-regulation	SGC-7901.DOX	63.42%	63.42%	85.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	28126034	DIS0024	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20359	SGC-7901.DOX	.	.	50 mg.l: 1 mg.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	p-mTOR	Down-regulation	SGC-7901.DOX	59.82%	59.82%	79.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	28126034	DIS0024	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20359	SGC-7901.DOX	.	.	50 mg.l: 1 mg.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7837	P-70S6K	Down-regulation	SGC-7901.DOX	1.15%	1.15%	79.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	28126034	DIS0024	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20359	SGC-7901.DOX	.	.	50 mg.l: 1 mg.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SGC-7901.DOX	357.95%	357.95%	413.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C57775	28134289	DIS0031	NP3369	Neferine	DR0141	Oxaliplatin	NEWCL00129	Hep-G2	.	48h:5.99u± u0.35uuM	10 uM:5 uM	NEWCL00141	Bel-7402	.	48h:4.81u± u0.39uuM	10 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Hep-G2	3.03%	24.19%	107.87%	Bel-7402	1.27%	43.59%	88.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Snail overexpression or TGF-Beta1-induced EMT attenuated Neferine-mediated OXA sensitization in HCC.
C57775	28134289	DIS0031	NP3369	Neferine	DR0141	Oxaliplatin	NEWCL00129	Hep-G2	.	48h:5.99u± u0.35uuM	10 uM:5 uM	NEWCL00141	Bel-7402	.	48h:4.81u± u0.39uuM	10 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Hep-G2	25.17%	80.44%	87.42%	Bel-7402	13.97%	28.10%	69.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Snail overexpression or TGF-Beta1-induced EMT attenuated Neferine-mediated OXA sensitization in HCC.
C76353	28134774	DIS0032	NP7968	Deguelin	DR8223	AG1478	NEWCL00271	HSC-4	.	.	1 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	HSC-4	96.99%	48.47%	98.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
C76353	28134774	DIS0032	NP7968	Deguelin	DR8223	AG1478	NEWCL00271	HSC-4	.	.	1 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	HSC-4	81.55%	97.04%	97.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
C07405	28208617	DIS0023	NP7968	Deguelin	DR4469	Doxorubicin	NEWCL00236	Mia PaCa-2	.	.	25 uM:10 uM	NEWCL00242	Panc-1	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3 II	Up-regulation	Mia PaCa-2	278.14%	8.11%	263.97%	Panc-1	47.42%	35.98%	265.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin.
C07405	28208617	DIS0023	NP7968	Deguelin	DR4469	Doxorubicin	NEWCL00236	Mia PaCa-2	.	.	25 uM:10 uM	NEWCL00242	Panc-1	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Up-regulation	Mia PaCa-2	552.32%	43.14%	499.63%	Panc-1	621.49%	168.91%	986.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin.
C07405	28208617	DIS0023	NP7968	Deguelin	DR4469	Doxorubicin	NEWCL00236	Mia PaCa-2	.	.	10 uM:2.5 uM	NEWCL00242	Panc-1	.	.	10 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-II	Up-regulation	Mia PaCa-2	453.40%	321.75%	513.20%	Panc-1	153.39%	63.99%	178.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin.
C07405	28208617	DIS0023	NP7968	Deguelin	DR4469	Doxorubicin	NEWCL00236	Mia PaCa-2	.	.	25 uM:2.5 uM	NEWCL00242	Panc-1	.	.	25 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Mia PaCa-2	657.45%	123.04%	716.02%	Panc-1	4.143312102	104.55%	810.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin.
C07405	28208617	DIS0023	NP7968	Deguelin	DR4469	Doxorubicin	NEWCL00236	Mia PaCa-2	.	.	25 uM:2.5 uM	NEWCL00242	Panc-1	.	.	25 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Mia PaCa-2	1077.70%	50.21%	1817.44%	Panc-1	38.31%	22.08%	1022.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin.
C39202	28214686	DIS0031	NP1644	Vincristine	DR7470	Combretastatin A-4 phosphate	NEWCL00129	Hep-G2	48h:38 nM	48h:56 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	CA4-P showed a potential anti-cancer activity against hepatocellular carcinoma and this effect was greatly enhanced by co-administration with vincristine.
C98290	28223119	DIS0022	NP3369	Neferine	DR1669	Cisplatin	NEWCL00170	A-549	48h:18uM	48h:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine reduces cisplatin-induced nephrotoxicity by enhancing autophagy via the AMPK/mTOR signaling pathway.
C98290	28223119	DIS0022	NP3369	Neferine	DR1669	Cisplatin	NEWCL00170	A-549	48h:18uM	48h:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine reduces cisplatin-induced nephrotoxicity by enhancing autophagy via the AMPK/mTOR signaling pathway.
C00042	28252027	DIS0127	NP6047	Metformin	DR0944	Nelfivir	NEWCL00139	Ca Ski	72h:39.23mM	72h:11.44uM	10mM:4uM	NEWCL00149	HeLa	72h: 223.23mM	72h: 26.47uM	10mM:4uM	NEWCL00137	SiHa	72h:68.38mM	72h:16.49uM	10mM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	PI3K(p110alpha)	Down-regulation	SiHa	1.25%	5.09%	11.76%	HeLa	35.14%	24.18%	36.51%	Ca Ski	40.98%	3.69%	51.77%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
C00042	28252027	DIS0127	NP6047	Metformin	DR0944	Nelfivir	NEWCL00139	Ca Ski	72h:39.23mM	72h:11.44uM	10mM:4uM	NEWCL00149	HeLa	72h: 223.23mM	72h: 26.47uM	10mM:4uM	NEWCL00137	SiHa	72h:68.38mM	72h:16.49uM	10mM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	SiHa	.	.	.	.	.	.	.	Ca Ski	123.15%	24.66%	171.65%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
C00042	28252027	DIS0127	NP6047	Metformin	DR0944	Nelfivir	NEWCL00139	Ca Ski	72h:39.23mM	72h:11.44uM	10mM:4uM	NEWCL00149	HeLa	72h: 223.23mM	72h: 26.47uM	10mM:4uM	NEWCL00137	SiHa	72h:68.38mM	72h:16.49uM	10mM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	SiHa	1.60%	30.05%	12.89%	HeLa	4.32%	11.92%	15.25%	Ca Ski	70.15%	65.25%	83.53%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
C04593	28282784	DIS0021	NP1928	Carnosic acid	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	5 mM:20mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	MCF-7	26.14%	18.98%	38.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.
C04593	28282784	DIS0021	NP1928	Carnosic acid	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	5 mM:20mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MCF-7	69.74%	63.01%	77.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.
C04593	28282784	DIS0021	NP1928	Carnosic acid	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	5 mM:20mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7	6.08%	3.31%	16.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.
C04593	28282784	DIS0021	NP1928	Carnosic acid	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	5 mM:20mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TRAIL	Up-regulation	MCF-7	237.73%	246.52%	274.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.
C04593	28282784	DIS0021	NP1928	Carnosic acid	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	5 mM:20mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2163	FADD	Up-regulation	MCF-7	26.03%	6.81%	24.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.
C04593	28282784	DIS0021	NP1928	Carnosic acid	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	5 mM:20mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DcR1	Up-regulation	MCF-7	23.47%	9.43%	22.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.
C04593	28282784	DIS0021	NP1928	Carnosic acid	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	5 mM:20mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DcR2	Up-regulation	MCF-7	9.37%	8.76%	23.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.
C04593	28282784	DIS0021	NP1928	Carnosic acid	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	5 mM:20mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	MCF-7	6.03%	3.75%	6.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.
C04593	28282784	DIS0021	NP1928	Carnosic acid	DR1563	Tamoxifen	NEWCL00155	MCF-7	.	.	5 mM:20mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P73	Up-regulation	MCF-7	6.03%	7.23%	7.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.
C39948	28285685	DIS0022	NP6465	Ampelopsin	DR8028	Erlotinib	NEWCL00171	NCI-H1975	.	.	20 uM:2.5 uM	NEWCL00200	NCI-H1650	.	.	20 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	NCI-H1975	2.74%	0.33%	16.31%	H1650	1.41%	2.34%	41.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"The combination of erlotinib and ampelopsin induces cell death via the Nox2-ROS-Bim pathway, and ampelopsin could be used as a novel anti-cancer agent combined with EGFR-TKI to overcome resistance to erlotinib in EGFR-mutant NSCLC."
C39948	28285685	DIS0022	NP6465	Ampelopsin	DR8028	Erlotinib	NEWCL00171	NCI-H1975	.	.	20 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	NCI-H1975	9.89%	27.39%	108.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"The combination of erlotinib and ampelopsin induces cell death via the Nox2-ROS-Bim pathway, and ampelopsin could be used as a novel anti-cancer agent combined with EGFR-TKI to overcome resistance to erlotinib in EGFR-mutant NSCLC."
C39948	28285685	DIS0022	NP6465	Ampelopsin	DR8028	Erlotinib	NEWCL00171	NCI-H1975	.	.	20 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	NCI-H1975	11.98%	29.81%	86.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"The combination of erlotinib and ampelopsin induces cell death via the Nox2-ROS-Bim pathway, and ampelopsin could be used as a novel anti-cancer agent combined with EGFR-TKI to overcome resistance to erlotinib in EGFR-mutant NSCLC."
C39948	28285685	DIS0022	NP6465	Ampelopsin	DR8028	Erlotinib	NEWCL00171	NCI-H1975	.	.	20 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-H1975	17.06%	31.54%	65.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"The combination of erlotinib and ampelopsin induces cell death via the Nox2-ROS-Bim pathway, and ampelopsin could be used as a novel anti-cancer agent combined with EGFR-TKI to overcome resistance to erlotinib in EGFR-mutant NSCLC."
C39948	28285685	DIS0022	NP6465	Ampelopsin	DR8028	Erlotinib	NEWCL00171	NCI-H1975	.	.	20 uM:2.5 uM	NEWCL00200	NCI-H1650	.	.	20 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	NOX2	Up-regulation	NCI-H1975	6.12%	3.65%	27.89%	H1650	46.40%	60.54%	75.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"The combination of erlotinib and ampelopsin induces cell death via the Nox2-ROS-Bim pathway, and ampelopsin could be used as a novel anti-cancer agent combined with EGFR-TKI to overcome resistance to erlotinib in EGFR-mutant NSCLC."
C39948	28285685	DIS0022	NP6465	Ampelopsin	DR8028	Erlotinib	NEWCL00171	NCI-H1975	.	.	20 uM:2.5 uM	NEWCL00200	NCI-H1650	.	.	20 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim	Up-regulation	NCI-H1975	3.17%	2.28%	30.32%	H1650	8.37%	8.65%	18.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"The combination of erlotinib and ampelopsin induces cell death via the Nox2-ROS-Bim pathway, and ampelopsin could be used as a novel anti-cancer agent combined with EGFR-TKI to overcome resistance to erlotinib in EGFR-mutant NSCLC."
C10054	28348518	DIS0029	NP8371	Monocyte activating polypeptide II	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	.	NEWCL00039	U-251MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-I	Down-regulation	U-87MG ATCC	6.34%	7.80%	14.44%	U251	9.76%	17.74%	2.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs."
C10054	28348518	DIS0029	NP8371	Monocyte activating polypeptide II	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	.	NEWCL00039	U-251MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9491	SQSTM1	Up-regulation	U-87MG ATCC	0.93%	3.78%	5.44%	U251	0.45%	0.59%	4.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs."
C10054	28348518	DIS0029	NP8371	Monocyte activating polypeptide II	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	.	NEWCL00039	U-251MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	p-PI3K	Down-regulation	U-87MG ATCC	10.06%	6.30%	35.56%	U251	6.95%	0.15%	15.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs."
C10054	28348518	DIS0029	NP8371	Monocyte activating polypeptide II	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	.	NEWCL00039	U-251MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	Down-regulation	U-87MG ATCC	15.58%	16.94%	13.63%	U251	0.96%	17.17%	16.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs."
C10054	28348518	DIS0029	NP8371	Monocyte activating polypeptide II	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	.	NEWCL00039	U-251MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	p-mTOR	Down-regulation	U-87MG ATCC	0.30%	1.33%	21.50%	U251	27.95%	18.30%	37.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs."
C10054	28348518	DIS0029	NP8371	Monocyte activating polypeptide II	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	.	NEWCL00039	U-251MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	p-S6K	Down-regulation	U-87MG ATCC	2.16%	11.57%	26.81%	U251	10.63%	20.96%	31.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs."
C10054	28348518	DIS0029	NP8371	Monocyte activating polypeptide II	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	.	NEWCL00039	U-251MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7832	P-4EBP1	Down-regulation	U-87MG ATCC	16.63%	34.31%	52.12%	U251	28.47%	25.78%	27.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs."
C10054	28348518	DIS0029	NP8371	Monocyte activating polypeptide II	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	.	NEWCL00039	U-251MG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MACC1	Up-regulation	U-87MG ATCC	18.32%	71.74%	30.76%	U251	35.56%	96.08%	78.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs."
C51917	28350076	DIS0020	NP5732	Osthole	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10134	Caki	.	.	30 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cleaved-cFLIP 	Down-regulation	Caki	1.62%	1.11%	46.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole enhances TRAIL-mediated apoptosis through downregulation of c-FLIP expression in renal carcinoma Caki cells.
C51917	28350076	DIS0020	NP5732	Osthole	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10134	Caki	.	.	30 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	Caki	0.79%	1.17%	43.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole enhances TRAIL-mediated apoptosis through downregulation of c-FLIP expression in renal carcinoma Caki cells.
C79238	28352348	DIS0115	NP5023	Gambogic acid	DR9021	5-fluorouracil	NEWCL00074	SW480	.	48h:122.14uM	0.75 uM:122.14uM	NEWCL00082	HCT 116	.	48h:18.43 uM	1 uM:18.43 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Down-regulation	SW480	2.16%	10.86%	32.16%	HCT116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	GA attenuated 5-FU-induced apoptosis by modulating metabolic enzymes of 5-FU and the antigastric cancer effect of two drugs combination was much stronger than that of GA or 5-FU alone.
C79238	28352348	DIS0115	NP5023	Gambogic acid	DR9021	5-fluorouracil	NEWCL00074	SW480	.	48h:122.14uM	0.75 uM:122.14uM	NEWCL00082	HCT 116	.	48h:18.43 uM	1 uM:18.43 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	SW480	4.66%	28.43%	34.04%	HCT116	14.77%	24.97%	24.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	GA attenuated 5-FU-induced apoptosis by modulating metabolic enzymes of 5-FU and the antigastric cancer effect of two drugs combination was much stronger than that of GA or 5-FU alone.
C79238	28352348	DIS0115	NP5023	Gambogic acid	DR9021	5-fluorouracil	NEWCL00074	SW480	.	48h:122.14uM	0.75 uM:122.14uM	NEWCL00082	HCT 116	.	48h:18.43 uM	1 uM:18.43 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TS	Down-regulation	SW480	24.50%	36.87%	32.59%	HCT116	1.19%	8.47%	11.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	GA attenuated 5-FU-induced apoptosis by modulating metabolic enzymes of 5-FU and the antigastric cancer effect of two drugs combination was much stronger than that of GA or 5-FU alone.
C46103	28355175	DIS0140	NP7102	Elemene	DR1669	Cisplatin	NEWCL00118	YD-38	.	.	40 ug.ml:1-64 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	YD38	66.70%	4.46%	84.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	28355175	DIS0140	NP7102	Elemene	DR1669	Cisplatin	NEWCL00118	YD-38	.	.	40 ug.ml:1-64 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7856	P-JAK2	Down-regulation	YD38	51.99%	0.17%	83.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	28355175	DIS0140	NP7102	Elemene	DR1669	Cisplatin	NEWCL00118	YD-38	.	.	40 ug.ml:1-64 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	YD38	34.36%	38.35%	64.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	28355175	DIS0140	NP7102	Elemene	DR1669	Cisplatin	NEWCL00118	YD-38	.	.	40 ug.ml:1-64 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	YD38	38.08%	232.76%	237.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	28355175	DIS0140	NP7102	Elemene	DR1669	Cisplatin	NEWCL00118	YD-38	.	.	40 ug.ml:1-64 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	YD38	172.03%	397.02%	471.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C16622	28366708	DIS0025	NP6084	Resveratrol	DR6631	ABT-737	NEWCL00032	MOLT-4	.	.	30 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	MOLT-4	181.34%	3.59%	709.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
C16622	28366708	DIS0025	NP6084	Resveratrol	DR6631	ABT-737	NEWCL00032	MOLT-4	.	.	30 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MOLT-4	8.66%	9.94%	84.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
C16622	28366708	DIS0025	NP6084	Resveratrol	DR6631	ABT-737	NEWCL00032	MOLT-4	.	.	30 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MOLT-4	31.36%	349.26%	296.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
C98009	28380412	DIS0029	NP6764	Beta asarone	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	360 uM:300 uM	NEWCL00255	C6	.	.	360 uM:300 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Down-regulation	U251	20.32%	45.41%	62.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-asarone could promote the entry of TMZ into U252 cells through the membrane.
C58456	28414177	DIS0273	NP9888	Acitretin	DR1258	Methotrexate	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Lnvolucrin	Up-regulation	LX-1	50.24%	35.48%	28.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis.
C58456	28414177	DIS0273	NP9888	Acitretin	DR1258	Methotrexate	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Loricrin	Up-regulation	LX-1	146.88%	82.77%	191.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis.
C58456	28414177	DIS0273	NP9888	Acitretin	DR1258	Methotrexate	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Laminin	Up-regulation	LX-1	1.13%	67.16%	33.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis.
C56476	28475922	DIS0021	NP3067	Paclitaxel	DR9535	Coralyne	NEWCL00155	MCF-7	48h:0.026 ±  0.91umol	48h:22.7 ±  0.83umol	.	NEWCL00049	MDA-MB-231	48h:0.018 ±  1.83	48h:21.9 ±  1.36	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Paclitaxel in combination with coralyne show a promising therapeutic potential effect in treating breast cancer at lower effective dose.
C76480	28477008	DIS0029	NP5775	Cyclopamine	DR6516	Temozolomide	NEWCL10089	DBTRG-05MG	48h:35.2uM	48h:1472.17uM	1uM:20uM	NEWCL00279	U-87MG ATCC	14.65 uM	1472.17uM	1uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Combination of TMZ with micellarized Cyp is a promising strategy for exerting different functions of drugs for tumor treatment.
C96101	28487980	DIS0025	NP6636	Daunorubicin	DR8611	Bortezomib	NEWCL00065	Jurkat	.	.	10.25uM:15nM	NEWCL00032	Molt-4	.	.	50nM:15nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Up-regulation	Jurkat	170.16%	15.85%	194.74%	Molt-4	69.89%	38.04%	53.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of bortezomib and daunorubicin significantly enhanced their apoptosis inducing effect in T ALL cells, which may warrant further investigation in preclinical and clinical investigations."
C96101	28487980	DIS0025	NP6636	Daunorubicin	DR8611	Bortezomib	NEWCL00065	Jurkat	.	.	10.25uM:15nM	NEWCL00032	Molt-4	.	.	50nM:15nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9 	Up-regulation	Jurkat T cells	24.36%	92.13%	131.37%	Molt-4	316.03%	7.98%	2323.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of bortezomib and daunorubicin significantly enhanced their apoptosis inducing effect in T ALL cells, which may warrant further investigation in preclinical and clinical investigations."
C96101	28487980	DIS0025	NP6636	Daunorubicin	DR8611	Bortezomib	NEWCL00065	Jurkat	.	.	10.25uM:15nM	NEWCL00032	Molt-4	.	.	50nM:15nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	Jurkat	55.98%	226.98%	289.04%	Molt-4	59.73%	37.88%	74.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of bortezomib and daunorubicin significantly enhanced their apoptosis inducing effect in T ALL cells, which may warrant further investigation in preclinical and clinical investigations."
C96101	28487980	DIS0025	NP6636	Daunorubicin	DR8611	Bortezomib	NEWCL00065	Jurkat	.	.	10.25uM:15nM	NEWCL00032	Molt-4	.	.	50nM:15nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim	Up-regulation	Jurkat	19.97%	92.04%	151.84%	Molt-4	24.20%	33.23%	36.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of bortezomib and daunorubicin significantly enhanced their apoptosis inducing effect in T ALL cells, which may warrant further investigation in preclinical and clinical investigations."
C19475	28599504	DIS0031	NP5233	Wogonin	DR2073	Sorafenib	NEWCL00283	Hep 3B2.1-7	.	.	20uM:4uM	NEWCL00141	Bel-7402	.	.	20uM:4uM	NEWCL00140	SMMC-7721	.	.	4 0uM:3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Hep 3B2.1-7	38.93%	54.54%	131.86%	BEL-7402	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition.
C19475	28599504	DIS0031	NP5233	Wogonin	DR2073	Sorafenib	NEWCL00283	Hep 3B2.1-7	.	.	20uM:4uM	NEWCL00141	Bel-7402	.	.	20uM:4uM	NEWCL00140	SMMC-7721	.	.	4 0uM:3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Hep 3B2.1-7	132.27%	109.92%	154.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition.
C95896	28624529	DIS0024	NP5775	Cyclopamine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00352	AGS	.	.	20 uM:50 ng.mL	NEWCL20413	MKN28	.	.	20 uM:50 ng.mL	NEWCL00108	MKN45	.	.	20 uM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AGS	.	.	.	MKN28	.	.	.	MKN45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation.
C76931	28627658	DIS0098	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00227	U2OS	.	.	0.01 uu:0.01 uu	NEWCL00226	MG-63	.	.	0.01 uu:0.01 uu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	U2OS	604.47%	23.65%	183.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C76931	28627658	DIS0098	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00227	U2OS	.	.	0.01 uu:0.01 uu	NEWCL00226	MG-63	.	.	0.01 uu:0.01 uu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	U2OS	169.35%	80.64%	256.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C76931	28627658	DIS0098	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00227	U2OS	.	.	0.01 uu:0.01 uu	NEWCL00226	MG-63	.	.	0.01 uu:0.01 uu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	U2OS	35.85%	38.81%	111.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C76931	28627658	DIS0098	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00227	U2OS	.	.	0.01 uu:0.01 uu	NEWCL00226	MG-63	.	.	0.01 uu:0.01 uu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	.	U2OS	32.84%	19.64%	11.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C76931	28627658	DIS0098	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00227	U2OS	.	.	0.01 uu:0.01 uu	NEWCL00226	MG-63	.	.	0.01 uu:0.01 uu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	U2OS	32.44%	55.84%	72.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C66062	28693242	DIS0130	NP9654	Bufalin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00047	T24	.	.	10 nM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	T24	8.40%	4.33%	0.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
C66062	28693242	DIS0130	NP9654	Bufalin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00047	T24	.	.	10 nM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	T24	0.96%	0.77%	35.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
C66062	28693242	DIS0130	NP9654	Bufalin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00047	T24	.	.	10 nM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR5	Up-regulation	T24	95.27%	59.84%	203.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	AGS	59.80%	21.24%	50.17%	SNU-216	118.34%	124.78%	152.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	AGS	38.75%	18.34%	51.74%	SNU-216	82.18%	6.18%	62.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2163	FADD	Up-regulation	AGS	94.31%	52.42%	124.89%	SNU-216	76.28%	22.90%	74.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR4	Up-regulation	AGS	91.82%	3.34%	123.69%	SNU-216	22.28%	0.35%	73.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR5	Up-regulation	AGS	62.55%	18.58%	88.33%	SNU-216	28.34%	0.59%	24.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	AGS	19.18%	8.84%	37.19%	SNU-216	11.35%	56.18%	58.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	vimentin	Down-regulation	AGS	9.24%	16.36%	34.91%	SNU-216	21.11%	34.49%	65.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5985	Twist	Down-regulation	AGS	19.30%	31.34%	62.80%	SNU-216	22.17%	36.21%	54.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	AGS	28.57%	32.92%	33.25%	SNU-216	38.40%	11.72%	34.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	AGS	32.51%	21.01%	20.33%	SNU-216	61.52%	39.54%	84.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	AGS	92.90%	27.69%	100.87%	SNU-216	69.96%	10.66%	76.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	AGS	39.88%	4.17%	60.89%	SNU-216	64.79%	17.33%	94.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	p-JNK	Up-regulation	AGS	87.34%	26.67%	105.83%	SNU-216	92.09%	5.60%	112.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	AGS	15.99%	13.16%	53.75%	SNU-216	26.14%	18.15%	56.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	D-cadherin	Down-regulation	AGS	14.29%	4.50%	24.49%	SNU-216	22.45%	5.76%	45.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	AGS	13.15%	4.97%	35.13%	SNU-216	31.53%	2.69%	52.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5985	Twist	Down-regulation	AGS	19.57%	13.37%	55.41%	SNU-216	23.54%	0.64%	39.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C41705	28715876	DIS0024	NP9253	Liquiritin	DR8680	TRAIL 	NEWCL00352	AGS	24h:185.73uM; 48h:138.59uM	.	50 uM:80 ng.ml	NEWCL10373	SNU-216	24h:198.86uM; 48h:137.62 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	AGS	22.64%	4.33%	29.06%	SNU-216	33.10%	18.96%	55.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."
C92213	28719077	DIS0022	NP6047	Metformin	DR8475	Pemetrexed	NEWCL00170	A-549	48h:11.92± 0.11 mmol.L	48h:1.82± 0.17 umol.L	11.92 mmol.L:1.82 umol.L	NEWCL00172	Hcc827	48h:4.72± 0.14 mmol.L	48h:1.54± 0.30 umol.L	4.72 mmol.L :1.54 umol.L	NEWCL00171	NCI-H1975	48h:5.41± 0.55 mmol.L	48h:3.37± 0.14 umol.L	5.41 mmol.L : 3.37 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	0.24%	81.70%	388.59%	Hcc827	5.51%	27.19%	369.20%	NCI-H1975	422.00%	290.59%	839.19%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro.
C92213	28719077	DIS0022	NP6047	Metformin	DR8475	Pemetrexed	NEWCL00170	A-549	48h:11.92± 0.11 mmol.L	48h:1.82± 0.17 umol.L	11.92 mmol.L:1.82 umol.L	NEWCL00172	Hcc827	48h:4.72± 0.14 mmol.L	48h:1.54± 0.30 umol.L	4.72 mmol.L :1.54 umol.L	NEWCL00171	NCI-H1975	48h:5.41± 0.55 mmol.L	48h:3.37± 0.14 umol.L	5.41 mmol.L : 3.37 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	75.81%	87.82%	88.79%	Hcc827	64.42%	78.83%	69.82%	NCI-H1975	2.68%	34.83%	49.89%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro.
C53856	28730769	DIS0021	NP8797	Celastrol	DR6077	Lapatinib	NEWCL00051	MDA-MB-453	.	.	5uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9440	P-HER2	Down-regulation	MDA-MB-453	30.20%	24.96%	33.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Celastrol strongly synergized with ErbB2-targeted therapeutics Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol."
C53856	28730769	DIS0021	NP8797	Celastrol	DR6077	Lapatinib	NEWCL00051	MDA-MB-453	.	.	5uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MDA-MB-453	31.18%	6.46%	27.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Celastrol strongly synergized with ErbB2-targeted therapeutics Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol."
C53856	28730769	DIS0021	NP8797	Celastrol	DR6077	Lapatinib	NEWCL00051	MDA-MB-453	.	.	5uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1	Down-regulation	MDA-MB-453	43.40%	36.24%	28.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Celastrol strongly synergized with ErbB2-targeted therapeutics Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol."
C53856	28730769	DIS0021	NP8797	Celastrol	DR6077	Lapatinib	NEWCL00051	MDA-MB-453	.	.	5uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Down-regulation	MDA-MB-453	1.11%	1.11%	1.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Celastrol strongly synergized with ErbB2-targeted therapeutics Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol."
C71802	28806703	DIS0032	NP6905	Curcumin	DR0683	Thioridazine	NEWCL00268	AMC-HN-4	.	.	0.5 uM :10 uM	NEWCL00049	MDA-MB-231	.	.	0.5 uM :10 uM	NEWCL00279	U-87MG ATCC	.	.	0.5 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	AMC-HN4	9.45%	7.77%	253.22%	MDA-MB-231	2.16%	4.72%	228.51%	U-87MG ATCCMG	9.53%	10.20%	101.18%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.
C71802	28806703	DIS0032	NP6905	Curcumin	DR0683	Thioridazine	NEWCL00268	AMC-HN-4	.	.	0.5 uM :10 uM	NEWCL00049	MDA-MB-231	.	.	0.5 uM :10 uM	NEWCL00279	U-87MG ATCC	.	.	0.5 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CIAP-2	Up-regulation	AMC-HN4	0.19%	6.05%	7.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.
C71802	28806703	DIS0032	NP6905	Curcumin	DR0683	Thioridazine	NEWCL00268	AMC-HN-4	.	.	0.5 uM :10 uM	NEWCL00049	MDA-MB-231	.	.	0.5 uM :10 uM	NEWCL00279	U-87MG ATCC	.	.	0.5 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	AMC-HN4	16.78%	17.29%	17.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.
C71802	28806703	DIS0032	NP6905	Curcumin	DR0683	Thioridazine	NEWCL00268	AMC-HN-4	.	.	0.5 uM :10 uM	NEWCL00049	MDA-MB-231	.	.	0.5 uM :10 uM	NEWCL00279	U-87MG ATCC	.	.	0.5 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	AMC-HN4	0.54%	2.15%	2.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.
C71802	28806703	DIS0032	NP6905	Curcumin	DR0683	Thioridazine	NEWCL00268	AMC-HN-4	.	.	0.5 uM :10 uM	NEWCL00049	MDA-MB-231	.	.	0.5 uM :10 uM	NEWCL00279	U-87MG ATCC	.	.	0.5 uM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4311	PSMA5	Down-regulation	AMC-HN4	13.67%	0.44%	-20.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.
C06862	28827665	DIS0021	NP3545	Schisandrol B	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	MCF-7.ADR	63.43%	53.97%	149.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
C06862	28827665	DIS0021	NP3545	Schisandrol B	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7.ADR	38.51%	1679.63%	8938.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
C06862	28827665	DIS0021	NP3545	Schisandrol B	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	MCF-7.ADR	37.28%	4.00%	76.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
C06862	28827665	DIS0021	NP3545	Schisandrol B	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR	.	.	10uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Down-regulation	MCF-7.ADR	86.05%	6.97%	61.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
C44840	28846180	DIS0022	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00170	A-549	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	A-549	22.67%	17.70%	24.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	28846180	DIS0022	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00170	A-549	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7897	CHOP	Up-regulation	A-549	36.85%	35.38%	164.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	28846180	DIS0022	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00170	A-549	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	0.80%	4.70%	33.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	28846180	DIS0022	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00170	A-549	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	A-549	8.94%	19.02%	13.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	28846180	DIS0022	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00170	A-549	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	96.69%	49.57%	112.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	28846180	DIS0022	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00170	A-549	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	A-549	136.71%	15.61%	112.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	28846180	DIS0022	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00170	A-549	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	A-549	1.24%	1.51%	30.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	28846180	DIS0022	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00170	A-549	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	3 ug.mL:1.3 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Up-regulation	A-549	0.98%	6.47%	10.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C24887	28859099	DIS0022	NP6815	Acacetin	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	25 nM:10 uM	NEWCL00181	NCI-H1299	.	.	25 nM:25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	A-549	2.84%	3.30%	21.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Their combination leads to more retention of doxorubicin in the cells by modulating drug trasporter and thus enhances its therapeutic potential.
C24887	28859099	DIS0022	NP6815	Acacetin	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	25 nM:10 uM	NEWCL00181	NCI-H1299	.	.	25 nM:25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cdc2	Down-regulation	A-549	0.51%	0.87%	6.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Their combination leads to more retention of doxorubicin in the cells by modulating drug trasporter and thus enhances its therapeutic potential.
C99313	28927070	DIS0031	NP9241	Amentoflavone	DR2073	Sorafenib	NEWCL20428	SK-Hep1	.	.	75 uM:25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-Caspase-8	Up-regulation	SK-Hep1	3738.68%	2698.76%	41711.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.
C99313	28927070	DIS0031	NP9241	Amentoflavone	DR2073	Sorafenib	NEWCL20428	SK-Hep1	.	.	75 uM:25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	SK-Hep1	0.95%	0.50%	7.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.
C99313	28927070	DIS0031	NP9241	Amentoflavone	DR2073	Sorafenib	NEWCL20428	SK-Hep1	.	.	75 uM:25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	SK-Hep1	0.10%	6.58%	19.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.
C99313	28927070	DIS0031	NP9241	Amentoflavone	DR2073	Sorafenib	NEWCL20428	SK-Hep1	.	.	75 uM:25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome-C	Up-regulation	SK-Hep1	142.73%	98.62%	196.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.
C76931	28943938	DIS0022	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00170	A-549	24h:1.6uM	0.75uM	1.6uM:0.75uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Down-regulation	A-549	10.48%	20.08%	21.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C76931	28943938	DIS0022	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00170	A-549	24h:1.6uM	0.75uM	1.6uM:0.75uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7849	BCRP	Down-regulation	A-549	14.14%	20.67%	47.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C76931	28943938	DIS0022	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00170	A-549	24h:1.6uM	0.75uM	1.6uM:0.75uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7872	MRP1	Down-regulation	A-549	17.85%	26.54%	43.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C18844	28959140	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00049	MDA-MB-231	.	.	0.5uM:5uM	NEWCL00155	MCF-7	.	.	0.1uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	MDA-MB-231	2.53%	0.13%	16.54%	MCF-7	24.92%	5.82%	29.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis.
C18844	28959140	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00049	MDA-MB-231	.	.	0.5uM:5uM	NEWCL00155	MCF-7	.	.	0.1uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Up-regulation	MDA-MB-231	12.55%	7.96%	7.15%	MCF-7	3.61%	6.56%	7.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis.
C18844	28959140	DIS0021	NP6905	Curcumin	DR8841	Mitomycin C	NEWCL00049	MDA-MB-231	.	.	0.5uM:5uM	NEWCL00155	MCF-7	.	.	0.1uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1245	BIK	Up-regulation	MDA-MB-231	8.80%	0.74%	14.35%	MCF-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis.
C61153	28978118	DIS0115	NP0016	Silibinin	DR6166	Regorafenib	NEWCL00081	SW48	.	.	90 uM:2 uM	NEWCL20389	SW48-CR	.	.	90 uM:2 uM	NEWCL20416	HCT15	.	.	90 uM:2 uM	NEWCL00074	SW480	.	.	90 uM:2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	SW48	.	.	.	SW48-CR	.	.	.	HCT15	.	.	.	SW480	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combined treatment with regorafenib and silybin induced synergistic anti-proliferative and apoptotic effects by blocking PI3K/AKT/mTOR intracellular pathway.
C55665	29030590	DIS0036	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL10030	UM-SCC-14C	24h:8.6uuM	24h:6.2u± u0.4uuM 	.	NEWCL10178	OEC	 24h:40.9u± u7.4uM	24h:30.5u± u2.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C27955	29034540	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL10146	HCT8	48h:20uM	48h:0.4uM	20uM:0.4uM	NEWCL00074	sw480	20uM	0.4uM	48H:0.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Up-regulation	HCT8	9.15%	8.26%	10.13%	SW480	5.11%	20.09%	24.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	29034540	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL10146	HCT8	48h:20uM	48h:0.4uM	20uM:0.4uM	NEWCL00074	sw480	20uM	0.4uM	48H:0.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PDH	Up-regulation	HCT8	20.00%	26.70%	34.77%	SW480	0.45%	14.17%	15.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	29034540	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL10146	HCT8	48h:20uM	48h:0.4uM	20uM:0.4uM	NEWCL00074	sw480	20uM	0.4uM	48H:0.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Up-regulation	HCT8	6.13%	13.96%	16.73%	SW480	11.94%	20.08%	24.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	29034540	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL10146	HCT8	48h:20uM	48h:0.4uM	20uM:0.4uM	NEWCL00074	sw480	20uM	0.4uM	48H:0.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7872	MRP	Up-regulation	HCT8	34.66%	50.31%	60.66%	SW480	3.40%	3.80%	29.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	29034540	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL10146	HCT8	48h:20uM	48h:0.4uM	20uM:0.4uM	NEWCL00074	sw480	20uM	0.4uM	48H:0.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7849	BCRP	Down-regulation	HCT8	0.61%	6.78%	10.78%	SW480	0.81%	7.77%	19.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C50333	29048549	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL00243	BxPC-3	.	.	8uM:20nM	NEWCL00342	Panc1	.	.	20uM:50nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Down-regulation	BxPC-3	47.00%	55.00%	77.00%	Panc1	77.00%	27.00%	63.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C76104	29061787	DIS0031	NP2960	Epigallocatechin gallate	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	.	24h; 50 uM :3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-erk1.2	Down-regulation	Hep-G2	1.20%	55.19%	33.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG could chemosensitize resistant tumor cells to DOX in vivo through an increase in the accumulation of DOX in the tumors.
C89396	29069821	DIS0031	NP7824	Ergosterol	DR5598	Amphotericin B	NEWCL10403	HepJ5	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	HepJ5	4.04%	0.34%	12.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells.
C89396	29069821	DIS0031	NP7824	Ergosterol	DR5598	Amphotericin B	NEWCL10403	HepJ5	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Down-regulation	HepJ5	0.65%	0.95%	11.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells.
C89396	29069821	DIS0031	NP7824	Ergosterol	DR5598	Amphotericin B	NEWCL10403	HepJ5	.	.	25 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-I.II	Up-regulation	HepJ5	11.13%	10.15%	27.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells.
C69797	29073729	DIS0021	NP3478	Eugenol	DR1669	Cisplatin	NEWCL00049	MDA-MB-231	.	.	1uM: 30uM	NEWCL00163	BT-20	.	.	1uM: 30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MDA-MB-231	40.72%	579.03%	601.07%	BT-20	10.65%	8.61%	28.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	29073729	DIS0021	NP3478	Eugenol	DR1669	Cisplatin	NEWCL00049	MDA-MB-231	.	.	1uM: 30uM	NEWCL00163	BT-20	.	.	1uM: 30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MDA-MB-231	48.73%	84.02%	77.43%	BT-20	69.04%	729.95%	1005.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	29073729	DIS0021	NP3478	Eugenol	DR1669	Cisplatin	NEWCL00049	MDA-MB-231	.	.	1uM: 30uM	NEWCL00163	BT-20	.	.	1uM: 30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MDA-MB-231	48.70%	60.39%	164.27%	BT-20	206.70%	301.37%	334.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	29073729	DIS0021	NP3478	Eugenol	DR1669	Cisplatin	NEWCL00049	MDA-MB-231	.	.	1uM: 30uM	NEWCL00163	BT-20	.	.	1uM: 30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MDA-MB-231	1.93%	44.18%	75.81%	BT-20	17.45%	48.42%	79.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	29073729	DIS0021	NP3478	Eugenol	DR1669	Cisplatin	NEWCL00049	MDA-MB-231	.	.	1uM: 30uM	NEWCL00163	BT-20	.	.	1uM: 30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MDA-MB-231	9.39%	10.95%	173.97%	BT-20	69.69%	86.85%	105.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	29073729	DIS0021	NP3478	Eugenol	DR1669	Cisplatin	NEWCL00049	MDA-MB-231	.	.	1uM: 30uM	NEWCL00163	BT-20	.	.	1uM: 30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	MDA-MB-231	18.65%	23.70%	65.15%	BT-20	5.89%	40.71%	91.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	29073729	DIS0021	NP3478	Eugenol	DR1669	Cisplatin	NEWCL00049	MDA-MB-231	.	.	1uM: 30uM	NEWCL00163	BT-20	.	.	1uM: 30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	MDA-MB-231	22.19%	43.03%	83.63%	BT-20	15.18%	55.05%	64.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	29073729	DIS0021	NP3478	Eugenol	DR1669	Cisplatin	NEWCL00049	MDA-MB-231	.	.	1uM: 30uM	NEWCL00163	BT-20	.	.	1uM: 30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-P50	Down-regulation	MDA-MB-231	22.74%	78.38%	88.39%	BT-20	54.20%	68.33%	74.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	29073729	DIS0021	NP3478	Eugenol	DR1669	Cisplatin	NEWCL00049	MDA-MB-231	.	.	1uM: 30uM	NEWCL00163	BT-20	.	.	1uM: 30uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P-P65	Down-regulation	MDA-MB-231	52.68%	19.81%	81.24%	BT-20	6.15%	40.80%	75.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C76914	29091869	DIS0022	NP8210	Galangin	DR1669	Cisplatin	NEWCL00170	A-549	.	.	10uM: 2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P65	Down-regulation	A-549	3.16%	1.91%	8.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-KappaB and Bcl-2/Bax signaling pathways.
C76914	29091869	DIS0022	NP8210	Galangin	DR1669	Cisplatin	NEWCL00170	A-549	.	.	10uM: 2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Lamin B	Down-regulation	A-549	1.30%	1.80%	1.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-KappaB and Bcl-2/Bax signaling pathways.
C76914	29091869	DIS0022	NP8210	Galangin	DR1669	Cisplatin	NEWCL00170	A-549	.	.	10uM: 2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IKBalpha	Down-regulation	A-549	2.09%	1.62%	7.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-KappaB and Bcl-2/Bax signaling pathways.
C22519	29137307	DIS0024	NP2960	Epigallocatechin gallate	DR9021	5-fluorouracil	NEWCL00142	SGC-7901	.	72h:7.394uM	.	NEWCL00113	MGC-803	.	72h:7.716uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.
C00179	29151957	DIS0024	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00108	MKN45	48h:20.66± 2.45uM; 72h: 11.95 ±  2.13uM	48h:70.97± 4.32uM; 72h: 38.22 ±  2.96uM	.	NEWCL00352	AGS	48h:29.94 ±  2.36uM; 72h: 25.57 ±  1.93 uM	48h:106.42 ±  4.38uM; 72h: 82.74 ±  3.55uM	.	NEWCL10018	GES-1	48h: 90.01 ±  3.19uM; 72h: 83.41 ±  2.36uM	48h:199.32 ±  3.09uM; 72h: 178.44 ±  4.87uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MKN45	.	.	.	AGS	.	.	.	GES	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combination of 5 uM curcumin with 5-FU significantly reduced its cytotoxicity in EJ138 cells, while 15 uM curcumin caused an opposite increase."
C35334	29152646	DIS0013	NP9386	Ringin	DR4469	Doxorubicin	NEWCL10337	H9c2(2-1)	.	.	1uM:5umol.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p83	Up-regulation	H9c2	11.19%	69.31%	15.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Naringin protects myocardial cells from doxorubicin induced apoptosis partially by inhibiting the p38MAPK pathway.
C55665	29156767	DIS0024	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL00142	SGC-7901	.	24h:1.78± 0.17uM	5uM:2ug.ml	NEWCL10086	HGC-27	.	24h:2.01± 0.37uM	5uM:2ug.ml	NEWCL00113	MGC-803	24h:1.72± 0.02uM	.	5uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	SGC-7901	0.96%	58.62%	72.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C55665	29156767	DIS0024	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL00142	SGC-7901	.	24h:1.78± 0.17uM	5uM:2ug.ml	NEWCL10086	HGC-27	.	24h:2.01± 0.37uM	5uM:2ug.ml	NEWCL00113	MGC-803	24h:1.72± 0.02uM	.	5uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Down-regulation	SGC-7901	35.43%	45.07%	72.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C55665	29156767	DIS0024	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL00142	SGC-7901	.	24h:1.78± 0.17uM	5uM:2ug.ml	NEWCL10086	HGC-27	.	24h:2.01± 0.37uM	5uM:2ug.ml	NEWCL00113	MGC-803	24h:1.72± 0.02uM	.	5uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SGC-7901	9.61%	9.61%	159.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C55665	29156767	DIS0024	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL00142	SGC-7901	.	24h:1.78± 0.17uM	5uM:2ug.ml	NEWCL10086	HGC-27	.	24h:2.01± 0.37uM	5uM:2ug.ml	NEWCL00113	MGC-803	24h:1.72± 0.02uM	.	5uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SGC-7901	51.94%	78.30%	95.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C55665	29156767	DIS0024	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL00142	SGC-7901	.	24h:1.78± 0.17uM	5uM:2ug.ml	NEWCL10086	HGC-27	.	24h:2.01± 0.37uM	5uM:2ug.ml	NEWCL00113	MGC-803	24h:1.72± 0.02uM	.	5uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytocrhome c	Up-regulation	SGC-7901	97.17%	137.69%	201.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C55665	29156767	DIS0024	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL00142	SGC-7901	.	24h:1.78± 0.17uM	5uM:2ug.ml	NEWCL10086	HGC-27	.	24h:2.01± 0.37uM	5uM:2ug.ml	NEWCL00113	MGC-803	24h:1.72± 0.02uM	.	5uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AIF	Up-regulation	SGC-7901	2.92%	183.73%	285.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C55665	29156767	DIS0024	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL00142	SGC-7901	.	24h:1.78± 0.17uM	5uM:2ug.ml	NEWCL10086	HGC-27	.	24h:2.01± 0.37uM	5uM:2ug.ml	NEWCL00113	MGC-803	24h:1.72± 0.02uM	.	5uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	SGC-7901	153.62%	12.52%	120.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C55665	29156767	DIS0024	NP6308	Thymoquinone	DR1669	Cisplatin	NEWCL00142	SGC-7901	.	24h:1.78± 0.17uM	5uM:2ug.ml	NEWCL10086	HGC-27	.	24h:2.01± 0.37uM	5uM:2ug.ml	NEWCL00113	MGC-803	24h:1.72± 0.02uM	.	5uM:2ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SGC-7901	9.93%	15.57%	76.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C03207	29164887	DIS0021	NP7687	Pterostilbene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00163	BT-20	.	.	40 uM:100 ng.mL	NEWCL00050	MDA-MB-468	.	.	40 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7897	CHOP	Up-regulation	BT-20	18.64%	0.69%	16.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells.
C03207	29164887	DIS0021	NP7687	Pterostilbene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00163	BT-20	.	.	40 uM:100 ng.mL	NEWCL00050	MDA-MB-468	.	.	40 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	BT-20	11.73%	23.10%	366.36%	MDA-MB-468	254.11%	0.31%	273.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells.
C03207	29164887	DIS0021	NP7687	Pterostilbene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00163	BT-20	.	.	40 uM:100 ng.mL	NEWCL00050	MDA-MB-468	.	.	40 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	BT-20	1.64%	3.18%	70.92%	MDA-MB-468	5.59%	3.87%	23.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells.
C03207	29164887	DIS0021	NP7687	Pterostilbene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00163	BT-20	.	.	40 uM:100 ng.mL	NEWCL00050	MDA-MB-468	.	.	40 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	BT-20	1.86%	15.79%	51.51%	MDA-MB-468	16.99%	13.67%	56.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells.
C03207	29164887	DIS0021	NP7687	Pterostilbene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00163	BT-20	.	.	40 uM:100 ng.mL	NEWCL00050	MDA-MB-468	.	.	40 uM:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	BT-20	4.48%	1.06%	37.10%	MDA-MB-468	10.29%	10.28%	34.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells.
C42090	29169726	DIS0127	NP7608	Piperine	DR8841	Mitomycin C	NEWCL00149	Hela	.	.	80uM:0.025ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Hela.MMC	15.91%	8.35%	31.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine potentiates MMC-induced anti-tumor effect on cervical cancer cells with drug resistance through blocking p-STAT3/p65 and Bcl-2 activation.
C42090	29169726	DIS0127	NP7608	Piperine	DR8841	Mitomycin C	NEWCL00149	Hela	.	.	80uM:0.025ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Hela.MMC	24.33%	4.44%	28.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine potentiates MMC-induced anti-tumor effect on cervical cancer cells with drug resistance through blocking p-STAT3/p65 and Bcl-2 activation.
C42090	29169726	DIS0127	NP7608	Piperine	DR8841	Mitomycin C	NEWCL00149	Hela	.	.	80uM:0.025ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Up-regulation	Hela.MMC	20.25%	7.52%	29.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine potentiates MMC-induced anti-tumor effect on cervical cancer cells with drug resistance through blocking p-STAT3/p65 and Bcl-2 activation.
C42090	29169726	DIS0127	NP7608	Piperine	DR8841	Mitomycin C	NEWCL00149	Hela	.	.	80uM:0.025ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	Hela.MMC	27.12%	10.65%	37.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine potentiates MMC-induced anti-tumor effect on cervical cancer cells with drug resistance through blocking p-STAT3/p65 and Bcl-2 activation.
C42090	29169726	DIS0127	NP7608	Piperine	DR8841	Mitomycin C	NEWCL00149	Hela	.	.	80uM:0.025ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	Hela.MMC	5.87%	8.79%	11.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine potentiates MMC-induced anti-tumor effect on cervical cancer cells with drug resistance through blocking p-STAT3/p65 and Bcl-2 activation.
C42090	29169726	DIS0127	NP7608	Piperine	DR8841	Mitomycin C	NEWCL00149	Hela	.	.	80uM:0.025ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hela.MMC	17.84%	5.78%	18.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine potentiates MMC-induced anti-tumor effect on cervical cancer cells with drug resistance through blocking p-STAT3/p65 and Bcl-2 activation.
C42090	29169726	DIS0127	NP7608	Piperine	DR8841	Mitomycin C	NEWCL00149	Hela	.	.	80uM:0.025ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IkBa	Down-regulation	Hela.MMC	49.36%	18.55%	53.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine potentiates MMC-induced anti-tumor effect on cervical cancer cells with drug resistance through blocking p-STAT3/p65 and Bcl-2 activation.
C13108	29181822	DIS0021	NP0239	Schisandrin A	DR4469	Doxorubicin	NEWCL20366	MCF-7.DOX 	48h:42.10 ±  6.20uM	.	20 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MCF-7.DOX	43.57%	58.24%	112.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Sch A specifically reverses P-gp-mediated DOX resistance in MCF-7/DOX cells by blocking P-gp, NF-KappaB, and Stat3 signaling. Inhibition of P65 and Stat3 shows potent anti-MDR effect on MCF-7/DOX cells."
C13108	29181822	DIS0021	NP0239	Schisandrin A	DR4469	Doxorubicin	NEWCL20366	MCF-7.DOX 	48h:42.10 ±  6.20uM	.	20 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7.DOX	24.43%	255.65%	554.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Sch A specifically reverses P-gp-mediated DOX resistance in MCF-7/DOX cells by blocking P-gp, NF-KappaB, and Stat3 signaling. Inhibition of P65 and Stat3 shows potent anti-MDR effect on MCF-7/DOX cells."
C76673	29187441	DIS0017	NP5424	Flavopiridol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00057	CLBL-1	.	.	100 nM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	CLBL-1	4.61%	0.62%	17.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway.
C76673	29187441	DIS0017	NP5424	Flavopiridol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00057	CLBL-1	.	.	100 nM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Up-regulation	CLBL-1	11.22%	7.31%	3.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway.
C76673	29187441	DIS0017	NP5424	Flavopiridol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00057	CLBL-1	.	.	100 nM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FLIP	Down-regulation	CLBL-1	35.93%	14.60%	63.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway.
C76673	29187441	DIS0017	NP5424	Flavopiridol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00057	CLBL-1	.	.	100 nM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Up-regulation	CLBL-1	11.52%	22.34%	5.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway.
C76673	29187441	DIS0017	NP5424	Flavopiridol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00057	CLBL-1	.	.	100 nM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	Mcl-1(L)	Up-regulation	CLBL-1	3.08%	2.22%	8.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway.
C76673	29187441	DIS0017	NP5424	Flavopiridol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00057	CLBL-1	.	.	100 nM:250 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	Mcl-1(S)	Up-regulation	CLBL-1	5.73%	0.38%	2.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway.
C96493	29188798	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00027	PLC.PRF.5	72h: 137.0 umol.L	72h:7.6 umol.L	100 umol.L: 10 umol.L	NEWCL00031	Huh-7	72h: 108.0 umol.L	72h:6.4 umol.L	.	NEWCL00129	Hep-G2	72h: 140.7 umol.L	72h:5.9 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	PLC.PRF.5	3.92%	4.70%	8.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	29188798	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00027	PLC.PRF.5	72h: 137.0 umol.L	72h:7.6 umol.L	100 umol.L: 10 umol.L	NEWCL00031	Huh-7	72h: 108.0 umol.L	72h:6.4 umol.L	.	NEWCL00129	Hep-G2	72h: 140.7 umol.L	72h:5.9 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	PLC.PRF.5	5.91%	7.47%	29.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	29188798	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00027	PLC.PRF.5	72h: 137.0 umol.L	72h:7.6 umol.L	100 umol.L: 10 umol.L	NEWCL00031	Huh-7	72h: 108.0 umol.L	72h:6.4 umol.L	.	NEWCL00129	Hep-G2	72h: 140.7 umol.L	72h:5.9 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Up-regulation	PLC.PRF.5	155.74%	4.00%	24.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	29188798	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00027	PLC.PRF.5	72h: 137.0 umol.L	72h:7.6 umol.L	100 umol.L: 10 umol.L	NEWCL00031	Huh-7	72h: 108.0 umol.L	72h:6.4 umol.L	.	NEWCL00129	Hep-G2	72h: 140.7 umol.L	72h:5.9 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	PLC.PRF.5	3.34%	64.08%	82.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C01021	29223572	DIS0094	NP6905	Curcumin	DR0618	Carfilzomib	NEWCL00286	U266B1	9.9uM	5.2uM	5uM+3.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Down-regulation	U266B1	8.53%	24.48%	88.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin significantly ameliorates CFZ cytotoxic effect. Induction of p53/p21 axis and G0/G1 cell cycle arrest were more pronounced for the CFZ-curcumin combination.
C01021	29223572	DIS0094	NP6905	Curcumin	DR0618	Carfilzomib	NEWCL00286	U266B1	9.9uM	5.2uM	5uM+3.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	U266B1	96.64%	96.78%	97.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin significantly ameliorates CFZ cytotoxic effect. Induction of p53/p21 axis and G0/G1 cell cycle arrest were more pronounced for the CFZ-curcumin combination.
C01021	29223572	DIS0094	NP6905	Curcumin	DR0618	Carfilzomib	NEWCL00286	U266B1	9.9uM	5.2uM	5uM+3.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	U266B1	95.29%	92.66%	94.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin significantly ameliorates CFZ cytotoxic effect. Induction of p53/p21 axis and G0/G1 cell cycle arrest were more pronounced for the CFZ-curcumin combination.
C97380	29228621	DIS0127	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00137	SiHa	.	.	2.4.8uM:1 .2.4uM	NEWCL00149	HeLa	.	.	2.4.8uM:1 .2.4uM	NEWCL00058	C-33 A	.	.	2.4.8uM:1 .2.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	SiHa	14.30%	1.21%	3.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C97380	29228621	DIS0127	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00138	ME-180	.	.	2.4.8uM:1 .2.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	SiHa	23.75%	31.08%	131.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C97380	29228621	DIS0127	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00138	ME-180	.	.	2.4.8uM:1 .2.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SiHa	12.16%	16.40%	63.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C97380	29228621	DIS0127	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00138	ME-180	.	.	2.4.8uM:1 .2.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SiHa	29.11%	22.54%	41.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C97380	29228621	DIS0127	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00138	ME-180	.	.	2.4.8uM:1 .2.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SiHa	7.70%	20.74%	79.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C97380	29228621	DIS0127	NP8902	Ursolic acid	DR1669	Cisplatin	NEWCL00138	ME-180	.	.	2.4.8uM:1 .2.4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SiHa	8.83%	64.85%	78.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
C69281	29241222	DIS0094	NP5424	Flavopiridol	DR2639	Venetoclax	NEWCL00286	U266B1	.	.	100nM:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	U266	12.57%	8.53%	3.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
C69281	29241222	DIS0094	NP5424	Flavopiridol	DR2639	Venetoclax	NEWCL00286	U266B1	.	.	100nM:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U266	63.08%	1.56%	563.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
C69281	29241222	DIS0094	NP5424	Flavopiridol	DR2639	Venetoclax	NEWCL00286	U266B1	.	.	150nM:750nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	U266	4.84%	0.82%	3.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
C69281	29241222	DIS0094	NP5424	Flavopiridol	DR2639	Venetoclax	NEWCL00286	U266B1	.	.	150nM:750nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-CTD(S5)	Down-regulation	U266	34.80%	12.63%	27.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
C69281	29241222	DIS0094	NP5424	Flavopiridol	DR2639	Venetoclax	NEWCL00286	U266B1	.	.	150nM:750nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Pol II	Down-regulation	U266	2.35%	1.03%	0.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
C69281	29241222	DIS0094	NP5424	Flavopiridol	DR2639	Venetoclax	NEWCL00286	U266B1	.	.	150nM:750nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1245	BIK	Down-regulation	U266	23.49%	4.82%	20.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SUP-B15	15.27%	11.34%	232.03%	TOM-1	37.03%	49.13%	396.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	SUP-B15	16.18%	51.43%	1900.44%	TOM-1	91.19%	95.13%	189.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SUP-B15	22.51%	52.87%	2266.62%	TOM-1	175.68%	255.90%	563.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PUMA	Up-regulation	SUP-B15	168.76%	45.48%	493.59%	TOM-1	55.48%	14.47%	269.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	JNK	Up-regulation	SUP-B15	.	.	.	TOM-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	SUP-B15	17.49%	13.61%	529.17%	TOM-1	215.60%	32.34%	252.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-Jun	Up-regulation	SUP-B15	35.74%	28.72%	68.92%	TOM-1	1339.42%	1.92%	1776.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8190	P-ATF2	Up-regulation	SUP-B15	13.59%	9.01%	42.68%	TOM-1	198.65%	64.36%	301.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7883	ATF4	Down-regulation	SUP-B15	5.79%	32.88%	60.81%	TOM-1	12.48%	-19430.53%	4.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	SUP-B15	7.01%	5.80%	10.74%	TOM-1	9.20%	15.22%	13.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C36543	29266867	DIS0025	NP6993	Arsenic trioxide	DR5851	Dasatinib	NEWCL00063	SUP-B15	.	.	2 uM:40 nM	NEWCL10065	TOM-1	.	.	0.5 uM:5 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	SUP-B15	.	.	.	TOM-1	2.09%	1.06%	6.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."
C95662	29270805	DIS0098	NP8606	Fisetin	DR0490	Etoposide	NEWCL00226	MG-63	.	.	36 uM:0.5 u; 48h	NEWCL00225	Saos-2	.	.	45.5 uM :1 uM; 48h	NEWCL00227	U2OS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination of fisetin with etoposide has higher anti-proliferative effects in osteosarcoma associated with cell cycle arrest, allowing the use of lower doses of the chemotherapeutic agent."
C69357	29277774	DIS0100	NP5732	Osthole	DR1669	Cisplatin	NEWCL00096	TE 671	96h:4.409± 1.053ug.mL	0.59± 0.187ug.mL	3.568± 0.555ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C00179	29281876	DIS0130	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00044	EJ138	.	.	5:100uM; 15:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	JNK	Up-regulation	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combination of 5 uM curcumin with 5-FU significantly reduced its cytotoxicity in EJ138 cells, while 15 uM curcumin caused an opposite increase."
C26342	29285650	DIS0019	NP6047	Metformin	DR3103	Gemigliptin	NEWCL20377	SW1763	.	.	30 mM: 1 mM	NEWCL00263	TPC-1	.	.	30 mM: 1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Up-regulation	SW1763	13.19%	43.77%	8.51%	TPC-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells."
C26342	29285650	DIS0019	NP6047	Metformin	DR3103	Gemigliptin	NEWCL20377	SW1763	.	.	30 mM: 1 mM	NEWCL00263	TPC-1	.	.	30 mM: 1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7840	P-MAPK	Up-regulation	SW1763	11.94%	34.80%	29.92%	TPC-1	3.52%	56.19%	55.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells."
C26342	29285650	DIS0019	NP6047	Metformin	DR3103	Gemigliptin	NEWCL20377	SW1763	.	.	30 mM: 1 mM	NEWCL00263	TPC-1	.	.	30 mM: 1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	SW1763	3.84%	66.86%	32.74%	TPC-1	22.19%	24.39%	70.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells."
C26342	29285650	DIS0019	NP6047	Metformin	DR3103	Gemigliptin	NEWCL20377	SW1763	.	.	30 mM: 1 mM	NEWCL00263	TPC-1	.	.	30 mM: 1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	SW1763	22.63%	5.06%	55.87%	TPC-1	7.77%	0.42%	27.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells."
C26342	29285650	DIS0019	NP6047	Metformin	DR3103	Gemigliptin	NEWCL20377	SW1763	.	.	30 mM: 1 mM	NEWCL00263	TPC-1	.	.	30 mM: 1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	SW1763	22.05%	21.48%	40.93%	TPC-1	4.01%	4.25%	19.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells."
C26342	29285650	DIS0019	NP6047	Metformin	DR3103	Gemigliptin	NEWCL20377	SW1763	.	.	30 mM: 1 mM	NEWCL00263	TPC-1	.	.	30 mM: 1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	SW1763	6.13%	16.32%	39.66%	TPC-1	29.31%	42.94%	55.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells."
C26342	29285650	DIS0019	NP6047	Metformin	DR3103	Gemigliptin	NEWCL20377	SW1763	.	.	30 mM: 1 mM	NEWCL00263	TPC-1	.	.	30 mM: 1 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	SW1763	44.78%	44.07%	13.65%	TPC-1	59.54%	14.16%	44.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells."
C96243	29328398	DIS0115	NP4401	Brusatol	DR1669	Cisplatin	NEWCL10031	CT26	48h:0.27± 0.01ug.ml	48h:1.44± 0.22ug.ml	0.27 ug.ml:1.44 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	CT-26	6.71%	7.17%	6.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of CDDP and BR was able to produce a synergistic antitumor effect in CRC cells, thus providing a solid foundation for further development of this combination regimen into an effective therapeutic method for CRC."
C96243	29328398	DIS0115	NP4401	Brusatol	DR1669	Cisplatin	NEWCL10031	CT26	48h:0.27± 0.01ug.ml	48h:1.44± 0.22ug.ml	0.27 ug.ml:1.44 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	CT-26	14.25%	30.69%	31.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of CDDP and BR was able to produce a synergistic antitumor effect in CRC cells, thus providing a solid foundation for further development of this combination regimen into an effective therapeutic method for CRC."
C96243	29328398	DIS0115	NP4401	Brusatol	DR1669	Cisplatin	NEWCL10031	CT26	48h:0.27± 0.01ug.ml	48h:1.44± 0.22ug.ml	0.27 ug.ml:1.44 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	CT-26	0.81%	0.63%	28.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of CDDP and BR was able to produce a synergistic antitumor effect in CRC cells, thus providing a solid foundation for further development of this combination regimen into an effective therapeutic method for CRC."
C96243	29328398	DIS0115	NP4401	Brusatol	DR1669	Cisplatin	NEWCL10031	CT26	48h:0.27± 0.01ug.ml	48h:1.44± 0.22ug.ml	0.27 ug.ml:1.44 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	CT-26	1.00%	1.88%	12.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of CDDP and BR was able to produce a synergistic antitumor effect in CRC cells, thus providing a solid foundation for further development of this combination regimen into an effective therapeutic method for CRC."
C96243	29328398	DIS0115	NP4401	Brusatol	DR1669	Cisplatin	NEWCL10031	CT26	48h:0.27± 0.01ug.ml	48h:1.44± 0.22ug.ml	0.27 ug.ml:1.44 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	CT-26	0.77%	14.71%	11.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of CDDP and BR was able to produce a synergistic antitumor effect in CRC cells, thus providing a solid foundation for further development of this combination regimen into an effective therapeutic method for CRC."
C48253	29358341	DIS0023	NP3067	Paclitaxel	DR7865	Biripant	NEWCL00242	Panc-1	72h:24.2 nm	72h:145 nm	10nM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0602	P-CDK1	Up-regulation	PDAC	229.19%	36.21%	454.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Paclitaxel combined to birinapant could interrupt cell cycle progression by inducing G2/M arrest, whereas the single-drug treatments would not."
C48253	29358341	DIS0023	NP3067	Paclitaxel	DR7865	Biripant	NEWCL00242	Panc-1	72h:24.2 nm	72h:145 nm	10nM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Paclitaxel combined to birinapant could interrupt cell cycle progression by inducing G2/M arrest, whereas the single-drug treatments would not."
C12505	29399200	DIS0115	NP6365	Phloretin	DR3599	Atorvastatin	NEWCL00076	SW620	.	48h:191.70± 2.28 uM	100 uM:10 uM	NEWCL00082	HCT 116	48h:137.48± 2.14uM	48h:19.52± 1.29 uM	100 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SW620	2.44%	25.34%	1255.98%	HCT116	0.71%	1.48%	164.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Phloretin and Atorvastatin produce a powerful synergistic interaction in suppressing colon cancer cell growth. This process was accomplished via the synergistic induction of apoptosis and the arrest of the cell cycle at the G2/M checkpoint, which resulted from downregulated cdc2 activation following combined treatment."
C12505	29399200	DIS0115	NP6365	Phloretin	DR3599	Atorvastatin	NEWCL00076	SW620	.	48h:191.70± 2.28 uM	100 uM:10 uM	NEWCL00082	HCT 116	48h:137.48± 2.14uM	48h:19.52± 1.29 uM	100 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-CDC2	Up-regulation	SW620	90.63%	637.24%	1621.09%	HCT116	323.08%	597.65%	1111.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Phloretin and Atorvastatin produce a powerful synergistic interaction in suppressing colon cancer cell growth. This process was accomplished via the synergistic induction of apoptosis and the arrest of the cell cycle at the G2/M checkpoint, which resulted from downregulated cdc2 activation following combined treatment."
C12505	29399200	DIS0115	NP6365	Phloretin	DR3599	Atorvastatin	NEWCL00076	SW620	.	48h:191.70± 2.28 uM	100 uM:10 uM	NEWCL00082	HCT 116	.	.	100 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	cleaved-PARP	Up-regulation	SW620	2.87%	24.62%	697.32%	HCT116	5.62%	2.70%	79.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Phloretin and Atorvastatin produce a powerful synergistic interaction in suppressing colon cancer cell growth. This process was accomplished via the synergistic induction of apoptosis and the arrest of the cell cycle at the G2/M checkpoint, which resulted from downregulated cdc2 activation following combined treatment."
C12505	29399200	DIS0115	NP6365	Phloretin	DR3599	Atorvastatin	NEWCL00076	SW620	.	48h:191.70± 2.28 uM	100 uM:10 uM	NEWCL00082	HCT 116	48h:137.48± 2.14uM	48h:19.52± 1.29 uM	100 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-CDC2	Up-regulation	SW620	57.23%	499.19%	1097.51%	HCT116	316.06%	482.91%	643.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Phloretin and Atorvastatin produce a powerful synergistic interaction in suppressing colon cancer cell growth. This process was accomplished via the synergistic induction of apoptosis and the arrest of the cell cycle at the G2/M checkpoint, which resulted from downregulated cdc2 activation following combined treatment."
C12505	29399200	DIS0115	NP6365	Phloretin	DR3599	Atorvastatin	NEWCL00076	SW620	.	48h:191.70± 2.28 uM	100 uM:10 uM	NEWCL00082	HCT 116	.	.	100 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8377	Myt1	Up-regulation	SW620	112.74%	29.62%	125.84%	HCT116	75.95%	65.21%	84.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Phloretin and Atorvastatin produce a powerful synergistic interaction in suppressing colon cancer cell growth. This process was accomplished via the synergistic induction of apoptosis and the arrest of the cell cycle at the G2/M checkpoint, which resulted from downregulated cdc2 activation following combined treatment."
C37534	29433678	DIS0024	NP5233	Wogonin	DR0141	Oxaliplatin	NEWCL00145	BGC-823	.	.	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Wogonin exacerbates the cytotoxic effect of oxaliplatin by inducing nitrosative stress and autophagy in human gastric cancer cells.
C48727	29434902	DIS0025	NP6993	Arsenic trioxide	DR1182	Chloroquine	NEWCL10125	NB4	.	.	40uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-I	Up-regulation	NB4	33.46%	31.02%	31.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"CQ exhibits a cytotoxic effect on NB4 cells and has a synergistic effect when combined with ATO, which thereby improves the curative effect of ATO on APL."
C48727	29434902	DIS0025	NP6993	Arsenic trioxide	DR1182	Chloroquine	NEWCL10125	NB4	.	.	40uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-II	Up-regulation	NB4	53.14%	95.87%	102.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"CQ exhibits a cytotoxic effect on NB4 cells and has a synergistic effect when combined with ATO, which thereby improves the curative effect of ATO on APL."
C31687	29456744	DIS0124	NP0445	Cardamonin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	20 uM:2 ug.ml; 48h	NEWCL00230	A2780	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SK-OV-3	1.52%	11.03%	27.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.
C31687	29456744	DIS0124	NP0445	Cardamonin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	20 uM:2 ug.ml; 48h	NEWCL00230	A2780	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	SK-OV-3	0.15%	20.51%	31.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.
C31687	29456744	DIS0124	NP0445	Cardamonin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	20 uM:2 ug.ml; 48h	NEWCL00230	A2780	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	SK-OV-3	0.12%	18.34%	53.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.
C31687	29456744	DIS0124	NP0445	Cardamonin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	20 uM:2 ug.ml; 48h	NEWCL00230	A2780	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	SK-OV-3	12.89%	42.93%	75.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.
C31687	29456744	DIS0124	NP0445	Cardamonin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	20 uM:2 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SK-OV-3	7.49%	0.97%	12.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.
C31687	29456744	DIS0124	NP0445	Cardamonin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	20 uM:2 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	SK-OV-3	30.39%	15.12%	39.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.
C31687	29456744	DIS0124	NP0445	Cardamonin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	20 uM:2 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	SK-OV-3	10.82%	11.25%	30.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.
C31687	29456744	DIS0124	NP0445	Cardamonin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	20 uM:2 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	SK-OV-3	38.48%	4.05%	59.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.
C31687	29456744	DIS0124	NP0445	Cardamonin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	20 uM:2 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7837	P-70S6K	Down-regulation	SK-OV-3	22.97%	16.13%	34.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	0.25 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	MCF-7	402.14%	32.88%	337.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	0.25 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7	14.35%	4.31%	339.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	0.25 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Up-regulation	MCF-7	23.29%	0.26%	38.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00155	MCF-7	.	.	0.25 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	MCF-7	81.34%	33.35%	64.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00155	MCF-7	.	.	0.25 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	MCF-7	21.97%	5.79%	23.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00155	MCF-7	.	.	0.25 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MCF-7	41.69%	4.39%	67.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	MCF-7	45.11%	18.28%	70.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Livin	Up-regulation	MCF-7	1.40%	18.05%	3.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	0.25 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MCF-7	43.52%	-8.69%	60.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C98888	29458160	DIS0021	NP5023	Gambogic acid	DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	0.25 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	MCF-7	39.18%	6.88%	66.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.
C76931	29463831	DIS0026	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00095	Raji	24h: 588.31nM	.	200 Nm:600 nM	NEWCL00094	namalwa	24H: 192.67 Nm	.	400 Nm:800 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	.malwa	0.47%	2.28%	17.48%	Raji	0.24%	5.88%	16.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C76931	29463831	DIS0026	NP8751	Shikonin	DR4469	Doxorubicin	NEWCL00095	Raji	24h: 588.31nM	.	200 Nm:600 nM	NEWCL00094	namalwa	24H: 192.67 Nm	.	400 Nm:800 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	.malwa	0.47%	5.18%	53.96%	Raji	13.95%	53.20%	63.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
C76104	29475441	DIS0098	NP2960	Epigallocatechin gallate	DR4469	Doxorubicin	NEWCL00225	SaOS-2	.	.	20 ug.ml :2.5 uM	NEWCL00227	U2OS	.	.	20 ug.ml :2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SaOS-2	.	.	.	U2OS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG could chemosensitize resistant tumor cells to DOX in vivo through an increase in the accumulation of DOX in the tumors.
C14937	29487530	DIS0022	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL20431	A-549.DDP	.	48h:16.07ug.mL	120uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549.DDP	223.93%	407.67%	736.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	29487530	DIS0022	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL20431	A-549.DDP	.	48h:16.07ug.mL	120uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549.DDP	68.71%	41.62%	186.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	29487530	DIS0022	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL20431	A-549.DDP	.	48h:16.07ug.mL	120uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	A-549.DDP	16.47%	55.59%	92.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	29487530	DIS0022	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL20431	A-549.DDP	.	48h:16.07ug.mL	120uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Up-regulation	A-549.DDP	57.07%	196.71%	277.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	29487530	DIS0022	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL20431	A-549.DDP	.	48h:16.07ug.mL	120uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B	Up-regulation	A-549.DDP	22.36%	56.85%	59.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	29487530	DIS0022	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL20431	A-549.DDP	.	48h:16.07ug.mL	120uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Down-regulation	A-549.DDP	46.85%	34.63%	76.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	29487530	DIS0022	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL20431	A-549.DDP	.	48h:16.07ug.mL	120uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C-Met	Down-regulation	A-549.DDP	3.73%	2.65%	62.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C44115	29535810	DIS0022	NP0016	Silibinin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	50 uM:75 ng.ml	NEWCL00180	NCI-H460	.	.	50 uM:75 ng.ml	NEWCL00019	U-937	.	.	50 uM:75 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	A-549	16.35%	60.78%	90.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca 2+-CaMKII-Sp1 pathway.
C44115	29535810	DIS0022	NP0016	Silibinin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	50 uM:75 ng.ml	NEWCL00180	NCI-H460	.	.	50 uM:75 ng.ml	NEWCL00019	U-937	.	.	50 uM:75 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	A-549	22.83%	33.33%	56.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca 2+-CaMKII-Sp1 pathway.
C44115	29535810	DIS0022	NP0016	Silibinin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	50 uM:75 ng.ml	NEWCL00180	NCI-H460	.	.	50 uM:75 ng.ml	NEWCL00019	U-937	.	.	50 uM:75 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	A-549	0.16%	12.22%	19.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca 2+-CaMKII-Sp1 pathway.
C44115	29535810	DIS0022	NP0016	Silibinin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	50 uM:75 ng.ml	NEWCL00180	NCI-H460	.	.	50 uM:75 ng.ml	NEWCL00019	U-937	.	.	50 uM:75 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	7.32%	17.25%	88.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca 2+-CaMKII-Sp1 pathway.
C44115	29535810	DIS0022	NP0016	Silibinin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	50 uM:75 ng.ml	NEWCL00180	NCI-H460	.	.	50 uM:75 ng.ml	NEWCL00019	U-937	.	.	50 uM:75 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	IAP-2	Down-regulation	A-549	11.67%	47.90%	91.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca 2+-CaMKII-Sp1 pathway.
C44115	29535810	DIS0022	NP0016	Silibinin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	50 uM:75 ng.ml	NEWCL00180	NCI-H460	.	.	50 uM:75 ng.ml	NEWCL00019	U-937	.	.	50 uM:75 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	IAP-1	Down-regulation	A-549	30.40%	49.52%	94.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca 2+-CaMKII-Sp1 pathway.
C44115	29535810	DIS0022	NP0016	Silibinin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	50 uM:75 ng.ml	NEWCL00180	NCI-H460	.	.	50 uM:75 ng.ml	NEWCL00019	U-937	.	.	50 uM:75 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	2.22%	30.64%	75.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca 2+-CaMKII-Sp1 pathway.
C49649	29541412	DIS0021	NP6905	Curcumin	DR1669	Cisplatin	NEWCL00155	MCF-7	48h:25 uM	48h:4 ug.mLu	20uM:2ug.mLu	NEWCL20397	MCF-7.DDP	48h:40 uM	48h:15 ug.mL	30uM:5ug.mLu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T-ERK	Up-regulation	MCF-7	60.60%	6.50%	21.16%	MCF-7DDP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis.
C49649	29541412	DIS0021	NP6905	Curcumin	DR1669	Cisplatin	NEWCL00155	MCF-7	48h:25 uM	48h:4 ug.mLu	20uM:2ug.mLu	NEWCL20397	MCF-7.DDP	48h:40 uM	48h:15 ug.mL	30uM:5ug.mLu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6786	FEN1	Down-regulation	MCF-7	19.06%	3.94%	64.11%	MCF-7DDP	8.33%	5.06%	33.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis.
C28568	29581752	DIS0031	NP6993	Arsenic trioxide	DR0832	Megestrol acetate	NEWCL00129	Hep-G2	.	.	5uM:75uM	NEWCL00141	BEL-7402	.	.	5uM:75uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hep-G2	1.18%	11.67%	110.31%	BEL-7402	3.79%	5.72%	4.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MA/ATO combined treatment enhanced antitumor efficacy.
C28568	29581752	DIS0031	NP6993	Arsenic trioxide	DR0832	Megestrol acetate	NEWCL00129	Hep-G2	.	.	5uM:75uM	NEWCL00141	BEL-7402	.	.	5uM:75uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Hep-G2	5.15%	21.35%	26.20%	BEL-7402	49.38%	124.09%	128.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MA/ATO combined treatment enhanced antitumor efficacy.
C28568	29581752	DIS0031	NP6993	Arsenic trioxide	DR0832	Megestrol acetate	NEWCL00129	Hep-G2	.	.	5uM:75uM	NEWCL00141	BEL-7402	.	.	5uM:75uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK1.2	Up-regulation	Hep-G2	3078.09%	235.04%	926.63%	BEL-7402	1342.65%	4.06%	792.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MA/ATO combined treatment enhanced antitumor efficacy.
C28568	29581752	DIS0031	NP6993	Arsenic trioxide	DR0832	Megestrol acetate	NEWCL00129	Hep-G2	.	.	5uM:75uM	NEWCL00141	BEL-7402	.	.	5uM:75uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Up-regulation	Hep-G2	165.15%	5.54%	182.55%	BEL-7402	448.89%	5.65%	879.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MA/ATO combined treatment enhanced antitumor efficacy.
C57718	29604587	DIS0111	NP4620	Apigenin	DR5221	Cetuximab	NEWCL20433	HONE1 	.	.	50 uM:0.25 mg.mL	NEWCL00340	CNE-2	.	.	50 uM:0.25 mg.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	.	HONE1	3.50%	13.74%	25.78%	CNE-2	0.51%	20.18%	33.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
C57718	29604587	DIS0111	NP4620	Apigenin	DR5221	Cetuximab	NEWCL20433	HONE1 	.	.	50 uM:0.25 mg.mL	NEWCL00340	CNE-2	.	.	50 uM:0.25 mg.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	p-EGFR	.	HONE1	2.08%	63.44%	75.87%	CNE-2	34.12%	75.88%	86.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
C57718	29604587	DIS0111	NP4620	Apigenin	DR5221	Cetuximab	NEWCL20433	HONE1 	.	.	50 uM:0.25 mg.mL	NEWCL00340	CNE-2	.	.	50 uM:0.25 mg.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-Akt	.	HONE1	3.91%	52.46%	76.07%	CNE-2	4.11%	46.77%	75.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
C57718	29604587	DIS0111	NP4620	Apigenin	DR5221	Cetuximab	NEWCL20433	HONE1 	.	.	50 uM:0.25 mg.mL	NEWCL00340	CNE-2	.	.	50 uM:0.25 mg.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	p-STAT3	.	HONE1	9.24%	58.02%	72.78%	CNE-2	0.37%	61.08%	73.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
C57718	29604587	DIS0111	NP4620	Apigenin	DR5221	Cetuximab	NEWCL20433	HONE1 	.	.	50 uM:0.25 mg.mL	NEWCL00340	CNE-2	.	.	50 uM:0.25 mg.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	.	HONE1	1.42%	54.25%	74.99%	CNE-2	13.42%	53.20%	61.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
C60407	29620223	DIS0021	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00155	MCF-7	101.1uM	11.91uM	100 uM:10 uM	NEWCL00156	T-47D	78.19uM	7.27uM	100 uM:10 uM	NEWCL00049	MDA-MB-231	87.01uM	21.48uM	100 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	Gama-h2ax	Up-regulation	MCFu7	12.73%	89.54%	75.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.
C60407	29620223	DIS0021	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00155	MCF-7	101.1uM	11.91uM	100 uM:10 uM	NEWCL00156	T-47D	78.19uM	7.27uM	100 uM:10 uM	NEWCL00049	MDA-MB-231	87.01uM	21.48uM	100 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9258	RAD51	.	MCFu7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.
C01919	29620259	DIS0031	NP9654	Bufalin	DR2073	Sorafenib	NEWCL00140	SMMC-7721	.	.	20 nM:10uM	NEWCL00027	PLC.PRF.5	.	.	20 nM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	Down-regulation	SMMC-7721	2.00%	7.36%	11.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis.
C01919	29620259	DIS0031	NP9654	Bufalin	DR2073	Sorafenib	NEWCL00140	SMMC-7721	.	.	20 nM:10uM	NEWCL00027	PLC.PRF.5	.	.	20 nM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p-ERK	Down-regulation	SMMC-7721	4.49%	23.17%	19.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis.
C65690	29634384	DIS0021	NP8310	Sulforaphane	DR3243	Clofarabine	NEWCL00155	MCF-7	.	.	10 uM:640nm	NEWCL00049	MDA-MB-231	.	.	10 uM:50nm	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Clofarabine in combination with sulforaphane significantly reactivates DNA methylation-silenced CDKN2A tumour suppressor and inhibits cancer cell growth at a non-invasive breast cancer stage.
C23876	29636623	DIS0031	NP1965	Tanshinone IIA	DR2073	Sorafenib	NEWCL00031	Huh-7	.	48h:4.5 uM	1.5 ug.mL:5 uM	NEWCL00129	Hep-G2	.	48h:10 uM	1.5 ug.mL:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	Huh-7	6.24%	75.33%	270.09%	Hep-G2	2.05%	44.53%	44.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Tan-IIA combined with sorafenib or SC-1 exerted synergistic cytotoxicity in HCC cells.
C23876	29636623	DIS0031	NP1965	Tanshinone IIA	DR2073	Sorafenib	NEWCL00031	Huh-7	.	48h:4.5 uM	1.5 ug.mL:5 uM	NEWCL00129	Hep-G2	.	48h:10 uM	1.5 ug.mL:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Huh-7	0.43%	176.43%	1574.94%	Hep-G2	783.79%	219.83%	1178.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Tan-IIA combined with sorafenib or SC-1 exerted synergistic cytotoxicity in HCC cells.
C23876	29636623	DIS0031	NP1965	Tanshinone IIA	DR2073	Sorafenib	NEWCL00031	Huh-7	.	48h:4.5 uM	1.5 ug.mL:5 uM	NEWCL00129	Hep-G2	.	48h:10 uM	1.5 ug.mL:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	cleaved-PARP	Up-regulation	Huh-7	9.24%	240.77%	1018.05%	Hep-G2	12.62%	9.91%	56.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Tan-IIA combined with sorafenib or SC-1 exerted synergistic cytotoxicity in HCC cells.
C23876	29636623	DIS0031	NP1965	Tanshinone IIA	DR2073	Sorafenib	NEWCL00031	Huh-7	.	48h:4.5 uM	1.5 ug.mL:5 uM	NEWCL00129	Hep-G2	.	48h:10 uM	1.5 ug.mL:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Snail	Down-regulation	Huh-7	9.34%	29.46%	65.38%	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Tan-IIA combined with sorafenib or SC-1 exerted synergistic cytotoxicity in HCC cells.
C23876	29636623	DIS0031	NP1965	Tanshinone IIA	DR2073	Sorafenib	NEWCL00031	Huh-7	.	48h:4.5 uM	1.5 ug.mL:5 uM	NEWCL00129	Hep-G2	.	48h:10 uM	1.5 ug.mL:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Slug	Down-regulation	Huh-7	34.55%	38.42%	81.56%	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Tan-IIA combined with sorafenib or SC-1 exerted synergistic cytotoxicity in HCC cells.
C23876	29636623	DIS0031	NP1965	Tanshinone IIA	DR2073	Sorafenib	NEWCL00031	Huh-7	.	48h:4.5 uM	1.5 ug.mL:5 uM	NEWCL00129	Hep-G2	.	48h:10 uM	1.5 ug.mL:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	Huh-7	49.71%	85.43%	95.82%	Hep-G2	6.72%	12.35%	95.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Tan-IIA combined with sorafenib or SC-1 exerted synergistic cytotoxicity in HCC cells.
C23876	29636623	DIS0031	NP1965	Tanshinone IIA	DR2073	Sorafenib	NEWCL00031	Huh-7	.	48h:4.5 uM	1.5 ug.mL:5 uM	NEWCL00129	Hep-G2	.	48h:10 uM	1.5 ug.mL:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	Huh-7	.	.	.	Hep-G2	0.71%	2.24%	9.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Tan-IIA combined with sorafenib or SC-1 exerted synergistic cytotoxicity in HCC cells.
C23876	29636623	DIS0031	NP1965	Tanshinone IIA	DR2073	Sorafenib	NEWCL00031	Huh-7	.	48h:4.5 uM	1.5 ug.mL:5 uM	NEWCL00129	Hep-G2	.	48h:10 uM	1.5 ug.mL:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	Huh-7	.	.	.	Hep-G2	6.55%	11.76%	50.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Tan-IIA combined with sorafenib or SC-1 exerted synergistic cytotoxicity in HCC cells.
C01919	29693132	DIS0031	NP9654	Bufalin	DR2073	Sorafenib	NEWCL00140	SMMC-7721	.	.	20uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SMMC-7721	2.68%	1.97%	0.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis.
C01919	29693132	DIS0031	NP9654	Bufalin	DR2073	Sorafenib	NEWCL00140	SMMC-7721	.	.	20uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SMMC-7721	0.65%	0.82%	0.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis.
C01919	29693132	DIS0031	NP9654	Bufalin	DR2073	Sorafenib	NEWCL00140	SMMC-7721	.	.	20uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	SMMC-7721	3.39%	2.91%	8.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis.
C01919	29693132	DIS0031	NP9654	Bufalin	DR2073	Sorafenib	NEWCL00140	SMMC-7721	.	.	20uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	SMMC-7721	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis.
C01919	29693132	DIS0031	NP9654	Bufalin	DR2073	Sorafenib	NEWCL00140	SMMC-7721	.	.	20uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SMMC-7721	58.28%	78.91%	780.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis.
C97955	29699374	DIS0028	NP6993	Arsenic trioxide	DR6736	Thalidomide	NEWCL00024	KG-1	1.618 uM	80 uM	.	NEWCL00019	U-937	1 uM	60 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide and thalidomide combination induces autophagy along with apoptosis in acute myeloid cell lines.
C10486	29701267	DIS0025	NP4837	Costunolide	DR8244	Imatinib	NEWCL00048	K-562	24h:16.30 ±  2.1uM	48h:1.00 ±  0.13 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	K-562	67.97%	128.26%	523.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
C10486	29701267	DIS0025	NP4837	Costunolide	DR8244	Imatinib	NEWCL00048	K-562	24h:16.30 ±  2.1uM	48h:1.00 ±  0.13 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9634	P-STAT5	Down-regulation	K-562	26.69%	47.34%	34.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
C10486	29701267	DIS0025	NP4837	Costunolide	DR8244	Imatinib	NEWCL00048	K-562	24h:16.30 ±  2.1uM	48h:1.00 ±  0.13 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7803	P-CrkL	Down-regulation	K-562	33.64%	21.21%	20.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
C10486	29701267	DIS0025	NP4837	Costunolide	DR8244	Imatinib	NEWCL00048	K-562	24h:16.30 ±  2.1uM	48h:1.00 ±  0.13 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	K-562	69.71%	168.61%	273.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
C10486	29701267	DIS0025	NP4837	Costunolide	DR8244	Imatinib	NEWCL00048	K-562	24h:16.30 ±  2.1uM	48h:1.00 ±  0.13 uM	15uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	K-562	34.76%	89.62%	44.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
C24569	29705353	DIS0021	NP6084	Resveratrol	DR4213	Raloxifene	NEWCL00155	MCF-7	.	.	20 uM:1uM	NEWCL00049	MDA-MB-231	.	.	20 uM:1uM	.	.	.	.	20 uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MCF-7	.	.	.	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of Res and Ral via increased expression of apoptotic genes including Bax, p53 and caspase-3 and caspase-8 is able to promote apoptosis as a mitochondrial dependent pathway in MCF7 and MDA-MB-231."
C59366	29731891	DIS0127	NP7459	Caffeic acid	DR1669	Cisplatin	NEWCL00149	HeLa	24h:327± 11.55uM	24h:12± 1.57uM	.	NEWCL00139	Ca Ski	24h:220± 18.03uM	24h:10± 0.00uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cisplatin and Caffeic acid in combination synergistically inhibited the growth of cells and induced apoptosis in HeLa and CaSki cells. The mechanism that is most likely to be behind the efficacy of this treatment is the modulation of apoptosis-regulated expression.
C14119	29738778	DIS0022	NP8751	Shikonin	DR9742	Gefitinib	NEWCL00170	A-549	.	.	4um: 5um	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7876	PKM2	Down-regulation	A-549	.	1.28%	74.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
C14119	29738778	DIS0022	NP8751	Shikonin	DR9742	Gefitinib	NEWCL00170	A-549	.	.	4um: 5um	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	A-549	.	1.97%	85.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
C14119	29738778	DIS0022	NP8751	Shikonin	DR9742	Gefitinib	NEWCL00170	A-549	.	.	4um: 5um	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	A-549	.	0.14%	30.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
C55696	29773987	DIS0094	NP8797	Celastrol	DR8611	Bortezomib	NEWCL00286	U266B1	.	.	0.5uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U266	352.52%	197.82%	347.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma.
C55696	29773987	DIS0094	NP8797	Celastrol	DR8611	Bortezomib	NEWCL00286	U266B1	.	.	0.5uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	U266	179.87%	63.20%	198.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma.
C74986	29782854	DIS0031	NP0016	Silibinin	DR2073	Sorafenib	NEWCL00143	Bel-7404	72h: 153.5uM	72h: 10.0uM	5uM:100uM	NEWCL00129	Hep-G2	72h: 136.1uM	72h: 11.1uM	.	NEWCL00141	Bel-7402	72h: 101.2uM	72h: 6.6uM	.	NEWCL00140	SMMC-7721	72h: 86.6uM	72h: 8.4uM	.	NEWCL00030	HCCLM3	72h: 263.2uM	72h: 14.5uM	.	NEWCL00029	MHCC97L	72h: 105.1uM	72h: 9.3uM	.	MO6742	P-AKT	Down-regulation	Bel-7404	1.63%	17.66%	35.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
C74986	29782854	DIS0031	NP0016	Silibinin	DR2073	Sorafenib	NEWCL00143	Bel-7404	72h: 153.5uM	72h: 10.0uM	5uM:100uM	NEWCL00129	Hep-G2	72h: 136.1uM	72h: 11.1uM	.	NEWCL00141	Bel-7402	72h: 101.2uM	72h: 6.6uM	.	NEWCL00140	SMMC-7721	72h: 86.6uM	72h: 8.4uM	.	NEWCL00030	HCCLM3	72h: 263.2uM	72h: 14.5uM	.	NEWCL00029	MHCC97L	72h: 105.1uM	72h: 9.3uM	.	.	P-ERK	Down-regulation	Bel-7404	8.93%	0.51%	17.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
C74986	29782854	DIS0031	NP0016	Silibinin	DR2073	Sorafenib	NEWCL00143	Bel-7404	72h: 153.5uM	72h: 10.0uM	5uM:100uM	NEWCL00129	Hep-G2	72h: 136.1uM	72h: 11.1uM	.	NEWCL00141	Bel-7402	72h: 101.2uM	72h: 6.6uM	.	NEWCL00140	SMMC-7721	72h: 86.6uM	72h: 8.4uM	.	NEWCL00030	HCCLM3	72h: 263.2uM	72h: 14.5uM	.	NEWCL00029	MHCC97L	72h: 105.1uM	72h: 9.3uM	.	MO2491	P-STAT3	Down-regulation	Bel-7404	6.79%	6.29%	28.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
C74986	29782854	DIS0031	NP0016	Silibinin	DR2073	Sorafenib	NEWCL00143	Bel-7404	72h: 153.5uM	72h: 10.0uM	5uM:100uM	NEWCL00129	Hep-G2	72h: 136.1uM	72h: 11.1uM	.	NEWCL00141	Bel-7402	72h: 101.2uM	72h: 6.6uM	.	NEWCL00140	SMMC-7721	72h: 86.6uM	72h: 8.4uM	.	NEWCL00030	HCCLM3	72h: 263.2uM	72h: 14.5uM	.	NEWCL00029	MHCC97L	72h: 105.1uM	72h: 9.3uM	.	MO7840	P-MAPK p38	Down-regulation	Bel-7404	9.23%	1.42%	8.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
C74986	29782854	DIS0031	NP0016	Silibinin	DR2073	Sorafenib	NEWCL00143	Bel-7404	72h: 153.5uM	72h: 10.0uM	5uM:100uM	NEWCL00129	Hep-G2	72h: 136.1uM	72h: 11.1uM	.	NEWCL00141	Bel-7402	72h: 101.2uM	72h: 6.6uM	.	NEWCL00140	SMMC-7721	72h: 86.6uM	72h: 8.4uM	.	NEWCL00030	HCCLM3	72h: 263.2uM	72h: 14.5uM	.	NEWCL00029	MHCC97L	72h: 105.1uM	72h: 9.3uM	.	MO2969	Bcl-2	Down-regulation	Bel-7404	5.28%	5.44%	99.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
C74986	29782854	DIS0031	NP0016	Silibinin	DR2073	Sorafenib	NEWCL00143	Bel-7404	72h: 153.5uM	72h: 10.0uM	5uM:100uM	NEWCL00129	Hep-G2	72h: 136.1uM	72h: 11.1uM	.	NEWCL00141	Bel-7402	72h: 101.2uM	72h: 6.6uM	.	NEWCL00140	SMMC-7721	72h: 86.6uM	72h: 8.4uM	.	NEWCL00030	HCCLM3	72h: 263.2uM	72h: 14.5uM	.	NEWCL00029	MHCC97L	72h: 105.1uM	72h: 9.3uM	.	MO5288	MCL-1	Down-regulation	Bel-7404	2.67%	0.22%	58.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
C74986	29782854	DIS0031	NP0016	Silibinin	DR2073	Sorafenib	NEWCL00143	Bel-7404	72h: 153.5uM	72h: 10.0uM	5uM:100uM	NEWCL00129	Hep-G2	72h: 136.1uM	72h: 11.1uM	.	NEWCL00141	Bel-7402	72h: 101.2uM	72h: 6.6uM	.	NEWCL00140	SMMC-7721	72h: 86.6uM	72h: 8.4uM	.	NEWCL00030	HCCLM3	72h: 263.2uM	72h: 14.5uM	.	NEWCL00029	MHCC97L	72h: 105.1uM	72h: 9.3uM	.	MO5373	Cleaved-Caspase-3	Up-regulation	Bel-7404	31.01%	24.30%	63.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
C74986	29782854	DIS0031	NP0016	Silibinin	DR2073	Sorafenib	NEWCL00143	Bel-7404	72h: 153.5uM	72h: 10.0uM	5uM:100uM	NEWCL00129	Hep-G2	72h: 136.1uM	72h: 11.1uM	.	NEWCL00141	Bel-7402	72h: 101.2uM	72h: 6.6uM	.	NEWCL00140	SMMC-7721	72h: 86.6uM	72h: 8.4uM	.	NEWCL00030	HCCLM3	72h: 263.2uM	72h: 14.5uM	.	NEWCL00029	MHCC97L	72h: 105.1uM	72h: 9.3uM	.	MO6898	Cleaved-PARP	Up-regulation	Bel-7404	525.56%	426.20%	784.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM: 1 uM	NEWCL00129	Hep-G2	.	.	100 uM: 1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	PLC.PRF.5	1.15%	14.77%	19.87%	Hep-G2	12.23%	27.07%	34.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM: 1 uM	NEWCL00129	Hep-G2	.	.	100 uM: 1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	PLC.PRF.5	8.76%	11.53%	22.02%	Hep-G2	15.28%	22.86%	43.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Caspase-7	Up-regulation	PLC.PRF.5	50.00%	40.00%	110.00%	Hep-G2	42.00%	30.00%	106.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	PLC.PRF.5	20.00%	20.00%	60.00%	Hep-G2	10.00%	20.00%	30.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	PLC.PRF.5	13.00%	12.00%	30.00%	Hep-G2	13.00%	13.00%	22.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	PLC.PRF.5	10.00%	20.00%	60.00%	Hep-G2	10.00%	0.00%	30.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	PLC.PRF.5	33.75%	49.30%	53.91%	Hep-G2	19.69%	26.76%	63.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Down-regulation	PLC.PRF.5	.	.	.	Hep-G2	2.17%	48.32%	38.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Down-regulation	PLC.PRF.5	30.46%	95.44%	95.42%	Hep-G2	1.02%	9.67%	40.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-s6	Down-regulation	PLC.PRF.5	11.47%	0.66%	38.93%	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9926	P-TSC2	Down-regulation	PLC.PRF.5	8.98%	8.61%	72.47%	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Caspase-7	Up-regulation	PLC.PRF.5	18.88%	30.63%	55.79%	Hep-G2	588.87%	202.36%	676.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C80534	29783729	DIS0031	NP6934	Chlorogenic acid	DR6166	Regorafenib	NEWCL00027	PLC.PRF.5	.	.	100 uM:1 uM	NEWCL00129	Hep-G2	.	.	100 uM:0.1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	PLC.PRF.5	23.46%	6.23%	63.56%	Hep-G2	4.63%	0.62%	16.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."
C96992	29848706	DIS0023	NP8606	Fisetin	DR2391	Gemcitabine	NEWCL00236	MIA Paca-2	.	.	50 uM:100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1	Down-regulation	MiaPaca-2	24.18%	19.89%	25.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin sensitized human pancreatic cancer cells to gemcitabine-induced cytotoxicity through inhibition of ERK-MYC signaling.
C96992	29848706	DIS0023	NP8606	Fisetin	DR2391	Gemcitabine	NEWCL00236	MIA Paca-2	.	.	50 uM:100 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	Cleaved-MYC	Down-regulation	MiaPaca-2	67.25%	51.00%	68.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Fisetin sensitized human pancreatic cancer cells to gemcitabine-induced cytotoxicity through inhibition of ERK-MYC signaling.
C13131	29849119	DIS0020	NP6905	Curcumin	DR1229	PP242	NEWCL10134	Caki	.	.	20 uM :0.5 uM	NEWCL00348	ACHN	.	.	20 uM :0.5 uM	NEWCL00257	A-498	.	.	20 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	RAPTOR	Down-regulation	U-87MG ATCCMG	0.84%	0.25%	42.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.
C13131	29849119	DIS0020	NP6905	Curcumin	DR1229	PP242	NEWCL10134	Caki	.	.	20 uM :0.5 uM	NEWCL00348	ACHN	.	.	20 uM :0.5 uM	NEWCL00257	A-498	.	.	20 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	U-87MG ATCCMG	8.29%	65.91%	70.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.
C13131	29849119	DIS0020	NP6905	Curcumin	DR1229	PP242	NEWCL10134	Caki	.	.	20 uM :0.5 uM	NEWCL00348	ACHN	.	.	20 uM :0.5 uM	NEWCL00257	A-498	.	.	20 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	U-87MG ATCCMG	3.34%	6.61%	42.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.
C13131	29849119	DIS0020	NP6905	Curcumin	DR1229	PP242	NEWCL10134	Caki	.	.	20 uM :0.5 uM	NEWCL00348	ACHN	.	.	20 uM :0.5 uM	NEWCL00257	A-498	.	.	20 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	U-87MG ATCCMG	5.87%	7.43%	80.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.
C13131	29849119	DIS0020	NP6905	Curcumin	DR1229	PP242	NEWCL10134	Caki	.	.	20 uM :0.5 uM	NEWCL00348	ACHN	.	.	20 uM :0.5 uM	NEWCL00257	A-498	.	.	20 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	U-87MG ATCCMG	4.16%	5.11%	6.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.
C13131	29849119	DIS0020	NP6905	Curcumin	DR1229	PP242	NEWCL10134	Caki	.	.	20 uM :0.5 uM	NEWCL00348	ACHN	.	.	20 uM :0.5 uM	NEWCL00257	A-498	.	.	20 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	U-87MG ATCCMG	0.98%	9.94%	179.02%	MDA-MB-231	8.70%	11.65%	239.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.
C13131	29849119	DIS0020	NP6905	Curcumin	DR1229	PP242	NEWCL00279	U-87MG ATCC	.	.	20 uM :0.5 uM	NEWCL00049	MDA-MB-231	.	.	20 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	U-87MG ATCCMG	10.98%	27.96%	72.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HCT 116	32.23%	37.92%	279.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	HCT 116	57.54%	122.70%	946.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	HCT 116	1.53%	2.62%	4921.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	HCT 116	0.37%	0.40%	21.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116	57.01%	10.24%	63.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	HCT 116	49.45%	20.26%	83.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	HCT 116	2.02%	3.25%	5.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT 116	4.16%	5.00%	6.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Up-regulation	HCT 116	12.96%	-1.09%	18.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C63959	29849804	DIS0115	NP9654	Bufalin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	HCT 116	3.79%	-1.90%	4.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.
C30853	29897998	DIS0023	NP6047	Metformin	DR8071	Liraglutide	NEWCL00236	MIA Paca-2	.	.	0.75mM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MiaPaca-2	84.91%	100.01%	112.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of metformin and liraglutide has synergistic protective effects on endothelial function.
C30853	29897998	DIS0023	NP6047	Metformin	DR8071	Liraglutide	NEWCL00236	MIA Paca-2	.	.	0.75mM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MiaPaca-2	90.48%	8.57%	49.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of metformin and liraglutide has synergistic protective effects on endothelial function.
C30853	29897998	DIS0023	NP6047	Metformin	DR8071	Liraglutide	NEWCL00236	MIA Paca-2	.	.	0.75mM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Down-regulation	MiaPaca-2	19.33%	100.00%	39.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of metformin and liraglutide has synergistic protective effects on endothelial function.
C30853	29897998	DIS0023	NP6047	Metformin	DR8071	Liraglutide	NEWCL00236	MIA Paca-2	.	.	0.75mM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0493	GLP-1R	Down-regulation	MiaPaca-2	57.85%	4.99%	64.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of metformin and liraglutide has synergistic protective effects on endothelial function.
C34583	29927769	DIS0022	NP8797	Celastrol	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	0.5umol.L : 1umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	NCI-H1975	3.66%	3.63%	28.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
C34583	29927769	DIS0022	NP8797	Celastrol	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	0.5umol.L : 1umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	NCI-H1975	7.66%	22.28%	29.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
C34583	29927769	DIS0022	NP8797	Celastrol	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	0.5umol.L : 1umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	NCI-H1975	47.92%	14.23%	19.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
C34583	29927769	DIS0022	NP8797	Celastrol	DR8028	Erlotinib	NEWCL00171	NCI-H1975	.	.	0.5umol.L : 1umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	NCI-H1975	7.66%	24.71%	35.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
C34583	29927769	DIS0022	NP8797	Celastrol	DR8028	Erlotinib	NEWCL00171	NCI-H1975	.	.	0.5umol.L : 1umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	..	P-ERK	Down-regulation	NCI-H1975	7.66%	15.24%	28.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
C34583	29927769	DIS0022	NP8797	Celastrol	DR8028	Erlotinib	NEWCL00171	NCI-H1975	.	.	0.5umol.L : 1umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	NCI-H1975	47.92%	15.05%	36.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
C01747	29928421	DIS0031	NP8797	Celastrol	DR3439	Apatinib	NEWCL00283	Hep 3B2.1-7	.	.	2.5 umol.l:30 umol.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hep 3B2.1-7	11.17%	2.82%	11.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of Apatinib and Tripterine significantly inhibited the proliferation, migration and invasion ability and promoted the apoptosis of Hep3B cells by downregulating the expression of p-Akt and p-ERK, and upregulating the expression of Caspase-3 and Bax."
C51993	29928452	DIS0031	NP1559	Luteolin	DR2073	Sorafenib	NEWCL00283	Hep 3B2.1-7	.	.	10 uM:3 uM	NEWCL00140	SMMC-7721	.	.	10 uM:3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	Hep 3B2.1-7	2.82%	7.54%	773.06%	SMMC-7721	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation.
C51993	29928452	DIS0031	NP1559	Luteolin	DR2073	Sorafenib	NEWCL00283	Hep 3B2.1-7	.	.	10 uM:3 uM	NEWCL00140	SMMC-7721	.	.	10 uM:3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Hep 3B2.1-7	6.59%	360.53%	1381.48%	SMMC-7721	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation.
C70450	29956726	DIS0114	NP6905	Curcumin	DR3489	Irinotecan	NEWCL00080	LoVo	.	24h:43.27uM	.	NEWCL20387	LoVo.CPT-11	.	24h:268.72uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells.
C76205	29957841	DIS0024	NP7102	Elemene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00145	BGC-823	.	.	20 ug.mL:100 ng.mL	NEWCL00142	SGC-7901	.	.	20 ug.mL:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P19.17	Up-regulation	.	5.17%	2.95%	137.09%	SGC-7901	1.33%	17.65%	30.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.
C76205	29957841	DIS0024	NP7102	Elemene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00145	BGC-823	.	.	20 ug.mL:100 ng.mL	NEWCL00142	SGC-7901	.	.	20 ug.mL:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P43.41	Up-regulation	.	0.40%	2.03%	29.54%	SGC-7901	14.95%	6.08%	103.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.
C76205	29957841	DIS0024	NP7102	Elemene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00145	BGC-823	.	.	20 ug.mL:100 ng.mL	NEWCL00142	SGC-7901	.	.	20 ug.mL:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Up-regulation	.	.	.	.	SGC-7901	1.35%	1.19%	23828.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.
C76205	29957841	DIS0024	NP7102	Elemene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00145	BGC-823	.	.	20 ug.mL:100 ng.mL	NEWCL00142	SGC-7901	.	.	20 ug.mL:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	IRE1a	Up-regulation	.	16.20%	9.91%	16.86%	SGC-7901	15.37%	9.17%	26586.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.
C76205	29957841	DIS0024	NP7102	Elemene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00145	BGC-823	.	.	20 ug.mL:100 ng.mL	NEWCL00142	SGC-7901	.	.	20 ug.mL:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7992	ATF6	Up-regulation	.	3.15%	4.54%	2.44%	SGC-7901	1.22%	5.01%	23446.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.
C76205	29957841	DIS0024	NP7102	Elemene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00145	BGC-823	.	.	20 ug.mL:100 ng.mL	NEWCL00142	SGC-7901	.	.	20 ug.mL:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	Caki	0.08%	2.25%	70.74%	SGC-7901	7.72%	4.99%	48.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.
C76205	29957841	DIS0024	NP7102	Elemene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00145	BGC-823	.	.	20 ug.mL:100 ng.mL	NEWCL00142	SGC-7901	.	.	20 ug.mL:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	.	0.01%	0.33%	20.53%	SGC-7901	6.30%	3.49%	7.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.
C76205	29957841	DIS0024	NP7102	Elemene	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00145	BGC-823	.	.	20 ug.mL:100 ng.mL	NEWCL00142	SGC-7901	.	.	20 ug.mL:100 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	.	0.05%	1.29%	3.87%	SGC-7901	6.69%	4.00%	12.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.25uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21 	Up-regulation	RPMI-8226	11.26%	6.31%	16.51%	U266	4.31%	26.34%	41.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.25uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	RPMI-8226	0.26%	29.51%	12.04%	U266	1.87%	0.09%	29.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.25uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6671	E2F1	Down-regulation	RPMI-8226	0.60%	-1.39%	-5.21%	U266	11.25%	23.22%	29.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.25uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6700	P27	Down-regulation	RPMI-8226	28.48%	16.46%	37.96%	U266	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.5uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	RPMI-8226	3.23%	25.61%	42.42%	U266	28.47%	62.35%	122.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.5uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	RPMI-8226	3.48%	76.95%	83.50%	U266	1.22%	45.15%	47.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.5uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	RPMI-8226	23.53%	15.64%	50.36%	U266	17.04%	31.16%	42.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.5uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	RPMI-8226	8.18%	12.45%	43.92%	U266	3.51%	18.27%	27.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.5uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	P-H2AX	Up-regulation	RPMI-8226	10.04%	23.43%	10.36%	U266	72.84%	65.35%	166.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.5uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9803	P-CHK2	Up-regulation	RPMI-8226	83.22%	2.10%	102.45%	U266	36.56%	16.61%	96.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C96418	29969371	DIS0094	NP5000	Cladribine	DR7967	Entinostat	NEWCL00278	RPMI-8226	.	.	0.5uM: 0.125uM	NEWCL00286	U266B1	.	.	1.0uM: 0.3uM	NEWCL10382	MM1.R	.	.	2.0uM: 0.1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4688	P-CHK1	Up-regulation	RPMI-8226	34.70%	45.50%	86.73%	U266	91.51%	74.77%	117.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."
C80755	30031063	DIS0022	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	.	NEWCL00185	HCC15	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	A-549	30.57%	13.10%	112.82%	HCC15	8.40%	88.51%	305.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-kappaB signaling.
C80755	30031063	DIS0022	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	.	NEWCL00185	HCC15	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	0.31%	327.62%	802.08%	HCC15	3.28%	166.06%	343.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-kappaB signaling.
C80755	30031063	DIS0022	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	.	NEWCL00185	HCC15	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	A-549	399.90%	12.87%	404.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-kappaB signaling.
C80755	30031063	DIS0022	NP6084	Resveratrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	.	NEWCL00185	HCC15	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PUMA	Up-regulation	A-549	2442.26%	0.82%	2640.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-kappaB signaling.
C74645	30099447	DIS0028	NP7424	Emodin	DR7876	Cytarabine	NEWCL00019	U-937	72h: 22.28uM-39.17uM	.	.	NEWCL00022	HL-60	72h: 22.28uM-39.17uM	.	.	NEWCL20446	HL-60.ADR	72h: 22.28uM-39.17uM	.	.	NEWCL00022	HL-60	72h: 22.28uM-39.17uM	.	.	NEWCL00310	CCRF-CEM	72h: 22.28uM-39.17uM	.	.	NEWCL00032	Molt-4	72h: 22.28uM-39.17uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Emodin significantly enhanced chemosensitivity of AML cells to Ara-C, inhibited leukemic cell growth, and improved survival in the mouse xenograft model of AML. Dual targeting of Akt and ERK signaling pathways might contribute to the anti-leukemia effects on AML cells in vitro and in vivo."
C23838	30099686	DIS0022	NP3327	Vicenin-2	DR8799	Radiation	NEWCL00178	NCI-H23	.	.	80 uM:6 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	NCI-H23	25.58%	41.37%	40.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	VCN 2 sensitizes NCI H23 cells to radiation.
C23838	30099686	DIS0022	NP3327	Vicenin-2	DR8799	Radiation	NEWCL00178	NCI-H23	.	.	80 uM:6 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9521	RAD50	Down-regulation	NCI-H23	61.32%	36.56%	54.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	VCN 2 sensitizes NCI H23 cells to radiation.
C23838	30099686	DIS0022	NP3327	Vicenin-2	DR8799	Radiation	NEWCL00178	NCI-H23	.	.	80 uM:6 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Down-regulation	NCI-H23	27.91%	40.76%	28.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	VCN 2 sensitizes NCI H23 cells to radiation.
C23838	30099686	DIS0022	NP3327	Vicenin-2	DR8799	Radiation	NEWCL00178	NCI-H23	.	.	80 uM:6 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	NCI-H23	29.53%	11.31%	37.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	VCN 2 sensitizes NCI H23 cells to radiation.
C60407	30103844	DIS0031	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00288	Hep-G2/C3A	.	.	12.5 ug.ml:0.625 ug.ml	NEWCL00140	SMMC-7721	.	.	12.5 ug.ml:0.625 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ASCT2	Down-regulation	C3A	71.61%	0.34%	57.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.
C60407	30103844	DIS0031	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00288	Hep-G2/C3A	.	.	12.5 ug.ml:0.625 ug.ml	NEWCL00140	SMMC-7721	.	.	12.5 ug.ml:0.625 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	C3A	9.13%	87.62%	180.67%	SMMC-7721	44.75%	203.38%	183.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.
C11915	30106087	DIS0031	NP5284	Ursodeoxycholic acid	DR2073	Sorafenib	NEWCL10155	Huh-BAT	.	.	750 uM:5 uM	NEWCL00129	Hep-G2	.	.	750 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Up-regulation	Huh-BAT	171.95%	169.04%	165.49%	HepG2	242.64%	61.98%	308.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sorafenib and ursodeoxycholic combination is efficacious in treating hepatocellular carcinoma by inhibiting cell proliferation and inducing apoptosis through reactive oxygen species dependent activation of ERK and dephosphorylation of STAT3.
C11915	30106087	DIS0031	NP5284	Ursodeoxycholic acid	DR2073	Sorafenib	NEWCL10155	Huh-BAT	.	.	750 uM:5 uM	NEWCL00129	Hep-G2	.	.	750 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	Huh-BAT	391.21%	43.80%	290.25%	HepG2	69.75%	254.72%	180.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sorafenib and ursodeoxycholic combination is efficacious in treating hepatocellular carcinoma by inhibiting cell proliferation and inducing apoptosis through reactive oxygen species dependent activation of ERK and dephosphorylation of STAT3.
C11915	30106087	DIS0031	NP5284	Ursodeoxycholic acid	DR2073	Sorafenib	NEWCL10155	Huh-BAT	.	.	750 uM:5 uM	NEWCL00129	Hep-G2	.	.	750 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Huh-BAT	488.01%	46.01%	492.81%	HepG2	72.87%	378.28%	896.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sorafenib and ursodeoxycholic combination is efficacious in treating hepatocellular carcinoma by inhibiting cell proliferation and inducing apoptosis through reactive oxygen species dependent activation of ERK and dephosphorylation of STAT3.
C11915	30106087	DIS0031	NP5284	Ursodeoxycholic acid	DR2073	Sorafenib	NEWCL10155	Huh-BAT	.	.	750 uM:5 uM	NEWCL00129	Hep-G2	.	.	750 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	Huh-BAT	32.17%	67.91%	67.14%	HepG2	51.29%	72.89%	60.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sorafenib and ursodeoxycholic combination is efficacious in treating hepatocellular carcinoma by inhibiting cell proliferation and inducing apoptosis through reactive oxygen species dependent activation of ERK and dephosphorylation of STAT3.
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72unM:1.9uug.mL	NEWCL10143	EJ	.	.	50unM:0.25uug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	AKT	Up-regulation	UMUC3	8.48%	3.54%	13.76%	EJ	4.18%	4.14%	22.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72nM:1.9ug.mL	NEWCL10143	EJ	.	.	50nM:0.25ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	UMUC3	12.88%	46.63%	57.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72nM:1.9ug.mL	NEWCL10143	EJ	.	.	50nM:0.25ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	UMUC3	59.54%	59.30%	53.03%	EJ	18.05%	35.31%	53.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72nM:1.9ug.mL	NEWCL10143	EJ	.	.	50nM:0.25ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5524	Cyclin A	Down-regulation	UMUC3	48.92%	62.71%	60.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72nM:1.9ug.mL	NEWCL10143	EJ	.	.	50nM:0.25ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	UMUC3	9.03%	17.39%	53.70%	EJ	22.45%	16.38%	54.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72nM:1.9ug.mL	NEWCL10143	EJ	.	.	50nM:0.25ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Catalase	Down-regulation	UMUC3	39.25%	59.71%	71.93%	EJ	34.50%	3.83%	91.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72nM:1.9ug.mL	NEWCL10143	EJ	.	.	50nM:0.25ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SOD1	Down-regulation	UMUC3	35.84%	38.81%	86.19%	EJ	83.02%	76.41%	86.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72nM:1.9ug.mL	NEWCL10143	EJ	.	.	50nM:0.25ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7814	P-GSK3beta	Down-regulation	UMUC3	2.72%	0.26%	28.09%	EJ	23.85%	28.43%	68.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72unM:1.9uug.mL	NEWCL10143	EJ	.	.	50unM:0.25uug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8159	GSK-3beta	.	UMUC3	0.02%	4.78%	7.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C05119	30119201	DIS0130	NP4621	Triptolide	DR2391	Gemcitabine	NEWCL10070	UM-UC-3	.	.	72nM:1.9ug.mL	NEWCL10143	EJ	.	.	50nM:0.25ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	UMUC3	40.16%	52.91%	4.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."
C68656	30125548	DIS0025	NP2010	Delphinidin	DR2770	Arsenite	NEWCL00022	HL-60	48h:10.9 uM	.	8 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	HL-60	7.02%	14.92%	102.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Delphinidin-induced sensitization of HL-60 cells to As(III) may lead to dose reduction of As(III) in clinical application, and ultimately contribute to minimizing its side effects."
C68656	30125548	DIS0025	NP2010	Delphinidin	DR2770	Arsenite	NEWCL00022	HL-60	48h:10.9 uM	.	8 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HL-60	27.34%	6.44%	190.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Delphinidin-induced sensitization of HL-60 cells to As(III) may lead to dose reduction of As(III) in clinical application, and ultimately contribute to minimizing its side effects."
C68656	30125548	DIS0025	NP2010	Delphinidin	DR2770	Arsenite	NEWCL00022	HL-60	48h:10.9 uM	.	8 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	HL-60	1.35%	2.32%	46.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Delphinidin-induced sensitization of HL-60 cells to As(III) may lead to dose reduction of As(III) in clinical application, and ultimately contribute to minimizing its side effects."
C83784	30127933	DIS0031	NP6993	Arsenic trioxide	DR2073	Sorafenib	NEWCL00031	Huh-7	.	.	1 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination effect of ATO and sorafenib in AML cell lines is apoptotic and autophagy.
C60407	30132509	DIS0022	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00183	NCI-H446	35ug.mL	.	35 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AIF	Up-regulation	H446	33.66%	21.61%	71.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.
C60407	30132509	DIS0022	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00183	NCI-H446	35ug.mL	.	35 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	H446	32.90%	8.59%	46.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.
C60407	30132509	DIS0022	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00183	NCI-H446	35ug.mL	.	35 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	H446	13.24%	14.44%	59.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.
C60407	30132509	DIS0022	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00183	NCI-H446	35ug.mL	.	35 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	H446	12.05%	24.31%	35.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.
C21366	30135355	DIS0018	NP2960	Epigallocatechin gallate	DR9274	6-OH-11-O-Hydroxyphenthrene	NEWCL00285	SK-N-BE(2)-C	.	.	20 ug.mL :20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4193	COX-2	Down-regulation	BE(2)-C	7.07%	36.73%	58.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro.
C21366	30135355	DIS0018	NP2960	Epigallocatechin gallate	DR9274	6-OH-11-O-Hydroxyphenthrene	NEWCL00285	SK-N-BE(2)-C	.	.	20 ug.mL :20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Up-regulation	BE(2)-C	34.16%	3.24%	5.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro.
C21366	30135355	DIS0018	NP2960	Epigallocatechin gallate	DR9274	6-OH-11-O-Hydroxyphenthrene	NEWCL00285	SK-N-BE(2)-C	.	.	20 ug.mL :20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	BE(2)-C	66.13%	82.30%	76.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro.
C21366	30135355	DIS0018	NP2960	Epigallocatechin gallate	DR9274	6-OH-11-O-Hydroxyphenthrene	NEWCL00285	SK-N-BE(2)-C	.	.	20 ug.mL :20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	EGFR	.	BE(2)-C	25.66%	27.73%	23.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro.
C21366	30135355	DIS0018	NP2960	Epigallocatechin gallate	DR9274	6-OH-11-O-Hydroxyphenthrene	NEWCL00285	SK-N-BE(2)-C	.	.	20 ug.mL :20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	N-myc	Down-regulation	BE(2)-C	8.40%	44.22%	37.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro.
C21366	30135355	DIS0018	NP2960	Epigallocatechin gallate	DR9274	6-OH-11-O-Hydroxyphenthrene	NEWCL00285	SK-N-BE(2)-C	.	.	20 ug.mL :20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	BE(2)-C	1.90%	2.16%	7.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro.
C95252	30136034	DIS0018	NP6905	Curcumin	DR4469	Doxorubicin	NEWCL00215	SH-SY5Y	24h:20 uM ;	24h:5 ug.mL;	20 uM:5ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumin reversed doxorubicin resistance in human breast cancer MCF 7/DOX and MDA MB231/DOX cells by inhibiting the ATPase activity of ABCB4.
C70205	30136359	DIS0022	NP9796	Betulinic Acid	DR9742	Gefitinib	NEWCL00172	HCC827	.	.	20 uM:10 uM	NEWCL00171	NCI-H1975	.	.	20 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combining betulinic acid with an EGFR TKI improves drug efficacy in EGFR TKI-resistant lung cancer cells.
C10359	30155693	DIS0031	NP6905	Curcumin	DR2742	Celecoxib	NEWCL00129	Hep-G2	.	.	13 uM:42.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model.
C85554	30170097	DIS0021	NP3147	Methylglyoxal	DR4469_DR1669	Doxorubicin 	NEWCL00049	MDA-MB-231	 24h:0.6 mM	24h:2 uM	0.2mM:2uM	NEWCL00155	MCF-7	24h:0.7 mM	24h:3.5 uM	0.2mM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B I	Up-regulation	MDA-MB-231	3.66%	36.43%	83.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment with doxorubicin or cisplatin hindered mammosphere forming efficiency and inclusively eliminated both cancer stem as well as non-stem cancer cells.
C85554	30170097	DIS0021	NP3147	Methylglyoxal	DR4469_DR1669	Doxorubicin 	NEWCL00049	MDA-MB-231	 24h:0.6 mM	24h:2 uM	0.2mM:2uM	NEWCL00155	MCF-7	24h:0.7 mM	24h:3.5 uM	0.2mM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B II	Up-regulation	MDA-MB-231	38.86%	50.18%	86.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment with doxorubicin or cisplatin hindered mammosphere forming efficiency and inclusively eliminated both cancer stem as well as non-stem cancer cells.
C49649	30195880	DIS0022	NP6905	Curcumin	DR1669	Cisplatin	NEWCL00170	A-549	72h:31.25 um	.	20uM:5ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis.
C04523	30217766	DIS0023	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL00242	PANC-1	317.7 uM	46.3 uM	106.3uuM:46.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PANC-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C73964	30223276	DIS0022	NP5145	Atractylenolide 1	DR8028	Erlotinib	NEWCL00181	NCI-H1299	.	.	70 mg.mL: 10 uM	NEWCL00170	A-549	.	.	70 mg.mL: 10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2909	EZH2	Down-regulation	NCI-H1299	15.25%	7.27%	30.98%	A-549	11.69%	2.49%	42.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Targeting the PDK1- and HOTAIR-mediated downstream molecule EZH2 by the combination of ATL-1 and erlotinib potentially facilitates the development of an additional novel strategy to combat lung cancer.
C73964	30223276	DIS0022	NP5145	Atractylenolide 1	DR8028	Erlotinib	NEWCL00181	NCI-H1299	.	.	70 mg.mL: 10 uM	NEWCL00170	A-549	.	.	70 mg.mL: 10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7878	PDK1	Down-regulation	NCI-H1299	7.17%	28.83%	44.55%	A-549	15.13%	37.89%	60.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Targeting the PDK1- and HOTAIR-mediated downstream molecule EZH2 by the combination of ATL-1 and erlotinib potentially facilitates the development of an additional novel strategy to combat lung cancer.
C42594	30233204	DIS0029	NP2740	Borneol	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	80ug.mL:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	uU251	2.73%	2.33%	62.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Natural borneol enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage.
C42594	30233204	DIS0029	NP2740	Borneol	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	80ug.mL:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	uU251	10.80%	8.21%	33.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Natural borneol enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage.
C42594	30233204	DIS0029	NP2740	Borneol	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	80ug.mL:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	uU251	25.92%	34.40%	51.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Natural borneol enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage.
C42594	30233204	DIS0029	NP2740	Borneol	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	80ug.mL:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ATR	Up-regulation	uU251	11.83%	3.22%	10.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Natural borneol enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage.
C42594	30233204	DIS0029	NP2740	Borneol	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	80ug.mL:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-P53	Up-regulation	uU251	182.28%	183.25%	172.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Natural borneol enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage.
C42594	30233204	DIS0029	NP2740	Borneol	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	80ug.mL:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	U251	7.69%	8.08%	6.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Natural borneol enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage.
C42594	30233204	DIS0029	NP2740	Borneol	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	80ug.mL:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	uU251	4.05%	8.63%	7.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Natural borneol enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	LM3	0.72%	2.30%	2.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	LM3	2.48%	33.21%	53.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	LM3	50.55%	49.09%	100.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	LM3	50.49%	122.21%	146.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7891	Beclin-1	Up-regulation	LM3	265.53%	51.90%	326.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B II	Up-regulation	LM3	75.85%	50.38%	120.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Down-regulation	LM3	5.78%	15.22%	16.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	LM3	47.58%	24.53%	52.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	LM3	67.84%	62.90%	92.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	LM3	2.57%	52.49%	59.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	LM3	30.66%	32.46%	61.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	LM3	28.48%	16.50%	50.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	p-EGFR	Down-regulation	LM3	0.91%	1.73%	36.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	Down-regulation	LM3	3.80%	58.76%	83.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	p-mTOR	Down-regulation	LM3	0.33%	5.01%	35.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C96493	30272354	DIS0031	NP6740	Capsaicin	DR2073	Sorafenib	NEWCL00358	LM3	.	.	80uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	p-p70s6k	Down-regulation	LM3	23.83%	35.79%	74.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
C08897	30311125	DIS0094	NP5204	Tanshinone I	DR6061	Lelidomide	NEWCL00278	RPMI-8226	24h:2.0 uM	.	2.0uM:10.0 uM	NEWCL00286	U266B1	24h:2.5 uM	.	2.5 uM:10.0 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2132	ACD	Down-regulation	RPMI-8226	1.22%	41.93%	52.39%	U266	31.28%	59.37%	61.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells."
C08897	30311125	DIS0094	NP5204	Tanshinone I	DR6061	Lelidomide	NEWCL00278	RPMI-8226	24h:2.0 uM	.	2.0uM:10.0 uM	NEWCL00286	U266B1	24h:2.5 uM	.	2.5 uM:10.0 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6499	TERF2IP	Down-regulation	RPMI-8226	11.08%	39.30%	53.15%	U266	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells."
C08897	30311125	DIS0094	NP5204	Tanshinone I	DR6061	Lelidomide	NEWCL00278	RPMI-8226	24h:2.0 uM	.	2.0uM:10.0 uM	NEWCL00286	U266B1	24h:2.5 uM	.	2.5 uM:10.0 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TANK1	Down-regulation	RPMI-8226	7.64%	47.82%	66.37%	U266	32.59%	40.44%	55.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells."
C08897	30311125	DIS0094	NP5204	Tanshinone I	DR6061	Lelidomide	NEWCL00278	RPMI-8226	24h:2.0 uM	.	2.0uM:10.0 uM	NEWCL00286	U266B1	24h:2.5 uM	.	2.5 uM:10.0 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TERF1	Down-regulation	RPMI-8226	2.81%	4.97%	4.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells."
C08897	30311125	DIS0094	NP5204	Tanshinone I	DR6061	Lelidomide	NEWCL00278	RPMI-8226	24h:2.0 uM	.	2.0uM:10.0 uM	NEWCL00286	U266B1	24h:2.5 uM	.	2.5 uM:10.0 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TERF2	Down-regulation	RPMI-8226	3.67%	0.55%	2728.85%	U266	7.59%	5.63%	1662.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells."
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	MG63	15.35%	15.12%	67.95%	143B	0.22%	0.18%	56.83%	HOS	2.53%	13.84%	47.82%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MG63	14.01%	35.62%	71.05%	143B	75.95%	74.71%	171.98%	HOS	3.00%	9.06%	24.65%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MG63	9.24%	11.79%	8.51%	143B	29.28%	34.92%	23.06%	HOS	9.74%	44.07%	76.55%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MG63	7.36%	587.73%	913.77%	143B	69.20%	875.45%	898.54%	HOS	37.91%	207.40%	335.86%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytocrhome c	Up-regulation	MG63	3.08%	116.61%	282.92%	143B	143.92%	166.22%	176.45%	HOS	41.97%	13.99%	30.63%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	MG63	72.81%	0.47%	91.81%	143B	66.31%	104.99%	153.56%	HOS	48.65%	68.80%	92.86%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P18	Up-regulation	MG63	203.89%	186.90%	150.08%	143B	29.38%	212.44%	247.54%	HOS	12.66%	15.72%	46.06%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	MG63	15.81%	15.28%	77.66%	143B	1.90%	5.12%	81.23%	HOS	31.90%	19.00%	23.90%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	MG63	3.69%	11.52%	72.51%	143B	53.89%	59.54%	21.50%	HOS	16.33%	17.37%	4.85%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	MG63	13.24%	19.18%	19.94%	143B	14.06%	19.08%	18.10%	HOS	39.22%	15.26%	11.98%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cyclin D3	Down-regulation	MG63	13.71%	18.26%	52.00%	143B	11.27%	21.00%	26.43%	HOS	27.60%	16.35%	17.71%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	MG63	11.92%	19.05%	33.71%	143B	1.83%	4.94%	-3.35%	HOS	47.26%	15.24%	23.48%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	MG63	3.07%	16.98%	92.74%	143B	6.83%	5.42%	27.00%	HOS	12.07%	5.14%	29.54%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	MG63	1.54%	4.74%	0.26%	143B	16.25%	55.98%	37.47%	HOS	2.92%	8.56%	17.22%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7891	Beclin-1	Up-regulation	MG63	36.63%	43.61%	36.14%	143B	2.95%	9.90%	9.65%	HOS	3.08%	0.46%	18.03%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2597	ATG5	Up-regulation	MG63	12.59%	6.89%	2.34%	143B	2.33%	5.55%	11.03%	HOS	12.73%	7.34%	23.30%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Atg16	Up-regulation	MG63	6.41%	20.00%	17.28%	143B	90.09%	105.53%	117.60%	HOS	3.56%	11.74%	37.22%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Atg3	Up-regulation	MG63	19.42%	43.40%	46.18%	143B	2.98%	5.33%	0.04%	HOS	7.85%	6.01%	18.69%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-II	Up-regulation	MG63	1.50%	3.37%	40.05%	143B	35.11%	2.34%	28.35%	HOS	133.68%	149.50%	235.62%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-I	Up-regulation	MG63	0.89%	1.54%	1.26%	143B	22.08%	22.05%	34.59%	HOS	59.67%	56.56%	81.69%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C81026	30326933	DIS0098	NP6740	Capsaicin	DR1669	Cisplatin	NEWCL00226	MG-63	24h:207.48uM	24h:70.52uM	100uM:16.7uM	NEWCL00228	143B	24h:209.34uM	24h:68.85uM	100uM:16.7uM	NEWCL00355	HOS	24h:209.17uM	24h:74.79uM	100uM:16.7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	p62	Down-regulation	MG63	5.32%	10.73%	13.32%	143B	26.48%	9.81%	10.51%	HOS	7.32%	5.70%	5.87%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.
C61515	30333889	DIS0036	NP6905	Curcumin	DR5221	Cetuximab	NEWCL00359	CAR	.	.	40 uM:20 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	CAR	22.33%	14.97%	25.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Co-treatment with cetuximab and curcumin exerts synergistic oral anticancer effects on CAR cells through the suppression of the EGFR signaling by regulation of the MAPK pathway.
C61515	30333889	DIS0036	NP6905	Curcumin	DR5221	Cetuximab	NEWCL00359	CAR	.	.	40 uM:20 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	CAR	24.21%	10.22%	25.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Co-treatment with cetuximab and curcumin exerts synergistic oral anticancer effects on CAR cells through the suppression of the EGFR signaling by regulation of the MAPK pathway.
C61515	30333889	DIS0036	NP6905	Curcumin	DR5221	Cetuximab	NEWCL00359	CAR	.	.	40 uM:20 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Down-regulation	CAR	34.49%	5.20%	49.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Co-treatment with cetuximab and curcumin exerts synergistic oral anticancer effects on CAR cells through the suppression of the EGFR signaling by regulation of the MAPK pathway.
C61515	30333889	DIS0036	NP6905	Curcumin	DR5221	Cetuximab	NEWCL00359	CAR	.	.	40 uM:20 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-P38	Down-regulation	CAR	38.25%	34.07%	28.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Co-treatment with cetuximab and curcumin exerts synergistic oral anticancer effects on CAR cells through the suppression of the EGFR signaling by regulation of the MAPK pathway.
C44840	30347681	DIS0023	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00241	AsPC-1	.	.	6 uM:5 uM	NEWCL00243	BxPC-3	.	.	6 uM:3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	AsPC-1	11.08%	12.18%	77.73%	BxPC-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	30347681	DIS0023	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00241	AsPC-1	.	.	6 uM:5 uM	NEWCL00243	BxPC-3	.	.	6 uM:3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	AsPC-1	11.14%	2.83%	47.59%	BxPC-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	30347681	DIS0023	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00241	AsPC-1	.	.	6 uM:5 uM	NEWCL00243	BxPC-3	.	.	6 uM:3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	AsPC-1	19.21%	9.05%	64.87%	BxPC-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C44840	30347681	DIS0023	NP9796	Betulinic Acid	DR2073	Sorafenib	NEWCL00241	AsPC-1	.	.	6 uM:5 uM	NEWCL00243	BxPC-3	.	.	6 uM:3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Up-regulation	AsPC-1	5.24%	22.32%	13.02%	BxPC-3	20.13%	13.84%	54.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.
C90372	30364631	DIS0124	NP8452_NP3850	"Theaflavin-3,3'-digallate "	DR1669	Cisplatin	NEWCL20391	A2780.CP70	24h:19.04 uM	24h:10.70 uM	7uM:7uM	NEWCL00134	OVCAR-3	24h:14.64 uM 	24h:10.70 uM	7uM:7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A278.CP70	4.27%	112.93%	170.36%	OVCAR3	4.36%	134.87%	100.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment showed a synergistic pro-apoptotic effect and synergistically induced G1/S phase cell cycle arrest.
C90372	30364631	DIS0124	NP8452_NP3850	"Theaflavin-3,3'-digallate "	DR1669	Cisplatin	NEWCL20391	A2780.CP70	24h:19.04 uM	24h:10.70 uM	7uM:7uM	NEWCL00134	OVCAR-3	24h:14.64 uM 	24h:10.70 uM	7uM:7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	A278.CP70	2.84%	42.23%	182.47%	OVCAR3	3.05%	203.98%	215.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment showed a synergistic pro-apoptotic effect and synergistically induced G1/S phase cell cycle arrest.
C90372	30364631	DIS0124	NP8452_NP3850	"Theaflavin-3,3'-digallate "	DR1669	Cisplatin	NEWCL20391	A2780.CP70	24h:19.04 uM	24h:10.70 uM	7uM:7uM	NEWCL00134	OVCAR-3	24h:14.64 uM 	24h:10.70 uM	7uM:7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome C	Up-regulation	A278.CP70	0.20%	24.61%	112.37%	OVCAR3	1.71%	23.75%	50.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment showed a synergistic pro-apoptotic effect and synergistically induced G1/S phase cell cycle arrest.
C90372	30364631	DIS0124	NP8452_NP3850	"Theaflavin-3,3'-digallate "	DR1669	Cisplatin	NEWCL20391	A2780.CP70	24h:19.04 uM	24h:10.70 uM	7uM:7uM	NEWCL00134	OVCAR-3	24h:14.64 uM 	24h:10.70 uM	7uM:7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Up-regulation	A278.CP70	2.39%	4.84%	9.49%	OVCAR3	1.33%	5.28%	3.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment showed a synergistic pro-apoptotic effect and synergistically induced G1/S phase cell cycle arrest.
C90372	30364631	DIS0124	NP8452_NP3850	"Theaflavin-3,3'-digallate "	DR1669	Cisplatin	NEWCL20391	A2780.CP70	24h:19.04 uM	24h:10.70 uM	7uM:7uM	NEWCL00134	OVCAR-3	24h:14.64 uM 	24h:10.70 uM	7uM:7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Up-regulation	A278.CP70	66.44%	18.06%	11.10%	OVCAR3	5.07%	33.51%	23.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment showed a synergistic pro-apoptotic effect and synergistically induced G1/S phase cell cycle arrest.
C90372	30364631	DIS0124	NP8452_NP3850	"Theaflavin-3,3'-digallate "	DR1669	Cisplatin	NEWCL20391	A2780.CP70	24h:19.04 uM	24h:10.70 uM	7uM:7uM	NEWCL00134	OVCAR-3	24h:14.64 uM 	24h:10.70 uM	7uM:7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A278.CP70	43.85%	43.10%	56.81%	OVCAR3	32.30%	1.23%	37.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment showed a synergistic pro-apoptotic effect and synergistically induced G1/S phase cell cycle arrest.
C90372	30364631	DIS0124	NP8452_NP3850	"Theaflavin-3,3'-digallate "	DR1669	Cisplatin	NEWCL20391	A2780.CP70	24h:19.04 uM	24h:10.70 uM	7uM:7uM	NEWCL00134	OVCAR-3	24h:14.64 uM 	24h:10.70 uM	7uM:7uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3122	CyclinE1	Down-regulation	A278.CP70	5.88%	16.90%	23.85%	OVCAR3	36.05%	34.39%	67.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment showed a synergistic pro-apoptotic effect and synergistically induced G1/S phase cell cycle arrest.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-II	Up-regulation	SUP-B15	3.73%	1.64%	0.83%	NALM-6	0.97%	3.79%	2.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6122	P-MDM2	Up-regulation	SUP-B15	8.15%	83.08%	77.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SUP-B15	3.57%	41.48%	58.33%	NALM-6	126.13%	170.07%	170.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	SUP-B15	47.49%	44.88%	65.48%	NALM-6	98.14%	167.69%	167.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SUP-B15	33.92%	55.91%	110.65%	NALM-6	75.44%	85.71%	169.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-I	Down-regulation	SUP-B15	26.26%	2.46%	51.26%	NALM-6	1.98%	3.79%	21.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Down-regulation	SUP-B15	10.72%	9.99%	31.87%	NALM-6	8.48%	8.86%	40.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	SUP-B15	25.43%	3.25%	37.00%	NALM-6	16.92%	4.04%	32.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	SUP-B15	14.83%	3.21%	45.52%	NALM-6	34.76%	11.63%	36.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	p-p70s6k	Down-regulation	SUP-B15	51.90%	5.85%	46.78%	NALM-6	48.54%	8.94%	34.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7832	P-4EBP1	Down-regulation	SUP-B15	5.27%	0.85%	40.07%	NALM-6	18.04%	2.89%	26.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	SUP-B15	76.07%	83.22%	82.16%	NALM-6	6.62%	43.54%	192.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SUP-B15	67.77%	100.38%	146.14%	NALM-6	46.19%	116.68%	188.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	SUP-B15	17.30%	5.31%	25.40%	NALM-6	85.14%	13.26%	129.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1418	P-cRAF	Up-regulation	SUP-B15	33.17%	11.73%	34.44%	NALM-6	17.99%	5.31%	35.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7389	P-MEK	Up-regulation	SUP-B15	56.62%	6.96%	39.69%	NALM-6	60.84%	6.41%	114.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Up-regulation	SUP-B15	142.54%	34.54%	113.27%	NALM-6	70.74%	3.70%	55.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	SUP-B15	60.91%	33.16%	65.23%	NALM-6	24.72%	2.07%	65.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	SUP-B15	40.49%	18.17%	63.50%	NALM-6	30.79%	11.34%	58.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C12647	30389549	DIS0028	NP1965	Tanshinone IIA	DR6385	Nutlin-3	NEWCL00063	SUP-B15	72h:8.80 ±  1.34 uM	72h:1.96u± u0.32uuM	10uM:2.5uM	NEWCL00026	NALM-6	72h:12.05 ±  2.72 uM	72h:2.19u± u0.45uuM	10uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SUP-B15	17.95%	19.58%	62.97%	NALM-6	55.38%	0.06%	59.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.
C70019	30389604	DIS0023	NP8848	Danthron	DR4469	Doxorubicin	NEWCL00242	Panc-1	.	.	100uuM:10uuM	NEWCL00236	Mia PaCa-2	.	.	100uuM:10uuM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-II	Up-regulation	HK-9	499.05%	89.74%	524.82%	Mia PaCa-2	623.85%	63.37%	646.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Danthron has an anticancer effect and can sensitize the chemotherapeutic effect of doxorubicin on pancreatic cancer cells.
C70019	30389604	DIS0023	NP8848	Danthron	DR4469	Doxorubicin	NEWCL00242	Panc-1	.	.	100uM:0.25mg.L	NEWCL00236	Mia PaCa-2	.	.	100uM:0.25mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Panc-1	7.51%	59.92%	198.71%	Mia PaCa-2	682.88%	964.53%	1345.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Danthron has an anticancer effect and can sensitize the chemotherapeutic effect of doxorubicin on pancreatic cancer cells.
C47170	30396879	DIS0015	NP1559	Luteolin	DR8244	Imatinib	NEWCL00048	K-562	100uM 	5uM 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination treatment may provide better outcomes in terms of cytotoxicity and thus reduce the dosages of imatinib used.
C74006	30430397	DIS0034	NP0551	Oridonin	DR5221	Cetuximab	NEWCL00129	Hep-G2	.	.	24 uM:10 ug.mL	NEWCL00128	Tu 212	.	.	36 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3II	Up-regulation	Hep2	160.80%	97.62%	236.97%	Tu 212	106.37%	11.79%	341.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Autophagy might be strongly associated with the antitumor efficacy of ORI/Cet, which may be beneficial to the clinical application of ORI/Cet in LSCC treatment ORI/Cet in LSCC treatment."
C74006	30430397	DIS0034	NP0551	Oridonin	DR5221	Cetuximab	NEWCL00129	Hep-G2	.	.	24 uM:10 ug.mL	NEWCL00128	Tu 212	.	.	36 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7891	Beclin-1	Up-regulation	Hep2	45.17%	2.45%	38.28%	Tu 212	60.66%	21.54%	81.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Autophagy might be strongly associated with the antitumor efficacy of ORI/Cet, which may be beneficial to the clinical application of ORI/Cet in LSCC treatment ORI/Cet in LSCC treatment."
C74006	30430397	DIS0034	NP0551	Oridonin	DR5221	Cetuximab	NEWCL00129	Hep-G2	.	.	24 uM:10 ug.mL	NEWCL00128	Tu 212	.	.	36 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	p-mTOR	Down-regulation	Hep2	1.15%	0.77%	27.20%	Tu 212	45.72%	2.19%	31.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Autophagy might be strongly associated with the antitumor efficacy of ORI/Cet, which may be beneficial to the clinical application of ORI/Cet in LSCC treatment ORI/Cet in LSCC treatment."
C74006	30430397	DIS0034	NP0551	Oridonin	DR5221	Cetuximab	NEWCL00129	Hep-G2	.	.	24 uM:10 ug.mL	NEWCL00128	Tu 212	.	.	36 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	Nucleus NF-kB	Down-regulation	Hep2	3.79%	0.46%	44.52%	Tu 212	47.54%	24.50%	68.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Autophagy might be strongly associated with the antitumor efficacy of ORI/Cet, which may be beneficial to the clinical application of ORI/Cet in LSCC treatment ORI/Cet in LSCC treatment."
C49644	30454003	DIS0124	NP1559	Luteolin	DR1669	Cisplatin	NEWCL20356	CAOV3.DDP	.	.	100 uM:2ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CAOV3.DDP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"A combinational treatment of cisplatin and luteolin induced more effectively cell growth inhibition, compared to cisplatin treatment alone."
C86746	30460630	DIS0029	NP1928	Carnosic acid	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM: 20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
C00179	30484020	DIS0114	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL10146	HCT8	48h:10.38ug.ml	48h:4.47ug.ml	.	NEWCL20385	HCT8.5-FU	48h:12.96ug.ml	48h:331.10ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combination of 5 uM curcumin with 5-FU significantly reduced its cytotoxicity in EJ138 cells, while 15 uM curcumin caused an opposite increase."
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	50 uM:60 uM	NEWCL00231	SK-OV-3	.	.	50 uM:60 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SK-OV-3	0.79%	0.83%	16.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	50 uM:60 uM	NEWCL00231	SK-OV-3	.	.	50 uM:60 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Prar	Down-regulation	SK-OV-3	10.00%	18.48%	29.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	50 uM:60 uM	NEWCL00231	SK-OV-3	.	.	50 uM:60 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SK-OV-3	8.11%	2.75%	9.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	50 uM:60 uM	NEWCL00231	SK-OV-3	.	.	50 uM:60 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SK-OV-3	6.27%	22.85%	47.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	50 uM:60 uM	NEWCL00231	SK-OV-3	.	.	50 uM:60 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	SK-OV-3	9.48%	37.86%	47.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	50 uM:60 uM	NEWCL00231	SK-OV-3	.	.	50 uM:60 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SK-OV-3	14.73%	19.69%	31.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	50 uM:60 uM	NEWCL00231	SK-OV-3	.	.	50 uM:60 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Down-regulation	SK-OV-3	3.96%	11.73%	19.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	60uM:40uM	NEWCL00134	OVCAR-3	.	.	60uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SK-OV-3u	5.59%	14.84%	34.61%	uOVCAR-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	60uM:40uM	NEWCL00134	OVCAR-3	.	.	60uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SK-OV-3u	9.24%	7.41%	76.51%	uOVCAR-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	60uM:40uM	NEWCL00134	OVCAR-3	.	.	60uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SK-OV-3u	13.39%	18.33%	32.74%	uOVCAR-3	6.05%	4.81%	13.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C14937	30503360	DIS0124	NP1886	Scutellarin	DR1669	Cisplatin	NEWCL00231	SK-OV-3	.	.	60uM:40uM	NEWCL00134	OVCAR-3	.	.	60uM:100uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Down-regulation	SK-OV-3u	.	.	.	uOVCAR-3	7.10%	17.75%	21.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.
C64576	30529816	DIS0031	NP4582	Glycyrrhetinic acid	DR4469	Doxorubicin	NEWCL00129	Hep-G2	72h:2.43uug.mL	72h:0.36uug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"DOX/PEG-Fmoc-GA containing micelles facilitated the efficient cleavage of GA in tumor tissues/cells, leading to a higher level of synergistic antitumor activity with DOX in vitro and in vivo."
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	30h:40uM	30h:10ug.mL	40uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	NCI-N87	52.78%	44.72%	55.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	30h:40uM	30h:10ug.mL	40uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-N87	249.26%	87.84%	311.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	30h:40uM	30h:10ug.mL	40uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	NCI-N87	276.81%	61.96%	352.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	30h:40uM	30h:10ug.mL	40uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	NCI-N87	48.19%	5.98%	66.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	30h:40uM	30h:10ug.mL	40uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	NCI-N87	74.92%	50.69%	87.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	30h:40uM	30h:10ug.mL	40uM:10ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7840	P-MAPK	Down-regulation	NCI-N87	8.89%	15.54%	17.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	.	.	40 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-N87	288.51%	98.60%	289.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	.	.	40 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	NCI-N87	238.45%	26.78%	238.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	.	.	40 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	NCI-N87	15.67%	2.09%	35.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	.	.	40 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	NCI-N87	61.41%	5.88%	73.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	.	.	40 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	NCI-N87	72.00%	48.49%	85.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C00848	30538636	DIS0024	NP5732	Osthole	DR6300	Trastuzumab	NEWCL00117	NCI-N87	.	.	40 uM:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7840	P-MAPK	Down-regulation	NCI-N87	3.65%	0.29%	5.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.
C60407	30552915	DIS0129	NP6084	Resveratrol	DR1669	Cisplatin	NEWCL00251	DU145	.	.	100 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DUSP1	Up-regulation	DU145	100.67%	155.67%	133.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	A-549	36.68%	62.38%	66.61%	H1299	44.02%	83.90%	104.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	NOG	Up-regulation	A-549	23.28%	17.52%	9.75%	H1299	1.52%	6.20%	9.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Snail	Down-regulation	A-549	14.71%	7.65%	30.37%	H1299	27.43%	53.50%	48.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5985	Twist	Down-regulation	A-549	4.33%	3.85%	7.95%	H1299	9.21%	20.71%	10.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	A-549	10.81%	41.98%	59.56%	H1299	15.83%	40.78%	67.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	A-549	2.81%	4.38%	54.44%	H1299	3.48%	2.21%	23.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2962	Hes1	Down-regulation	A-549	8.76%	0.65%	33.85%	H1299	0.83%	0.01%	6.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1462	SOX2	Down-regulation	A-549	5.06%	5.90%	18.73%	H1299	4.66%	12.11%	8.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	NEWCL00181	NCI-H1299	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	A-549	26.82%	48.58%	67.14%	H1299	32.96%	75.58%	103.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C11292	30555330	DIS0022	NP7102	Elemene	DR9742	Gefitinib	NEWCL00170	A-549	.	.	40 ug.ml:5 uM	NEWCL00181	NCI-H1299	.	.	40 ug.ml:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4-Oct	Down-regulation	A-549	4.98%	11.06%	50.65%	H1299	8.89%	10.42%	28.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.
C58722	30569150	DIS0022	NP8797	Celastrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4uM:200 ng.ml	NEWCL00185	HCC15	.	.	.	NEWCL00173	Calu-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Down-regulation	A-549	9.43%	22.77%	69.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL-induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species.
C58722	30569150	DIS0022	NP8797	Celastrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4uM:200 ng.ml	NEWCL00185	HCC15	.	.	.	NEWCL00173	Calu-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL-induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species.
C48730	30572191	DIS0021	NP8902	Ursolic acid	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR 	24 h 35.01 ±  2.91 uM; 48h 18.79 ±  3.78 uM	.	2.4.6 uM:10 uM	NEWCL00155	MCF-7	36.43 ±  1.52 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C99340	30591440	DIS0029	NP4862	Biochanin A	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	70 uM :70 uM ; 72h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	U-87MG ATCC MG	6.82%	5.68%	33.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Biochanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells.
C99340	30591440	DIS0029	NP4862	Biochanin A	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	70 uM :70 uM ; 72h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	U-87MG ATCC MG	10.57%	8.94%	23.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Biochanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells.
C99340	30591440	DIS0029	NP4862	Biochanin A	DR6516	Temozolomide	NEWCL00279	U-87MG ATCC	.	.	70 uM :70 uM ; 72h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53	Up-regulation	U-87MG ATCC MG	5.26%	17.29%	19.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Biochanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells.
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	959.24%	679.71%	1162.15%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	A-549	270.61%	21.99%	522.67%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	A-549	530.78%	406.03%	590.90%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	A-549	3.04%	0.96%	15.48%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	75.15%	3.82%	59.11%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	A-549	1.74%	4.94%	58.34%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	3.21%	3.82%	5.68%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cleaved-cFLIP 	Down-regulation	A-549	15.82%	0.30%	91.31%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	A-549	5.94%	2.12%	92.05%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Up-regulation	A-549	999.64%	168.65%	1911.51%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	A-549	410.36%	152.98%	554.86%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	A-549	24.90%	3.94%	22.71%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C07957	30594131	DIS0022	NP8751	Shikonin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	4 uM:50 ng.ml	NEWCL10120	HEK293	.	.	4 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-549	0.56%	0.34%	74.84%	HEK-293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."
C84395	30595215	DIS0022	NP1928	Carnosic acid	DR1669	Cisplatin	NEWCL00298	LL/2 (LLC1)	.	.	10 mg.kg: 1 mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Granzyme B	Up-regulation	Lewis	0.41%	0.07%	-0.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Carnosic acid enhances the anti-lung cancer effect of cisplatin by inhibiting myeloid-derived suppressor cells.
C12043	30627053	DIS0023	NP5023	Gambogic acid	DR1182	Chloroquine	NEWCL00242	PANC-1	.	.	2uM:40uM	NEWCL00243	BxPC-3	.	.	2uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3A	Up-regulation	PANC-1	81.41%	470.41%	499.01%	BxPC-3	65.22%	213.70%	331.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species.
C12043	30627053	DIS0023	NP5023	Gambogic acid	DR1182	Chloroquine	NEWCL00242	PANC-1	.	.	2uM:40uM	NEWCL00243	BxPC-3	.	.	2uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B	Up-regulation	PANC-1	365.47%	637.94%	649.66%	BxPC-3	515.01%	629.23%	726.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species.
C12043	30627053	DIS0023	NP5023	Gambogic acid	DR1182	Chloroquine	NEWCL00242	PANC-1	.	.	2uM:40uM	NEWCL00243	BxPC-3	.	.	2uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	PANC-1	602.28%	2.49%	615.48%	BxPC-3	1760.38%	14.79%	1697.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species.
C12043	30627053	DIS0023	NP5023	Gambogic acid	DR1182	Chloroquine	NEWCL00242	PANC-1	.	.	2uM:40uM	NEWCL00243	BxPC-3	.	.	2uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	PANC-1	206.54%	248.12%	734.43%	BxPC-3	91.63%	24.47%	416.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species.
C47047	30643431	DIS0034	NP9078_NP3067	Cinobufotalin 	DR1669_DR9021	Cisplatin	NEWCL10088	FADU	19.4 ug.mL 	.	.	NEWCL10378	UM-SCC-5	 35.78 ug.mL 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TPF regimen combining cinobufotalin suppressed proliferation and promoted apoptosis synergistically in hypopharyngeal squamous cell carcinoma and laryngeal squamous cell carcinoma cells.
C47047	30643431	DIS0034	NP9078_NP3067	Cinobufotalin 	DR1669_DR9021	5-fluorouracil	NEWCL10088	FADU	19.4 ug.mL 	.	.	NEWCL10378	UM-SCC-5	 35.78 ug.mL 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TPF regimen combining cinobufotalin suppressed proliferation and promoted apoptosis synergistically in hypopharyngeal squamous cell carcinoma and laryngeal squamous cell carcinoma cells.
C04358	30655370	DIS0025	NP6711	Glucocorticoids	DR6609	Selumetinib	NEWCL20355	L829R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	L829R	8.56%	85.11%	72.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A selumetinib-dexamethasone combination may be highly effective in RAS pathway-mutated acute lymphoblastic leukemia.
C04358	30655370	DIS0025	NP6711	Glucocorticoids	DR6609	Selumetinib	NEWCL20355	L829R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim	Up-regulation	L829R	3.95%	22.82%	25.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A selumetinib-dexamethasone combination may be highly effective in RAS pathway-mutated acute lymphoblastic leukemia.
C04358	30655370	DIS0025	NP6711	Glucocorticoids	DR6609	Selumetinib	NEWCL20355	L829R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	L829R	9.10%	26.82%	29.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A selumetinib-dexamethasone combination may be highly effective in RAS pathway-mutated acute lymphoblastic leukemia.
C04358	30655370	DIS0025	NP6711	Glucocorticoids	DR6609	Selumetinib	NEWCL20355	L829R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	L829R	5.10%	78.39%	53.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A selumetinib-dexamethasone combination may be highly effective in RAS pathway-mutated acute lymphoblastic leukemia.
C06415	30664150	DIS0029	NP0074	Acteoside	DR6516	Temozolomide	NEWCL00255	C6	.	24h:5 mM	50 uM:5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	C6	2.81%	104.44%	579.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.
C06415	30664150	DIS0029	NP0074	Acteoside	DR6516	Temozolomide	NEWCL00255	C6	.	24h:5 mM	50 uM:5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	C6	39.98%	548.16%	881.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.
C06415	30664150	DIS0029	NP0074	Acteoside	DR6516	Temozolomide	NEWCL00255	C6	.	24h:5 mM	50 uM:5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53	Up-regulation	C6	5.23%	96.12%	198.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.
C06415	30664150	DIS0029	NP0074	Acteoside	DR6516	Temozolomide	NEWCL00255	C6	.	24h:5 mM	50 uM:5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Up-regulation	C6	5.98%	112.13%	115.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.
C06415	30664150	DIS0029	NP0074	Acteoside	DR6516	Temozolomide	NEWCL00255	C6	.	24h:5 mM	50 uM:5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Up-regulation	C6	90.96%	5782.20%	5901.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.
C06415	30664150	DIS0029	NP0074	Acteoside	DR6516	Temozolomide	NEWCL00255	C6	.	24h:5 mM	50 uM:5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	C6	41.97%	197.56%	287.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.
C06415	30664150	DIS0029	NP0074	Acteoside	DR6516	Temozolomide	NEWCL00255	C6	.	24h:5 mM	50 uM:5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Up-regulation	C6	98.24%	1888.42%	2333.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.
C06415	30664150	DIS0029	NP0074	Acteoside	DR6516	Temozolomide	NEWCL00255	C6	.	24h:5 mM	50 uM:5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	C6	46.09%	45.23%	82.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.
C06415	30664150	DIS0029	NP0074	Acteoside	DR6516	Temozolomide	NEWCL00255	C6	.	24h:5 mM	50 uM:5 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3-I	Down-regulation	C6	85.32%	89.69%	96.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.
C28922	30668408	DIS0022	NP6514	Demethoxycurcumin	DR1669	Cisplatin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	AKT	Up-regulation	.	3.43%	1.76%	3.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.
C28922	30668408	DIS0022	NP6514	Demethoxycurcumin	DR1669	Cisplatin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	.	33.26%	136.69%	160.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.
C28922	30668408	DIS0022	NP6514	Demethoxycurcumin	DR1669	Cisplatin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	.	6.12%	157.91%	123.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.
C28922	30668408	DIS0022	NP6514	Demethoxycurcumin	DR1669	Cisplatin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	.	2.02%	2.20%	68.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8199	Ki67	Down-regulation	HCT 116	1.16%	1.64%	28.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Down-regulation	HCT 116	3.85%	5.10%	25.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	HCT 116	24.80%	27.98%	42.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	HCT 116	94.64%	92.94%	68.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	HCT 116	44.38%	36.01%	70.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Fibronectin	Down-regulation	HCT 116	14.28%	29.43%	39.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	HCT 116	5.99%	17.35%	17.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HCT 116	6.15%	1.29%	15.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	HCT 116	4.88%	20.77%	21.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C72994	30689555	DIS0115	NP4240	Esculetin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	20 g.mL: 10 g.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MMP-7	Down-regulation	HCT 116	17.75%	21.87%	42.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."
C04523	30697969	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20354	MCF7.ADR	.	.	50 umol Lu1:4 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Beta-Catenin	Down-regulation	MCF7.ADR	13.82%	0.44%	13.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	30697969	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20354	MCF7.ADR	.	.	50 umol Lu1:4 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	MCF7.ADR	4.40%	0.20%	15.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	30697969	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20354	MCF7.ADR	.	.	50 umol Lu1:4 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	MCF7.ADR	38.03%	0.92%	34.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C04523	30697969	DIS0021	NP6084	Resveratrol	DR4469	Doxorubicin	NEWCL20354	MCF7.ADR	.	.	50 umol Lu1:4 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3236	SIRT1	Up-regulation	MCF7.ADR	50.03%	3.64%	53.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
C88839	30711947	DIS0031	NP9120	Chrysin	DR2073	Sorafenib	NEWCL00283	Hep 3B2.1-7	.	.	25 uM :5 uM	NEWCL00129	Hep-G2	.	.	25 uM :5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin-induced ERK1/2 phosphorylation enhances the sensitivity of human gepatocellular carcinoma cells to sorafenib.
C01797	30727807	DIS0024	NP6905	Curcumin	DR4666	PD98059	NEWCL00113	MGC-803	.	.	20 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MGC-803	9.79%	2.69%	32.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin regulates the miR-21/PTEN/Akt pathway and acts in synergy with PD98059 to induce apoptosis of human gastric cancer MGC-803 cells.
C01797	30727807	DIS0024	NP6905	Curcumin	DR4666	PD98059	NEWCL00113	MGC-803	.	.	20 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	MGC-803	35.64%	123.81%	11.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Curcumin regulates the miR-21/PTEN/Akt pathway and acts in synergy with PD98059 to induce apoptosis of human gastric cancer MGC-803 cells.
C22519	30741544	DIS0115	NP2960	Epigallocatechin gallate	DR9021	5-fluorouracil	NEWCL00082	HCT 116	24h: 270uM	24h: 40uM	50 uM : 5 um	NEWCL00079	DLD-1	24h: 375 uM	24h: 150 uM	50 uM : 11 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HCT 116	3.00%	0.42%	22.70%	DLD1	0.19%	1.53%	79.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.
C22519	30741544	DIS0115	NP2960	Epigallocatechin gallate	DR9021	5-fluorouracil	NEWCL00082	HCT 116	24h: 270uM	24h: 40uM	50 uM : 5 um	NEWCL00079	DLD-1	24h: 375 uM	24h: 150 uM	50 uM : 11 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Down-regulation	HCT 116	1.54%	1.76%	1.30%	DLD1	1.05%	0.96%	0.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.
C22519	30741544	DIS0115	NP2960	Epigallocatechin gallate	DR9021	5-fluorouracil	NEWCL00082	HCT 116	24h: 270uM	24h: 40uM	50 uM : 5 um	NEWCL00079	DLD-1	24h: 375 uM	24h: 150 uM	50 uM : 11 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HCT 116	0.67%	183.85%	250.94%	DLD1	0.19%	1.53%	73.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.
C22519	30741544	DIS0115	NP2960	Epigallocatechin gallate	DR9021	5-fluorouracil	NEWCL00082	HCT 116	24h: 270uM	24h: 40uM	50 uM : 5 um	NEWCL00079	DLD-1	24h: 375 uM	24h: 150 uM	50 uM : 11 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116	2.73%	10.30%	28.46%	DLD1	2.12%	2.19%	5.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.
C22519	30741544	DIS0115	NP2960	Epigallocatechin gallate	DR9021	5-fluorouracil	NEWCL00082	HCT 116	24h: 270uM	24h: 40uM	50 uM : 5 um	NEWCL00079	DLD-1	24h: 375 uM	24h: 150 uM	50 uM : 11 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Up-regulation	HCT 116	6.72%	21.01%	45.52%	DLD1	27.75%	99.77%	132.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.
C22519	30741544	DIS0115	NP2960	Epigallocatechin gallate	DR9021	5-fluorouracil	NEWCL00082	HCT 116	24h: 270uM	24h: 40uM	50 uM : 5 um	NEWCL00079	DLD-1	24h: 375 uM	24h: 150 uM	50 uM : 11 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7879	MDR1	Down-regulation	HCT 116	9.54%	2.97%	17.69%	DLD1	11.59%	0.76%	12.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.
C22519	30741544	DIS0115	NP2960	Epigallocatechin gallate	DR9021	5-fluorouracil	NEWCL00082	HCT 116	24h: 270uM	24h: 40uM	50 uM : 5 um	NEWCL00079	DLD-1	24h: 375 uM	24h: 150 uM	50 uM : 11 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7849	BCRP	Up-regulation	HCT 116	7.46%	7.45%	3.16%	DLD1	0.17%	0.46%	0.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.
C22519	30741544	DIS0115	NP2960	Epigallocatechin gallate	DR9021	5-fluorouracil	NEWCL00082	HCT 116	24h: 270uM	24h: 40uM	50 uM : 5 um	NEWCL00079	DLD-1	24h: 375 uM	24h: 150 uM	50 uM : 11 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7872	MRP1	Up-regulation	HCT 116	7.25%	6.75%	6.78%	DLD1	0.14%	2.57%	1.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.
C39765	30747218	DIS0022	NP5538	Gallic acid	DR1669	Cisplatin	NEWCL00170	A-549	.	.	28uM :2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	20.35%	22.19%	10.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.
C39765	30747218	DIS0022	NP5538	Gallic acid	DR1669	Cisplatin	NEWCL00170	A-549	.	.	28uM :2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	73.97%	31.09%	88.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.
C39765	30747218	DIS0022	NP5538	Gallic acid	DR1669	Cisplatin	NEWCL00170	A-549	.	.	28uM :2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	A-549	30.49%	4.10%	78.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.
C39765	30747218	DIS0022	NP5538	Gallic acid	DR1669	Cisplatin	NEWCL00170	A-549	.	.	28uM :2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	A-549	158.05%	991.73%	1167.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.
C86266	30811726	DIS0024	NP9073	Gingerol	DR1669	Cisplatin	NEWCL00113	MGC-803	.	.	400 uM:2 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7071	Cyclin A1	Up-regulation	MGC-803	7.27%	242.44%	221.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	[6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway.
C86266	30811726	DIS0024	NP9073	[6]-Gingerol	DR1669	Cisplatin	NEWCL10086	HGC-27	.	.	300 uM:2 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HGC-27	16.53%	44.20%	66.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	[6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway.
C86266	30811726	DIS0024	NP9073	[6]-Gingerol	DR1669	Cisplatin	NEWCL10086	HGC-27	.	.	300 uM:2 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	HGC-27	17.44%	19.06%	41.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	[6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway.
C86266	30811726	DIS0024	NP9073	[6]-Gingerol	DR1669	Cisplatin	NEWCL10086	HGC-27	.	.	300 uM:2 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	p-PI3K	Down-regulation	HGC-27	34.26%	9.30%	35.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	[6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway.
C86266	30811726	DIS0024	NP9073	[6]-Gingerol	DR1669	Cisplatin	NEWCL10086	HGC-27	.	.	300 uM:2 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	Down-regulation	HGC-27	7.81%	5.18%	36.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	[6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway.
C15248	30866043	DIS0025	NP3369	Neferine	DR8244	Imatinib	NEWCL20371	BCR-ABL	63.48 uM	8uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Hsp90	Down-regulation	BCR-ABL	2.15%	4.53%	22.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	These results suggest that neferine might be a potential imatinib sensitizer in CML treatment.
C15248	30866043	DIS0025	NP3369	Neferine	DR8244	Imatinib	NEWCL20371	BCR-ABL	63.48 uM	8uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	BCR-ABL	2.23%	3.28%	55.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	These results suggest that neferine might be a potential imatinib sensitizer in CML treatment.
C50185	30889488	DIS0022	NP0031	Hesperetin	DR6969	Platinum	NEWCL00170	A-549	24h:240uM	24h:120uM	240uM:120uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Hesperetin can synergize platinum drugs by inhibiting UGT1A3 and increasing levels of reactive oxygen species (ROS).
C47697	30899398	DIS0023	NP6993	Arsenic trioxide	DR2391	Gemcitabine	NEWCL00292	PaTu 8988s	.	.	3 uM:20 uM	NEWCL00342	Panc1	.	.	3 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9685	SKP2	Down-regulation	Patu8988	2.63%	5.19%	36.15%	Panc1	26.24%	16.56%	46.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide inhibits Skp2 expression to increase chemosensitivity to gemcitabine in pancreatic cancer cells.
C47697	30899398	DIS0023	NP6993	Arsenic trioxide	DR2391	Gemcitabine	NEWCL00292	PaTu 8988s	.	.	3 uM:20 uM	NEWCL00342	Panc1	.	.	3 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P57	Up-regulation	Patu8988	84.75%	100.81%	139.16%	Panc1	17.73%	48.36%	96.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide inhibits Skp2 expression to increase chemosensitivity to gemcitabine in pancreatic cancer cells.
C47697	30899398	DIS0023	NP6993	Arsenic trioxide	DR2391	Gemcitabine	NEWCL00292	PaTu 8988s	.	.	3 uM:20 uM	NEWCL00342	Panc1	.	.	3 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	Patu8988	69.16%	111.17%	271.74%	Panc1	8.73%	50.55%	88.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide inhibits Skp2 expression to increase chemosensitivity to gemcitabine in pancreatic cancer cells.
C92813	30930425	DIS0031	NP9520	Ginsenoside Rg3	DR0141	Oxaliplatin	NEWCL00140	SMMC-7721	.	.	15 ug.ml :0.25 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	SMMC-7721	11.14%	5.70%	35.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cells treated with oxaliplatin+ ginsenoside enhanced the anti-tumor effect and may inhibit the proliferation and promoted apoptosis of hepatocellular carcinoma via regulating the expression of PCNA and cyclin D1.
C09338	30937974	DIS0025	NP4837	Costunolide	DR4469	Doxorubicin	NEWCL00048	K-562	24h:16.5 ±  1.9uM	.	15uM:10uM	NEWCL20372	K-562.ADR	24h:15.2 ±  1.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Up-regulation	K-562	103.53%	80.36%	111.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
C09338	30937974	DIS0025	NP4837	Costunolide	DR4469	Doxorubicin	NEWCL00048	K-562	24h:16.5 ±  1.9uM	.	15uM:10uM	NEWCL20372	K-562.ADR	24h:15.2 ±  1.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	K-562	2011.11%	1215.79%	16994.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
C09338	30937974	DIS0025	NP4837	Costunolide	DR4469	Doxorubicin	NEWCL00048	K-562	24h:16.5 ±  1.9uM	.	15uM:10uM	NEWCL20372	K-562.ADR	24h:15.2 ±  1.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	K-562	17344.44%	886.84%	15117.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
C09338	30937974	DIS0025	NP4837	Costunolide	DR4469	Doxorubicin	NEWCL00048	K-562	24h:16.5 ±  1.9uM	.	15uM:10uM	NEWCL20372	K-562.ADR	24h:15.2 ±  1.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Down-regulation	K-562	6.72%	9.65%	13.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
C09338	30937974	DIS0025	NP4837	Costunolide	DR4469	Doxorubicin	NEWCL00048	K-562	24h:16.5 ±  1.9uM	.	15uM:10uM	NEWCL20372	K-562.ADR	24h:15.2 ±  1.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	K-562	24.18%	6.88%	71.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
C09338	30937974	DIS0025	NP4837	Costunolide	DR4469	Doxorubicin	NEWCL00048	K-562	24h:16.5 ±  1.9uM	.	15uM:10uM	NEWCL20372	K-562.ADR	24h:15.2 ±  1.3uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	P-PI3K	Down-regulation	K-562	61.80%	36.73%	69.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
C09338	30937974	DIS0025	NP4837	Costunolide	DR4469	Doxorubicin	NEWCL00048	K-562	24h:16.5 ±  1.9uM	.	15uM:10uM	NEWCL20372	K-562.ADR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	Bad	Up-regulation	K-562	37.65%	39.19%	63.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
C09338	30937974	DIS0025	NP4837	Costunolide	DR4469	Doxorubicin	NEWCL00048	K-562	24h:16.5 ±  1.9uM	.	15uM:10uM	NEWCL20372	K-562.ADR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	K-562	129.73%	36.70%	1671.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
C09338	30937974	DIS0025	NP4837	Costunolide	DR4469	Doxorubicin	NEWCL00048	K-562	24h:16.5 ±  1.9uM	.	15uM:10uM	NEWCL20372	K-562.ADR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	K-562	677.69%	23.23%	816.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
C26107	30945389	DIS0021	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	20 ug.ml:2 ug.ml	NEWCL00155	MCF-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MCF-7	8.04%	1.72%	43.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tan IIA enhanced the chemotherapeutic effect of Dox against breast cancer while reducing its toxic side effects including weight loss, myelosuppression, cardiotoxicity, and nephrotoxicity."
C26107	30945389	DIS0021	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	20 ug.ml:2 ug.ml	NEWCL00155	MCF-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Down-regulation	MCF-7	0.14%	0.53%	46.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tan IIA enhanced the chemotherapeutic effect of Dox against breast cancer while reducing its toxic side effects including weight loss, myelosuppression, cardiotoxicity, and nephrotoxicity."
C26107	30945389	DIS0021	NP1965	Tanshinone IIA	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	20 ug.ml:2 ug.ml	NEWCL00155	MCF-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7872	MRP1	Down-regulation	MCF-7	5.58%	4.79%	38.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Tan IIA enhanced the chemotherapeutic effect of Dox against breast cancer while reducing its toxic side effects including weight loss, myelosuppression, cardiotoxicity, and nephrotoxicity."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-CDC2	Up-regulation	NCI-H1975	7.12%	3.53%	3.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	NCI-H1975	41.87%	60.34%	70.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	NCI-H1975	24.74%	46.33%	79.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Down-regulation	NCI-H1975	80.09%	95.00%	98.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	NCI-H1975	3.07%	5.27%	42.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	NCI-H1975	10.81%	5.42%	66.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	NCI-H1975	29.65%	42.03%	61.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7878	PDK1	Down-regulation	NCI-H1975	63.16%	68.93%	79.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MCT1	Down-regulation	NCI-H1975	23.86%	57.55%	54.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Glut4	Down-regulation	NCI-H1975	54.26%	66.70%	71.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Glut3	Down-regulation	NCI-H1975	35.61%	80.70%	84.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Glut1	Down-regulation	NCI-H1975	3.86%	6.58%	41.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1735	LDHA	.	NCI-H1975	0.81%	1.39%	1.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	p-EGFR	Down-regulation	NCI-H1975	47.58%	63.71%	69.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5267	Kras	Down-regulation	NCI-H1975	43.52%	60.78%	58.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	NCI-H1975	12.52%	22.71%	64.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1629	HIF-1a	Down-regulation	NCI-H1975	49.01%	57.26%	57.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p-AMPKa	Down-regulation	NCI-H1975	0.69%	5.01%	8.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C17243	30967777	DIS0022	NP4620	Apigenin	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	24h; 40 uM:40uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	p62	Up-regulation	NCI-H1975	0.15%	2.04%	2.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."
C49580	30987009	DIS0115	NP1559	Luteolin	DR0141	Oxaliplatin	NEWCL00082	HCT 116	.	.	5.25 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	HCT 116	242.11%	467.17%	914.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
C49580	30987009	DIS0115	NP1559	Luteolin	DR0141	Oxaliplatin	NEWCL00082	HCT 116	.	.	5.25 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	HCT 116	85.93%	613.15%	222.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
C49580	30987009	DIS0115	NP1559	Luteolin	DR0141	Oxaliplatin	NEWCL00082	HCT 116	.	.	5.25 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HCT 116	900.69%	25.55%	597.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
C10156	30991098	DIS0029	NP1644	Vincristine	DR2889	Tolfemic acid	NEWCL00289	DAOY	48h:4.3 ng.mL	48h:14.06 ug.mL	2 ng.mL:10 ug.mL	NEWCL10091	D283 Med	48h:12.06 ng.mL	48h:13.72 ug.mL	2 ng.mL:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	DAOY	64.10%	0.49%	89.35%	D283	477.24%	453.50%	1700.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.
C10156	30991098	DIS0029	NP1644	Vincristine	DR2889	Tolfemic acid	NEWCL00289	DAOY	48h:4.3 ng.mL	48h:14.06 ug.mL	2 ng.mL:10 ug.mL	NEWCL10091	D283 Med	48h:12.06 ng.mL	48h:13.72 ug.mL	2 ng.mL:10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Up-regulation	DAOY	517.54%	3.35%	366.40%	D283	212.56%	83.21%	153.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.
C42706	31003140	DIS0021	NP3147	Methylglyoxal	DR9021	5-fluorouracil	NEWCL00155	MCF-7	24h: 0.84 mM	24h: 22 uM	0.5mM:2uM	NEWCL00170	A-549	24h:1.1 mM	24h:51 uM	.	NEWCL00341	WI-38	24h: 3.8 mM	24h: 85 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Up-regulation	MCF-7	16.26%	51.05%	11.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MG could be a potential candidate for combination therapy to reduce the toxicity burden of 5-FU without any toxic impact on host cells.
C42706	31003140	DIS0021	NP3147	Methylglyoxal	DR9021	5-fluorouracil	NEWCL00155	MCF-7	24h: 0.84 mM	24h: 22 uM	0.5mM:2uM	NEWCL00170	A-549	24h:1.1 mM	24h:51 uM	.	NEWCL00341	WI-38	24h: 3.8 mM	24h: 85 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MCF-7	80.89%	111.81%	247.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MG could be a potential candidate for combination therapy to reduce the toxicity burden of 5-FU without any toxic impact on host cells.
C42706	31003140	DIS0021	NP3147	Methylglyoxal	DR9021	5-fluorouracil	NEWCL00155	MCF-7	24h: 0.84 mM	24h: 22 uM	0.5mM:2uM	NEWCL00170	A-549	24h:1.1 mM	24h:51 uM	.	NEWCL00341	WI-38	24h: 3.8 mM	24h: 85 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MCF-7	231.76%	169.21%	359.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MG could be a potential candidate for combination therapy to reduce the toxicity burden of 5-FU without any toxic impact on host cells.
C42706	31003140	DIS0021	NP3147	Methylglyoxal	DR9021	5-fluorouracil	NEWCL00155	MCF-7	24h: 0.84 mM	24h: 22 uM	0.5mM:2uM	NEWCL00170	A-549	24h:1.1 mM	24h:51 uM	.	NEWCL00341	WI-38	24h: 3.8 mM	24h: 85 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Up-regulation	MCF-7	17.15%	29.51%	33.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MG could be a potential candidate for combination therapy to reduce the toxicity burden of 5-FU without any toxic impact on host cells.
C42706	31003140	DIS0021	NP3147	Methylglyoxal	DR9021	5-fluorouracil	NEWCL00155	MCF-7	24h: 0.84 mM	24h: 22 uM	0.5mM:2uM	NEWCL00170	A-549	24h:1.1 mM	24h:51 uM	.	NEWCL00341	WI-38	24h: 3.8 mM	24h: 85 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	MCF-7	14.10%	29.60%	13.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MG could be a potential candidate for combination therapy to reduce the toxicity burden of 5-FU without any toxic impact on host cells.
C42706	31003140	DIS0021	NP3147	Methylglyoxal	DR9021	5-fluorouracil	NEWCL00155	MCF-7	24h: 0.84 mM	24h: 22 uM	0.5mM:2uM	NEWCL00170	A-549	24h:1.1 mM	24h:51 uM	.	NEWCL00341	WI-38	24h: 3.8 mM	24h: 85 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	MCF-7	15.55%	37.97%	3.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MG could be a potential candidate for combination therapy to reduce the toxicity burden of 5-FU without any toxic impact on host cells.
C08577	31013600	DIS0127	NP2960	Epigallocatechin gallate	DR6122	Enoxacin	NEWCL00149	HeLa	.	.	265 uM:50 uM	NEWCL00058	C-33 A	.	.	270 uM:45 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HeLa	28.29%	322.07%	448.29%	C33A	3.94%	72.06%	542.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG functions synergistically against cancer cell proliferation in combined treatment with enoxacin.
C08577	31013600	DIS0127	NP2960	Epigallocatechin gallate	DR6122	Enoxacin	NEWCL00149	HeLa	.	.	265 uM:50 uM	NEWCL00058	C-33 A	.	.	270 uM:45 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	HeLa	18.54%	397.76%	311.57%	C33A	6.98%	125.76%	404.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG functions synergistically against cancer cell proliferation in combined treatment with enoxacin.
C08577	31013600	DIS0127	NP2960	Epigallocatechin gallate	DR6122	Enoxacin	NEWCL00149	HeLa	.	.	265 uM:50 uM	NEWCL00058	C-33 A	.	.	270 uM:45 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	HeLa	9.38%	7.99%	101.22%	C33A	0.83%	4.85%	72.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG functions synergistically against cancer cell proliferation in combined treatment with enoxacin.
C08577	31013600	DIS0127	NP2960	Epigallocatechin gallate	DR6122	Enoxacin	NEWCL00149	HeLa	.	.	265 uM:50 uM	NEWCL00058	C-33 A	.	.	270 uM:45 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HeLa	18.01%	46.00%	75.66%	C33A	0.57%	0.19%	47.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EGCG functions synergistically against cancer cell proliferation in combined treatment with enoxacin.
C16256	31015105	DIS0115	NP4620	Apigenin	DR9021	5-fluorouracil	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of 5-FU and apigenin had a greater effect than each of 5-FU or apigenin alone against solid Ehrlich carcinoma in mice.
C88733	31018249	DIS0115	NP8606	Fisetin	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	90uM:50 uM; 48h	NEWCL00082	HCT 116	.	.	90uM:50 uM; 48h	NEWCL00344	HT29	.	.	90uM:50 uM; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	PI3K	.	HCT116	0.27%	17.69%	87.29%	HT29	1.52%	73.32%	75.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."
C88733	31018249	DIS0115	NP8606	Fisetin	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	90uM:50 uM; 48h	NEWCL00082	HCT 116	.	.	90uM:50 uM; 48h	NEWCL00344	HT29	.	.	90uM:50 uM; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT(Ser473)	.	HCT116	7.07%	74.14%	48.84%	HT29	28.30%	8.31%	90.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."
C88733	31018249	DIS0115	NP8606	Fisetin	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	90uM:50 uM; 48h	NEWCL00082	HCT 116	.	.	90uM:50 uM; 48h	NEWCL00344	HT29	.	.	90uM:50 uM; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7832	P-4EBP1	.	HCT116	12.47%	41.94%	51.66%	HT29	20.05%	6.10%	42.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."
C88733	31018249	DIS0115	NP8606	Fisetin	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	90uM:50 uM; 48h	NEWCL00082	HCT 116	.	.	90uM:50 uM; 48h	NEWCL00344	HT29	.	.	90uM:50 uM; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7834	p-elF4E	.	HCT116	3.84%	70.26%	82.08%	HT29	0.02%	4.41%	51.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."
C88733	31018249	DIS0115	NP8606	Fisetin	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	90uM:50 uM; 48h	NEWCL00082	HCT 116	.	.	90uM:50 uM; 48h	NEWCL00344	HT29	.	.	90uM:50 uM; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	p-p70s6k	.	HCT116	5.18%	48.15%	83.76%	HT29	4.62%	45.08%	64.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."
C88733	31018249	DIS0115	NP8606	Fisetin	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	90uM:50 uM; 48h	NEWCL00082	HCT 116	.	.	90uM:50 uM; 48h	NEWCL00344	HT29	.	.	90uM:50 uM; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Rictor	.	HCT116	1.58%	53.29%	86.24%	HT29	5.13%	56.92%	41.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."
C88733	31018249	DIS0115	NP8606	Fisetin	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	90uM:50 uM; 48h	NEWCL00082	HCT 116	.	.	90uM:50 uM; 48h	NEWCL00344	HT29	.	.	90uM:50 uM; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	RAPTOR	.	HCT116	1.21%	31.68%	79.64%	HT29	9.64%	17.58%	78.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."
C88733	31018249	DIS0115	NP8606	Fisetin	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	90uM:50 uM; 48h	NEWCL00082	HCT 116	.	.	90uM:50 uM; 48h	NEWCL00344	HT29	.	.	90uM:50 uM; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GBL	.	HCT116	12.90%	80.34%	75.30%	HT29	61.91%	22.60%	88.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."
C88733	31018249	DIS0115	NP8606	Fisetin	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	90uM:50 uM; 48h	NEWCL00082	HCT 116	.	.	90uM:50 uM; 48h	NEWCL00344	HT29	.	.	90uM:50 uM; 48h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."
C73865	31030489	DIS0021	NP6308	Thymoquinone	DR2176	Cyclophosphamide	NEWCL00052	SK-BR-3	48h:24mM	.	20 uM:0.5mM	NEWCL00049	MDA-MB-231	48h:22.5mM	.	20 uM:0.5mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PEA3	Up-regulation	Her2+	1.32%	1065.60%	518.75%	Her2-	2.18%	12.20%	3.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TQ can broadly augment the effect of cyclo in breast cancer cases irrespective of Her-2+ or Her-.
C73865	31030489	DIS0021	NP6308	Thymoquinone	DR2176	Cyclophosphamide	NEWCL00052	SK-BR-3	48h:24mM	.	20 uM:0.5mM	NEWCL00049	MDA-MB-231	48h:22.5mM	.	20 uM:0.5mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	Her2+	.	.	.	Her2-	62.00%	19.04%	73.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TQ can broadly augment the effect of cyclo in breast cancer cases irrespective of Her-2+ or Her-.
C73865	31030489	DIS0021	NP6308	Thymoquinone	DR2176	Cyclophosphamide	NEWCL00052	SK-BR-3	48h:24mM	.	20 uM:0.5mM	NEWCL00049	MDA-MB-231	48h:22.5mM	.	20 uM:0.5mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Down-regulation	Her2+	69.34%	11.54%	83.30%	Her2-	21.28%	1.99%	71.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TQ can broadly augment the effect of cyclo in breast cancer cases irrespective of Her-2+ or Her-.
C73865	31030489	DIS0021	NP6308	Thymoquinone	DR2176	Cyclophosphamide	NEWCL00052	SK-BR-3	48h:24mM	.	20 uM:0.5mM	NEWCL00049	MDA-MB-231	48h:22.5mM	.	20 uM:0.5mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	Her2+	32.28%	1.82%	186.13%	Her2-	181.95%	77.85%	1316.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TQ can broadly augment the effect of cyclo in breast cancer cases irrespective of Her-2+ or Her-.
C58717	31037974	DIS0129	NP0395	Nobiletin	DR2073	Sorafenib	NEWCL00253	PC-3	.	.	20 uM:2.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PC-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"NOB and SOR combination was more effective than SOR and NOB alone and reduced the exposure time for SOR and NOB in PC-3 cells. NOB and SOR combination significantly caused much more apoptotic cell death and cell cycle arrest at G0/G1 phase by up-regulation of Bax, Rb1, and CDKN1A levels in PC-3 cells."
C69357	31056260	DIS0127	NP5732	Osthole	DR1669	Cisplatin	NEWCL20383	SiHa.CDDP	.	.	40uM:2uM	NEWCL20390	CaSki.CDDP 	.	.	40uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SiHa.CDDP	0.05%	9.93%	132.74%	CaSki.CDDP	0.95%	0.50%	57.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C69357	31056260	DIS0127	NP5732	Osthole	DR1669	Cisplatin	NEWCL20383	SiHa.CDDP	.	.	40uM:2uM	NEWCL20390	CaSki.CDDP 	.	.	40uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	PI3K	Down-regulation	SiHa.CDDP	0.60%	3.68%	23.37%	CaSki.CDDP	0.60%	8.20%	37.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C69357	31056260	DIS0127	NP5732	Osthole	DR1669	Cisplatin	NEWCL20383	SiHa.CDDP	.	.	40uM:2uM	NEWCL20390	CaSki.CDDP 	.	.	40uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	SiHa.CDDP	0.74%	1.29%	58.62%	CaSki.CDDP	6.39%	7.80%	25.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C95085	31102118	DIS0024	NP0445	Cardamonin	DR9021	5-fluorouracil	NEWCL00145	BGC-823	.	72h:5.755uM	20uM:20uM	NEWCL20384	BGC-823.5-FU	72h:139.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Down-regulation	.	.	.	.	BGC-823.5-FU	2.87%	42.43%	53.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/beta-catenin signal pathway.
C95085	31102118	DIS0024	NP0445	Cardamonin	DR9021	5-fluorouracil	NEWCL00145	BGC-823	.	72h:5.755uM	20uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TCF4	Down-regulation	.	.	.	.	BGC-823.5-FU	0.73%	2.81%	3.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/beta-catenin signal pathway.
C95085	31102118	DIS0024	NP0445	Cardamonin	DR9021	5-fluorouracil	NEWCL00145	BGC-823	.	72h:5.755uM	20uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Beta-Catenin	Down-regulation	.	.	.	.	BGC-823.5-FU	13.00%	13.26%	22.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Cardamonin reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/beta-catenin signal pathway.
C76221	31105818	DIS0098	NP0790	Saikosaponin D	DR5051	SP600125	NEWCL00227	U2OS	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	U-2OS	1.15%	27.96%	71.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."
C76221	31105818	DIS0098	NP0790	Saikosaponin D	DR5051	SP600125	NEWCL00227	U2OS	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	U-2OS	4.08%	51.82%	64.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."
C76221	31105818	DIS0098	NP0790	Saikosaponin D	DR5051	SP600125	NEWCL00227	U2OS	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	U-2OS	58.69%	4.19%	60.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."
C76221	31105818	DIS0098	NP0790	Saikosaponin D	DR5051	SP600125	NEWCL00227	U2OS	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-Erk1.2	Down-regulation	U-2OS	1.62%	28.57%	53.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."
C76221	31105818	DIS0098	NP0790	Saikosaponin D	DR5051	SP600125	NEWCL00227	U2OS	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U-2OS	3.96%	0.35%	33.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."
C76221	31105818	DIS0098	NP0790	Saikosaponin D	DR5051	SP600125	NEWCL00227	U2OS	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome C	Up-regulation	U-2OS	72.92%	4.03%	83.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."
C76221	31105818	DIS0098	NP0790	Saikosaponin D	DR5051	SP600125	NEWCL00227	U2OS	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	U-2OS	12.09%	31.67%	62.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."
C76221	31105818	DIS0098	NP0790	Saikosaponin D	DR5051	SP600125	NEWCL00227	U2OS	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	U-2OS	1.80%	2.60%	45.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."
C76221	31105818	DIS0098	NP0790	Saikosaponin D	DR5051	SP600125	NEWCL00227	U2OS	.	.	20 uM:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	U-2OS	29.73%	39.18%	40.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."
C23318	31160978	DIS0022	NP6740	Capsaicin	DR8028	Erlotinib	NEWCL00170	A-549	.	.	25 uM:5 uM	NEWCL00171	NCI-H1975	.	.	25 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-549	11.87%	1.02%	69.93%	NCI-H1975	22.82%	39.60%	72.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Capsaicin enhances erlotinib-induced cytotoxicity via AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cells.
C23318	31160978	DIS0022	NP6740	Capsaicin	DR8028	Erlotinib	NEWCL00170	A-549	.	.	25 uM:5 uM	NEWCL00171	NCI-H1975	.	.	25 uM:5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-549	2.89%	25.30%	74.96%	NCI-H1975	19.10%	34.42%	65.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Capsaicin enhances erlotinib-induced cytotoxicity via AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cells.
C79321	31178149	DIS0126	NP6047	Metformin	DR2980	Simvastatin	NEWCL10342	RL95-2	.	.	4nM:1uM	NEWCL10338	HEC-1-B	.	.	4nM:4uM	NEWCL20447	Ishikawa endometrial cancer cell lines	.	.	8nM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	RL95-2	4.51%	36.08%	64.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells."
C79321	31178149	DIS0126	NP6047	Metformin	DR2980	Simvastatin	NEWCL10342	RL95-2	.	.	4nM:1uM	NEWCL10338	HEC-1-B	.	.	4nM:4uM	NEWCL20447	Ishikawa endometrial cancer cell lines	.	.	8nM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim-EL	Up-regulation	RL95-2	3.76%	11.77%	25.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells."
C79321	31178149	DIS0126	NP6047	Metformin	DR2980	Simvastatin	NEWCL10342	RL95-2	.	.	4nM:1uM	NEWCL10338	HEC-1-B	.	.	4nM:4uM	NEWCL20447	Ishikawa endometrial cancer cell lines	.	.	8nM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim-L	Up-regulation	RL95-2	3.69%	65.51%	101.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells."
C79321	31178149	DIS0126	NP6047	Metformin	DR2980	Simvastatin	NEWCL10342	RL95-2	.	.	4nM:1uM	NEWCL10338	HEC-1-B	.	.	4nM:4uM	NEWCL20447	Ishikawa endometrial cancer cell lines	.	.	8nM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim-S	Up-regulation	RL95-2	9.72%	110.21%	87.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells."
C79321	31178149	DIS0126	NP6047	Metformin	DR2980	Simvastatin	NEWCL10342	RL95-2	.	.	4nM:1uM	NEWCL10338	HEC-1-B	.	.	4nM:4uM	NEWCL20447	Ishikawa endometrial cancer cell lines	.	.	8nM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-AMPK	Up-regulation	RL95-2	71.50%	79.83%	152.85%	HEC-1B	39.25%	21.86%	243.73%	Ishikawa	60.11%	28.49%	361.81%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells."
C79321	31178149	DIS0126	NP6047	Metformin	DR2980	Simvastatin	NEWCL10342	RL95-2	.	.	4nM:1uM	NEWCL10338	HEC-1-B	.	.	4nM:4uM	NEWCL20447	Ishikawa endometrial cancer cell lines	.	.	8nM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-S6	Down-regulation	RL95-2	41.44%	8.07%	45.04%	HEC-1B	47.64%	8.08%	55.47%	Ishikawa	84.09%	9.20%	66.41%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells."
C79321	31178149	DIS0126	NP6047	Metformin	DR2980	Simvastatin	NEWCL10342	RL95-2	.	.	4nM:1uM	NEWCL10338	HEC-1-B	.	.	4nM:4uM	NEWCL20447	Ishikawa endometrial cancer cell lines	.	.	8nM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	RL95-2	12.27%	19.42%	8.64%	HEC-1B	60.72%	71.57%	33.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells."
C79321	31178149	DIS0126	NP6047	Metformin	DR2980	Simvastatin	NEWCL10342	RL95-2	.	.	4nM:1uM	NEWCL10338	HEC-1-B	.	.	4nM:4uM	NEWCL20447	Ishikawa endometrial cancer cell lines	.	.	8nM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2700	ERK	Down-regulation	RL95-2	0.43%	5.45%	7.65%	HEC-1B	14.88%	28.21%	2.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells."
C80215	31180555	DIS0115	NP4440	Kaempferol	DR9021	5-fluorouracil	NEWCL10146	HCT8	350 uM	177.78 uM	100 uM: 50 uM	NEWCL00082	HCT 116	184.33 uM	77.63 uM	100 uM: 50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT8	37.00%	13.20%	469.04%	HCT116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol has a synergistic effect with 5-FU by inhibiting cell proliferation and inducing apoptosis in colorectal cancer cells via suppression of TS or attenuation of p-Akt activation.
C80215	31180555	DIS0115	NP4440	Kaempferol	DR9021	5-fluorouracil	NEWCL10146	HCT8	350 uM	177.78 uM	100 uM: 50 uM	NEWCL00082	HCT 116	184.33 uM	77.63 uM	100 uM: 50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT8	34.36%	39.16%	57.68%	HCT116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol has a synergistic effect with 5-FU by inhibiting cell proliferation and inducing apoptosis in colorectal cancer cells via suppression of TS or attenuation of p-Akt activation.
C80215	31180555	DIS0115	NP4440	Kaempferol	DR9021	5-fluorouracil	NEWCL10146	HCT8	24h:350 uM	24h:177.78uM	100uM:50 uM	NEWCL00082	HCT 116	24h:184.33 uM	24h:77.63uM	100uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT-8	42.28%	39.55%	189.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol has a synergistic effect with 5-FU by inhibiting cell proliferation and inducing apoptosis in colorectal cancer cells via suppression of TS or attenuation of p-Akt activation.
C80215	31180555	DIS0115	NP4440	Kaempferol	DR9021	5-fluorouracil	NEWCL10146	HCT8	24h:350 uM	24h:177.78uM	100uM:50 uM	NEWCL00082	HCT 116	24h:184.33 uM	24h:77.63uM	100uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	HCT-8	2.08%	4.30%	80.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol has a synergistic effect with 5-FU by inhibiting cell proliferation and inducing apoptosis in colorectal cancer cells via suppression of TS or attenuation of p-Akt activation.
C80215	31180555	DIS0115	NP4440	Kaempferol	DR9021	5-fluorouracil	NEWCL10146	HCT8	24h:350 uM	24h:177.78uM	100uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT-8	32.95%	18.45%	61.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol has a synergistic effect with 5-FU by inhibiting cell proliferation and inducing apoptosis in colorectal cancer cells via suppression of TS or attenuation of p-Akt activation.
C80215	31180555	DIS0115	NP4440	Kaempferol	DR9021	5-fluorouracil	NEWCL10146	HCT8	24h:350 uM	24h:177.78uM	100uM:50 uM	NEWCL00082	HCT 116	24h:184.33 uM	24h:77.63uM	100uM:50 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT-8	12.14%	23.71%	67.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Kaempferol has a synergistic effect with 5-FU by inhibiting cell proliferation and inducing apoptosis in colorectal cancer cells via suppression of TS or attenuation of p-Akt activation.
C75746	31190888	DIS0115	NP6905	Curcumin	DR0141	Oxaliplatin	NEWCL20379	HCT 116.OXA	.	48h:20.5± 1.96 uM	8uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HCT 116.OXA	1.83%	58.86%	94.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway.
C75746	31190888	DIS0115	NP6905	Curcumin	DR0141	Oxaliplatin	NEWCL20379	HCT 116.OXA	.	48h:20.5± 1.96 uM	8uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	P-P65	Down-regulation	HCT 116.OXA	1.59%	0.13%	10.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway.
C75746	31190888	DIS0115	NP6905	Curcumin	DR0141	Oxaliplatin	NEWCL20379	HCT 116.OXA	.	48h:20.5± 1.96 uM	8uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HCT 116.OXA	2.63%	1.42%	57.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway.
C75746	31190888	DIS0115	NP6905	Curcumin	DR0141	Oxaliplatin	NEWCL20379	HCT 116.OXA	.	48h:20.5± 1.96 uM	8uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7709	P-Smad2	Down-regulation	HCT 116.OXA	15.88%	0.82%	20.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway.
C75746	31190888	DIS0115	NP6905	Curcumin	DR0141	Oxaliplatin	NEWCL20379	HCT 116.OXA	.	48h:20.5± 1.96 uM	8uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2407	P-Smad3	Down-regulation	HCT 116.OXA	60.79%	8.36%	43.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway.
C75746	31190888	DIS0115	NP6905	Curcumin	DR0141	Oxaliplatin	NEWCL20379	HCT 116.OXA	.	48h:20.5± 1.96 uM	8uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	HCT 116.OXA	29.87%	2.59%	63.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway.
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Sp1	Down-regulation	H157	9.81%	1.90%	38.29%	H1299	13.04%	8.81%	17.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Sp3	Down-regulation	H157	25.10%	0.72%	41.42%	H1299	6.27%	11.52%	12.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	H157	20.38%	7.55%	18.98%	H1299	4.99%	8.23%	10.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	H157	4.75%	0.63%	13.36%	H1299	13.41%	7.36%	22.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	H157	6.34%	0.39%	13.37%	H1299	12.43%	15.60%	23.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	H157	11.81%	2.43%	14.94%	H1299	2.67%	12.20%	12.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Down-regulation	H157	0.78%	2.30%	10.26%	H1299	25.96%	1.07%	17.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Down-regulation	H157	0.94%	0.08%	9.02%	H1299	13.36%	3.96%	20.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-p70S6K	Down-regulation	H157	3.75%	1.65%	22.78%	H1299	2.02%	1.17%	19.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B II	Up-regulation	H157	350.42%	146.61%	419.84%	H1299	364.79%	206.90%	368.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9491	SQSTM1	Down-regulation	H157	4.40%	0.43%	19.31%	H1299	3.53%	0.01%	8.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7891	Beclin-1	Up-regulation	H157	2.38%	4.72%	9.94%	H1299	3.50%	2.10%	3.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	H157	191.86%	0.14%	295.62%	H1299	252.47%	1.63%	279.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C36886	31196210	DIS0022	NP6905	Curcumin	DR9742	Gefitinib	NEWCL00345	H157	.	.	10uM:5uM	NEWCL00181	NCI-H1299	.	.	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Down-regulation	H157	238.77%	0.67%	295.45%	H1299	214.64%	2.40%	246.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."
C28471	31278946	DIS0037	NP6308	Thymoquinone	DR4469	Doxorubicin	NEWCL00065	Jurkat	.	48h:50nM	10uM:50nM	NEWCL00209	HuT 102	.	48h:100nM	40uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53	Up-regulation	Jurkat	2010.08%	97.22%	1960.55%	HuT-102	2568.37%	48.47%	1580.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms.
C58722	31281953	DIS0029	NP8797	Celastrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	1.216uM 	.	0.5 uM :100ng.mL	NEWCL00039	U-251MG	2.219uM 	.	0.5 uM :100ng.mL	NEWCL00122	LN-229	4.576uM 	.	0.5 uM :100ng.mL	NEWCL20456	HEB	2.188uM 	.	0.5 uM :100ng.mL	.	HEB	2.188uM 	.	0.5 uM :100ng.mL	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	U-87MG ATCCMG	33.78%	376.80%	341.24%	U251	.	.	.	LN-229	.	.	.	HEB	.	.	.	HEB	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL-induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species.
C58722	31281953	DIS0029	NP8797	Celastrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	1.216uM 	.	0.5 uM :100ng.mL	NEWCL00039	U-251MG	2.219uM 	.	0.5 uM :100ng.mL	NEWCL00122	LN-229	4.576uM 	.	0.5 uM :100ng.mL	NEWCL20456	HEB	2.188uM 	.	0.5 uM :100ng.mL	.	HEB	2.188uM 	.	0.5 uM :100ng.mL	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U-87MG ATCCMG	29.85%	356.75%	196.14%	U251	.	.	.	LN-229	.	.	.	HEB	.	.	.	HEB	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL-induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species.
C58722	31281953	DIS0029	NP8797	Celastrol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00279	U-87MG ATCC	1.216uM 	.	0.5 uM :100ng.mL	NEWCL00039	U-251MG	2.219uM 	.	0.5 uM :100ng.mL	NEWCL00122	LN-229	4.576uM 	.	0.5 uM :100ng.mL	NEWCL20456	HEB	2.188uM 	.	0.5 uM :100ng.mL	.	HEB	2.188uM 	.	0.5 uM :100ng.mL	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	U-87MG ATCCMG	38.68%	85.05%	447.34%	U251	.	.	.	LN-229	.	.	.	HEB	.	.	.	HEB	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL-induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species.
C43311	31301315	DIS0022	NP9654	Bufalin	DR6823	Osimertinib	NEWCL00175	PC-9	.	.	.	NEWCL00172	HCC827	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	PC-9	1.24%	31.40%	31.51%	HCC827	2.12%	23.50%	23.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer.
C93193	31319879	DIS0124	NP1844	Berberine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	99 ±  1.58 uM	 13.23 ±  2.83 uM	500 umol.L:5 mg.L	NEWCL20394	POCCLs	.	.	500 umol.L:5 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8199	KI67	Down-regulation	OVCAR3	2.73%	11.02%	29.00%	POCCLs	3.62%	18.05%	23.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination therapy of BBR and DDP markedly enhanced more ovarian cancer cell death by inducing apoptosis and necroptosis, which may improve the anticancer effect of chemotherapy drugs. The apoptosis involved the caspase-dependent pathway, while the necroptosis involved the activation of the RIPK3-MLKL pathway."
C93193	31319879	DIS0124	NP1844	Berberine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	99 ±  1.58 uM	 13.23 ±  2.83 uM	500 umol.L:5 mg.L	NEWCL20394	POCCLs 	.	.	500 umol.L:5 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Down-regulation	OVCAR3	20.67%	35.44%	43.81%	POCCLs	16.93%	24.49%	38.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination therapy of BBR and DDP markedly enhanced more ovarian cancer cell death by inducing apoptosis and necroptosis, which may improve the anticancer effect of chemotherapy drugs. The apoptosis involved the caspase-dependent pathway, while the necroptosis involved the activation of the RIPK3-MLKL pathway."
C93193	31319879	DIS0124	NP1844	Berberine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	99 ±  1.58 uM	 13.23 ±  2.83 uM	500 umol.L:5 mg.L	NEWCL20394	POCCLs 	.	.	500 umol.L:5 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	OVCAR3	1.87%	9.58%	6.06%	POCCLs	19.15%	28.89%	42.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination therapy of BBR and DDP markedly enhanced more ovarian cancer cell death by inducing apoptosis and necroptosis, which may improve the anticancer effect of chemotherapy drugs. The apoptosis involved the caspase-dependent pathway, while the necroptosis involved the activation of the RIPK3-MLKL pathway."
C93193	31319879	DIS0124	NP1844	Berberine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	99 ±  1.58 uM	 13.23 ±  2.83 uM	500 umol.L:5 mg.L	NEWCL20394	POCCLs 	.	.	500 umol.L:5 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	OVCAR3	8.50%	39.25%	53.30%	POCCLs	5.12%	14.85%	40.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination therapy of BBR and DDP markedly enhanced more ovarian cancer cell death by inducing apoptosis and necroptosis, which may improve the anticancer effect of chemotherapy drugs. The apoptosis involved the caspase-dependent pathway, while the necroptosis involved the activation of the RIPK3-MLKL pathway."
C93193	31319879	DIS0124	NP1844	Berberine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	99 ±  1.58 uM	 13.23 ±  2.83 uM	500 umol.L:5 mg.L	NEWCL20394	POCCLs 	.	.	500 umol.L:5 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	OVCAR3	42.64%	48.39%	95.74%	POCCLs	10.42%	35.80%	47.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination therapy of BBR and DDP markedly enhanced more ovarian cancer cell death by inducing apoptosis and necroptosis, which may improve the anticancer effect of chemotherapy drugs. The apoptosis involved the caspase-dependent pathway, while the necroptosis involved the activation of the RIPK3-MLKL pathway."
C93193	31319879	DIS0124	NP1844	Berberine	DR1669	Cisplatin	NEWCL00134	OVCAR-3	99 ±  1.58 uM	 13.23 ±  2.83 uM	500 umol.L:5 mg.L	NEWCL20394	POCCLs 	.	.	500 umol.L:5 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6762	P-MLKL	Up-regulation	OVCAR3	30.13%	48.72%	65.62%	POCCLs	40.25%	84.33%	173.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination therapy of BBR and DDP markedly enhanced more ovarian cancer cell death by inducing apoptosis and necroptosis, which may improve the anticancer effect of chemotherapy drugs. The apoptosis involved the caspase-dependent pathway, while the necroptosis involved the activation of the RIPK3-MLKL pathway."
C23676	31367332	DIS0022	NP4620	Apigenin	DR7304	ABT-263	NEWCL00171	NCI-H1975	48h:34.09±0.29uM;	.	15 uM:2 uM	NEWCL00172	HCC827	36.31+0.58	.	15 uM:2 uM	NEWCL00200	NCI-H1650	39.72+0.77	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	.	OVCAR3	5.58%	6.38%	9.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo."
C23676	31367332	DIS0022	NP4620	Apigenin	DR7304	ABT-263	NEWCL00171	NCI-H1975	48h:34.09±0.29uM;	.	15 uM:2 uM	NEWCL00172	HCC827	36.31+0.58	.	15 uM:2 uM	NEWCL00200	NCI-H1650	39.72+0.77	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	.	OVCAR3	12.57%	9.58%	11.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo."
C23676	31367332	DIS0022	NP4620	Apigenin	DR7304	ABT-263	NEWCL00171	NCI-H1975	48h:34.09±0.29uM;	.	15 uM:2 uM	NEWCL00172	HCC827	36.31+0.58	.	15 uM:2 uM	NEWCL00200	NCI-H1650	39.72+0.77	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	.	OVCAR3	9.87%	8.64%	11.07%	POCCLs	8.05%	4.99%	6.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo."
C23676	31367332	DIS0022	NP4620	Apigenin	DR7304	ABT-263	NEWCL00171	NCI-H1975	48h:34.09±0.29uM;	.	15 uM:2 uM	NEWCL00172	HCC827	36.31+0.58	.	15 uM:2 uM	NEWCL00200	NCI-H1650	39.72+0.77	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	OVCAR3	2.31%	0.88%	27.10%	POCCLs	73.81%	11.81%	94.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo."
C23676	31367332	DIS0022	NP4620	Apigenin	DR7304	ABT-263	NEWCL00171	NCI-H1975	48h:34.09±0.29uM;	.	15 uM:2 uM	NEWCL00172	HCC827	36.31+0.58	.	15 uM:2 uM	NEWCL00200	NCI-H1650	39.72+0.77	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	.	OVCAR3	86.67%	6.61%	92.68%	POCCLs	61.33%	14.40%	92.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo."
C23676	31367332	DIS0022	NP4620	Apigenin	DR7304	ABT-263	NEWCL00171	NCI-H1975	48h:34.09±0.29uM;	.	15 uM:2 uM	NEWCL00172	HCC827	36.31+0.58	.	15 uM:2 uM	NEWCL00200	NCI-H1650	39.72+0.77	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p-ERK1.2	Down-regulation	OVCAR3	37.62%	0.67%	89.84%	POCCLs	37.25%	8.37%	75.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo."
C23676	31367332	DIS0022	NP4620	Apigenin	DR7304	ABT-263	NEWCL00171	NCI-H1975	48h:34.09±0.29uM;	.	15 uM:2 uM	NEWCL00172	HCC827	36.31+0.58	.	15 uM:2 uM	NEWCL00200	NCI-H1650	39.72+0.77	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5767	p-FOXO3a	.	OVCAR3	46.97%	1.32%	73.49%	POCCLs	17.79%	6.45%	74.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo."
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4172	P-ATM	Up-regulation	U251	6.24%	24.73%	45.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ATR	Up-regulation	U251	11.06%	42.70%	67.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-P53	Up-regulation	U251	2.65%	22.98%	40.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	U251	3.28%	15.76%	33.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-Histone	Up-regulation	U251	4.46%	23.97%	41.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	U251	17.30%	10.07%	105.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Up-regulation	U251	4.54%	10.39%	5.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Up-regulation	U251	9.06%	62.61%	69.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B	Down-regulation	U251	4.71%	8.93%	31.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cdc2	Down-regulation	U251	3.86%	6.56%	15.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	31374355	DIS0029	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00039	U-251MG	.	.	80ug.mL:0.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	U251	0.41%	2.53%	62.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C22534	31395855	DIS0115	NP0601	Piperlongumine	DR0141	Oxaliplatin	NEWCL00082	HCT 116	.	24h:18.5uM	5uM:10uM	NEWCL00080	LoVo	.	24h:21.5uM	5uM:10uM	NEWCL10018	GES-1	24h:27.6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HCT 116	0.42%	13.55%	138.92%	LoVo	94.86%	34.43%	240.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
C22534	31395855	DIS0115	NP0601	Piperlongumine	DR0141	Oxaliplatin	NEWCL00082	HCT 116	.	24h:18.5uM	5uM:10uM	NEWCL00080	LoVo	.	24h:21.5uM	5uM:10uM	NEWCL10018	GES-1	24h:27.6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AFT4	Up-regulation	HCT 116	181.19%	210.85%	635.32%	LoVo	167.65%	167.33%	261.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
C22534	31395855	DIS0115	NP0601	Piperlongumine	DR0141	Oxaliplatin	NEWCL00082	HCT 116	.	24h:18.5uM	5uM:10uM	NEWCL00080	LoVo	.	24h:21.5uM	5uM:10uM	NEWCL10018	GES-1	24h:27.6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-elF2alpha	Up-regulation	HCT 116	43.58%	9.43%	144.65%	LoVo	98.48%	8.93%	121.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
C22534	31395855	DIS0115	NP0601	Piperlongumine	DR0141	Oxaliplatin	NEWCL00082	HCT 116	.	24h:18.5uM	5uM:10uM	NEWCL00080	LoVo	.	24h:21.5uM	5uM:10uM	NEWCL10018	GES-1	24h:27.6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7897	CHOP	Up-regulation	HCT 116	216.87%	2.12%	368.32%	LoVo	102.00%	4.28%	196.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
C22534	31395855	DIS0115	NP0601	Piperlongumine	DR0141	Oxaliplatin	NEWCL00082	HCT 116	.	24h:18.5uM	5uM:10uM	NEWCL00080	LoVo	.	24h:21.5uM	5uM:10uM	NEWCL10018	GES-1	24h:27.6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT 116	24.40%	6.75%	66.69%	LoVo	61.29%	51.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
C60870	31405071	DIS0023	NP2960	Epigallocatechin gallate	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	40uM : 20nM	NEWCL00236	MIA PaCa-2	.	.	40uM : 20nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9202	P-IGFIR 	Down-regulation	Panc-1	10.41%	4.68%	14.06%	MIA PaCa-2	33.45%	19.28%	35.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EGCG synergized with gemcitabine to suppress pancreatic cancer cell growth, migration, and invasion, through modulating epithelial-mesenchymal transition markers and inhibiting Akt pathway."
C60870	31405071	DIS0023	NP2960	Epigallocatechin gallate	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	40uM : 20nM	NEWCL00236	MIA PaCa-2	.	.	40uM : 20nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	P-PI3K p85	Down-regulation	Panc-1	5.23%	4.40%	14.93%	MIA PaCa-2	36.37%	19.96%	49.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EGCG synergized with gemcitabine to suppress pancreatic cancer cell growth, migration, and invasion, through modulating epithelial-mesenchymal transition markers and inhibiting Akt pathway."
C60870	31405071	DIS0023	NP2960	Epigallocatechin gallate	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	40uM : 20nM	NEWCL00236	MIA PaCa-2	.	.	40uM : 20nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	Panc-1	24.89%	9.69%	43.47%	MIA PaCa-2	18.06%	3.63%	18.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EGCG synergized with gemcitabine to suppress pancreatic cancer cell growth, migration, and invasion, through modulating epithelial-mesenchymal transition markers and inhibiting Akt pathway."
C60870	31405071	DIS0023	NP2960	Epigallocatechin gallate	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	40uM : 20nM	NEWCL00236	MIA PaCa-2	.	.	40uM : 20nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-Cadherin	Up-regulation	Panc-1	23.11%	4.62%	16.28%	MIA PaCa-2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EGCG synergized with gemcitabine to suppress pancreatic cancer cell growth, migration, and invasion, through modulating epithelial-mesenchymal transition markers and inhibiting Akt pathway."
C60870	31405071	DIS0023	NP2960	Epigallocatechin gallate	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	40uM : 20nM	NEWCL00236	MIA PaCa-2	.	.	40uM : 20nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TCF8.ZEB1	Down-regulation	Panc-1	19.30%	18.18%	33.01%	MIA PaCa-2	2.02%	2.02%	13.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EGCG synergized with gemcitabine to suppress pancreatic cancer cell growth, migration, and invasion, through modulating epithelial-mesenchymal transition markers and inhibiting Akt pathway."
C60870	31405071	DIS0023	NP2960	Epigallocatechin gallate	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	40uM : 20nM	NEWCL00236	MIA PaCa-2	.	.	40uM : 20nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Beta-Catenin	Down-regulation	Panc-1	12.18%	5.52%	27.79%	MIA PaCa-2	3.46%	3.46%	22.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EGCG synergized with gemcitabine to suppress pancreatic cancer cell growth, migration, and invasion, through modulating epithelial-mesenchymal transition markers and inhibiting Akt pathway."
C60870	31405071	DIS0023	NP2960	Epigallocatechin gallate	DR2391	Gemcitabine	NEWCL00242	Panc-1	.	.	40uM : 20nM	NEWCL00236	MIA PaCa-2	.	.	40uM : 20nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	Panc-1	25.68%	18.64%	59.33%	MIA PaCa-2	14.72%	14.72%	33.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"EGCG synergized with gemcitabine to suppress pancreatic cancer cell growth, migration, and invasion, through modulating epithelial-mesenchymal transition markers and inhibiting Akt pathway."
C93664	31408695	DIS0021	NP4127	Daidzein	DR2080	Topotecan	NEWCL00155	MCF-7	48h:268; 73uM	48h:10.86uM	12.5uM:3; 13uM	NEWCL20354	MCF7.ADR	48h:258.19uM	48h:77.86uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MCF7	0.34%	28.41%	34.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer.
C93664	31408695	DIS0021	NP4127	Daidzein	DR2080	Topotecan	NEWCL00155	MCF-7	48h:268; 73uM	48h:10.86uM	12.5uM:3; 13uM	NEWCL20354	MCF7.ADR	48h:258.19uM	48h:77.86uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MCF7	3.63%	8.82%	0.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer.
C93664	31408695	DIS0021	NP4127	Daidzein	DR2080	Topotecan	NEWCL00155	MCF-7	48h:268; 73uM	48h:10.86uM	12.5uM:3; 13uM	NEWCL20354	MCF7.ADR	48h:258.19uM	48h:77.86uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MCF7	4.90%	27.79%	25.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer.
C49649	31423287	DIS0032	NP6905	Curcumin	DR1669	Cisplatin	NEWCL20433	HONE1 	21.9 uM	5.5 uM	2 uM:3.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis.
C14137	31434088	DIS0031	NP2960	Epigallocatechin gallate	DR7558	ONO-8711	NEWCL00129	Hep-G2	.	.	100 ug.mL:4 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Hep-G2	155.38%	155.29%	153.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	ONO-8711 significantly inhibited PGE2-induced HCC proliferation while increased the inhibitory effect of EGCG on HCC cell viability and migration ability compared with EGCG alone.
C07326	31440060	DIS0022	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL20434	16HBE	48h:33.82uM	48h:6.343uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-MEK1.2	Down-regulation	A-549	0.92%	6.03%	13.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC.
C07326	31440060	DIS0022	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL20434	16HBE	48h:33.82uM	48h:6.343uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Down-regulation	A-549	1.15%	3.89%	34.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC.
C07326	31440060	DIS0022	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL20434	16HBE	48h:33.82uM	48h:6.343uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2597	ATG5	Down-regulation	A-549	4.95%	0.99%	5.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC.
C07326	31440060	DIS0022	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL20434	16HBE	48h:33.82uM	48h:6.343uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	ATG12	Down-regulation	A-549	0.98%	4.86%	4.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC.
C07326	31440060	DIS0022	NP2960	Epigallocatechin gallate	DR9742	Gefitinib	NEWCL20434	16HBE	48h:33.82uM	48h:6.343uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Up-regulation	A-549	11.42%	4.82%	11.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC.
C27185	31440098	DIS0124	NP0016	Silibinin	DR1669	Cisplatin	NEWCL20368	A2780.DDP	.	48h:113.78uM	50uM:115uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	silibinin could restore the sensitivity of cisplatin in drug-resistant human ovarian cancer cells and reduce durg-induced hepatotoxicity in cell level.
C27185	31440098	DIS0124	NP0016	Silibinin	DR1669	Taxolu	NEWCL20368	A2780.DDP	.	48h:48.51uM	50uM:50uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	silibinin could restore the sensitivity of cisplatin in drug-resistant human ovarian cancer cells and reduce durg-induced hepatotoxicity in cell level.
C69797	31470883	DIS0124	NP3478	Eugenol	DR1669	Cisplatin	NEWCL20358	OV2774	.	.	2 uM:10uM	NEWCL00231	SK-OV-3	.	.	2 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	OV2774	80.67%	120.11%	113.62%	SKOV3	41.11%	24.55%	92.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	31470883	DIS0124	NP3478	Eugenol	DR1669	Cisplatin	NEWCL20358	OV2774	.	.	2 uM:10uM	NEWCL00231	SK-OV-3	.	.	2 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	OV2775	52.15%	156.18%	188.21%	SKOV4	13.07%	169.12%	209.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	31470883	DIS0124	NP3478	Eugenol	DR1669	Cisplatin	NEWCL20358	OV2774	.	.	2 uM:10uM	NEWCL00231	SK-OV-3	.	.	2 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Jagged1	Down-regulation	OV2777	40.72%	88.47%	94.83%	SKOV6	2.93%	34.16%	31.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C69797	31470883	DIS0124	NP3478	Eugenol	DR1669	Cisplatin	NEWCL20358	OV2774	.	.	2 uM:10uM	NEWCL00231	SK-OV-3	.	.	2 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Nicastrin	Down-regulation	OV2783	47.85%	19.36%	48.47%	SKOV12	1.28%	8.75%	36.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.
C45594	31471393	DIS0021	NP2960	Epigallocatechin gallate	DR1957	Tapentadol	NEWCL00049	MDA-MB-231	.	.	40 uM; 20 mg.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	EGCG and TAP reduced the proliferation of MDA-MB-231 cells by impairing cell-cycle progression.
C31120	31492947	DIS0021	NP3067	Paclitaxel	DR6300	Trastuzumab	NEWCL00160	BT-474	.	.	25 nM:25 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Trastuzumab and paclitaxel combination showed synergistic therapy for HER2+ breast cancer.
C11166	31519576	DIS0025	NP6905	Curcumin	DR2370	Azacitidine	NEWCL00022	HL-60	.	.	10 uM:1 uM	NEWCL00019	U-937	.	.	10 uM:1 uM	NEWCL00048	K-562	.	.	10 uM:1 uM	NEWCL00021	OCI-AML-3	.	.	10 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	HL-60	.	.	.	U-937	.	.	.	K-562	.	.	.	OCI-AML3	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Combination of Azacitidine and curcumin showed a synergy in all leukemic lines and in most leukemic samples, with a decrease in proliferation and an increase in apoptosis compared to the activity of each drug separately. Azacitidine plus curcumin showed low cytotoxicity in healthy samples."
C10758	31538075	DIS0127	NP9279	Genistein	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	6 uM: 10 uM	NEWCL00139	Ca Ski	.	.	8uM: 10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo.
C23313	31564411	DIS0114	NP6882	Arctigenin	DR1669	Cisplatin	NEWCL00074	SW480	.	.	100 uM :20 mg.L	NEWCL00076	SW620	.	.	100 uM :20 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3I	Down-regulation	SW480	7.56%	3.73%	11.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arctigenin has a therapeutic potential in combination with chemotherapeutic agents for NSLC.
C23313	31564411	DIS0114	NP6882	Arctigenin	DR1669	Cisplatin	NEWCL00074	SW480	.	.	100 uM :20 mg.L	NEWCL00076	SW620	.	.	100 uM :20 mg.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7854	p65	Up-regulation	SW480	7.09%	10.64%	26.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arctigenin has a therapeutic potential in combination with chemotherapeutic agents for NSLC.
C29611	31592435	DIS0129	NP3889	Rutin	DR9021	5-fluorouracil	NEWCL00253	PC-3	900 uM	3 uM	700 uM:0.75 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	PC-3	26.04%	14.24%	26.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Synergistic effects of 5-FU/rutin combination on PC3 cells line enhanced apoptosis, p53 gene expression, and down-regulation of Bcl-2 protein, compared to control separate application."
C83293	31677606	DIS0024	NP1339	Vitamin C	DR1669	Cisplatin	NEWCL00352	AGS	48h:49.38 ±  0.82 ug.mL	48h:10.58 ±  0.49 ug.mL	50ug.mL: 10 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Ascorbic acid renders cisplatin more effective as an antitumor agent.
C03344	31698751	DIS0021	NP6905	Curcumin	DR3078	"1,25-dihydroxyvitamin D3"	NEWCL20410	MBCDF-T	.	.	10 uM:10 nM	NEWCL20411	EA.hy926	.	.	10 uM:10 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MBCDF-T	.	.	.	EA.hy926	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The concomitant administration of calcitriol with curcumin synergistically promoted anticancer effects in vitro and in vivo.
C97955	31721534	DIS0025	NP6993	Arsenic trioxide	DR6736	Thalidomide	NEWCL00024	KG-1	1.618 uM	80 uM	.	NEWCL00019	U-937	1 uM	60 uM	1 uM:60 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide and thalidomide combination induces autophagy along with apoptosis in acute myeloid cell lines.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AIF	Up-regulation	MCF-7	22.09%	21.27%	21.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Up-regulation	MCF-7	2.90%	27.74%	16.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MCF-7	30.04%	27.80%	12.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MCF-7	57.59%	11.32%	52.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MCF-7	17.04%	15.64%	26.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Cleaved-caspase-7	Up-regulation	MCF-7	29.10%	34.33%	47.60%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7	65.24%	7.11%	50.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	MCF-7	23.54%	2.22%	11.94%	MCA MB-231	5.35%	-5.16%	-52.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	MCF-7	8.15%	0.94%	30.66%	MCA MB-231	1.57%	17.49%	76.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C40238	31751581	DIS0021	NP9279	Genistein	DR5916	Centchroman	NEWCL00155	MCF-7	.	.	5uM:10uM	NEWCL00049	MDA-MB-231	.	.	5uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	.	14.53%	2.89%	30.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
C87092	31754333	DIS0022	NP7687	Pterostilbene	DR6823	Osimertinib	NEWCL00175	PC-9	.	.	10 uM :0.02uM	NEWCL00171	NCI-H1975	.	.	10 uM :0.02uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5260	P-Src	Down-regulation	PC-9	49.95%	24.87%	15.15%	NCI-H1975	6.17%	13.00%	37.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of osimertinib and pterostilbene reversed the osimertinib-induced STAT3, YAP1, and CUB domain-containing protein-1 (CDCP1) phosphorylation and slightly suppressed Src phosphorylation in PC9 and H1975 cells."
C87092	31754333	DIS0022	NP7687	Pterostilbene	DR6823	Osimertinib	NEWCL00175	PC-9	.	.	10 uM :0.02uM	NEWCL00171	NCI-H1975	.	.	10 uM :0.02uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	PC-9	46.59%	312.07%	251.11%	NCI-H1975	35.00%	160.28%	173.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of osimertinib and pterostilbene reversed the osimertinib-induced STAT3, YAP1, and CUB domain-containing protein-1 (CDCP1) phosphorylation and slightly suppressed Src phosphorylation in PC9 and H1975 cells."
C87092	31754333	DIS0022	NP7687	Pterostilbene	DR6823	Osimertinib	NEWCL00175	PC-9	.	.	10 uM :0.02uM	NEWCL00171	NCI-H1975	.	.	10 uM :0.02uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4335	P-CDCP1	Down-regulation	PC-9	80.32%	190.86%	67.76%	NCI-H1975	40.61%	60.94%	31.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of osimertinib and pterostilbene reversed the osimertinib-induced STAT3, YAP1, and CUB domain-containing protein-1 (CDCP1) phosphorylation and slightly suppressed Src phosphorylation in PC9 and H1975 cells."
C49649	31780732	DIS0034	NP6905	Curcumin	DR1669	Cisplatin	NEWCL00129	Hep-G2	.	.	10 uM:25 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TRPM2	Up-regulation	PC-9	5.67%	66.23%	35.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis.
C25680	31864387	DIS0112	NP2322	Periplocin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10391	YES-2	.	.	200 ng.ml:1 ug.ml	NEWCL20399	KYSE-150	.	.	200 ng.ml:1 ug.ml	NEWCL10350	KYSE-510	.	.	200 ng.ml:1 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR5	Up-regulation	YES-2	492.15%	636.36%	789.28%	KYSE-150	1085.01%	531.89%	1044.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy.
C25680	31864387	DIS0112	NP2322	Periplocin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10391	YES-2	.	.	200 ng.ml:1 ug.ml	NEWCL20399	KYSE-150	.	.	200 ng.ml:1 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2163	FADD	Up-regulation	YES-2	351.85%	128.22%	345.03%	KYSE-150	987.39%	747.32%	999.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy.
C25680	31864387	DIS0112	NP2322	Periplocin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10391	YES-2	.	.	200 ng.ml:1 ug.ml	NEWCL20399	KYSE-150	.	.	200 ng.ml:1 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	YES-2	6.69%	2.67%	5.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy.
C25680	31864387	DIS0112	NP2322	Periplocin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10391	YES-2	.	.	200 ng.ml:1 ug.ml	NEWCL20399	KYSE-150	.	.	200 ng.ml:1 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	YES-2	19.26%	3.13%	52.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy.
C25680	31864387	DIS0112	NP2322	Periplocin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL10391	YES-2	.	.	200 ng.ml:1 ug.ml	NEWCL20399	KYSE-150	.	.	200 ng.ml:1 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	YES-2	21.77%	5.17%	88.23%	KYSE-150	68.53%	9.93%	89.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy.
C67056	31892549	DIS0021	NP2960	Epigallocatechin gallate	DR2632	Vorinostat	NEWCL00054	MDA-MB-157	.	.	3uM :5uM	NEWCL00049	MDA-MB-231	.	.	3uM :5uM	NEWCL00155	MCF-7	.	.	3uM :5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CIAP-2	Down-regulation	MDA-MB-157	15.29%	41.82%	44.84%	MCF-7	29.25%	29.49%	46.53%	HCC1806	43.48%	44.68%	42.02%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."
C67056	31892549	DIS0021	NP2960	Epigallocatechin gallate	DR2632	Vorinostat	NEWCL00054	MDA-MB-157	.	.	3uM :5uM	NEWCL00049	MDA-MB-231	.	.	3uM :5uM	NEWCL00155	MCF-7	.	.	3uM :5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Caspase-7	Up-regulation	MDA-MB-157	.	.	.	MCF-7	30.00%	3.30%	34.19%	HCC1806	32.88%	4.51%	7.49%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."
C46103	31897141	DIS0130	NP7102	Elemene	DR1669	Cisplatin	NEWCL20412	SW780	 37.703± 7.323	.	.	NEWCL00349	5637	 61.553± 4.070	.	.	NEWCL10112	J82	 68.201± 0.441	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	SW780	181.56%	125.00%	606.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	31897141	DIS0130	NP7102	Elemene	DR1669	Cisplatin	NEWCL10070	UM-UC-3	 72.129± 1.121	.	.	NEWCL10071	TCCSUP	 3.661± 0.735	.	.	NEWCL00047	T24	 47.403± 8.950	20.07± 2.18 uM 24 h;  8.68± 1.31 uM 48 h ; 4.63± 0.40 uM  72 h	50 ug.ml :20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SW780	94.80%	105.23%	208.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	31897141	DIS0130	NP7102	Elemene	DR1669	Cisplatin	NEWCL10048	SV-HUC-1	72.860± 4.128ug.ml	.	.	NEWCL10123	RT-4	37.894± 10.307	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	SW780	16.89%	28.82%	44.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	31897141	DIS0130	NP7102	Elemene	DR1669	Cisplatin	NEWCL10048	SV-HUC-1	72.860± 4.128ug.ml	.	.	NEWCL10123	RT-4	37.894± 10.307	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SW780	10.47%	24.05%	59.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	31897141	DIS0130	NP7102	Elemene	DR1669	Cisplatin	NEWCL10048	SV-HUC-1	72.860± 4.128ug.ml	.	.	NEWCL10123	RT-4	37.894± 10.307	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	SW780	18.22%	33.93%	174.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C46103	31897141	DIS0130	NP7102	Elemene	DR1669	Cisplatin	NEWCL00047	T24	24h:47.403± 8.950ug.mL	.	50 ug.mL:20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	T24	1.17%	1.38%	38.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
C99416	31905887	DIS0031	NP3528	Magnolol	DR2073	Sorafenib	NEWCL20428	SK-Hep1	.	.	50 uM:10 uM	NEWCL00283	Hep 3B2.1-7	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-PARAS40	Down-regulation	SK-Hep1	26.55%	31.94%	87.82%	Hep 3B2.1-7	55.00%	29.44%	92.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	AKT inhibition is associated with magnolol-enhanced the therapeutic effect of sorafenib in HCC.
C99416	31905887	DIS0031	NP3528	Magnolol	DR2073	Sorafenib	NEWCL20428	SK-Hep1	.	.	50 uM:10 uM	NEWCL00283	Hep 3B2.1-7	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	SK-Hep1	53.24%	73.51%	82.33%	Hep 3B2.1-7	77.99%	34.58%	65.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	AKT inhibition is associated with magnolol-enhanced the therapeutic effect of sorafenib in HCC.
C99416	31905887	DIS0031	NP3528	Magnolol	DR2073	Sorafenib	NEWCL20428	SK-Hep1	.	.	50 uM:10 uM	NEWCL00283	Hep 3B2.1-7	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C-FLIP	Down-regulation	SK-Hep1	58.52%	61.39%	65.46%	Hep 3B2.1-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	AKT inhibition is associated with magnolol-enhanced the therapeutic effect of sorafenib in HCC.
C99416	31905887	DIS0031	NP3528	Magnolol	DR2073	Sorafenib	NEWCL20428	SK-Hep1	.	.	50 uM:10 uM	NEWCL00283	Hep 3B2.1-7	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	SK-Hep1	80.04%	83.22%	88.83%	Hep 3B2.1-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	AKT inhibition is associated with magnolol-enhanced the therapeutic effect of sorafenib in HCC.
C99416	31905887	DIS0031	NP3528	Magnolol	DR2073	Sorafenib	NEWCL20428	SK-Hep1	.	.	50 uM:10 uM	NEWCL00283	Hep 3B2.1-7	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	SK-Hep1	1.13%	22.59%	68.58%	Hep 3B2.1-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	AKT inhibition is associated with magnolol-enhanced the therapeutic effect of sorafenib in HCC.
C02511	31906221	DIS0105	NP2632	Fucoidan	DR2391	Gemcitabine	NEWCL00275	SK-UT-1	 0.966mg.mL ; 3.348mg.mL 	96h: 31.173ng.mL; 25.243ng.mL	2.493 :9.016 ; 1.714 :4.713	NEWCL00276	MES-SA	.	72.482 ng.mL	.	NEWCL20448	ESS-1	0.848 mg.mL 	13.875 ng.mL	0.052:0.101 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Isobolographic analysis demonstrates the additive and synergistic effects of gemcitabine combined with fucoidan in uterine sarcomas and carcinosarcoma cells.
C44873	31917699	DIS0021	NP6905	Curcumin	DR0904	Bicalutamide	NEWCL00051	MDA-MB-453	.	.	25 umol.l :25 umol.l	NEWCL00290	MFM-223	.	.	25 umol.l :25 umol.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MDA MB-453	69.16%	47.77%	357.62%	MFM-223	35.81%	12.50%	66.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"There are synergistic effects of curcumin and bicalutamide. Curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein."
C44873	31917699	DIS0021	NP6905	Curcumin	DR0904	Bicalutamide	NEWCL00051	MDA-MB-453	.	.	25 umol.l :25 umol.l	NEWCL00290	MFM-223	.	.	25 umol.l :25 umol.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MDA MB-453	246.06%	303.71%	369.92%	MFM-223	9.66%	211.65%	304.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"There are synergistic effects of curcumin and bicalutamide. Curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein."
C44873	31917699	DIS0021	NP6905	Curcumin	DR0904	Bicalutamide	NEWCL00051	MDA-MB-453	.	.	25 umol.l :25 umol.l	NEWCL00290	MFM-223	.	.	25 umol.l :25 umol.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1857	AR 	Down-regulation	MDA MB-453	7.83%	4.63%	46.43%	MFM-223	44.25%	1.99%	83.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"There are synergistic effects of curcumin and bicalutamide. Curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein."
C44873	31917699	DIS0021	NP6905	Curcumin	DR0904	Bicalutamide	NEWCL00051	MDA-MB-453	.	.	25 umol.l :25 umol.l	NEWCL00290	MFM-223	.	.	25 umol.l :25 umol.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Beta-Catenin	Down-regulation	MDA MB-453	7.34%	20.94%	42.11%	MFM-223	16.48%	3.24%	69.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"There are synergistic effects of curcumin and bicalutamide. Curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein."
C44873	31917699	DIS0021	NP6905	Curcumin	DR0904	Bicalutamide	NEWCL00051	MDA-MB-453	.	.	25 umol.l :25 umol.l	NEWCL00290	MFM-223	.	.	25 umol.l :25 umol.l	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	MDA MB-453	7.42%	4.80%	16.44%	MFM-223	81.95%	1.51%	85.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"There are synergistic effects of curcumin and bicalutamide. Curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Acetylated-H3	Up-regulation	K-562R	605.37%	106.73%	606.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Acetylated-H4	Up-regulation	K-562R	19.06%	8.24%	18.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	K-562R	2381.45%	220.93%	6220.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	K-562R	1629.84%	201.42%	1701.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	K-562R	172.24%	4.00%	172.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	K-562R	188.03%	45.37%	191.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HDAC3	Down-regulation	K-562R	43.90%	9.92%	67.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	K-562R	4.41%	1.15%	62.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7847	P-RB	Down-regulation	K-562R	28.50%	4.62%	89.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C58834	31930541	DIS0015	NP9796	Betulinic Acid	DR8244	Imatinib	NEWCL20364	K562-r	24h:11.286uM	24h:6.993uM	5uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CDK1	Down-regulation	K-562R	11.10%	1.61%	36.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."
C72640	31960257	DIS0021	NP2458	Methyl jasmote	DR5481	3-bromopyruvate	NEWCL00189	4T1	24h: 2.8 mM	24h: 70 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"This combination therapy didn't have any noticeable side effects on kidney, liver, and immune system and body weight."
C29891	31965535	DIS0031	NP0904	Ginsenoside	DR8666	Reorafenib	NEWCL00129	Hep-G2	.	.	10mg.mL:1mg.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	Hep-G2	283.80%	408.65%	421.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic inhibitory effect presented by the combination therapy was dependent on the gradient concentration and treatment time.
C29891	31965535	DIS0031	NP0904	Ginsenoside	DR8666	Reorafenib	NEWCL00129	Hep-G2	.	.	10mg.mL:1mg.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	Hep-G2	0.81%	2.77%	38.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic inhibitory effect presented by the combination therapy was dependent on the gradient concentration and treatment time.
C57697	32003107	DIS0022	NP3718	Honokiol	DR6823	Osimertinib	NEWCL20369	PC-9.3M	.	.	5 um:200 nM	NEWCL20400	PC-9.GR.AR	.	.	5 um:200 nM	NEWCL20449	PC-9.AR	.	.	5 um:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CF(p89)	Up-regulation	PC-9.3M	2.59%	196.00%	580.64%	PC-9.GR.AR	.	.	.	PC-9.AR	412.51%	292.77%	434.20%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol."
C57697	32003107	DIS0022	NP3718	Honokiol	DR6823	Osimertinib	NEWCL20369	PC-9.3M	.	.	5 um:200 nM	NEWCL20400	PC-9.GR.AR	.	.	5 um:200 nM	NEWCL20449	PC-9.AR	.	.	5 um:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim	Up-regulation	PC-9.3M	2.22%	0.96%	2.57%	PC-9.GR.AR	95.93%	92.98%	116.48%	PC-9.AR	21.71%	2.46%	14.79%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol."
C57697	32003107	DIS0022	NP3718	Honokiol	DR6823	Osimertinib	NEWCL20369	PC-9.3M	.	.	5 um:200 nM	NEWCL20400	PC-9.GR.AR	.	.	5 um:200 nM	NEWCL20449	PC-9.AR	.	.	5 um:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	PC-9.3M	.	.	.	PC-9.GR.AR	6.19%	4.75%	14.37%	PC-9.AR	2.35%	11.39%	85.39%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol."
C57697	32003107	DIS0022	NP3718	Honokiol	DR6823	Osimertinib	NEWCL20369	PC-9.3M	.	.	5 um:200 nM	NEWCL20400	PC-9.GR.AR	.	.	5 um:200 nM	NEWCL20449	PC-9.AR	.	.	5 um:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	PC-9.3M	5.73%	1.97%	72.44%	PC-9.GR.AR	24.53%	2.40%	65.41%	PC-9.AR	12.16%	0.92%	30.38%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol."
C57697	32003107	DIS0022	NP3718	Honokiol	DR6823	Osimertinib	NEWCL20369	PC-9.3M	.	.	5 um:200 nM	NEWCL20400	PC-9.GR.AR	.	.	5 um:200 nM	NEWCL20449	PC-9.AR	.	.	5 um:200 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p-ERK	Down-regulation	PC-9.3M	9.59%	38.91%	89.78%	PC-9.GR.AR	7.72%	78.26%	84.35%	PC-9.AR	3.77%	10.20%	82.22%	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol."
C97187	32014914	DIS0023	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00242	PANC-1	.	.	50 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PANC-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model.
C47590	32021103	DIS0028	NP6905	Curcumin	DR6736	Thalidomide	NEWCL00019	U-937	 40 uM	80 uM	40uM:60uM	NEWCL00024	KG-1	 40 uM	60uM	40uM:80uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl-xL, Leading to Apoptosis in Acute Myeloid Leukemia Cell Lines."
C75715	32027051	DIS0025	NP8751	Shikonin	DR5956	Dimethylaminoparthenolide	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of dimethylaminoparthenolide and shikonin alters metabolism and inhibits proliferation of pediatric precursor-B cell acute lymphoblastic leukemia.
C18595	32045658	DIS0031	NP4620	Apigenin	DR2073	Sorafenib	NEWCL00129	Hep-G2	40 uM	40 uM	50 uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	The combination of apigenin and sorafenib arrested cell cycle and increased apoptotic gene expressions more than single treatment groups.
C53657	32070867	DIS0022	NP8751	Shikonin	DR6823	Osimertinib	NEWCL00170	A-549	.	.	1.0 uM : 3.0uM	NEWCL00181	NCI-H1299	.	.	0.6 uM :3.5 uM	NEWCL00180	NCI-H460	.	.	3.0uM : 8 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1771	P-eif2a	Up-regulation	A-549	22.01%	38.05%	64.96%	NCI-NCI-NCI-H1299	36.84%	90.08%	514.38%	NCI-NCI-H460	2.75%	159.79%	277.86%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin increased the anticancer activity of AZD9291 in primary wtEGFR NSCLC cells through ROS-mediated ER stress.
C53657	32070867	DIS0022	NP8751	Shikonin	DR6823	Osimertinib	NEWCL00170	A-549	.	.	1.0 uM : 3.0uM	NEWCL00181	NCI-H1299	.	.	0.6 uM :3.5 uM	NEWCL00180	NCI-H460	.	.	3.0uM : 8 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7883	ATF4	Up-regulation	A-549	396.86%	425.09%	712.01%	NCI-NCI-NCI-H1299	17.11%	20.20%	68.68%	NCI-NCI-H460	0.58%	8.65%	51.11%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin increased the anticancer activity of AZD9291 in primary wtEGFR NSCLC cells through ROS-mediated ER stress.
C53657	32070867	DIS0022	NP8751	Shikonin	DR6823	Osimertinib	NEWCL00170	A-549	.	.	1.0 uM : 3.0uM	NEWCL00181	NCI-H1299	.	.	0.6 uM :3.5 uM	NEWCL00180	NCI-H460	.	.	3.0uM : 8 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	6.93%	5.16%	72.14%	NCI-NCI-NCI-H1299	214.86%	37.85%	1311.34%	NCI-NCI-H460	20.31%	70.77%	145.57%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin increased the anticancer activity of AZD9291 in primary wtEGFR NSCLC cells through ROS-mediated ER stress.
C53657	32070867	DIS0022	NP8751	Shikonin	DR6823	Osimertinib	NEWCL00170	A-549	.	.	1.0 uM : 3.0uM	NEWCL00181	NCI-H1299	.	.	0.6 uM :3.5 uM	NEWCL00180	NCI-H460	.	.	3.0uM : 8 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	A-549	3.05%	18.55%	86.32%	NCI-NCI-NCI-H1299	4.95%	27.45%	41.96%	NCI-NCI-H460	3.93%	27.30%	51.12%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin increased the anticancer activity of AZD9291 in primary wtEGFR NSCLC cells through ROS-mediated ER stress.
C53657	32070867	DIS0022	NP8751	Shikonin	DR6823	Osimertinib	NEWCL00170	A-549	.	.	1.0 uM : 3.0uM	NEWCL00181	NCI-H1299	.	.	0.6 uM :3.5 uM	NEWCL00180	NCI-H460	.	.	3.0uM : 8 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	A-549	.	.	.	NCI-NCI-NCI-H1299	.	.	.	NCI-NCI-H460	31.37%	48.82%	82.95%	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Shikonin increased the anticancer activity of AZD9291 in primary wtEGFR NSCLC cells through ROS-mediated ER stress.
C08388	32082378	DIS0122	NP0944	Ferulic acid	DR8472	2-methoxyestradiol	NEWCL00036	A-375	 24h:701.9 uM	.	1 mM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6632	Hsp70	Up-regulation	A-375	5.67%	1.11%	18.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	2-Methoxyestradiol and its combination with ferulic acid induces melanoma cell death via downregulation of Hsp60 and Hsp90.
C08388	32082378	DIS0122	NP0944	Ferulic acid	DR8472	2-methoxyestradiol	NEWCL00036	A-375	 24h:701.9 uM	.	1 mM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Hsp60	Down-regulation	A-375	15.94%	37.90%	53.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	2-Methoxyestradiol and its combination with ferulic acid induces melanoma cell death via downregulation of Hsp60 and Hsp90.
C08388	32082378	DIS0122	NP0944	Ferulic acid	DR8472	2-methoxyestradiol	NEWCL00036	A-375	 24h:701.9 uM	.	1 mM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Hsp90	Down-regulation	A-375	8.70%	19.38%	49.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	2-Methoxyestradiol and its combination with ferulic acid induces melanoma cell death via downregulation of Hsp60 and Hsp90.
C08388	32082378	DIS0122	NP0944	Ferulic acid	DR8472	2-methoxyestradiol	NEWCL00036	A-375	 24h:701.9 uM	.	1 mM :10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6632	Hsp70	Up-regulation	A-375	1.46%	32.13%	81.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	2-Methoxyestradiol and its combination with ferulic acid induces melanoma cell death via downregulation of Hsp60 and Hsp90.
C30637	32088816	DIS0115	NP9772	Diosmin	DR7812	Dactolisib	NEWCL00082	HCT 116	250 ±  2.08 uM	1 ±  0.06 uM	250 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HCT 116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-kappaB axis.
C11337	32105783	DIS0021	NP3718	Honokiol	DR2742	Celecoxib	NEWCL00189	4T1	24h:17.68 ±  0.98 ug.mL	24h:25.53 ±  0.64ug.mL	723.5 ug.mL:563.4 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	4T1	10.27%	1.38%	47.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	The combined treatment with PV-CXB and PV-HNK showed synergistic effect both in vitro and in vivo.
C11337	32105783	DIS0021	NP3718	Honokiol	DR2742	Celecoxib	NEWCL00189	4T1	24h:17.68 ±  0.98 ug.mL	24h:25.53 ±  0.64ug.mL	723.5 ug.mL:563.4 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0372	FOXM1	Down-regulation	4T1	18.03%	9.27%	28.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	The combined treatment with PV-CXB and PV-HNK showed synergistic effect both in vitro and in vivo.
C48068	32127939	DIS0017	NP4620	Apigenin	DR2915	Abivertinib	NEWCL00093	U-2932	.	.	20 uM:320 nM	.	LY10	.	.	20 uM:320 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	U2932	.	.	.	LY10	17.71%	26.81%	26.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apigenin can synergize with Abivertinib in treating DLBCL visa synergistically inducing apoptosis and inhibiting the p-GS3K-beta and its downstream targets.
C48068	32127939	DIS0017	NP4620	Apigenin	DR2915	Abivertinib	NEWCL00093	U-2932	.	.	20 uM:320 nM	NEWCL00092	OCI-Ly10	.	.	20 uM:320 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	U2932	29.84%	32.39%	15.68%	LY10	19.57%	21.69%	29.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apigenin can synergize with Abivertinib in treating DLBCL visa synergistically inducing apoptosis and inhibiting the p-GS3K-beta and its downstream targets.
C48068	32127939	DIS0017	NP4620	Apigenin	DR2915	Abivertinib	NEWCL00093	U-2932	.	.	20 uM:320 nM	NEWCL00092	OCI-Ly10	.	.	20 uM:320 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	U2932	6.04%	129.90%	53.98%	LY10	61.29%	86.57%	122.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apigenin can synergize with Abivertinib in treating DLBCL visa synergistically inducing apoptosis and inhibiting the p-GS3K-beta and its downstream targets.
C48068	32127939	DIS0017	NP4620	Apigenin	DR2915	Abivertinib	NEWCL00093	U-2932	.	.	20 uM:320 nM	NEWCL00092	OCI-Ly10	.	.	20 uM:320 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	U2932	31.86%	38.22%	56.71%	LY10	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apigenin can synergize with Abivertinib in treating DLBCL visa synergistically inducing apoptosis and inhibiting the p-GS3K-beta and its downstream targets.
C48068	32127939	DIS0017	NP4620	Apigenin	DR2915	Abivertinib	NEWCL00093	U-2932	.	.	20 uM:320 nM	NEWCL00092	OCI-Ly10	.	.	20 uM:320 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IKK	Down-regulation	U2932	23.21%	9.59%	23.18%	LY10	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Apigenin can synergize with Abivertinib in treating DLBCL visa synergistically inducing apoptosis and inhibiting the p-GS3K-beta and its downstream targets.
C68125	32133284	DIS0022	NP9343	Cucurbitacin D	DR9742	Gefitinib	NEWCL00172	HCC827	.	.	0.1 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-cdc25c	Down-regulation	HCC827	17.41%	4.39%	14.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs.
C68125	32133284	DIS0022	NP9343	Cucurbitacin D	DR9742	Gefitinib	NEWCL00172	HCC827	.	.	0.1 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HCC827	1210.11%	9.15%	1114.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs.
C68125	32133284	DIS0022	NP9343	Cucurbitacin D	DR9742	Gefitinib	NEWCL00172	HCC827	.	.	0.1 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6539	P-EGFR	Down-regulation	HCC827	62.81%	3.88%	85.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs.
C68125	32133284	DIS0022	NP9343	Cucurbitacin D	DR9742	Gefitinib	NEWCL00172	HCC827	.	.	0.1 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERbB2	Down-regulation	HCC827	39.72%	2.08%	75.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs.
C68125	32133284	DIS0022	NP9343	Cucurbitacin D	DR9742	Gefitinib	NEWCL00172	HCC827	.	.	0.1 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERbB3	Down-regulation	HCC827	72.72%	24.85%	35.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs.
C68125	32133284	DIS0022	NP9343	Cucurbitacin D	DR9742	Gefitinib	NEWCL00172	HCC827	.	.	0.1 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	HCC827	40.18%	7.14%	47.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs.
C68125	32133284	DIS0022	NP9343	Cucurbitacin D	DR9742	Gefitinib	NEWCL00172	HCC827	.	.	0.1 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	HCC827	31.60%	4.20%	68.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs.
C68125	32133284	DIS0022	NP9343	Cucurbitacin D	DR9742	Gefitinib	NEWCL00172	HCC827	.	.	0.1 uM:50 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-CDC2	Down-regulation	HCC827	88.52%	19.08%	89.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs.
C49580	32149146	DIS0024	NP1559	Luteolin	DR0141	Oxaliplatin	NEWCL00142	SGC-7901	.	.	40 uM: 30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	SGC-7901	104.87%	111.93%	470.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
C49580	32149146	DIS0024	NP1559	Luteolin	DR0141	Oxaliplatin	NEWCL00142	SGC-7901	.	.	40 uM: 30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	SGC-7901	103.30%	102.08%	174.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
C49580	32149146	DIS0024	NP1559	Luteolin	DR0141	Oxaliplatin	NEWCL00142	SGC-7901	.	.	40 uM: 30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	SGC-7901	57.63%	42.16%	71.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
C49580	32149146	DIS0024	NP1559	Luteolin	DR0141	Oxaliplatin	NEWCL00142	SGC-7901	.	.	40 uM: 30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	SGC-7901	29.96%	84.12%	75.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
C74648	32174728	DIS0078	NP4533	Apigenin-7-o-glucoside	DR7308	Pyrimethamine	NEWCL10412	HFF	48h:1.7ug.mL	48h:25ug.mL 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Apigenin-7-O-glucoside alone, and apigenin-7-O-glucoside in combination with pyrimethamine, were found to be potent anti-T. gondii agents."
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7	84.26%	83.60%	131.06%	MDA-MB-435	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MCF-7	35.57%	55.28%	100.68%	MDA-MB-435	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Smac	Up-regulation	MCF-7	9.07%	30.38%	97.65%	MDA-MB-435	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MCF-7	69.00%	176.38%	599.08%	MDA-MB-435	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4294	Fas L	Up-regulation	MCF-7	95.39%	57.41%	135.10%	MDA-MB-435	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	MCF-7	109.80%	81.91%	218.97%	MDA-MB-435	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MCF-7	60.04%	49.22%	70.13%	MDA-MB-435	28.41%	1.20%	57.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	PI3K	Down-regulation	MCF-7	.	.	.	MDA-MB-435	32.95%	9.97%	22.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	AKT	Down-regulation	MCF-7	18.59%	53.07%	90.75%	MDA-MB-435	40.89%	28.59%	10.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C47686	32175001	DIS0021	NP8751	Shikonin	DR5291	4-hydroxy-tamoxifen	NEWCL00155	MCF-7	.	.	3 uM:15 uM	NEWCL00314	MDA-MB-435	.	.	3 uM:17.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	MCF-7	15.97%	0.68%	2.66%	MDA-MB-435	15.08%	40.60%	65.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
C24059	32185829	DIS0023	NP8902	Ursolic acid	DR2391	Gemcitabine	NEWCL00236	MIA Paca-2	.	.	50 uM:0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
C73132	32226300	DIS0022	NP0956	Bisdemethoxycurcumin	DR8812	Lcotinib	NEWCL00180	NCI-H460	.	48h:>20uM	10uM:5uM	NEWCL10353	NCI-H1781	.	48h:>20uM	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3I 	Up-regulation	NCI-H460	42.83%	14.02%	44.20%	H1781	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."
C73132	32226300	DIS0022	NP0956	Bisdemethoxycurcumin	DR8812	Lcotinib	NEWCL00180	NCI-H460	.	48h:>20uM	10uM:5uM	NEWCL10353	NCI-H1781	.	48h:>20uM	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3II	Up-regulation	NCI-H460	101.92%	149.45%	121.07%	H1781	33.30%	49.44%	28.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."
C73132	32226300	DIS0022	NP0956	Bisdemethoxycurcumin	DR8812	Lcotinib	NEWCL00180	NCI-H460	.	48h:>20uM	10uM:5uM	NEWCL10353	NCI-H1781	.	48h:>20uM	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7891	Beclin-1	Up-regulation	NCI-H460	57.40%	68.66%	105.40%	H1781	31.01%	53.17%	10.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."
C73132	32226300	DIS0022	NP0956	Bisdemethoxycurcumin	DR8812	Lcotinib	NEWCL00180	NCI-H460	.	48h:>20uM	10uM:5uM	NEWCL10353	NCI-H1781	.	48h:>20uM	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VDAC1	Up-regulation	NCI-H460	28.51%	36.95%	22.40%	H1781	29.03%	89.60%	24.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."
C73132	32226300	DIS0022	NP0956	Bisdemethoxycurcumin	DR8812	Lcotinib	NEWCL00180	NCI-H460	.	48h:>20uM	10uM:5uM	NEWCL10353	NCI-H1781	.	48h:>20uM	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8159	GSK-3beta	Up-regulation	NCI-H460	2.18%	0.63%	19.80%	H1781	24.45%	27.79%	14.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."
C73132	32226300	DIS0022	NP0956	Bisdemethoxycurcumin	DR8812	Lcotinib	NEWCL00180	NCI-H460	.	48h:>20uM	10uM:5uM	NEWCL10353	NCI-H1781	.	48h:>20uM	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Total Cyt c	Up-regulation	NCI-H460	31.86%	56.50%	15.31%	H1781	20.47%	43.48%	32.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."
C73132	32226300	DIS0022	NP0956	Bisdemethoxycurcumin	DR8812	Lcotinib	NEWCL00180	NCI-H460	.	48h:>20uM	10uM:5uM	NEWCL10353	NCI-H1781	.	48h:>20uM	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9491	SQSTM1	Down-regulation	NCI-H460	9.58%	0.65%	12.31%	H1781	16.65%	33.28%	50.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."
C73132	32226300	DIS0022	NP0956	Bisdemethoxycurcumin	DR8812	Lcotinib	NEWCL00180	NCI-H460	.	48h:>20uM	10uM:5uM	NEWCL10353	NCI-H1781	.	48h:>20uM	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VDAC2	Down-regulation	NCI-H460	0.04%	6.31%	15.37%	H1781	2.50%	6.84%	7.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."
C73132	32226300	DIS0022	NP0956	Bisdemethoxycurcumin	DR8812	Lcotinib	NEWCL00180	NCI-H460	.	48h:>20uM	10uM:5uM	NEWCL10353	NCI-H1781	.	48h:>20uM	10uM:5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HK1	Down-regulation	NCI-H460	3.04%	13.92%	13.06%	H1781	7.20%	20.01%	33.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."
C07341	32246216	DIS0122	NP6084	Resveratrol	DR4154	Thymidine kiseganciclovir	NEWCL00207	B16	48h: 40uM	.	5-20 uM: 15.7 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol could synergistically enhance the killing effect of TK/GCV suicide gene system in melanoma B16 cells and transplanted melanoma.
C62720	32290325	DIS0022	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00180	NCI-H460	24h: >10 uM	 24h: 8 mM	3 uM :3 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-H460	133.85%	246.00%	418.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2/M-phase arrest and apoptotic cell death.
C62720	32290325	DIS0022	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00180	NCI-H460	 24h: >10 uM	 24h: 8 mM	3 uM :3 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	NCI-H460	144.58%	232.98%	258.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2/M-phase arrest and apoptotic cell death.
C62720	32290325	DIS0022	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00180	NCI-H460	 24h: >10 uM	 24h: 8 mM	3 uM :3 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	NCI-H460	0.25%	6.27%	50.39%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2/M-phase arrest and apoptotic cell death.
C62720	32290325	DIS0022	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00180	NCI-H460	 24h: >10 uM	 24h: 8 mM	3 uM :3 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	NCI-H460	3.20%	38.39%	29.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2/M-phase arrest and apoptotic cell death.
C62720	32290325	DIS0022	NP6993	Arsenic trioxide	DR0727	Valproic acid	NEWCL00180	NCI-H460	 24h: >10 uM	 24h: 8 mM	3 uM :3 mM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	NCI-H460	10.13%	25.19%	138.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2/M-phase arrest and apoptotic cell death.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8212	GPX4	Down-regulation	HCT 116	2.00%	1.48%	48.41%	LoVo	67.62%	30.49%	89.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3072	SLC7A11	Down-regulation	HCT 116	3.99%	4.59%	23.41%	LoVo	2.20%	26.79%	75.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7859	HO-1	Up-regulation	HCT 116	19.58%	10.00%	25.19%	LoVo	515.00%	440.82%	524.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7861	FTH1	Down-regulation	HCT 116	4.67%	1.09%	67.59%	LoVo	3.23%	0.89%	65.56%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Glutaminase	Down-regulation	HCT 116	5.45%	1.03%	80.05%	LoVo	3.37%	0.55%	85.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6616	SLC40A1	Down-regulation	HCT 116	8.15%	90.63%	92.76%	LoVo	12.00%	0.34%	97.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Transferrin	Up-regulation	HCT 116	462.47%	17.13%	480.37%	LoVo	27.22%	25.92%	31.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	HCT 116	3.30%	2.25%	66.92%	LoVo	53.12%	29.30%	86.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	HCT 116	17.30%	3.53%	6.16%	LoVo	131.88%	102.40%	381.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	HCT 116	3.87%	2.42%	98.47%	LoVo	67.73%	44.62%	97.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Snail	Down-regulation	HCT 116	55.69%	44.14%	98.61%	LoVo	20.73%	6.94%	81.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Slug	Down-regulation	HCT 116	4.04%	2.82%	64.99%	LoVo	43.16%	6.03%	69.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	HCT 116	8.65%	3.41%	96.75%	LoVo	34.39%	67.98%	69.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C77192	32308771	DIS0115	NP7102	Elemene	DR5221	Cetuximab	NEWCL00082	HCT 116	.	.	125ug:25ug	NEWCL00080	LoVo	.	.	125ug:25ug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8212	GPX4	Down-regulation	HCT 116	2.00%	1.48%	48.41%	LoVo	67.62%	30.49%	89.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
C24900	32319589	DIS0129	NP3369	Neferine	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00251	DU145	.	.	20 uM:200 ng.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3 	Up-regulation	DU145	0.67%	0.02%	539.01%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Neferine treatment effectively promotes TRAIL-mediated cell death and this effect likely occurs via the autophagic flux and the JNK pathway.
C50887	32323848	DIS0022	NP4621	Triptolide	DR9742	Gefitinib	NEWCL00170	A-549	48h:10.985 ng.ml	48h:5.801 ug.ml	2 ng.mL:1.25 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1678	CDH1	Up-regulation	A-549	55.16%	11.96%	55.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Triptolide inhibits epithelial mesenchymal transition and induces apoptosis in gefitinib resistant lung cancer cells.
C50887	32323848	DIS0022	NP4621	Triptolide	DR9742	Gefitinib	NEWCL00170	A-549	48h:10.985 ng.ml	48h:5.801 ug.ml	2 ng.mL:1.25 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	A-549	42.24%	18.03%	66.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Triptolide inhibits epithelial mesenchymal transition and induces apoptosis in gefitinib resistant lung cancer cells.
C50887	32323848	DIS0022	NP4621	Triptolide	DR9742	Gefitinib	NEWCL00170	A-549	48h:10.985 ng.ml	48h:5.801 ug.ml	2 ng.mL:1.25 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Snail	Down-regulation	A-549	23.48%	30.50%	47.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Triptolide inhibits epithelial mesenchymal transition and induces apoptosis in gefitinib resistant lung cancer cells.
C00179	32328199	DIS0031	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:4.32uM	48h:2.16uM	2.5 umol.L: 5 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB protein in nucleus	Down-regulation	SMMC-7721	8.49%	20.62%	8.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combination of 5 uM curcumin with 5-FU significantly reduced its cytotoxicity in EJ138 cells, while 15 uM curcumin caused an opposite increase."
C00179	32328199	DIS0031	NP6905	Curcumin	DR9021	5-fluorouracil	NEWCL00140	SMMC-7721	48h:4.32uM	48h:2.16uM	2.5 umol.L: 5 umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB protein in cytoplasm	Up-regulation	SMMC-7721	3.68%	10.65%	9.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Combination of 5 uM curcumin with 5-FU significantly reduced its cytotoxicity in EJ138 cells, while 15 uM curcumin caused an opposite increase."
C03662	32331446	DIS0022	NP9032	Allicin	DR9021	5-fluorouracil	NEWCL00079	DLD-1	53.53 uM	214.3 uM	53.53 uM:214.3 uM	NEWCL00184	SK-MES-1	8.625 uM	202.2 uM	8.625 uM:202.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DLD-1	.	.	.	SK-MES-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway.
C14802	32351601	DIS0024	NP6764	Beta asarone	DR1669	Cisplatin	NEWCL00113	MGC-803	24h:39.92ug.ml 	.	.	NEWCL00116	MKN74	.	96.22 ug.ml 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The increase of chemotherapy sensitization by Beta-asarone is associated with the inhibition of tumor glycolysis.
C58370	32351887	DIS0032	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL20382	HN-CICs	.	.	3uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-AMPK	Up-regulation	HN-CICs	21.28%	17.40%	122.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK/STAT3 signaling on targeting head and neck cancer Initiating cells.
C58370	32351887	DIS0032	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL20382	HN-CICs	.	.	3uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	NOG	Down-regulation	HN-CICs	20.00%	8.00%	40.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK/STAT3 signaling on targeting head and neck cancer Initiating cells.
C58370	32351887	DIS0032	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL20382	HN-CICs	.	.	3uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.OCT-4	Down-regulation	HN-CICs	20.00%	20.00%	40.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK/STAT3 signaling on targeting head and neck cancer Initiating cells.
C58370	32351887	DIS0032	NP6993	Arsenic trioxide	DR1669	Cisplatin	NEWCL20382	HN-CICs	.	.	3uM:4uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	HN-CICs	61.74%	19.25%	85.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK/STAT3 signaling on targeting head and neck cancer Initiating cells.
C62137	32370057	DIS0020	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00348	ACHN	.	.	25 uM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	ACHN	4.38%	8.39%	32.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin inhibited growth of LNCaP xenografts in nude mice by inducing apoptosis (TUNEL staining) and inhibiting proliferation (PCNA and Ki67 staining), and sensitized these tumors to undergo apoptosis by TRAIL via regulation of death receptors and members of Bcl-2 family and inactivation of NFkappaB."
C62137	32370057	DIS0020	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00348	ACHN	.	.	25 uM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cleaved-cFLIP L	Up-regulation	ACHN	14.84%	48.01%	35.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin inhibited growth of LNCaP xenografts in nude mice by inducing apoptosis (TUNEL staining) and inhibiting proliferation (PCNA and Ki67 staining), and sensitized these tumors to undergo apoptosis by TRAIL via regulation of death receptors and members of Bcl-2 family and inactivation of NFkappaB."
C62137	32370057	DIS0020	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00348	ACHN	.	.	25 uM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2163	FADD	Up-regulation	ACHN	20.67%	57.25%	49.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin inhibited growth of LNCaP xenografts in nude mice by inducing apoptosis (TUNEL staining) and inhibiting proliferation (PCNA and Ki67 staining), and sensitized these tumors to undergo apoptosis by TRAIL via regulation of death receptors and members of Bcl-2 family and inactivation of NFkappaB."
C62137	32370057	DIS0020	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00348	ACHN	.	.	25 uM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	ACHN	51.13%	1.54%	35.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin inhibited growth of LNCaP xenografts in nude mice by inducing apoptosis (TUNEL staining) and inhibiting proliferation (PCNA and Ki67 staining), and sensitized these tumors to undergo apoptosis by TRAIL via regulation of death receptors and members of Bcl-2 family and inactivation of NFkappaB."
C62137	32370057	DIS0020	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00348	ACHN	.	.	25 uM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	ACHN	11.76%	14.18%	5.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin inhibited growth of LNCaP xenografts in nude mice by inducing apoptosis (TUNEL staining) and inhibiting proliferation (PCNA and Ki67 staining), and sensitized these tumors to undergo apoptosis by TRAIL via regulation of death receptors and members of Bcl-2 family and inactivation of NFkappaB."
C62137	32370057	DIS0020	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00348	ACHN	.	.	25 uM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Down-regulation	ACHN	2.73%	0.42%	7.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin inhibited growth of LNCaP xenografts in nude mice by inducing apoptosis (TUNEL staining) and inhibiting proliferation (PCNA and Ki67 staining), and sensitized these tumors to undergo apoptosis by TRAIL via regulation of death receptors and members of Bcl-2 family and inactivation of NFkappaB."
C62137	32370057	DIS0020	NP6905	Curcumin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00348	ACHN	.	.	25 uM:50 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CDK1	Down-regulation	ACHN	57.04%	0.76%	47.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin inhibited growth of LNCaP xenografts in nude mice by inducing apoptosis (TUNEL staining) and inhibiting proliferation (PCNA and Ki67 staining), and sensitized these tumors to undergo apoptosis by TRAIL via regulation of death receptors and members of Bcl-2 family and inactivation of NFkappaB."
C55582	32380701	DIS0124	NP9219	Withaferin A	DR5742	Caffeic acid phenethyl ester	NEWCL00149	HeLa	48h:2.8uM	48h:45uM	1 uM: 20 uM	NEWCL10363	SKG-II	48h:1.8uM	48h:45uM	.	NEWCL20450	SKGIIIb	48h:1.8uM	48h:>100uM	.	NEWCL00231	SK-OV-3	48h:>3.0uM	48h:>100uM	.	NEWCL00138	ME-180	48h:2uM	48h:>100uM	.	.	OKV18	48h:2uM	48h:41uM	.	.	Mortalin	Down-regulation	HELA	5.50%	5.14%	38.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of Wi-A and CAPE offers selective toxicity and better potency to cancer cells.
C55582	32380701	DIS0124	NP9219	Withaferin A	DR5742	Caffeic acid phenethyl ester	NEWCL00149	HeLa	48h:2.8uM	48h:45uM	1 uM: 20 uM	NEWCL10363	SKG-II	48h:1.8uM	48h:45uM	.	NEWCL20450	SKGIIIb	48h:1.8uM	48h:>100uM	.	NEWCL00231	SK-OV-3	48h:>3.0uM	48h:>100uM	.	NEWCL00138	ME-180	48h:2uM	48h:>100uM	.	.	OKV18	48h:2uM	48h:41uM	.	MO6386	P53	Up-regulation	HELA	1.20%	22.77%	24.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of Wi-A and CAPE offers selective toxicity and better potency to cancer cells.
C55582	32380701	DIS0124	NP9219	Withaferin A	DR5742	Caffeic acid phenethyl ester	NEWCL00149	HeLa	48h:2.8uM	48h:45uM	1 uM: 20 uM	NEWCL10363	SKG-II	48h:1.8uM	48h:45uM	.	NEWCL20450	SKGIIIb	48h:1.8uM	48h:>100uM	.	NEWCL00231	SK-OV-3	48h:>3.0uM	48h:>100uM	.	NEWCL00138	ME-180	48h:2uM	48h:>100uM	.	.	OKV18	48h:2uM	48h:41uM	.	MO6898	Cleaved-PARP	Up-regulation	HELA	1474.83%	107.02%	991.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of Wi-A and CAPE offers selective toxicity and better potency to cancer cells.
C55582	32380701	DIS0124	NP9219	Withaferin A	DR5742	Caffeic acid phenethyl ester	NEWCL00149	HeLa	48h:2.8uM	48h:45uM	1 uM: 20 uM	NEWCL10363	SKG-II	48h:1.8uM	48h:45uM	.	NEWCL20450	SKGIIIb	48h:1.8uM	48h:>100uM	.	NEWCL00231	SK-OV-3	48h:>3.0uM	48h:>100uM	.	NEWCL00138	ME-180	48h:2uM	48h:>100uM	.	.	OKV18	48h:2uM	48h:41uM	.	MO6898	PARP	Down-regulation	HELA	9.70%	17.10%	51.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of Wi-A and CAPE offers selective toxicity and better potency to cancer cells.
C55582	32380701	DIS0124	NP9219	Withaferin A	DR5742	Caffeic acid phenethyl ester	NEWCL00149	HeLa	48h:2.8uM	48h:45uM	1 uM: 20 uM	NEWCL10363	SKG-II	48h:1.8uM	48h:45uM	.	NEWCL20450	SKGIIIb	48h:1.8uM	48h:>100uM	.	NEWCL00231	SK-OV-3	48h:>3.0uM	48h:>100uM	.	NEWCL00138	ME-180	48h:2uM	48h:>100uM	.	.	OKV18	48h:2uM	48h:41uM	.	MO5373	Cleaved-Caspase-3	Up-regulation	HELA	30.39%	60.58%	78.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of Wi-A and CAPE offers selective toxicity and better potency to cancer cells.
C55582	32380701	DIS0124	NP9219	Withaferin A	DR5742	Caffeic acid phenethyl ester	NEWCL00149	HeLa	48h:2.8uM	48h:45uM	1 uM: 20 uM	NEWCL10363	SKG-II	48h:1.8uM	48h:45uM	.	NEWCL20450	SKGIIIb	48h:1.8uM	48h:>100uM	.	NEWCL00231	SK-OV-3	48h:>3.0uM	48h:>100uM	.	NEWCL00138	ME-180	48h:2uM	48h:>100uM	.	.	OKV18	48h:2uM	48h:41uM	.	MO7829	Gama-H2AX	Up-regulation	HELA	12.16%	102.44%	211.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	A combination of Wi-A and CAPE offers selective toxicity and better potency to cancer cells.
C29634	32393373	DIS0114	NP1541	6-shogaol	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	25 uM:125 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4779	ATG7	Up-regulation	SW480	52.87%	80.92%	133.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	6-Shogaol enhances the anticancer effect of 5-fluorouracil via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.
C29634	32393373	DIS0114	NP1541	6-shogaol	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	25 uM:125 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7891	Beclin-1	Up-regulation	SW480	42.04%	113.32%	119.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	6-Shogaol enhances the anticancer effect of 5-fluorouracil via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.
C29634	32393373	DIS0114	NP1541	6-shogaol	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	25 uM:125 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3 I.II	Up-regulation	SW480	45.20%	-18.95%	59.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	6-Shogaol enhances the anticancer effect of 5-fluorouracil via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.
C29634	32393373	DIS0114	NP1541	6-shogaol	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	25 uM:125 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax 	Up-regulation	SW480	-10.86%	37.41%	114.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	6-Shogaol enhances the anticancer effect of 5-fluorouracil via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.
C29634	32393373	DIS0114	NP1541	6-shogaol	DR9021	5-fluorouracil	NEWCL00074	SW480	.	.	25 uM:125 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	SW480	2.74%	43.19%	42.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	6-Shogaol enhances the anticancer effect of 5-fluorouracil via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.
C81147	32437713	DIS0124	NP8310	Sulforaphane	DR1669	Cisplatin	NEWCL00230	A2780	48h:1.63uM	48h:30.97uM	.	NEWCL20391	A2780.CP70	48h:1.78uM	48h:157.00uM	1.5uM:30uM	NEWCL10084	IGROV-1	48h:2.68uM	48h:35.92uM	.	NEWCL20454	IGROV1-R10	48h:3.03uM	48h:189.10uM	1.5uM:30uM	.	.	.	.	.	.	.	.	.	.	.	ATP7A	Down-regulation	A2780.CP70	13.10%	2.48%	11.64%	IGROV1-R10	15.25%	3.66%	22.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SFN enhances cisplatin sensitivity of ovarian carcinoma cells through up-regulating miR-30a-3p to induce DNA damage and accumulation of intracellular cisplatin.
C81147	32437713	DIS0124	NP8310	Sulforaphane	DR1669	Cisplatin	NEWCL00230	A2780	48h:1.63uM	48h:30.97uM	.	NEWCL20391	A2780.CP70	48h:1.78uM	48h:157.00uM	1.5uM:30uM	NEWCL10084	IGROV-1	48h:2.68uM	48h:35.92uM	.	NEWCL20454	IGROV1-R10	48h:3.03uM	48h:189.10uM	1.5uM:30uM	.	.	.	.	.	.	.	.	.	.	.	ATP7B	Down-regulation	A2780.CP70	8.49%	6.34%	8.51%	IGROV1-R10	6.30%	4.42%	8.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SFN enhances cisplatin sensitivity of ovarian carcinoma cells through up-regulating miR-30a-3p to induce DNA damage and accumulation of intracellular cisplatin.
C81147	32437713	DIS0124	NP8310	Sulforaphane	DR1669	Cisplatin	NEWCL00230	A2780	48h:1.63uM	48h:30.97uM	.	NEWCL20391	A2780.CP70	48h:1.78uM	48h:157.00uM	1.5uM:30uM	NEWCL10084	IGROV-1	48h:2.68uM	48h:35.92uM	.	NEWCL20454	IGROV1-R10	48h:3.03uM	48h:189.10uM	1.5uM:30uM	.	.	.	.	.	.	.	.	.	.	.	CTR1	Down-regulation	A2780.CP70	1.18%	3.93%	2.92%	IGROV1-R10	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SFN enhances cisplatin sensitivity of ovarian carcinoma cells through up-regulating miR-30a-3p to induce DNA damage and accumulation of intracellular cisplatin.
C81147	32437713	DIS0124	NP8310	Sulforaphane	DR1669	Cisplatin	NEWCL00230	A2780	48h:1.63uM	48h:30.97uM	.	NEWCL20391	A2780.CP70	48h:1.78uM	48h:157.00uM	1.5uM:30uM	NEWCL10084	IGROV-1	48h:2.68uM	48h:35.92uM	.	NEWCL20454	IGROV1-R10	48h:3.03uM	48h:189.10uM	1.5uM:30uM	.	.	.	.	.	.	.	.	.	.	MO6614	ERCC1	Down-regulation	A2780.CP70	17.00%	0.68%	9.61%	IGROV1-R10	18.52%	5.94%	17.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	SFN enhances cisplatin sensitivity of ovarian carcinoma cells through up-regulating miR-30a-3p to induce DNA damage and accumulation of intracellular cisplatin.
C35946	32458631	DIS0021	NP0031	Hesperetin	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	95 uM:0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HER2	Down-regulation	MCF-7	62.18%	61.40%	56.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of Hst and Dox-induced cell cycle arrest, apoptosis, decreased HER2, Rac1, MMP9 expression, and cell migration."
C35946	32458631	DIS0021	NP0031	Hesperetin	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	95 uM:0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	MCF-7	16.29%	20.39%	26.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of Hst and Dox-induced cell cycle arrest, apoptosis, decreased HER2, Rac1, MMP9 expression, and cell migration."
C35946	32458631	DIS0021	NP0031	Hesperetin	DR4469	Doxorubicin	NEWCL00155	MCF-7	.	.	95 uM:0.2 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Rac1	Down-regulation	MCF-7	74.37%	54.24%	85.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of Hst and Dox-induced cell cycle arrest, apoptosis, decreased HER2, Rac1, MMP9 expression, and cell migration."
C99902	32489337	DIS0124	NP9550	Garcinol	DR1669	Cisplatin	NEWCL00134	OVCAR-3	.	.	25 uM:4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	OVCAR-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Garcinol in combination with DDP promoted cell apoptosis in human ovarian cancer cells.
C20591	32497083	DIS0042	NP4688	Methyl gallate	DR4000	Marbofloxacin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	MG has shown to increase the antimicrobial activity of MAR in vitro and ex vivo experiments without affecting the pharmacokinetics of MAR in rats.
C98052	32531316	DIS0019	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00250	KTC-1	12h:150.8uM; 24h:93.36uM; 48h:43.56uM	12h:115uM; 24h:67.56uM; 48h:37.08uM	50uM:100nM	NEWCL00263	TPC-1	12h:155.5uM; 24h:94.38uM; 48h:37.62uM	12h:98.23uM; 24h:58.69uM; 48h:34.83uM	50uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	KTC-1	4.13%	12.77%	13.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol sensitizes the anti-tumor effects of rapamycin and the PI3K/AKT/mTOR signaling is involved.
C98052	32531316	DIS0019	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00250	KTC-1	12h:150.8uM; 24h:93.36uM; 48h:43.56uM	12h:115uM; 24h:67.56uM; 48h:37.08uM	50uM:100nM	NEWCL00263	TPC-1	12h:155.5uM; 24h:94.38uM; 48h:37.62uM	12h:98.23uM; 24h:58.69uM; 48h:34.83uM	50uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Up-regulation	KTC-1	0.99%	12.67%	13.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol sensitizes the anti-tumor effects of rapamycin and the PI3K/AKT/mTOR signaling is involved.
C98052	32531316	DIS0019	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00250	KTC-1	12h:150.8uM; 24h:93.36uM; 48h:43.56uM	12h:115uM; 24h:67.56uM; 48h:37.08uM	50uM:100nM	NEWCL00263	TPC-1	12h:155.5uM; 24h:94.38uM; 48h:37.62uM	12h:98.23uM; 24h:58.69uM; 48h:34.83uM	50uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	KTC-1	4.16%	17.04%	8.76%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol sensitizes the anti-tumor effects of rapamycin and the PI3K/AKT/mTOR signaling is involved.
C98052	32531316	DIS0019	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00250	KTC-1	12h:150.8uM; 24h:93.36uM; 48h:43.56uM	12h:115uM; 24h:67.56uM; 48h:37.08uM	50uM:100nM	NEWCL00263	TPC-1	12h:155.5uM; 24h:94.38uM; 48h:37.62uM	12h:98.23uM; 24h:58.69uM; 48h:34.83uM	50uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	KTC-1	27.99%	27.41%	39.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol sensitizes the anti-tumor effects of rapamycin and the PI3K/AKT/mTOR signaling is involved.
C98052	32531316	DIS0019	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00250	KTC-1	12h:150.8uM; 24h:93.36uM; 48h:43.56uM	12h:115uM; 24h:67.56uM; 48h:37.08uM	50uM:100nM	NEWCL00263	TPC-1	12h:155.5uM; 24h:94.38uM; 48h:37.62uM	12h:98.23uM; 24h:58.69uM; 48h:34.83uM	50uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	KTC-1	4.71%	20.98%	15.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol sensitizes the anti-tumor effects of rapamycin and the PI3K/AKT/mTOR signaling is involved.
C98052	32531316	DIS0019	NP6084	Resveratrol	DR4137	Rapamycin	NEWCL00250	KTC-1	12h:150.8uM; 24h:93.36uM; 48h:43.56uM	12h:115uM; 24h:67.56uM; 48h:37.08uM	50uM:100nM	NEWCL00263	TPC-1	12h:155.5uM; 24h:94.38uM; 48h:37.62uM	12h:98.23uM; 24h:58.69uM; 48h:34.83uM	50uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	KTC-1	0.07%	6.91%	1.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Resveratrol sensitizes the anti-tumor effects of rapamycin and the PI3K/AKT/mTOR signaling is involved.
C27955	32539919	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL00353	RKO	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Up-regulation	RKO	1.30%	38.25%	50.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C27955	32539919	DIS0115	NP8902	Ursolic acid	DR0141	Oxaliplatin	NEWCL00353	RKO	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	RKO	34.32%	46.74%	38.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."
C87707	32565734	DIS0025	NP6993	Arsenic trioxide	DR6231	Gilteritinib	NEWCL10119	MV4-11	48h:0.82uM	48h:3.02nM	0.5uM:2.5nM	NEWCL00020	MOLM-13	48h:0.89uM	48h:2.58nM	0.5uM:2.5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-FLT3	Down-regulation	MV4-11	68.83%	4.39%	67.35%	MOLM13	68.50%	1.37%	73.95%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress.
C87707	32565734	DIS0025	NP6993	Arsenic trioxide	DR6231	Gilteritinib	NEWCL10119	MV4-11	48h:0.82uM	48h:3.02nM	0.5uM:2.5nM	NEWCL00020	MOLM-13	48h:0.89uM	48h:2.58nM	0.5uM:2.5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9634	P-STAT5	Down-regulation	MV4-11	11.19%	73.19%	75.43%	MOLM13	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress.
C87707	32565734	DIS0025	NP6993	Arsenic trioxide	DR6231	Gilteritinib	NEWCL10119	MV4-11	48h:0.82uM	48h:3.02nM	0.5uM:2.5nM	NEWCL00020	MOLM-13	48h:0.89uM	48h:2.58nM	0.5uM:2.5nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MV4-11	10.31%	54.98%	59.97%	MOLM13	7.97%	47.03%	45.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress.
C96787	32575994	DIS0112	NP9796	Betulinic Acid	DR1669	Cisplatin	NEWCL00102	TE-11	.	.	3 uM :15 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Down-regulation	TE-11	33.27%	54.05%	73.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Betulinic acid enhances the chemical sensitivity of esophageal cancer cells to cisplatin by inhibiting cell proliferation, reducing cell stemness, and inducing pyroptosis."
C96787	32575994	DIS0112	NP9796	Betulinic Acid	DR1669	Cisplatin	NEWCL00102	TE-11	.	.	3 uM :15 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1113	Cleave-caspase-1	Up-regulation	TE-11	7.23%	37.88%	59.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Betulinic acid enhances the chemical sensitivity of esophageal cancer cells to cisplatin by inhibiting cell proliferation, reducing cell stemness, and inducing pyroptosis."
C96787	32575994	DIS0112	NP9796	Betulinic Acid	DR1669	Cisplatin	NEWCL00102	TE-11	.	.	3 uM :15 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1462	SOX2	Down-regulation	TE-11	1.73%	24.39%	45.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Betulinic acid enhances the chemical sensitivity of esophageal cancer cells to cisplatin by inhibiting cell proliferation, reducing cell stemness, and inducing pyroptosis."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Down-regulation	BT-549	1.26%	0.62%	62.48%	MDA-MB-231	16.02%	50.82%	72.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p85	Down-regulation	BT-549	11.07%	23.44%	31.97%	MDA-MB-231	0.97%	59.07%	74.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7878	P-PDK1	Down-regulation	BT-549	10.04%	1.87%	51.07%	MDA-MB-231	6.15%	3.70%	7.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1418	P-cRAF	Down-regulation	BT-549	.	.	.	MDA-MB-231	4.40%	0.65%	58.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	BT-549	23.33%	28.10%	28.74%	MDA-MB-231	40.65%	49.22%	51.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	BT-549	1.47%	11.53%	39.15%	MDA-MB-231	40.07%	3.19%	53.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	BT-549	24.39%	41.36%	65.63%	MDA-MB-231	2.57%	27.33%	24.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	BT-549	21.69%	15.54%	49.92%	MDA-MB-231	0.42%	19.82%	42.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	BT-549	26.06%	48.97%	64.67%	MDA-MB-231	5.99%	17.86%	42.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	MDA-MB-231	50.27%	60.67%	67.85%	BT549	36.80%	10.36%	71.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	MDA-MB-231	6.90%	4.20%	63.45%	BT549	4.79%	12.49%	50.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	MDA-MB-231	2.66%	36.96%	56.21%	BT549	4.59%	27.47%	23.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	MDA-MB-231	23.23%	6.42%	49.19%	BT549	1.94%	10.95%	29.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MDA-MB-231	6.46%	44.24%	47.93%	BT549	1.81%	9.47%	28.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MDA-MB-231	24.30%	63.99%	66.23%	BT549	50.99%	92.20%	94.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MDA-MB-231	133.82%	154.56%	248.52%	BT549	79.69%	94.14%	121.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MDA-MB-231	0.62%	9.62%	38.55%	BT549	9.33%	5.66%	59.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	NOG	Down-regulation	MDA-MB-231	6.60%	7.35%	17.10%	BT549	13.37%	9.93%	52.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7943	CD44	Down-regulation	MDA-MB-231	2.78%	2.81%	13.28%	BT549	29.56%	30.12%	33.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	MDA-MB-231	8.43%	38.90%	56.45%	BT549	2.17%	1.65%	52.26%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-P85	Down-regulation	MDA-MB-231	0.41%	47.58%	71.48%	BT549	12.39%	26.34%	28.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P110r	Down-regulation	MDA-MB-231	2.26%	12.85%	24.03%	BT549	10.24%	21.74%	35.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PPDK1	Down-regulation	MDA-MB-231	.	.	.	BT549	15.07%	10.34%	54.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P110a	Down-regulation	MDA-MB-231	14.99%	19.86%	18.07%	BT549	1.13%	9.80%	59.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-P38	Up-regulation	MDA-MB-231	2.04%	11.00%	57.02%	BT549	67.03%	194.21%	282.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	MDA-MB-231	33.63%	44.53%	70.19%	BT549	21.56%	17.89%	27.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C85377	32606741	DIS0021	NP7102	Elemene	DR9021	5-fluorouracil	NEWCL00049	MDA-MB-231	24h:143.562uM	24h:99.141uM	50uM:10uM	NEWCL00162	BT-549	24h:109.258uM	24h:42.038uM	50uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1418	P-cRAF	Down-regulation	MDA-MB-231	6.96%	1.64%	60.07%	BT549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SOD1	Down-regulation	HCT 116	0.98%	20.51%	47.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SOD2	Down-regulation	HCT 116	16.51%	13.80%	30.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CAT	Down-regulation	HCT 116	1.97%	20.05%	20.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7891	Beclin-1	Down-regulation	HCT 116	11.59%	10.74%	10.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	LAMP-1	Down-regulation	HCT 116	9.00%	18.39%	53.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3 II	Down-regulation	HCT 116	18.21%	7.02%	34.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Down-regulation	HCT 116	1.94%	4.06%	3.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	HCT 116	18.68%	17.10%	16.59%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53	Up-regulation	HCT 116	5.22%	181.96%	210.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7847	P-RB	Up-regulation	HCT 116	155.62%	206.47%	357.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AIF	Up-regulation	HCT 116	19.77%	35.07%	92.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	IRE1a	Up-regulation	HCT 116	60.59%	124.97%	163.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HCT 116	11.82%	7.68%	187.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C32924	32619557	DIS0115	NP2717	Tangeretin	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	60 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	HCT 116	2.76%	225.62%	371.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.
C76480	32622951	DIS0029	NP5775	Cyclopamine	DR6516	Temozolomide	NEWCL20373	GBM95	.	.	7.5 uM:250 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1462	SOX2	Up-regulation	GBM95	173.84%	1232.79%	639.22%	GBM02	22.35%	1575.78%	1438.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Combination of TMZ with micellarized Cyp is a promising strategy for exerting different functions of drugs for tumor treatment.
C40950	32626988	DIS0025	NP6636	Daunorubicin	DR6085	NL-101	NEWCL10119	MV4-11	.	.	8nM:300nM	NEWCL00022	HL-60	.	.	16nM:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	Gama-H2AX	Up-regulation	MV4-11	43.60%	18.22%	132.73%	HL-60	57.56%	20.03%	264.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	NL 101 in combination with daunorubicin could be an alternative novel therapeutic strategy for treating leukemia.
C40950	32626988	DIS0025	NP6636	Daunorubicin	DR6085	NL-101	NEWCL10119	MV4-11	.	.	8nM:300nM	NEWCL00022	HL-60	.	.	16nM:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ATR	Up-regulation	MV4-11	42.43%	10.12%	73.85%	HL-60	120.24%	46.69%	303.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	NL 101 in combination with daunorubicin could be an alternative novel therapeutic strategy for treating leukemia.
C40950	32626988	DIS0025	NP6636	Daunorubicin	DR6085	NL-101	NEWCL10119	MV4-11	.	.	8nM:300nM	NEWCL00022	HL-60	.	.	16nM:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4172	P-ATM	Up-regulation	MV4-11	162.73%	5.88%	451.92%	HL-60	12.28%	24.03%	109.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	NL 101 in combination with daunorubicin could be an alternative novel therapeutic strategy for treating leukemia.
C40950	32626988	DIS0025	NP6636	Daunorubicin	DR6085	NL-101	NEWCL10119	MV4-11	.	.	8nM:300nM	NEWCL00022	HL-60	.	.	16nM:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4688	P-CHK1	Up-regulation	MV4-11	112.06%	180.08%	384.34%	HL-60	0.25%	-20.27%	123.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	NL 101 in combination with daunorubicin could be an alternative novel therapeutic strategy for treating leukemia.
C40950	32626988	DIS0025	NP6636	Daunorubicin	DR6085	NL-101	NEWCL10119	MV4-11	.	.	8nM:300nM	NEWCL00022	HL-60	.	.	16nM:500nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9803	P-CHK2	Up-regulation	MV4-11	90.76%	35.66%	138.72%	HL-60	117.54%	74.42%	352.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	NL 101 in combination with daunorubicin could be an alternative novel therapeutic strategy for treating leukemia.
C46171	32635337	DIS0020	NP3718	Honokiol	DR4137	Rapamycin	NEWCL00256	786-O	.	.	40 uM:15 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	786-O	37.97%	100.99%	126.66%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Honokiol can effectively overcome the limitation of Rapamycin treatment alone, and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer."
C46171	32635337	DIS0020	NP3718	Honokiol	DR4137	Rapamycin	NEWCL00256	786-O	.	.	40 uM:15 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	786-O	30.99%	2.68%	54.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Honokiol can effectively overcome the limitation of Rapamycin treatment alone, and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer."
C46171	32635337	DIS0020	NP3718	Honokiol	DR4137	Rapamycin	NEWCL00256	786-O	.	.	40 uM:15 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	786-O	4.67%	3.84%	23.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Honokiol can effectively overcome the limitation of Rapamycin treatment alone, and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer."
C46171	32635337	DIS0020	NP3718	Honokiol	DR4137	Rapamycin	NEWCL00256	786-O	.	.	40 uM:15 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	786-O	3.03%	1.49%	47.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Honokiol can effectively overcome the limitation of Rapamycin treatment alone, and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer."
C46171	32635337	DIS0020	NP3718	Honokiol	DR4137	Rapamycin	NEWCL00256	786-O	.	.	40 uM:15 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	786-O	13.67%	11.93%	54.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Honokiol can effectively overcome the limitation of Rapamycin treatment alone, and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer."
C46171	32635337	DIS0020	NP3718	Honokiol	DR4137	Rapamycin	NEWCL00256	786-O	.	.	40 uM:15 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7859	HO-1	Down-regulation	786-O	6.38%	7.46%	52.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Honokiol can effectively overcome the limitation of Rapamycin treatment alone, and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer."
C31463	32635653	DIS0054	NP3545	Schisandrol B	DR4185	Albendazole	.	.	.	.	20mg.kg:20mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	NLRC4	Down-regulation	.	51.47%	65.21%	83.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Albendazole-schisandrin B co-treatment significantly inhibited inflammasome activation, pyroptosis, and apoptosis."
C31463	32635653	DIS0054	NP3545	Schisandrol B	DR4185	Albendazole	.	.	.	.	20mg.kg:20mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	NLRP1B	Down-regulation	.	30.27%	29.59%	21.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Albendazole-schisandrin B co-treatment significantly inhibited inflammasome activation, pyroptosis, and apoptosis."
C31463	32635653	DIS0054	NP3545	Schisandrol B	DR4185	Albendazole	.	.	.	.	20mg.kg:20mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1113	Caspase-1	Down-regulation	.	76.85%	61.56%	82.07%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Albendazole-schisandrin B co-treatment significantly inhibited inflammasome activation, pyroptosis, and apoptosis."
C31463	32635653	DIS0054	NP3545	Schisandrol B	DR4185	Albendazole	.	.	.	.	20mg.kg:20mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	IL-18	Down-regulation	.	58.78%	44.19%	60.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Albendazole-schisandrin B co-treatment significantly inhibited inflammasome activation, pyroptosis, and apoptosis."
C31463	32635653	DIS0054	NP3545	Schisandrol B	DR4185	Albendazole	.	.	.	.	20mg.kg:20mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5331	IL-1beta	Down-regulation	.	69.78%	35.27%	72.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Albendazole-schisandrin B co-treatment significantly inhibited inflammasome activation, pyroptosis, and apoptosis."
C31463	32635653	DIS0054	NP3545	Schisandrol B	DR4185	Albendazole	.	.	.	.	20mg.kg:20mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GSDMD	Down-regulation	.	38.61%	49.48%	62.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Albendazole-schisandrin B co-treatment significantly inhibited inflammasome activation, pyroptosis, and apoptosis."
C92614	32637030	DIS0028	NP1644	Vincristine	DR9224	BI-D1870	NEWCL00020	MOLM-13	.	48h:1.62uM	.	NEWCL10119	MV4-11	.	48h:1.91uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"BI-D1870 induces apoptosis of AML cells alone and in combination with vincristine through blocking mitotic exit, providing a novel approach to overcoming vincristine resistance in AML cells."
C95098	32645343	DIS0021	NP6993	Arsenic trioxide	DR7740	BIBR1532	NEWCL00155	MCF-7	.	48h:13.4 uM	.	NEWCL10166	MDA-231	.	48h:7.3 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-KappaB signaling pathway.
C74309	32657048	DIS0112	NP3247	Artemisinin	DR0141	Oxaliplatin	NEWCL00098	Eca-109	55.33uM	38.99uM	20 uM:18 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	EC109	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/beta-catenin signaling pathway.
C69357	32673286	DIS0031	NP5732	Osthole	DR1669	Cisplatin	NEWCL00031	Huh-7	.	.	10 umol.L:5umol.L	NEWCL00129	Hep-G2	.	.	10 umol.L:5umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	Huh-7 CD133+ cells	60.80%	14.24%	80.26%	Hep-G2CD133+ cells	75.61%	20.33%	-58.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C69357	32673286	DIS0031	NP5732	Osthole	DR1669	Cisplatin	NEWCL00031	Huh-7	.	.	10 umol.L:5umol.L	NEWCL00129	Hep-G2	.	.	10 umol.L:5umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	Huh-7 CD133+ cells	53.90%	0.21%	57.56%	Hep-G2CD133+ cells	24.18%	2.00%	31.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C69357	32673286	DIS0031	NP5732	Osthole	DR1669	Cisplatin	NEWCL00031	Huh-7	.	.	10 umol.L:5umol.L	NEWCL00129	Hep-G2	.	.	10 umol.L:5umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8745	P-Bad	Down-regulation	Huh-7 CD133+ cells	29.63%	0.12%	60.53%	Hep-G2CD133+ cells	27.44%	4.63%	34.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C69357	32673286	DIS0031	NP5732	Osthole	DR1669	Cisplatin	NEWCL00031	Huh-7	.	.	10 umol.L:5umol.L	NEWCL00129	Hep-G2	.	.	10 umol.L:5umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	Huh-7 CD133+ cells	13.87%	66.89%	174.37%	Hep-G2CD133+ cells	19.81%	51.10%	197.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C69357	32673286	DIS0031	NP5732	Osthole	DR1669	Cisplatin	NEWCL00031	Huh-7	.	.	10 umol.L:5umol.L	NEWCL00129	Hep-G2	.	.	10 umol.L:5umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	Huh-7 CD133+ cells	23.13%	87.91%	216.72%	Hep-G2CD133+ cells	36.72%	103.67%	212.67%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C69357	32673286	DIS0031	NP5732	Osthole	DR1669	Cisplatin	NEWCL00031	Huh-7	.	.	10 umol.L:5umol.L	NEWCL00129	Hep-G2	.	.	10 umol.L:5umol.L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Huh-7 CD133+ cells	30.41%	69.40%	202.62%	Hep-G2CD133+ cells	32.00%	65.81%	207.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Up-regulation	U251-MG	7.24%	54.46%	493.06%	T98G	-33.68%	18.12%	141.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	U251-MG	.	.	.	T98G	19.74%	6.29%	312.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Up-regulation	U-87MG ATCC	4.95%	0.55%	6.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Down-regulation	U251-MG	.	.	.	T98G	11.76%	16.84%	68.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Down-regulation	U251-MG	.	.	.	T98G	34.30%	20.67%	65.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	U251-MG	0.30%	0.56%	14.29%	T98G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	U251-MG	11.68%	2.61%	7.94%	T98G	1.78%	2.81%	8.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	U251-MG	5.72%	0.73%	77.09%	T98G	0.08%	1.03%	73.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	U251-MG	4.68%	5.66%	60.97%	T98G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3122	Cyclin E	Down-regulation	U251-MG	51.41%	18.81%	72.99%	T98G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C67973	32693671	DIS0029	NP7608	Piperine	DR6516	Temozolomide	NEWCL00039	U-251MG	.	.	10 uM:10 uM	NEWCL00123	T98G	.	.	50 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	U251-MG	26.82%	0.14%	84.89%	T98G	3.47%	27.96%	80.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
C12780	32699295	DIS0028	NP4621	Triptolide	DR2639	Venetoclax	NEWCL10119	MV4-11	.	.	3nM:3nM	NEWCL00023	KG-1a	.	.	5nM:30nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PUMA	Up-regulation	MV4-11	137.02%	64.54%	124.33%	KG-1a	2.56%	7.24%	8.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
C12780	32699295	DIS0028	NP4621	Triptolide	DR2639	Venetoclax	NEWCL10119	MV4-11	.	.	3nM:3nM	NEWCL00023	KG-1a	.	.	5nM:30nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim	Up-regulation	MV4-11	65.62%	64.28%	71.19%	KG-1a	41.19%	59.82%	377.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
C12780	32699295	DIS0028	NP4621	Triptolide	DR2639	Venetoclax	NEWCL10119	MV4-11	.	.	3nM:3nM	NEWCL00023	KG-1a	.	.	5nM:30nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Up-regulation	MV4-11	18.96%	13.49%	19.30%	KG-1a	129.15%	90.19%	142.46%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
C12780	32699295	DIS0028	NP4621	Triptolide	DR2639	Venetoclax	NEWCL10119	MV4-11	.	.	3nM:3nM	NEWCL00023	KG-1a	.	.	5nM:30nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7894	NOXA	Up-regulation	MV4-11	24.96%	23.89%	18.67%	KG-1a	55.22%	25.61%	49.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
C12780	32699295	DIS0028	NP4621	Triptolide	DR2639	Venetoclax	NEWCL10119	MV4-11	.	.	3nM:3nM	NEWCL00023	KG-1a	.	.	5nM:30nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	MV4-11	0.20%	1.87%	34.23%	KG-1a	1.00%	2.95%	21.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
C12780	32699295	DIS0028	NP4621	Triptolide	DR2639	Venetoclax	NEWCL10119	MV4-11	.	.	3nM:3nM	NEWCL00023	KG-1a	.	.	5nM:30nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MV4-11	.	.	.	KG-1a	3.75%	3.08%	69.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
C12780	32699295	DIS0028	NP4621	Triptolide	DR2639	Venetoclax	NEWCL10119	MV4-11	.	.	3nM:3nM	NEWCL00023	KG-1a	.	.	5nM:30nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	MV4-11	.	.	.	KG-1a	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
C12780	32699295	DIS0028	NP4621	Triptolide	DR2639	Venetoclax	NEWCL10119	MV4-11	.	.	3nM:3nM	NEWCL00023	KG-1a	.	.	5nM:30nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	MV4-11	0.52%	0.23%	8.21%	KG-1a	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
C97336	32718121	DIS0127	NP4931	Lycopene	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	10 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HeLa	25.83%	47.74%	63.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-kappaB) pathway.
C97336	32718121	DIS0127	NP4931	Lycopene	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	10 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HeLa	6.77%	91.83%	209.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-kappaB) pathway.
C97336	32718121	DIS0127	NP4931	Lycopene	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	10 uM:1 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	NF-KB	Down-regulation	HeLa	11.08%	-30.08%	55.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-kappaB) pathway.
C87955	32748870	DIS0023	NP6047	Metformin	DR7612	Everolimus	NEWCL10368	QGP-1	.	.	10mM:10nM	NEWCL20436	H727-R	.	.	10mM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	QGP-1	13.88%	32.02%	65.83%	H727	9.69%	27.83%	43.93%	QGP-1R	16.20%	3.30%	27.48%	H727-R	2.28%	0.14%	5.88%	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
C87955	32748870	DIS0023	NP6047	Metformin	DR7612	Everolimus	NEWCL10368	QGP-1	.	.	10mM:10nM	NEWCL20436	H727-R	.	.	10mM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	QGP-1	28.48%	35.28%	53.68%	H727-R	21.63%	42.60%	26.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
C33862	32768576	DIS0022	NP4620	Apigenin	DR1669	Cisplatin	NEWCL00170	A-549	.	.	20 uM:2uM	NEWCL00180	NCI-H460	.	.	20 uM:2uM	NEWCL00181	NCI-H1299	.	.	20 uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A-549	.	.	.	NCI-H460	.	.	.	H1299	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Apigenin and myricetin exhibited a protective and promising preventive strategy against cisplatin-induced nephrotoxicity due to their antioxidant and anti-inflammatory effects.
C97187	32777260	DIS0022	NP1559	Luteolin	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	20 uM:25 ng.mL	NEWCL00171	NCI-H1975	.	.	20 uM:25 ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DR5	Up-regulation	A-549	15.06%	2.58%	12.54%	NCI-H1975	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model.
C98820	32800546	DIS0021	NP1559	Luteolin	DR6077	Lapatinib	NEWCL00160	BT-474	24h:14.84	24h:29.36	.	NEWCL00159	ZR-75-1	14.84	42.41	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5767	FOXO3	Up-regulation	BT-474	12.40%	24.41%	26.06%	ZR-75-1	25.06%	19.33%	30.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway.
C78723	32805254	DIS0022	NP5023	Gambogic acid	DR2391	Gemcitabine	NEWCL00170	A-549	.	.	200nM:200nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2144	BAK	Up-regulation	A-549	35.62%	131.23%	203.15%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
C78723	32805254	DIS0022	NP5023	Gambogic acid	DR2391	Gemcitabine	NEWCL00170	A-549	.	.	200nM:200nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	36.96%	637.84%	1062.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
C78723	32805254	DIS0022	NP5023	Gambogic acid	DR2391	Gemcitabine	NEWCL00170	A-549	.	.	200nM:200nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	14.02%	272.86%	383.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
C76104	32818507	DIS0023	NP2960	Epigallocatechin gallate	DR4469	Doxorubicin	NEWCL00242	Panc-1	48h:62.8± 2.5	.	.	NEWCL00236	MIA PaCa-2	32.4± 5.5	.	.	NEWCL00243	BxPC-3	9.8± 4.1 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2491	P-STAT3	Down-regulation	PANC-1	5.81%	35.29%	60.09%	MIA PACA-2	3.00%	19.95%	47.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG could chemosensitize resistant tumor cells to DOX in vivo through an increase in the accumulation of DOX in the tumors.
C76104	32818507	DIS0023	NP2960	Epigallocatechin gallate	DR2391	Gemcitabine	NEWCL00074	SW480	 4.5± 1.4 	.	.	NEWCL20416	HCT15	0.3± 0.2	.	.	NEWCL00344	HT29	59.1± 3.1 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK1.2	Up-regulation	PANC-1	330.23%	263.01%	318.82%	MIA PACA-2	1.05%	2.99%	-10.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG could chemosensitize resistant tumor cells to DOX in vivo through an increase in the accumulation of DOX in the tumors.
C76104	32818507	DIS0023	NP2960	Epigallocatechin gallate	DR2391	Gemcitabine	NEWCL00171	NCI-H1975	21.6± 0.9	.	.	NEWCL00199	NCI-H358	45.9± 4.0 	.	.	NEWCL00170	A-549	36.0± 2.4 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	EGCG could chemosensitize resistant tumor cells to DOX in vivo through an increase in the accumulation of DOX in the tumors.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5524	Cyclin A	Down-regulation	PC-3	47.94%	29.12%	56.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MPM-2	Up-regulation	PC-3	598.23%	9.77%	802.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0602	P-CDK1(Tyr15)	Down-regulation	PC-3	72.37%	45.49%	92.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0602	P-CDK1(Tyr161)	Down-regulation	PC-3	1.70%	5.69%	2.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-stathmin	Up-regulation	PC-3	58.57%	0.65%	149.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	PC-3	37.63%	28.26%	67.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	P-Bcl2	Up-regulation	PC-3	149.15%	15.47%	192.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	PC-3	18.31%	3.71%	79.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	Up-regulation	PC-3	6.79%	4.10%	9.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	PC-3	5.29%	6.33%	1.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP-1	Down-regulation	PC-3	8.24%	1.40%	0.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C66872	32850387	DIS0129	NP1644	Vincristine	DR9900	Sildefil	NEWCL00253	PC-3	.	.	10 nM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-BUBR1	Up-regulation	PC-3	241.19%	23.58%	292.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.
C49649	32859062	DIS0133	NP6905	Curcumin	DR1669	Cisplatin	NEWCL00266	PE.CA-PJ49	59.3 ±  6.1uM	9.72 ±  1.7uM	15 uM: 5.20 uM	NEWCL10158	HUVEC	59.3 ±  6.1uM	20.93 ±  2.1uM	15 uM: 5.20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis.
C03179	32883022	DIS0025	NP6993	Arsenic trioxide	DR6061	Lelidomide	NEWCL10096	BC-3	.	.	1uM:0.5uM	NEWCL10117	BCBL-1	.	.	1uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	LANA-1	Down-regulation	BC3	6.92%	7.13%	77.22%	BCBL-1	43.27%	80.96%	80.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Lenalidomide in combination with arsenic trioxide is an effective therapy for primary effusion lymphoma.
C03179	32883022	DIS0025	NP6993	Arsenic trioxide	DR6061	Lelidomide	NEWCL10096	BC-3	.	.	1uM:0.5uM	NEWCL10117	BCBL-1	.	.	1uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	LANA-2	Down-regulation	BC3	24.24%	8.68%	66.47%	BCBL-1	14.77%	41.48%	72.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Lenalidomide in combination with arsenic trioxide is an effective therapy for primary effusion lymphoma.
C03179	32883022	DIS0025	NP6993	Arsenic trioxide	DR6061	Lelidomide	NEWCL10096	BC-3	.	.	1uM:0.5uM	NEWCL10117	BCBL-1	.	.	1uM:0.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-IKBalpha	Down-regulation	BC3	2.89%	14.09%	71.00%	BCBL-1	1.72%	13.09%	69.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Lenalidomide in combination with arsenic trioxide is an effective therapy for primary effusion lymphoma.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	1.96%	9.28%	23.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Caspase-8	.	A-549	0.53%	14.74%	22.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	15.30%	32.49%	82.99%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	TBid	Up-regulation	A-549	49.41%	173.91%	466.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	22.66%	41.35%	54.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	11.50%	30.80%	104.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P-p53	Up-regulation	A-549	3.04%	160.74%	297.87%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ATR	Up-regulation	A-549	50.02%	41.34%	61.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4172	P-ATM	Up-regulation	A-549	28.08%	134.64%	310.05%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	P-H2AX	Up-regulation	A-549	72.91%	84.03%	92.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A-549	38.78%	123.60%	203.83%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C99302	32929340	DIS0022	NP2740	Borneol	DR4469	Doxorubicin	NEWCL00170	A-549	.	.	160 ug.mL:250nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4847	P-JNK	Up-regulation	A-549	9.77%	76.86%	194.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.
C50333	32945513	DIS0023	NP6905	Curcumin	DR2391	Gemcitabine	NEWCL00242	PANC-1	9.87uM	.	5 uM:10uM	NEWCL00238	HPAF-II	13.49uM	.	5 uM:10uM	NEWCL00236	MIA PaCa-2	45.96 uM	.	5 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	N-cadherin	Down-regulation	PANC-1	19.37%	35.58%	56.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	32945513	DIS0023	NP6905	Curcumin	DR7626	Docetaxel	NEWCL00242	PANC-1	9.87uM	.	5 uM:10uM	NEWCL00238	HPAF-II	13.49uM	.	5 uM:10uM	NEWCL00236	MIA PaCa-2	45.96 uM	.	5 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	PANC-1	64.56%	85.03%	169.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	32945513	DIS0023	NP6905	Curcumin	DR7626	Docetaxel	NEWCL00242	PANC-1	9.87uM	.	5 uM:10uM	NEWCL00238	HPAF-II	13.49uM	.	5 uM:10uM	NEWCL00236	MIA PaCa-2	45.96 uM	.	5 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2143	TIMP1	Down-regulation	PANC-1	12.05%	18.07%	58.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	32945513	DIS0023	NP6905	Curcumin	DR7626	Docetaxel	NEWCL00242	PANC-1	9.87uM	.	5 uM:10uM	NEWCL00238	HPAF-II	13.49uM	.	5 uM:10uM	NEWCL00236	MIA PaCa-2	45.96 uM	.	5 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	PANC-1	0.81%	5.69%	2.84%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	32945513	DIS0023	NP6905	Curcumin	DR7626	Docetaxel	NEWCL00242	PANC-1	9.87uM	.	5 uM:10uM	NEWCL00238	HPAF-II	13.49uM	.	5 uM:10uM	NEWCL00236	MIA PaCa-2	45.96 uM	.	5 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TIMP2	Down-regulation	PANC-1	10.29%	17.65%	82.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	32945513	DIS0023	NP6905	Curcumin	DR7626	Docetaxel	NEWCL00242	PANC-1	9.87uM	.	5 uM:10uM	NEWCL00238	HPAF-II	13.49uM	.	5 uM:10uM	NEWCL00236	MIA PaCa-2	45.96 uM	.	5 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	PANC-1	9.19%	30.45%	24.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C50333	32945513	DIS0023	NP6905	Curcumin	DR7626	Docetaxel	NEWCL00242	PANC-1	9.87uM	.	5 uM:10uM	NEWCL00238	HPAF-II	13.49uM	.	5 uM:10uM	NEWCL00236	MIA PaCa-2	45.96 uM	.	5 uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	PANC-1	33.16%	30.33%	49.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."
C28922	32963615	DIS0022	NP6514	Demethoxycurcumin	DR1669	Cisplatin	NEWCL00170	A-549	48h:19.88uM	48h:3.8uM	5uM:3.8uM	NEWCL10341	MRC-5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A-549	1.27%	7.41%	54.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.
C28922	32963615	DIS0022	NP6514	Demethoxycurcumin	DR1669	Cisplatin	NEWCL00170	A-549	48h:19.88uM	48h:3.8uM	5uM:3.8uM	NEWCL10341	MRC-5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A-549	47.83%	103.13%	109.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.
C28922	32963615	DIS0022	NP6514	Demethoxycurcumin	DR1669	Cisplatin	NEWCL00170	A-549	48h:19.88uM	48h:3.8uM	5uM:3.8uM	NEWCL10341	MRC-5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	27.78%	37.34%	69.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.
C28922	32963615	DIS0022	NP6514	Demethoxycurcumin	DR1669	Cisplatin	NEWCL00170	A-549	48h:19.88uM	48h:3.8uM	5uM:3.8uM	NEWCL10341	MRC-5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6614	ERCC1	Down-regulation	A-549	6.58%	34.32%	31.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0645	PTEN	Up-regulation	HGC-27	181.92%	70.91%	190.81%	SGC-7901	0.80%	0.85%	5.27%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	AIF	Up-regulation	HGC-27	3.39%	1.74%	2.76%	SGC-7901	2.00%	0.43%	2.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	HGC-27	219.16%	102.31%	223.73%	SGC-7901	11.41%	12.07%	16.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	HGC-27	238.20%	208.80%	241.30%	SGC-7901	46.90%	36.93%	54.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	HGC-27	6.47%	6.03%	6.71%	SGC-7901	80.36%	80.66%	89.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HGC-27	184.88%	114.82%	197.40%	SGC-7901	46.70%	47.76%	53.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	HGC-27	3.45%	2.29%	47.31%	SGC-7901	1.32%	0.65%	34.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	HGC-27	0.30%	1.22%	40.23%	SGC-7901	4.25%	2.33%	17.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	HGC-27	2.52%	3.74%	48.56%	SGC-7901	18.18%	5.79%	75.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HGC-27	1.68%	0.91%	4.75%	SGC-7901	7.79%	3.31%	58.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C36772	32973533	DIS0024	NP0031	Hesperetin	DR1669	Cisplatin	NEWCL10086	HGC-27	.	24h:3.85 ±  0.08	200 uM:4 ug.ml	NEWCL00142	SGC-7901	.	24h:4.36 ±  0.22	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	HGC-27	0.37%	0.73%	6.08%	SGC-7901	4.99%	2.80%	4.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."
C59754	33014856	DIS0022	NP0754	Cordycepin	DR3439	Apatinib	NEWCL00170	A-549	160.78uM	19.26uM	150 uM :15 uM	NEWCL00175	PC-9	155.59uM	15.2uM	30 uM:6 uM	NEWCL00181	NCI-H1299	127.89uM	12.79uM	127.89uM:12.79uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VEGFR2	Down-regulation	A-549	3.06%	43.16%	37.87%	PC9	15.34%	15.80%	44.76%	H1993	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of cordycepin and apatinib synergistically inhibits NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway.
C59754	33014856	DIS0022	NP0754	Cordycepin	DR3439	Apatinib	NEWCL00170	A-549	160.78uM	19.26uM	150 uM :15 uM	NEWCL00175	PC-9	155.59uM	15.2uM	30 uM:6 uM	NEWCL00181	NCI-H1299	127.89uM	12.79uM	127.89uM:12.79uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	A550	27.66%	55.84%	56.98%	PC-9	.	.	.	H1993	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of cordycepin and apatinib synergistically inhibits NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway.
C59754	33014856	DIS0022	NP0754	Cordycepin	DR3439	Apatinib	NEWCL00170	A-549	160.78uM	19.26uM	150 uM :15 uM	NEWCL00175	PC-9	155.59uM	15.2uM	30 uM:6 uM	NEWCL00181	NCI-H1299	127.89uM	12.79uM	127.89uM:12.79uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A551	19.85%	11.21%	47.71%	PC-9	84.56%	99.10%	85.78%	H1993	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of cordycepin and apatinib synergistically inhibits NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway.
C59754	33014856	DIS0022	NP0754	Cordycepin	DR3439	Apatinib	NEWCL00170	A-549	160.78uM	19.26uM	150 uM :15 uM	NEWCL00175	PC-9	155.59uM	15.2uM	30 uM:6 uM	NEWCL00181	NCI-H1299	127.89uM	12.79uM	127.89uM:12.79uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	A552	28.58%	53.34%	57.66%	PC-9	25.32%	30.54%	42.93%	H1993	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of cordycepin and apatinib synergistically inhibits NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway.
C59754	33014856	DIS0022	NP0754	Cordycepin	DR3439	Apatinib	NEWCL00170	A-549	160.78uM	19.26uM	150 uM :15 uM	NEWCL00175	PC-9	155.59uM	15.2uM	30 uM:6 uM	NEWCL00181	NCI-H1299	127.89uM	12.79uM	127.89uM:12.79uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7852	P-PI3K	Down-regulation	A553	0.61%	24.56%	48.88%	PC-9	44.87%	39.73%	62.68%	H1993	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of cordycepin and apatinib synergistically inhibits NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway.
C59754	33014856	DIS0022	NP0754	Cordycepin	DR3439	Apatinib	NEWCL00170	A-549	160.78uM	19.26uM	150 uM :15 uM	NEWCL00175	PC-9	155.59uM	15.2uM	30 uM:6 uM	NEWCL00181	NCI-H1299	127.89uM	12.79uM	127.89uM:12.79uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	A554	3.04%	12.61%	19.56%	PC-9	2.20%	42.68%	42.84%	H1993	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of cordycepin and apatinib synergistically inhibits NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway.
C59754	33014856	DIS0022	NP0754	Cordycepin	DR3439	Apatinib	NEWCL00170	A-549	160.78uM	19.26uM	150 uM :15 uM	NEWCL00175	PC-9	155.59uM	15.2uM	30 uM:6 uM	NEWCL00181	NCI-H1299	127.89uM	12.79uM	127.89uM:12.79uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	A555	40.23%	61.05%	70.14%	PC-9	84.93%	127.18%	193.43%	H1993	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Combination of cordycepin and apatinib synergistically inhibits NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway.
C59959	33030061	DIS0031	NP0649	Ellagic acid	DR2073	Sorafenib	.	.	24h:12 uM	24h:8 uM	12uM:8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	EA and SOR are effective on the HCC rat model through mitochondria and hepatocytes targeting.
C55665	33041795	DIS0031	NP6308	Thymoquinone	DR4469	Doxorubicin	NEWCL00151	HL-7702	48h:144.35 ±  3.31uM	48h:0.70 ±  0.08uM	70 uM: 0.25 uM	NEWCL00129	Hep-G2	48h:84.27 ±  1.72uM	48h:1.88 ±  0.07uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71± 1.23uM	24h:3.85± 0.23uM	.	NEWCL00108	MKN45	24h:65.63± 1.52uM	24h:6.27± 0.34uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	NCI-N87	38.30%	48.83%	378.40%	MKN45	294.94%	71.85%	996.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71± 1.23uM	24h:3.85± 0.23uM	.	NEWCL00108	MKN45	24h:65.63± 1.52uM	24h:6.27± 0.34uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	NCI-N87	24.02%	3.18%	63.43%	MKN45	1.55%	12.35%	81.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71± 1.23uM	24h:3.85± 0.23uM	.	NEWCL00108	MKN45	24h:65.63± 1.52uM	24h:6.27± 0.34uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Down-regulation	NCI-N87	10.49%	3.34%	33.23%	MKN45	1.88%	16.80%	16.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71± 1.23uM	24h:3.85± 0.23uM	.	NEWCL00108	MKN45	24h:65.63± 1.52uM	24h:6.27± 0.34uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Up-regulation	NCI-N87	4.96%	1.80%	0.58%	MKN45	4.25%	0.62%	2.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71± 1.23uM	24h:3.85± 0.23uM	.	NEWCL00108	MKN45	24h:65.63± 1.52uM	24h:6.27± 0.34uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-N87	8.25%	133.34%	174.93%	MKN45	43.48%	213.57%	338.11%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71 ±  1.23 uM	24h:3.85 ±  0.23 uM	30uM:4uM	NEWCL00108	MKN45	24h:65.63 ±  1.52uM	24h:6.27 ±  0.34uM	30uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	NCI-N87	10.97%	0.58%	214.59%	MKN45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71 ±  1.23 uM	24h:3.85 ±  0.23 uM	30uM:4uM	NEWCL00108	MKN45	24h:65.63 ±  1.52uM	24h:6.27 ±  0.34uM	30uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	NCI-N87	63.96%	97.47%	260.89%	MKN45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71 ±  1.23 uM	24h:3.85 ±  0.23 uM	30uM:4uM	NEWCL00108	MKN45	24h:65.63 ±  1.52uM	24h:6.27 ±  0.34uM	30uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	NCI-N87	103.35%	235.90%	598.36%	MKN45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71 ±  1.23 uM	24h:3.85 ±  0.23 uM	30uM:4uM	NEWCL00108	MKN45	24h:65.63 ±  1.52uM	24h:6.27 ±  0.34uM	30uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-N87	11.14%	137.71%	162.95%	MKN45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71 ±  1.23 uM	24h:3.85 ±  0.23 uM	30uM:4uM	NEWCL00108	MKN45	24h:65.63 ±  1.52uM	24h:6.27 ±  0.34uM	30uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	NCI-N87	25.29%	21.75%	74.92%	MKN45	1.88%	38.01%	80.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71 ±  1.23 uM	24h:3.85 ±  0.23 uM	30uM:4uM	NEWCL00108	MKN45	24h:65.63 ±  1.52uM	24h:6.27 ±  0.34uM	30uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	NCI-N87	.	.	.	MKN45	5.90%	69.72%	75.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71 ±  1.23 uM	24h:3.85 ±  0.23 uM	30uM:4uM	NEWCL00108	MKN45	24h:65.63 ±  1.52uM	24h:6.27 ±  0.34uM	30uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	NCI-N87	.	.	.	MKN45	3.26%	17.11%	60.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71 ±  1.23 uM	24h:3.85 ±  0.23 uM	30uM:4uM	NEWCL00108	MKN45	24h:65.63 ±  1.52uM	24h:6.27 ±  0.34uM	30uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	NCI-N87	.	.	.	MKN45	13.93%	30.77%	49.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C72207	33047871	DIS0024	NP7687	Pterostilbene	DR2073	Sorafenib	NEWCL00117	NCI-N87	24h:52.71 ±  1.23 uM	24h:3.85 ±  0.23 uM	30uM:4uM	NEWCL00108	MKN45	24h:65.63 ±  1.52uM	24h:6.27 ±  0.34uM	30uM:6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3995	PCNA	Down-regulation	NCI-N87	5.44%	36.32%	32.11%	MKN45	5.56%	12.91%	12.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."
C62469	33049304	DIS0022	NP1406	Cryptotanshinone	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	2.5uM:20uM	NEWCL00170	A-549	.	.	2.5uM:20uM	NEWCL20451	PC9.GR	.	.	2.5uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	NCI-H1975	2.48%	7.22%	10.22%	A-549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase.
C62469	33049304	DIS0022	NP1406	Cryptotanshinone	DR9742	Gefitinib	NEWCL00171	NCI-H1975	.	.	2.5uM:20uM	NEWCL00170	A-549	.	.	2.5uM:20uM	NEWCL20451	PC9.GR	.	.	2.5uM:20uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	NCI-H1975	4.73%	9.75%	42.18%	A-549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase.
C08841	33053721	DIS0124	NP3788	Rosmarinic acid	DR1669	Cisplatin	NEWCL20435	TOV21G.CisR	.	24h:69uM	40uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0372	FOXM1	Down-regulation	TOV21G.CisR	.	6.04%	34.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Rosmarinic acid methyl ester regulates ovarian cancer cell migration and reverses cisplatin resistance by inhibiting the expression of forkhead box M1.
C06881	33059263	DIS0028	NP3806	Ginsenoside compound K	DR7876	Cytarabine	NEWCL00059	THP-1	.	.	30uM:4uM; 24h	NEWCL00019	U-937	.	.	30uM:100nM; 24h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	THP-1	54.35%	78.90%	329.67%	U-937	44.59%	57.71%	419.78%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ara-C combined with CK could achieve the efficacy of higher concentration of ara-C. CK promoted ara-C-induced cell membrane damage and mitochondrial dysfunction and increased ara-C-induced DNA damage.
C06881	33059263	DIS0028	NP3806	Ginsenoside compound K	DR7876	Cytarabine	NEWCL00059	THP-1	.	.	30uM:4uM; 24h	NEWCL00019	U-937	.	.	30uM:100nM; 24h	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	P-H2AX	Up-regulation	THP-1	.	.	.	U-937	24.13%	146.30%	481.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Ara-C combined with CK could achieve the efficacy of higher concentration of ara-C. CK promoted ara-C-induced cell membrane damage and mitochondrial dysfunction and increased ara-C-induced DNA damage.
C94751	33061291	DIS0127	NP1214	Wedelolactone	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	HeLa	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Sequential combination of cisplatin with wedelolactone showed synergistic antitumor effect in cervical cancer cells.
C01479	33114555	DIS0025	NP6636	Daunorubicin	DR6756	Olaparib	NEWCL00082	HCT 116	.	2.48 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	"Olaparib interferes with anthracycline metabolism, and suggest that this phenomenon might be utilized for combating anthracycline resistance."
C31047	33205649	DIS0115	NP0703	Cucurbitacin E	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	1uM:80uM	NEWCL00079	DLD-1	.	.	1uM:80uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9307	ABCC1	Down-regulation	HCT 116	36.83%	26.47%	38.52%	DLD1	61.81%	39.26%	90.96%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cucurbitacin E chemosensitizes colorectal cancer cells via mitigating TFAP4/Wnt/Beta-Catenin signaling.
C31047	33205649	DIS0115	NP0703	Cucurbitacin E	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	1uM:80uM	NEWCL00079	DLD-1	.	.	1uM:80uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7879	MDR1	Down-regulation	HCT 116	55.08%	28.26%	75.05%	DLD1	49.84%	34.19%	59.43%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cucurbitacin E chemosensitizes colorectal cancer cells via mitigating TFAP4/Wnt/Beta-Catenin signaling.
C31047	33205649	DIS0115	NP0703	Cucurbitacin E	DR9021	5-fluorouracil	NEWCL00082	HCT 116	.	.	1uM:80uM	NEWCL00079	DLD-1	.	.	1uM:80uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Beta-Catenin	Down-regulation	HCT 116	14.81%	38.10%	81.75%	DLD1	4.16%	36.12%	74.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Cucurbitacin E chemosensitizes colorectal cancer cells via mitigating TFAP4/Wnt/Beta-Catenin signaling.
C64576	33234363	DIS0021	NP4582	Glycyrrhetinic acid	DR4469	Doxorubicin	NEWCL00155	MCF-7	48h:29.21 uM	48h:0.87 uM	20uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MCF-7	1.23%	7.07%	39.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"DOX/PEG-Fmoc-GA containing micelles facilitated the efficient cleavage of GA in tumor tissues/cells, leading to a higher level of synergistic antitumor activity with DOX in vitro and in vivo."
C64576	33234363	DIS0021	NP4582	Glycyrrhetinic acid	DR4469	Doxorubicin	NEWCL00155	MCF-7	48h:29.21 uM	48h:0.87 uM	20uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	MCF-7	19.01%	70.00%	522.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"DOX/PEG-Fmoc-GA containing micelles facilitated the efficient cleavage of GA in tumor tissues/cells, leading to a higher level of synergistic antitumor activity with DOX in vitro and in vivo."
C64576	33234363	DIS0021	NP4582	Glycyrrhetinic acid	DR4469	Doxorubicin	NEWCL00155	MCF-7	48h:29.21 uM	48h:0.87 uM	20uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MCF-7	6.57%	9.42%	71.75%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"DOX/PEG-Fmoc-GA containing micelles facilitated the efficient cleavage of GA in tumor tissues/cells, leading to a higher level of synergistic antitumor activity with DOX in vitro and in vivo."
C64576	33234363	DIS0021	NP4582	Glycyrrhetinic acid	DR4469	Doxorubicin	NEWCL00155	MCF-7	48h:29.21 uM	48h:0.87 uM	20uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	MCF-7	12.86%	77.01%	171.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"DOX/PEG-Fmoc-GA containing micelles facilitated the efficient cleavage of GA in tumor tissues/cells, leading to a higher level of synergistic antitumor activity with DOX in vitro and in vivo."
C64576	33234363	DIS0021	NP4582	Glycyrrhetinic acid	DR4469	Doxorubicin	NEWCL00155	MCF-7	48h:29.21 uM	48h:0.87 uM	20uM:1uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MCF-7	3.16%	5.07%	8.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"DOX/PEG-Fmoc-GA containing micelles facilitated the efficient cleavage of GA in tumor tissues/cells, leading to a higher level of synergistic antitumor activity with DOX in vitro and in vivo."
C22567	33240430	DIS0024	NP9120	Chrysin	DR9021	5-fluorouracil	NEWCL00352	AGS	.	.	50uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	AGS	2.75%	9.97%	9.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin potentiated the chemotherapeutic effect of 5-FU in gastric cancer AGS and AGS/FR cells via cell cycle arrest.
C22567	33240430	DIS0024	NP9120	Chrysin	DR9021	5-fluorouracil	NEWCL00352	AGS	.	.	50uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	AGS	107.21%	99.91%	110.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin potentiated the chemotherapeutic effect of 5-FU in gastric cancer AGS and AGS/FR cells via cell cycle arrest.
C22567	33240430	DIS0024	NP9120	Chrysin	DR9021	5-fluorouracil	NEWCL00352	AGS	.	.	50uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-Akt	Down-regulation	AGS	43.90%	2.86%	52.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin potentiated the chemotherapeutic effect of 5-FU in gastric cancer AGS and AGS/FR cells via cell cycle arrest.
C22567	33240430	DIS0024	NP9120	Chrysin	DR9021	5-fluorouracil	NEWCL00352	AGS	.	.	50uM:25uM	NEWCL20425	AGS.FR	.	.	50uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	AGS	2.44%	1.97%	8.90%	AGS.FR	11.11%	40.21%	23.51%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin potentiated the chemotherapeutic effect of 5-FU in gastric cancer AGS and AGS/FR cells via cell cycle arrest.
C22567	33240430	DIS0024	NP9120	Chrysin	DR9021	5-fluorouracil	NEWCL00352	AGS	.	.	50uM:25uM	NEWCL20425	AGS.FR	.	.	50uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	AGS	172.54%	1.93%	177.05%	AGS.FR	213.75%	7.95%	362.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Chrysin potentiated the chemotherapeutic effect of 5-FU in gastric cancer AGS and AGS/FR cells via cell cycle arrest.
C01098	33240775	DIS0022	NP8268	Curcumol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	150uM:25ng.mL	NEWCL00181	NCI-H1299	.	.	150uM:50ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	A-549	2.11%	15.14%	204.92%	H1299	9.16%	5.22%	163.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumol overcomes TRAIL resistance of non-small cell lung cancer by targeting NRH:Quinone Oxidoreductase 2 (NQO2).
C01098	33240775	DIS0022	NP8268	Curcumol	DR8680	TNF-related apoptosis inducing ligand 	NEWCL00170	A-549	.	.	150uM:25ng.mL	NEWCL00181	NCI-H1299	.	.	150uM:50ng.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	A-549	21.71%	21.03%	99.93%	H1299	2.74%	4.58%	305.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Curcumol overcomes TRAIL resistance of non-small cell lung cancer by targeting NRH:Quinone Oxidoreductase 2 (NQO2).
C75724	33241006	DIS0127	NP3545	Schisandrol B	DR7626	Docetaxel	NEWCL00139	Ca Ski	.	.	60uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Ca Ski	43.64%	111.66%	112.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sch B enhanced the anti-tumor effects of DTX in vitro and in vivo via growth, invasion, and apoptosis regulating."
C75724	33241006	DIS0127	NP3545	Schisandrol B	DR7626	Docetaxel	NEWCL00139	Ca Ski	.	.	60uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Ca Ski	3.46%	1.53%	23.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sch B enhanced the anti-tumor effects of DTX in vitro and in vivo via growth, invasion, and apoptosis regulating."
C75724	33241006	DIS0127	NP3545	Schisandrol B	DR7626	Docetaxel	NEWCL00139	Ca Ski	.	.	60uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Up-regulation	Ca Ski	24.89%	36.29%	102.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sch B enhanced the anti-tumor effects of DTX in vitro and in vivo via growth, invasion, and apoptosis regulating."
C75724	33241006	DIS0127	NP3545	Schisandrol B	DR7626	Docetaxel	NEWCL00139	Ca Ski	.	.	60uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8116	VEGF	Down-regulation	Ca Ski	3.38%	24.84%	49.47%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sch B enhanced the anti-tumor effects of DTX in vitro and in vivo via growth, invasion, and apoptosis regulating."
C75724	33241006	DIS0127	NP3545	Schisandrol B	DR7626	Docetaxel	NEWCL00139	Ca Ski	.	.	60uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	Ca Ski	30.85%	54.92%	95.24%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sch B enhanced the anti-tumor effects of DTX in vitro and in vivo via growth, invasion, and apoptosis regulating."
C75724	33241006	DIS0127	NP3545	Schisandrol B	DR7626	Docetaxel	NEWCL00139	Ca Ski	.	.	60uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	V-cadherin	Down-regulation	Ca Ski	36.65%	48.66%	56.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sch B enhanced the anti-tumor effects of DTX in vitro and in vivo via growth, invasion, and apoptosis regulating."
C75724	33241006	DIS0127	NP3545	Schisandrol B	DR7626	Docetaxel	NEWCL00139	Ca Ski	.	.	60uM:10nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	Ca Ski	18.26%	42.65%	65.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Sch B enhanced the anti-tumor effects of DTX in vitro and in vivo via growth, invasion, and apoptosis regulating."
C98479	33249080	DIS0036	NP6047	Metformin	DR8712	C1632	NEWCL00273	SCC-9	.	.	10mM:60uM	NEWCL00269	CAL-27	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	LIN28	Down-regulation	SCC-9	26.07%	27.38%	45.14%	CAL-27	27.15%	11.01%	53.02%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"C1632 and metformin exerts synergistic anti-tumor effects in OSCC cell lines SCC9 and CAL27, and also inhibits xenograft tumor growth in vivo."
C98479	33249080	DIS0036	NP6047	Metformin	DR8712	C1632	NEWCL00273	SCC-9	.	.	10mM:60uM	NEWCL00269	CAL-27	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7952	HMGA2	Down-regulation	SCC-9	0.16%	1.67%	56.32%	CAL-27	59.52%	52.97%	52.12%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"C1632 and metformin exerts synergistic anti-tumor effects in OSCC cell lines SCC9 and CAL27, and also inhibits xenograft tumor growth in vivo."
C98479	33249080	DIS0036	NP6047	Metformin	DR8712	C1632	NEWCL00273	SCC-9	.	.	10mM:60uM	NEWCL00269	CAL-27	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	p-AMPK	Up-regulation	SCC-9	5.62%	226.70%	264.66%	CAL-27	22.67%	167.13%	247.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"C1632 and metformin exerts synergistic anti-tumor effects in OSCC cell lines SCC9 and CAL27, and also inhibits xenograft tumor growth in vivo."
C40913	33274495	DIS0031	NP1559	Luteolin	DR7601	IL-24	NEWCL00028	MHCC97-H	.	.	5 ug.ml:4 MOI	NEWCL00129	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	IL-24	Up-regulation	MHCC97-H	81.12%	11.10%	176.64%	HepG2	395.33%	27.89%	402.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells.
C40913	33274495	DIS0031	NP1559	Luteolin	DR7601	IL-24	NEWCL00028	MHCC97-H	.	.	5 ug.ml:4 MOI	NEWCL00129	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MHCC97-H	23.92%	30.16%	32.07%	HepG2	42.71%	7.43%	104.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells.
C40913	33274495	DIS0031	NP1559	Luteolin	DR7601	IL-24	NEWCL00028	MHCC97-H	.	.	5 ug.ml:4 MOI	NEWCL00129	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	MHCC97-H	1998.64%	420.89%	5056.93%	HepG2	132.13%	61.38%	136.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells.
C40913	33274495	DIS0031	NP1559	Luteolin	DR7601	IL-24	NEWCL00028	MHCC97-H	.	.	5 ug.ml:4 MOI	NEWCL00129	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	MHCC97-H	211.22%	149.46%	235.29%	HepG2	177.97%	159.26%	210.29%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells.
C40913	33274495	DIS0031	NP1559	Luteolin	DR7601	IL-24	NEWCL00028	MHCC97-H	.	.	5 ug.ml:4 MOI	NEWCL00129	Hep-G2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	MHCC97-H	35.45%	2.14%	82.97%	HepG2	68.78%	19.93%	87.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells.
C13748	33301843	DIS0023	NP5891	Pristimerin	DR2391	Gemcitabine	NEWCL00241	AsPC-1	.	.	1 uM :0.5 uM	NEWCL00243	BxPC-3	.	.	1 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-RPA32(Ser5)	Up-regulation	AsPC-1	14.86%	1328.21%	795.83%	BxPC-3	39.45%	143.88%	104.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells.
C13748	33301843	DIS0023	NP5891	Pristimerin	DR2391	Gemcitabine	NEWCL00241	AsPC-1	.	.	1 uM :0.5 uM	NEWCL00243	BxPC-3	.	.	1 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7829	Gama-H2AX	Up-regulation	AsPC-1	83.09%	30.67%	226.07%	BxPC-3	100.46%	636.25%	707.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells.
C13748	33301843	DIS0023	NP5891	Pristimerin	DR2391	Gemcitabine	NEWCL00241	AsPC-1	.	.	1 uM :0.5 uM	NEWCL00243	BxPC-3	.	.	1 uM :0.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6543	53BP1	Down-regulation	AsPC-1	41.83%	1.74%	95.88%	BxPC-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells.
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9 	Up-regulation	MDA-MB-231	5.34%	1.56%	86.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6386	P53	Up-regulation	MDA-MB-231	1187.69%	1856.27%	3487.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-p38	Up-regulation	MDA-MB-231	71.86%	16.57%	154.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6147	P-NFKB	Up-regulation	MDA-MB-231	92.09%	179.19%	303.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	MDA-MB-231	1352.13%	1677.74%	3166.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-Cdk1.2	Up-regulation	MDA-MB-231	87.71%	137.05%	121.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MDA-MB-231	21.41%	23.79%	34.92%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	MDA-MB-231	1.55%	26.79%	461.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	MDA-MB-231	4.56%	18.54%	22.82%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C54856	33321563	DIS0021	NP2665	Alpha lipoic acid	DR8799	Radiation	NEWCL00049	MDA-MB-231	.	.	2 mM:10 Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	MDA-MB-231	7.83%	14.60%	26.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."
C47401	33363464	DIS0013	NP5733	Daphnetin	DR1669	Cisplatin	NEWCL10339	HK2	.	.	20mg.kg:40mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5308	Nrf2	Up-regulation	HK2	91.91%	5.56%	20.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Daphnetin inhibited cisplatin-induced nephrotoxicity by inhibiting NF-KappaB and activating Nrf2 signaling pathways.
C47401	33363464	DIS0013	NP5733	Daphnetin	DR1669	Cisplatin	NEWCL10339	HK2	.	.	20mg.kg:40mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7859	HO-1	Up-regulation	HK-6	114.17%	3.80%	118.09%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	Daphnetin inhibited cisplatin-induced nephrotoxicity by inhibiting NF-KappaB and activating Nrf2 signaling pathways.
C44803	33365077	DIS0031	NP9635	Matrine	DR1669	Cisplatin	NEWCL00129	Hep-G2	.	.	100mg.kg:2mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Up-regulation	Hep-G2	33.50%	33.12%	35.93%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of matrine and cisplatin may promote tumor cell apoptosis in liver cancer by activating the caspase apoptosis pathway and suppressing the survivin-associated inhibition of caspase-9.
C44803	33365077	DIS0031	NP9635	Matrine	DR1669	Cisplatin	NEWCL00129	Hep-G2	.	.	100mg.kg:2mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0153	Caspase-7	Up-regulation	Hep-G2	34.55%	33.48%	34.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of matrine and cisplatin may promote tumor cell apoptosis in liver cancer by activating the caspase apoptosis pathway and suppressing the survivin-associated inhibition of caspase-9.
C44803	33365077	DIS0031	NP9635	Matrine	DR1669	Cisplatin	NEWCL00129	Hep-G2	.	.	100mg.kg:2mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Caspase-9	Up-regulation	Hep-G2	3.13%	2.42%	3.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of matrine and cisplatin may promote tumor cell apoptosis in liver cancer by activating the caspase apoptosis pathway and suppressing the survivin-associated inhibition of caspase-9.
C44803	33365077	DIS0031	NP9635	Matrine	DR1669	Cisplatin	NEWCL00129	Hep-G2	.	.	100mg.kg:2mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1193	XIAP	Down-regulation	Hep-G2	1.00%	2.65%	7.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of matrine and cisplatin may promote tumor cell apoptosis in liver cancer by activating the caspase apoptosis pathway and suppressing the survivin-associated inhibition of caspase-9.
C44803	33365077	DIS0031	NP9635	Matrine	DR1669	Cisplatin	NEWCL00129	Hep-G2	.	.	100mg.kg:2mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	Hep-G2	1.29%	6.16%	29.31%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of matrine and cisplatin may promote tumor cell apoptosis in liver cancer by activating the caspase apoptosis pathway and suppressing the survivin-associated inhibition of caspase-9.
C80620	33430369	DIS0122	NP0166	osthole 	DR1669	Cisplatin	NEWCL10389	FM55P	72h:67.26 ±  16.357uM	72h: 1.49 ±  0.30uM	.	NEWCL10388	FM55M2	72h:89.58 ±  16.30uM	 72h:1.70 ±  0.35uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of CDDP and osthole was characterized by the most desirable synergistic interaction.
C54031	33445795	DIS0124	NP2010	Delphinidin	DR5481	3-bromopyruvate	NEWCL10419	PEO1	24h:18.7 uM	24h:18.7uM	.	NEWCL00231	SK-OV-3	24h:40.5 uM	24h:40.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Delphinidin increases the sensitivity of ovarian cancer cell lines to 3-bromopyruvate.
C90835	33502699	DIS0115	NP6984	Isoliquiritigenin	DR5834	Docosahexaenoic acid	.	.	.	.	20 uM: 20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HCT 116	113.79%	60.34%	223.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Isoliquiritigenin in combination with docosahexaenoic acid has synergistic anticancer effect on human colorectal cancer cells through ROS-mediated regulation of the JNK and cytochrome c release.
C90835	33502699	DIS0115	NP6984	Isoliquiritigenin	DR5834	Docosahexaenoic acid	.	.	.	.	20 uM: 20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	HCT 116	72.22%	62.06%	384.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Isoliquiritigenin in combination with docosahexaenoic acid has synergistic anticancer effect on human colorectal cancer cells through ROS-mediated regulation of the JNK and cytochrome c release.
C90835	33502699	DIS0115	NP6984	Isoliquiritigenin	DR5834	Docosahexaenoic acid	.	.	.	.	20 uM: 20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	HCT 116	105.83%	28.34%	236.16%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Isoliquiritigenin in combination with docosahexaenoic acid has synergistic anticancer effect on human colorectal cancer cells through ROS-mediated regulation of the JNK and cytochrome c release.
C90835	33502699	DIS0115	NP6984	Isoliquiritigenin	DR5834	Docosahexaenoic acid	.	.	.	.	20 uM: 20 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HCT 116	12.69%	26.70%	265.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Isoliquiritigenin in combination with docosahexaenoic acid has synergistic anticancer effect on human colorectal cancer cells through ROS-mediated regulation of the JNK and cytochrome c release.
C27119	33527319	DIS0115	NP8525	Lactobacillus plantarum	DR9021	5-fluorouracil	NEWCL00077	HT-29	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	"GABA-producing L. plantarum is promising as an adjuvant treatment for 5-FU-resistant CRC, and its intervention in neurobiological signaling imply new possibilities for chemoprevention and the treatment of colon cancer-related diseases."
C02581	33623367	DIS0127	NP1168	Quercetin	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	15 uM :10 uM	NEWCL00137	SiHa	.	.	30 uM :12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Ezrin	Down-regulation	HeLa	2.82%	3.39%	17.03%	SiHa	1.74%	7.31%	26.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Quercetin and cisplatin had synergistic inhibitory effect on cervical cancer cells. Quercetin might enhance the antitumor effect of cisplatin via inhibiting proliferation, migration and invasion and elevating apoptosis through weakening MMP2, ezrin, METTL3 and P-Gp expression of cancer cells."
C02581	33623367	DIS0127	NP1168	Quercetin	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	15 uM :10 uM	NEWCL00137	SiHa	.	.	30 uM :12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Down-regulation	HeLa	19.43%	81.84%	97.15%	SiHa	2.80%	2.94%	34.86%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Quercetin and cisplatin had synergistic inhibitory effect on cervical cancer cells. Quercetin might enhance the antitumor effect of cisplatin via inhibiting proliferation, migration and invasion and elevating apoptosis through weakening MMP2, ezrin, METTL3 and P-Gp expression of cancer cells."
C02581	33623367	DIS0127	NP1168	Quercetin	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	15 uM :10 uM	NEWCL00137	SiHa	.	.	30 uM :12 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6366	METTL3	Down-regulation	HeLa	47.78%	60.73%	85.88%	SiHa	44.76%	43.36%	75.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Quercetin and cisplatin had synergistic inhibitory effect on cervical cancer cells. Quercetin might enhance the antitumor effect of cisplatin via inhibiting proliferation, migration and invasion and elevating apoptosis through weakening MMP2, ezrin, METTL3 and P-Gp expression of cancer cells."
C58411	33649865	DIS0031	NP4440	Kaempferol	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	.	40 uM:900 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9861	Cytochrome c	Up-regulation	Hep-G2	51.79%	56.83%	66.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer."
C58411	33649865	DIS0031	NP4440	Kaempferol	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	.	40 uM:900 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	Hep-G2	170.16%	18.81%	247.73%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer."
C58411	33649865	DIS0031	NP4440	Kaempferol	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	.	40 uM:900 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9098	Cleaved-caspase-8	Up-regulation	Hep-G2	16.59%	23.25%	32.04%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer."
C58411	33649865	DIS0031	NP4440	Kaempferol	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	.	40 uM:900 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	Hep-G2	5.86%	5.82%	8.98%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer."
C58411	33649865	DIS0031	NP4440	Kaempferol	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	.	40 uM:900 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Hep-G2	22.12%	57.28%	75.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer."
C58411	33649865	DIS0031	NP4440	Kaempferol	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	.	40 uM:900 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Down-regulation	Hep-G2	1.45%	12.83%	94.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer."
C58411	33649865	DIS0031	NP4440	Kaempferol	DR4469	Doxorubicin	NEWCL00129	Hep-G2	.	.	40 uM:900 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	Hep-G2	1.35%	2.25%	59.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer."
C10359	33660801	DIS0021	NP6905	Curcumin	DR2742	Celecoxib	NEWCL00049	MDA-MB-231	.	.	20 uM:25uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MDA-MB-231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9126	Wnt 3a	Down-regulation	HT-29	6.60%	0.50%	6.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FZH 4	Up-regulation	HT-29	10.03%	13.77%	18.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8159	GSK-3beta	Up-regulation	HT-29	13.91%	5.45%	5.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Axin 1	Up-regulation	HT-29	216.58%	3.02%	236.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HT-29	14.65%	4.65%	7.36%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	HT-29	12.16%	0.77%	20.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	HT-29	0.40%	9.39%	26.21%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HT-29	335.62%	83.49%	318.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8944	ALDH1A1	Down-regulation	HT-29	0.48%	0.50%	18.58%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.OCT-3.4	Down-regulation	HT-29	12.57%	13.39%	53.89%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5985	Twist	Down-regulation	HT-29	72.47%	65.66%	59.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Slug	Down-regulation	HT-29	3.61%	22.10%	55.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C82796	33667839	DIS0114	NP7608	Piperine	DR2742	Celecoxib	NEWCL00077	HT-29	48h:46.95ug.ml	48h: 35.81ug.ml	30 ug.ml:5 ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Snail	Down-regulation	HT-29	0.14%	4.14%	51.41%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.
C49649	33670440	DIS0022	NP6905	Curcumin	DR1669	Cisplatin	NEWCL00170	A-549	.	.	41 uM:30 uM	NEWCL00186	NCI-H2170	.	.	33 uM:7 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A-549	.	.	.	H2170	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis.
C31241	33783002	DIS0115	NP6308	Thymoquinone	DR8244	Imatinib	NEWCL00082	HCT 116	24h:20uM; 48h:10.3uM; 72h:6.5 uM	48h:105uM; 72h:72 uM 	10 uM:30 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TQ potentiates IM efficacy on HCT116 cells via uptake/efflux genes modulation.
C04549	33792091	DIS0021	NP1829	Aloe emodin	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR	.	20.48 ±  2.68 uM	20 uM:4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7860	P62	Up-regulation	MCF-7.ADR	18.83%	17.53%	14.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	AE could be a potential reversal agent to resensitize ADR resistant in tumor chemotherapy.
C04549	33792091	DIS0021	NP1829	Aloe emodin	DR4469	Doxorubicin	NEWCL20424	MCF-7.ADR	.	20.48 ±  2.68 uM	20 uM:4 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3 II	Down-regulation	MCF-7.ADR	40.19%	-21.62%	40.54%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	AE could be a potential reversal agent to resensitize ADR resistant in tumor chemotherapy.
C13054	33796463	DIS0029	NP4353	Gamabufotalin	DR2770	Arsenite	NEWCL00279	U-87MG ATCC	48h:64.8 ±  6.8 nM	48h:4.4 ±  1.1 uM	50 nM:2 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3 II	Up-regulation	U-87MG ATCC	80.41%	66.31%	113.30%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"G2/M arrest, necrosis and autophagy appeared to cooperatively contribute to the synergistic cytotoxicity of AsIII and gamabufotalin."
C13054	33796463	DIS0029	NP4353	Gamabufotalin	DR2770	Arsenite	NEWCL00279	U-87MG ATCC	48h:64.8 ±  6.8 nM	48h:4.4 ±  1.1 uM	50 nM:2 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Cdc25C	Down-regulation	U-87MG ATCC	19.64%	0.54%	83.68%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"G2/M arrest, necrosis and autophagy appeared to cooperatively contribute to the synergistic cytotoxicity of AsIII and gamabufotalin."
C13054	33796463	DIS0029	NP4353	Gamabufotalin	DR2770	Arsenite	NEWCL00279	U-87MG ATCC	48h:64.8 ±  6.8 nM	48h:4.4 ±  1.1 uM	50 nM:2 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO9311	Cyclin B1	Down-regulation	U-87MG ATCC	0.98%	1.48%	83.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"G2/M arrest, necrosis and autophagy appeared to cooperatively contribute to the synergistic cytotoxicity of AsIII and gamabufotalin."
C13054	33796463	DIS0029	NP4353	Gamabufotalin	DR2770	Arsenite	NEWCL00279	U-87MG ATCC	48h:64.8 ±  6.8 nM	48h:4.4 ±  1.1 uM	50 nM:2 nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	Down-regulation	U-87MG ATCC	30.74%	1.70%	88.57%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"G2/M arrest, necrosis and autophagy appeared to cooperatively contribute to the synergistic cytotoxicity of AsIII and gamabufotalin."
C10101	33822896	DIS0115	NP2096	Andrographolide	DR9021	5-fluorouracil	NEWCL00082	HCT 116	48h:15.7uM	48h:51.85uM	30 ng.ul:10 uM	NEWCL00074	SW480	48h:15.22uM	48h:39.25uM	30 ng.ul:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3490	DKK1	Down-regulation	HCT 116	23.87%	2.38%	33.13%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancer.
C10101	33822896	DIS0115	NP2096	Andrographolide	DR9021	5-fluorouracil	NEWCL20380	HCT 116.FUR	48h:15.7uM	48h:51.85uM	30 ng.ul:10 uM	NEWCL20423	SW480-5FUR	48h:15.22uM	48h:39.25uM	30 ng.ul:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	p-AKT	Down-regulation	HCT 116	3.62%	43.36%	87.20%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	Reversing Drug Resistance	Reversing Drug Resistance	Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancer.
C14683	33981825	DIS0115	NP1886	Scutellarin	DR0141	Oxaliplatin	NEWCL00074	SW480	.	.	20uM:10uM	NEWCL00344	HT29	.	.	20uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Scutellarin resensitizes oxaliplatin-resistant CRC cells to oxaliplatin treatment through inhibition of PKM2.
C19292	33987471	DIS0013	NP9855	Asiaticoside	DR6157	Ionizing radiation	NEWCL10144	Fibroblasts	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Fibroblasts	51.62%	166.51%	111.70%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	Decreasing Adverse Drug Reaction	Decreasing Adverse Drug Reaction	AC is able to prevent radiation-initiated genotoxicity by mitigating DNA damage.
C18809	34026624	DIS0129	NP2927	Platycodin D	DR2073	Sorafenib	NEWCL00253	PC-3	.	.	10 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	PC-3	56.67%	60.53%	86.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Platycodin D and sorafenib may exert potent anti-cancer effects specifically via FOXO3a.
C18809	34026624	DIS0129	NP2927	Platycodin D	DR2073	Sorafenib	NEWCL00253	PC-3	.	.	10 uM:10 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	PC-3	27.86%	27.15%	63.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Platycodin D and sorafenib may exert potent anti-cancer effects specifically via FOXO3a.
C18809	34026624	DIS0129	NP2927	Platycodin D	DR2073	Sorafenib	NEWCL00253	PC-3	.	.	5 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	PC-3	3.62%	41.25%	77.23%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Platycodin D and sorafenib may exert potent anti-cancer effects specifically via FOXO3a.
C18809	34026624	DIS0129	NP2927	Platycodin D	DR2073	Sorafenib	NEWCL00253	PC-3	.	.	5 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	PC-3	3.44%	0.75%	6.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Platycodin D and sorafenib may exert potent anti-cancer effects specifically via FOXO3a.
C18809	34026624	DIS0129	NP2927	Platycodin D	DR2073	Sorafenib	NEWCL00253	PC-3	.	.	5 uM:2.5 uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	PC-3	2.55%	7.19%	28.88%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The combination of Platycodin D and sorafenib may exert potent anti-cancer effects specifically via FOXO3a.
C42889	34058790	DIS0031	NP3947	Toosendanin	DR6166	Regorafenib	NEWCL00029	MHCC97-L	24h:0.23 ±  0.06 uM	24h:16.06 ±  2.77 uM	0.05uM:8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	WWOX	Up-regulation	MHCC97-L	2.89%	0.41%	4.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC.
C42889	34058790	DIS0031	NP3947	Toosendanin	DR6166	Regorafenib	NEWCL00029	MHCC97-L	24h:0.23 ±  0.06 uM	24h:16.06 ±  2.77 uM	0.05uM:8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7814	P-GSK3beta	Up-regulation	MHCC97-L	197.98%	29.74%	199.42%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC.
C42889	34058790	DIS0031	NP3947	Toosendanin	DR6166	Regorafenib	NEWCL00029	MHCC97-L	24h:0.23 ±  0.06 uM	24h:16.06 ±  2.77 uM	0.05uM:8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7948	MMP-2	Down-regulation	MHCC97-L	33.72%	42.82%	61.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC.
C42889	34058790	DIS0031	NP3947	Toosendanin	DR6166	Regorafenib	NEWCL00029	MHCC97-L	24h:0.23 ±  0.06 uM	24h:16.06 ±  2.77 uM	0.05uM:8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	Cleaved-MYC	Down-regulation	MHCC97-L	59.17%	44.15%	61.65%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC.
C42889	34058790	DIS0031	NP3947	Toosendanin	DR6166	Regorafenib	NEWCL00029	MHCC97-L	24h:0.23 ±  0.06 uM	24h:16.06 ±  2.77 uM	0.05uM:8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	DVL2	Down-regulation	MHCC97-L	17.38%	6.46%	18.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC.
C42889	34058790	DIS0031	NP3947	Toosendanin	DR6166	Regorafenib	NEWCL00029	MHCC97-L	24h:0.23 ±  0.06 uM	24h:16.06 ±  2.77 uM	0.05uM:8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Beta-Catenin	Down-regulation	MHCC97-L	12.63%	6.90%	22.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC.
C79146	34080212	DIS0127	NP6160	Cyanidin-3-O-glucoside chloride	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	400 ug.mL:5 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8206	Keap1	Up-regulation	HeLa	36.80%	54.32%	42.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Potentiation of DDP with C3G improves cancer cell susceptibility, specifically cervical cancer cells, to DDP."
C79146	34080212	DIS0127	NP6160	Cyanidin-3-O-glucoside chloride	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	400 ug.mL:5 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7859	HO-1	Up-regulation	HeLa	0.58%	3.93%	14.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Potentiation of DDP with C3G improves cancer cell susceptibility, specifically cervical cancer cells, to DDP."
C79146	34080212	DIS0127	NP6160	Cyanidin-3-O-glucoside chloride	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	400 ug.mL:5 ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5308	Nrf2	Down-regulation	HeLa	29.05%	100.00%	26.06%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Potentiation of DDP with C3G improves cancer cell susceptibility, specifically cervical cancer cells, to DDP."
C51473	34237314	DIS0127	NP5868	Salicylic acid	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	4uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	PARP	Down-regulation	HeLa	31.14%	6.19%	61.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Reduction in cisplatin concentration, enhanced anti-cancer effects and UHRF1 downregulation due to synergistic interaction between salicylic acid and cisplatin underscores the therapeutic importance of the combination to overcome chemo-resistance and side effects of cisplatin."
C51473	34237314	DIS0127	NP5868	Salicylic acid	DR1669	Cisplatin	NEWCL00149	HeLa	.	.	4uM:10uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Caspase-3	Down-regulation	HeLa	28.66%	11.60%	55.97%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Reduction in cisplatin concentration, enhanced anti-cancer effects and UHRF1 downregulation due to synergistic interaction between salicylic acid and cisplatin underscores the therapeutic importance of the combination to overcome chemo-resistance and side effects of cisplatin."
C01014	34320467	DIS0375	.	Fraxetin	.	Gemcitabine	NEWCL00242	PANC-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4532	Vimentin	Down-regulation	PANC-1	0.10%	17.66%	66.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	the effects of fraxetin on the sensitivity of PCCs to the chemotherapy drug gemcitabine were activated
C00456	34336674	DIS0124	.	asparagus officilis	.	paclitaxel	NEWCL20349	OVCAR 5	72h:3.5mg.ml	.	.	NEWCL00231	SK-OV-3	72h:4.2mg.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	The results showed that 0.1 mg/ml or 0.5 mg/ml (data not shown) of ASP combined with paclitaxel (0.1-5 nM) caused a synergistic cytotoxic effect (CI<1) in both cell lines
C00039	34826601	DIS0022	.	Berberine	.	Osimertinib	NEWCL20361	HCC827.AR	.	.	5uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim	Up-regulation	HCC827.AR	124.28%	183.06%	357.25%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	Apoptosis likely through Bim elevation and Mcl-1 reduction
C00039	34826601	DIS0022	.	Berberine	.	Osimertinib	NEWCL20361	HCC827.AR	.	.	5uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	HCC827.AR	29.74%	6.16%	68.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	Apoptosis likely through Bim elevation and Mcl-1 reduction
C00039	34826601	DIS0022	.	Berberine	.	Osimertinib	NEWCL20361	HCC827.AR	.	.	5uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HCC827.AR	2.99%	36.94%	84.74%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	Apoptosis likely through Bim elevation and Mcl-1 reduction
C00039	34826601	DIS0022	.	Berberine	.	Osimertinib	NEWCL20361	HCC827.AR	.	.	5uM:100nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	HCC827.AR	5.80%	20.32%	134.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	Apoptosis likely through Bim elevation and Mcl-1 reduction
C00345	34917504	DIS0372	.	Borneol	.	Radiotherapy	NEWCL20422	Fresh human glioma cells	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1629	HIF-1a	Down-regulation	Fresh human glioma cells	47.90%	30.72%	76.61%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	 The Combination of Borneol and Radiotherapy Inhibited Glioma Growth by Inducing Autophagy.Borneol Sensitized Glioma Cells to Radiation by Targeting the mTORC1/eIF4E/HIF-1a Pathway
C00345	34917504	DIS0372	.	Borneol	.	Radiotherapy	NEWCL20422	Fresh human glioma cells	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	mTORC1	Down-regulation	Fresh human glioma cells	5.91%	38.25%	64.53%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	 The Combination of Borneol and Radiotherapy Inhibited Glioma Growth by Inducing Autophagy.Borneol Sensitized Glioma Cells to Radiation by Targeting the mTORC1/eIF4E/HIF-1a Pathway
C00499	35458590	DIS0021	.	Evening Primrose Oil	.	Tamoxifen	NEWCL00155	MCF-7	72h:183.96ug.ml	72h:0.78ug.ml	.	NEWCL00049	MDA-MB-231	72h:216.9ug.ml	72h:5.92ug.ml	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The qRT-PCR results showed significant (p < 0.05) downregulation in the expression of VEGF and Bcl2 genes, and upregulation in the expression of Bax"
C00032	35534851	DIS0129	.	Myricetin	.	poly lactic-co-glycolic acid	NEWCL00252	LNcaP	72h:18.5uM	.	.	NEWCL20345	LNCaP C4-2B	72h:20.6uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"KDM4A is overexpressed in PCa tumors, particularly in metastatic tumors."
C00068	35785724	DIS0021	.	Nobiletin	.	Vorinostat	NEWCL20330	NCI-H82	.	.	300mg.kg:30mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Bim	Up-regulation	NCI-H82	45.38%	41.20%	67.69%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	PARP1 inhibition and antiproliferative activity of the representative analogues.
C00068	35785724	DIS0021	.	Nobiletin	.	Vorinostat	NEWCL20330	NCI-H82	.	.	300mg.kg:30mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1397	Bid	Up-regulation	NCI-H82	74.88%	111.36%	119.00%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	PARP1 inhibition and antiproliferative activity of the representative analogues.
C00068	35785724	DIS0021	.	Nobiletin	.	Vorinostat	NEWCL20330	NCI-H82	.	.	300mg.kg:30mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	NCI-H82	33.49%	37.69%	39.17%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	PARP1 inhibition and antiproliferative activity of the representative analogues.
C00068	35785724	DIS0021	.	Nobiletin	.	Vorinostat	NEWCL20330	NCI-H82	.	.	300mg.kg:30mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	NCI-H82	3.17%	2.52%	14.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	PARP1 inhibition and antiproliferative activity of the representative analogues.
C00068	35785724	DIS0021	.	Nobiletin	.	Vorinostat	NEWCL20330	NCI-H82	.	.	300mg.kg:30mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3195	BCL-XL	Down-regulation	NCI-H82	30.83%	17.01%	53.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	PARP1 inhibition and antiproliferative activity of the representative analogues.
C00068	35785724	DIS0021	.	Nobiletin	.	Vorinostat	NEWCL20330	NCI-H82	.	.	300mg.kg:30mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5288	MCL-1	Down-regulation	NCI-H82	9.37%	22.00%	46.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	PARP1 inhibition and antiproliferative activity of the representative analogues.
C00610	36139451	DIS0115	.	UnripeuRubus coreanusuMiquel	.	Oxaliplatin	NEWCL20325	MC38	72h:416.2ug.ml	72h:9.397ug.ml	100mg.kg:2.5mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"RCE plus oxaliplatin apparently activates hPD-1 tumor-infiltrating CD8+ T cells, resulting in elevations of released interleukin-2 (IL-2) and granzyme B (GrB), and kills hPD-L1 MC38 CRC cells. RCE plus oxaliplatin considerably reduced tumor growth in humanized PD-1/PD-L1-expressing mouse MC38 CRC allograft. Moreover, RCE plus oxaliplatin remarkably increased the infiltration of CD8+ T cells in tumor tissues, as well as increasingly produced GrB of tumor-infiltrating CD8+ T cells in the tumor microenvironment."
C02528	36220508	DIS0088	.	Piperlongumine	.	imatinib	NEWCL20421	KBM3	48h:1.936uM	.	.	NEWCL00048	K-562	48h:5.969uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	PL effectively reduces viability and triggers apoptosis in IM-sensitive- and -resistant CML cells. We have shown that PL is a novel proteasome inhibitor through inhibition of 20S proteasome and 19S proteasomal deubiquitinase in CML cells. 
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	HCT 116	266.64%	260.01%	409.39%	HT29	310.78%	212.49%	477.81%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1404	Cleaved-caspase-9	Up-regulation	HCT 116	13.80%	52.79%	144.67%	HT29	212.23%	143.50%	253.77%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3080	CDK6	Down-regulation	HCT 116	34.30%	16.97%	48.87%	HT29	23.55%	-14.88%	57.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	HCT 116	2.50%	33.20%	68.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7853	E-cadherin	Up-regulation	HCT 116	18.36%	10.02%	14.76%	HT29	29.12%	221.04%	258.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5046	MMP-9	Down-regulation	HCT 116	23.11%	33.48%	49.33%	HT29	14.82%	9.85%	47.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	UPA	Down-regulation	HCT 116	3.89%	24.88%	28.88%	HT29	0.03%	1.36%	45.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	HCT 116	18.25%	70.32%	85.78%	HT29	2.00%	39.46%	61.45%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0702	C-MYC	Down-regulation	HCT 116	27.73%	25.81%	55.28%	HT29	30.27%	38.48%	84.55%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7814	P-GSK3beta	Down-regulation	HCT 116	10.98%	12.55%	53.30%	HT29	2.66%	1.27%	32.14%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C48730	36382656	DIS0115	.	Ursolic acid	.	Doxorubicin	NEWCL00082	HCT 116	.	.	15uM:1.5uM	NEWCL00344	HT29	.	.	15uM:1.5uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	CTGF	Down-regulation	HCT 116	15.67%	48.66%	51.43%	HT29	7.72%	8.38%	65.35%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.
C00290	37272203	DIS0371	.	Cryptotanshinone	.	Trifluridine 	NEWCL10086	HGC-27	72h:10.68uM	72h:0.87uM	.	NEWCL00352	AGS	72h:5.43uM	72h:2.36uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	.	HGC-27	51.39%	8.17%	1.64%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"HGC-27 cells result in G2/M phase arrest, which is mainly in the G2 phase rather than the mitotic phase."
C00290	37272203	DIS0371	.	Cryptotanshinone	.	Trifluridine 	NEWCL10086	HGC-27	72h:10.68uM	72h:0.87uM	.	NEWCL00352	AGS	72h:5.43uM	72h:2.36uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MPM-2	Down-regulation	HGC-27	3.80%	21.49%	75.19%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"HGC-27 cells result in G2/M phase arrest, which is mainly in the G2 phase rather than the mitotic phase."
C00290	37272203	DIS0371	.	Cryptotanshinone	.	Trifluridine 	NEWCL10086	HGC-27	72h:10.68uM	72h:0.87uM	.	NEWCL00352	AGS	72h:5.43uM	72h:2.36uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	.	HGC-27	0.95%	23.01%	91.52%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"HGC-27 cells result in G2/M phase arrest, which is mainly in the G2 phase rather than the mitotic phase."
C00290	37272203	DIS0371	.	Cryptotanshinone	.	Trifluridine 	NEWCL10086	HGC-27	72h:10.68uM	72h:0.87uM	.	NEWCL00352	AGS	72h:5.43uM	72h:2.36uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7874	Survivin	.	HGC-27	2.05%	44.38%	93.10%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"HGC-27 cells result in G2/M phase arrest, which is mainly in the G2 phase rather than the mitotic phase."
C02635	37323083	DIS0124	.	Astragaloside II	.	cisplatin	NEWCL00231	SK-OV-3	48h:215.32 uM	48h:10.56uM	.	NEWCL00230	A2780	48h:726.18 uM	48h:9.88uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	ASII enhanced the sensitivity of DDP-resistant OC cells to DDP by suppressing growth and inducing apoptosis. It suggests that ASII may be a promising drug for the treatment of DDP resistance in OC.
C02532	37490119	DIS0031	.	quercetin	.	Sorafenib	NEWCL00031	Huh-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	Huh-7	28.03%	8.36%	59.40%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	"Quercetin significantly impeded proliferation and stimulated apoptosis in Huh7R cells, while also suppressing the growth of transplanted tumors. The impact of QUE enhanced the efficacy of SOR treatment for Huh7R. Additionally, bioinformatic and western blot analyses indicated that the underlying mechanisms may be associated with EGFR tyrosine kinase inhibitor resistance, the PI3K-AKT signaling pathway, and HCC. Furthermore, molecular docking and dynamics simulation assays revealed that QUE exhibited strong affinity and stability towards its hub targets, EGFR and AKT1. It is noteworthy that the activation of EGFR by its ligand, EGF, mitigated the effects of co-treatment with QUE and SOR."
C02532	37490119	DIS0031	.	quercetin	.	Sorafenib	NEWCL00031	Huh-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-ERK	Down-regulation	Huh-7	23.05%	27.21%	79.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	"Quercetin significantly impeded proliferation and stimulated apoptosis in Huh7R cells, while also suppressing the growth of transplanted tumors. The impact of QUE enhanced the efficacy of SOR treatment for Huh7R. Additionally, bioinformatic and western blot analyses indicated that the underlying mechanisms may be associated with EGFR tyrosine kinase inhibitor resistance, the PI3K-AKT signaling pathway, and HCC. Furthermore, molecular docking and dynamics simulation assays revealed that QUE exhibited strong affinity and stability towards its hub targets, EGFR and AKT1. It is noteworthy that the activation of EGFR by its ligand, EGF, mitigated the effects of co-treatment with QUE and SOR."
C02532	37490119	DIS0031	.	quercetin	.	Sorafenib	NEWCL00031	Huh-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6898	Cleaved-PARP	Up-regulation	Huh-7	90.32%	128.73%	406.38%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	"Quercetin significantly impeded proliferation and stimulated apoptosis in Huh7R cells, while also suppressing the growth of transplanted tumors. The impact of QUE enhanced the efficacy of SOR treatment for Huh7R. Additionally, bioinformatic and western blot analyses indicated that the underlying mechanisms may be associated with EGFR tyrosine kinase inhibitor resistance, the PI3K-AKT signaling pathway, and HCC. Furthermore, molecular docking and dynamics simulation assays revealed that QUE exhibited strong affinity and stability towards its hub targets, EGFR and AKT1. It is noteworthy that the activation of EGFR by its ligand, EGF, mitigated the effects of co-treatment with QUE and SOR."
C02532	37490119	DIS0031	.	quercetin	.	Sorafenib	NEWCL00031	Huh-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	Huh-7	10.99%	23.86%	220.91%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	"Quercetin significantly impeded proliferation and stimulated apoptosis in Huh7R cells, while also suppressing the growth of transplanted tumors. The impact of QUE enhanced the efficacy of SOR treatment for Huh7R. Additionally, bioinformatic and western blot analyses indicated that the underlying mechanisms may be associated with EGFR tyrosine kinase inhibitor resistance, the PI3K-AKT signaling pathway, and HCC. Furthermore, molecular docking and dynamics simulation assays revealed that QUE exhibited strong affinity and stability towards its hub targets, EGFR and AKT1. It is noteworthy that the activation of EGFR by its ligand, EGF, mitigated the effects of co-treatment with QUE and SOR."
C02532	37490119	DIS0031	.	quercetin	.	Sorafenib	NEWCL00031	Huh-7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	Huh-7	25.70%	10.97%	56.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	"Quercetin significantly impeded proliferation and stimulated apoptosis in Huh7R cells, while also suppressing the growth of transplanted tumors. The impact of QUE enhanced the efficacy of SOR treatment for Huh7R. Additionally, bioinformatic and western blot analyses indicated that the underlying mechanisms may be associated with EGFR tyrosine kinase inhibitor resistance, the PI3K-AKT signaling pathway, and HCC. Furthermore, molecular docking and dynamics simulation assays revealed that QUE exhibited strong affinity and stability towards its hub targets, EGFR and AKT1. It is noteworthy that the activation of EGFR by its ligand, EGF, mitigated the effects of co-treatment with QUE and SOR."
C00644	37963994	DIS0031	.	Osthole	.	Radiotherapy	NEWCL00030	HCCLM3	.	.	100mg.kg:4Gy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Osthole inhibits GSK-3beta/AMPK/mTOR pathway-controlled glycolysis and increases radiosensitivity of subcutaneous transplanted hepatocellular carcinoma in nude mice
C00949	38114593	DIS0115	.	Corilagin	.	5-Fluorouracilu	NEWCL10146	HCT8	.	.	4.6uM:13.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5160	CDK2	Down-regulation	HCT8	9.03%	18.03%	21.63%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Corilagin enhanced the efficacy of 5-FU targeting human CRC by promoting the regulatory effects of 5-FU on GRP 78 protein expression.
C00949	38114593	DIS0115	.	Corilagin	.	5-Fluorouracilu	NEWCL10146	HCT8	.	.	4.6uM:13.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3063	P21	Up-regulation	HCT8	20.63%	32.25%	31.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Corilagin enhanced the efficacy of 5-FU targeting human CRC by promoting the regulatory effects of 5-FU on GRP 78 protein expression.
C00949	38114593	DIS0115	.	Corilagin	.	5-Fluorouracilu	NEWCL10146	HCT8	.	.	4.6uM:13.8uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GRP78	Down-regulation	HCT8	0.41%	9.84%	19.80%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	Corilagin enhanced the efficacy of 5-FU targeting human CRC by promoting the regulatory effects of 5-FU on GRP 78 protein expression.
C00489	38675387	DIS0130	.	Trichostatin C	.	DNMT Down-regulation	NEWCL10112	J82	72h:4.16uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"When combined with the DNMT inhibitor decitabine, TSC exhibits a synergistic anti-cancer effect. Additionally, protein analysis elucidates a significant reduction in the expression of the tyrosine kinase receptor Axl. Notably, elevated concentrations of TSC correlate with the up-regulation of the transcription factor forkhead box class O1 (FoxO1) and increased levels of the proapoptotic proteins Bim and p21."
C00489	38675387	DIS0130	.	Trichostatin C	.	DNMT Down-regulation	NEWCL00170	A-549	72h:6.24uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"When combined with the DNMT inhibitor decitabine, TSC exhibits a synergistic anti-cancer effect. Additionally, protein analysis elucidates a significant reduction in the expression of the tyrosine kinase receptor Axl. Notably, elevated concentrations of TSC correlate with the up-regulation of the transcription factor forkhead box class O1 (FoxO1) and increased levels of the proapoptotic proteins Bim and p21."
C00658	38833034	DIS0022	.	Rocaglamide	.	anti-PD-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	RocA promoted the infiltration and differentiation of CD4+ TILs and coordinated with anti-PD-1 antibody to overcome checkpoint resistance in multiple tumor models.
C00010	38916633	DIS0028	.	Hesperidin	.	Salinomycin	NEWCL00023	KG-1a	.	.	85uM:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Study concluded that the mRNA expression level of PTEN had a remarkable reduction in AML patients. 
In our research, PTEN was overexpressed by SAL/HESP compared to the other two treatment groups. PTEN stimulates PIP3 dephosphorylation, resulting in the inactivation of the PI3K-AKT signaling."
C00059	39310106	DIS0115	.	Honokiol	.	Cetuximab	NEWCL00082	HCT 116	24h:36.05uM; 48h:12.99uM	.	25uM:20ug.mL	NEWCL00080	LoVo	24h:63.7uM; 48h:11.27uM	.	25uM:20ug.mL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SNX3	Down-regulation	HCT 116	17.60%	5.00%	14.74%	LoVo	8.42%	0.39%	2.85%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	pEGFR was nearly completely suppressed in both HCT116 and LoVo cells
C02522	39362388	DIS0022	.	Dauricine 	.	Gefitinib	NEWCL00175	PC-9	.	.	10uM:0.2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1248	P-gp	Down-regulation	PC-9	61.45%	3.97%	65.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	"Dauricine reverses drug resistance by activating the STK11/AMPK signaling pathway, upregulating the expression of STK11, inhibiting the growth and metabolism of tumor cells, and downregulating the expression of Nrf2 and Pgp."
C00623	39362582	DIS0022	.	Paeoniae radix	.	erlotinib 	NEWCL00200	NCI-H1650	.	.	200ug:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Aurora-B	Up-regulation	NCI-H1650	104.69%	184.30%	371.77%	NCI-H1975	2.64%	3.58%	35.44%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Experi- mental validation demonstrated that combining PR with erlotinib and gefitinib enhanced drug responsiveness by inhibiting Aurora kinase activity and inducing apoptosis in LUAD cells. Additionally, gene expression changes confirmed these combined effects, with the suppression of the Aurora B pathway and upregulation of the apoptotic pathway, which was accompanied by increased expression of multiple pro-apoptotic genes."
C00623	39362582	DIS0022	.	Paeoniae radix	.	erlotinib 	NEWCL00200	NCI-H1650	.	.	200ug:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-AuroraA	Up-regulation	NCI-H1650	117.22%	187.63%	391.26%	NCI-H1975	31.05%	35.79%	6.90%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Experi- mental validation demonstrated that combining PR with erlotinib and gefitinib enhanced drug responsiveness by inhibiting Aurora kinase activity and inducing apoptosis in LUAD cells. Additionally, gene expression changes confirmed these combined effects, with the suppression of the Aurora B pathway and upregulation of the apoptotic pathway, which was accompanied by increased expression of multiple pro-apoptotic genes."
C00623	39362582	DIS0022	.	Paeoniae radix	.	erlotinib 	NEWCL00200	NCI-H1650	.	.	200ug:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-AuroraABC	Up-regulation	NCI-H1650	237.93%	189.85%	953.33%	NCI-H1975	1.74%	9.61%	78.48%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Experi- mental validation demonstrated that combining PR with erlotinib and gefitinib enhanced drug responsiveness by inhibiting Aurora kinase activity and inducing apoptosis in LUAD cells. Additionally, gene expression changes confirmed these combined effects, with the suppression of the Aurora B pathway and upregulation of the apoptotic pathway, which was accompanied by increased expression of multiple pro-apoptotic genes."
C00623	39362582	DIS0022	.	Paeoniae radix	.	gefitinib	NEWCL00200	NCI-H1650	.	.	200ug:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Up-regulation	NCI-H1650	9.40%	0.09%	79.94%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Experi- mental validation demonstrated that combining PR with erlotinib and gefitinib enhanced drug responsiveness by inhibiting Aurora kinase activity and inducing apoptosis in LUAD cells. Additionally, gene expression changes confirmed these combined effects, with the suppression of the Aurora B pathway and upregulation of the apoptotic pathway, which was accompanied by increased expression of multiple pro-apoptotic genes."
C00623	39362582	DIS0022	.	Paeoniae radix	.	gefitinib	NEWCL00200	NCI-H1650	.	.	200ug:2uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Up-regulation	NCI-H1650	21.10%	13.53%	103.49%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"Experi- mental validation demonstrated that combining PR with erlotinib and gefitinib enhanced drug responsiveness by inhibiting Aurora kinase activity and inducing apoptosis in LUAD cells. Additionally, gene expression changes confirmed these combined effects, with the suppression of the Aurora B pathway and upregulation of the apoptotic pathway, which was accompanied by increased expression of multiple pro-apoptotic genes."
C00119	39550701	DIS0129	.	Nodularin-R	.	Abiraterone	NEWCL20362	22Rv1 tumor	.	.	7.5mg.kg:150mg.kg	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO1285	PPP1CA	Down-regulation	22Rv1 tumor	2.41%	29.36%	58.33%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Reversing Drug Resistance	Reversing Drug Resistance	Revealed the high PPP1CA expression in tumour tissues of PCa patients 
C00590	39714535	DIS0028	.	Niacin	.	Rapamycin	NEWCL00059	THP-1	24h:28.86uM; 48h:14.14uM; 72h:14.84uM	24h:18.51uM; 48h:4.937uM; 72h:5.453uM	.	NEWCL10125	NB4	24h:12.80uM; 48h:12.98uM; 72h:10.78uM	24h:16.69uM; 48h:3.993uM; 72h:5.934uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2597	ATG5	Down-regulation	THP1	53.36%	8.72%	50.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of Rapamycin and Niacin synergistically decreased cell viability of AML cell lines. The combination treatment induced the apoptotic cell population of THP-1 and NB4 by 4.9-fold and 7.3-fold, respectively. In THP-1 cells, the cell cycle was arrested at the G2/M phase by 10% whereas the NB4 cells were accumulated at the G0/G1 phase. The combination treat_x0002_ment decreased Akt and p-Akt expression. Besides, the ATG7 expression was reduced by combination treatment on THP-1 cells. Similarly, the ATG5 level was downregulated in NB4 cells. The level of LC3B-II/LC3B-I, which is an indicator of autophagy flux, was upregulated in THP-1 and NB4 cells."
C00590	39714535	DIS0028	.	Niacin	.	Rapamycin	NEWCL00059	THP-1	24h:28.86uM; 48h:14.14uM; 72h:14.84uM	24h:18.51uM; 48h:4.937uM; 72h:5.453uM	.	NEWCL10125	NB4	24h:12.80uM; 48h:12.98uM; 72h:10.78uM	24h:16.69uM; 48h:3.993uM; 72h:5.934uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4779	ATG7	Down-regulation	NB4	21.97%	2.47%	46.50%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of Rapamycin and Niacin synergistically decreased cell viability of AML cell lines. The combination treatment induced the apoptotic cell population of THP-1 and NB4 by 4.9-fold and 7.3-fold, respectively. In THP-1 cells, the cell cycle was arrested at the G2/M phase by 10% whereas the NB4 cells were accumulated at the G0/G1 phase. The combination treat_x0002_ment decreased Akt and p-Akt expression. Besides, the ATG7 expression was reduced by combination treatment on THP-1 cells. Similarly, the ATG5 level was downregulated in NB4 cells. The level of LC3B-II/LC3B-I, which is an indicator of autophagy flux, was upregulated in THP-1 and NB4 cells."
C00590	39714535	DIS0028	.	Niacin	.	Rapamycin	NEWCL00059	THP-1	24h:28.86uM; 48h:14.14uM; 72h:14.84uM	24h:18.51uM; 48h:4.937uM; 72h:5.453uM	.	NEWCL10125	NB4	24h:12.80uM; 48h:12.98uM; 72h:10.78uM	24h:16.69uM; 48h:3.993uM; 72h:5.934uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO6742	P-AKT	Down-regulation	.	31.84%	0.10%	65.75%	NB4	2.78%	2.27%	28.18%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of Rapamycin and Niacin synergistically decreased cell viability of AML cell lines. The combination treatment induced the apoptotic cell population of THP-1 and NB4 by 4.9-fold and 7.3-fold, respectively. In THP-1 cells, the cell cycle was arrested at the G2/M phase by 10% whereas the NB4 cells were accumulated at the G0/G1 phase. The combination treat_x0002_ment decreased Akt and p-Akt expression. Besides, the ATG7 expression was reduced by combination treatment on THP-1 cells. Similarly, the ATG5 level was downregulated in NB4 cells. The level of LC3B-II/LC3B-I, which is an indicator of autophagy flux, was upregulated in THP-1 and NB4 cells."
C00590	39714535	DIS0028	.	Niacin	.	Rapamycin	NEWCL00059	THP-1	24h:28.86uM; 48h:14.14uM; 72h:14.84uM	24h:18.51uM; 48h:4.937uM; 72h:5.453uM	.	NEWCL10125	NB4	24h:12.80uM; 48h:12.98uM; 72h:10.78uM	24h:16.69uM; 48h:3.993uM; 72h:5.934uM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7892	LC3B I	Down-regulation	.	62.89%	48.88%	57.04%	NB4	53.38%	4.93%	53.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Achieving Therapeutic Synergy	"The combination of Rapamycin and Niacin synergistically decreased cell viability of AML cell lines. The combination treatment induced the apoptotic cell population of THP-1 and NB4 by 4.9-fold and 7.3-fold, respectively. In THP-1 cells, the cell cycle was arrested at the G2/M phase by 10% whereas the NB4 cells were accumulated at the G0/G1 phase. The combination treat_x0002_ment decreased Akt and p-Akt expression. Besides, the ATG7 expression was reduced by combination treatment on THP-1 cells. Similarly, the ATG5 level was downregulated in NB4 cells. The level of LC3B-II/LC3B-I, which is an indicator of autophagy flux, was upregulated in THP-1 and NB4 cells."
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO7830	ACSL4	Up-regulation	DU145	42.65%	32.43%	57.32%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO3072	SLC7A11	Down-regulation	DU145	14.48%	13.18%	35.37%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8212	GPX4	Down-regulation	DU145	9.20%	12.40%	75.08%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2969	Bcl-2	Down-regulation	DU145	16.62%	21.22%	52.03%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO8729	Bax	Up-regulation	DU145	7.19%	3.95%	16.72%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO5373	Cleaved-Caspase-3	Up-regulation	DU145	167.37%	147.93%	242.34%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO4258	CDK4	Down-regulation	DU145	23.29%	14.69%	67.62%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO2596	Cyclin D1	Down-regulation	DU145	30.03%	29.42%	70.71%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P-AMPK	Up-regulation	DU145	65.97%	54.87%	153.22%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0518	P-mTOR	Down-regulation	DU145	24.58%	14.15%	66.28%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"
C02638	39871642	DIS0129	.	Polyphyllin VII	.	Docetaxel	NEWCL00251	DU145	.	.	1uM:2nM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	MO0066	P-p70S6K	Down-regulation	DU145	29.67%	10.23%	61.79%	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Enhancing Drug Efficacy	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"